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ABSTRACT 
Glioblastoma multiforme (GBM) is a malignant and highly aggressive form of 
brain tumour, with extremely poor prognosis. One of its features is the ability of 
the tumour to invade through normal brain resulting in tumour relapse. 
Our hypothesis was that Caveolin-1 (Cav-1), a major component of the 
caveolae and recognized to be involved in a number of signalling pathways, has 
a key pro-invasive role in GBM.  
We pursued our hypothesis by inhibiting the expression of Cav-1 in different 
adult GBM cell lines using different genetic techniques (liposome shRNA, 
lentiviral shRNA and CRISPR).  
We found that Cav-1 drives clonogenicity (CHAPTER 3) and invasion in a 
combination of two- and three-dimensional models (CHAPTER 5). We focused 
our research on the invasion phenomenon and, in order to provide a robust 
quantification approach to study invasion in 3D spheroid assays, we developed 
(CHAPTER 4) a open-source semi-automated script, INSIDIA, available for all 
researchers in the community to use. This tool was used to quantify the impact 
of Cav-1 on invasive capacity. 
In in-vitro systems, we explored the impact of Cav-1 expression upon molecules 
associated with the invasion phenomenon (CHAPTER 5). We found Cav-1 to be 
associated with  CTSB, MMP1 and UPA and receptors like UPAR and CD44, as 
well as AKT activation. 
Interrogating the “The Cancer Genome Atlas” (TCGA) database, we confirmed 
that Cav-1 is an independent biomarker of poor prognosis in GBM patients 
(CHAPTER 6). This clinical data also found association of genes that may 
cooperate with Cav-1, including CD44, ITGA3, VIM, CTSB, CTSL, TSP-1, 
TIMP1 and MT1MMP. 
Collectively this thesis provides strong in vitro and clinical data supporting that 
Cav-1 as a key molecule promoting GBM invasion, and further identifying Cav-1 
as a potential drug discovery target in GBM. 
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In this chapter, we reported a background introduction to the main themes that 
are recurrent in the present study. They are: 
1. Caveolin 1 
2. High-grade gliomas 
3. Stemness markers 
4. Markers of aggressiveness 
5. Genetic knockdowns and knockouts 
Specific information regarding single chapters is reported also in the introduction 
of each chapter.  
 
1.1 CAVEOLINS AND CAVEOLAE 
Caveolae are defined as flask-shaped plasma membrane domains of 60-100 nm 
(Goetz, Lajoie, Wiseman, & Nabi, 2008) in diameter that were first observed by 
electron microscopy in the 1950s (Palade, 1953; Yamada, 1955). The 
cytoplasmic face of these vesicles is coated by a protein termed Caveolin 
(Figure 1.1) which is responsible for many of their functional attributes (Parat, 
2009).  
 
Figure 1.1 Caveolae structure and major components. 
 
There are principally three caveolins that form the Caveolin family – Caveolin-1 
(Cav-1), Caveolin-2 (Cav-2), and Caveolin-3 (Cav-3). Cav-1 is expressed in a 
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variety of tissues and cells (among these epithelial, endothelial and brain glial 
cells) and is mostly co-expressed in hetero-oligomers with Cav-2. 22kDa Cav-1 
binds cholesterol (Murata et al., 1995) within the plasma membrane and forms 
higher-order oligomers (Monier, Dietzen, Hastings, Lublin, & Kurzchalia, 1996) 
(Figure 1.2) which are important for the generation of the characteristic caveola 
structure (Pelkmans & Zerial, 2005). While Cav-2 requires Cav-1 for its 
stabilisation and plasma membrane localization (Parolini et al., 1999), Cav-1 can 
exist independently and is the unequivocal marker for caveolae. Cav-3 
expression is mostly limited to the muscle cells where it forms homo-oligomers 
or hetero-oligomers with Cav-1. Embryonic genetic ablation of Cav-1 or Cav-3, 
although not fatal, abolishes caveolae formation, leading to vascular, pulmonary 
and muscular defects in mice (Drab et al., 2001; Galbiati, Engelman, et al., 
2001; Razani et al., 2001). 
Among the other components of the Caveolin family, Cavin-1  is a soluble 
protein shown to be an abundant caveolar coat protein and to be required for 
caveolae stabilisation and probably for the interaction with the cytoskeleton 
(Gupta, Toufaily, & Annabi, 2014; Hill et al., 2008; Inder et al., 2012; L. Liu & 
Pilch, 2008). Cav-1 and Cav-3 recruit Cavin-1 to the plasma membrane where it 
also binds to cholesterol, phosphatidylserine and oligomerises with caveolins 
(Burgener, Wolf, Ganz, & Baggiolini, 1990). The membrane curvature of 
caveolae is stabilized by the binding of Cavin-1, leading to the characteristic 
flask-shape of the caveolae. Cavin-1 and Cav-1 appear not to interact directly 
but through microtubules and actin filaments (Hill et al., 2008). 
 
 
Figure 1.2 Caveolin-1 structure showing single molecule (a), dimer with Cavin-1 (b) and oligomer 
(c).  
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Located on chromosome 7, the Cav-1 gene consists of 3 exons (respectively 30, 
165 and 342 bp long) separated by two introns of 1.5 kb and 32 kb (Figure 1.3). 
Two isoforms of Cav-1 have been identified: Caveolin-1α (residues 1-178) and 
Caveolin-1β (residues 32-178). These two isoforms of Cav-1 are generated by 
alternative initiation of the same mRNA translation (Kogo & Fujimoto, 2000; 
Shatz & Liscovitch, 2008). 
 
 
Figure 1.3 Caveolin gene structure with Cav-1 and Cav-2 located on chromosome 7 and Cav-3 
located on chromosome 3. 
 
Cav-1 is an integral membrane protein but has both the N’- and C’-terminals 
facing the cytoplasm (Figure 1.4). The protein comprises several domains 
including two membrane-compassing domains (residues 82–101 and 135–150) 
(Schlegel, Schwab, Scherer, & Lisanti, 1999; Woodman, Schlegel, Cohen, & 
Lisanti, 2002), an oligomerization domain (residues 61–101) (Sargiacomo et al., 
1995; Song, Tang, Li, & Lisanti, 1997), and a Caveolin-scaffolding domain 
(CSD) (residues 82–101) (Schlegel et al., 1999); each of these domains display 
a specific functionality. 
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Figure 1.4 Caveolin-1 membrane topology and protein domains. 
 
1.2 CAV-1 CELL SIGNALLING PATHWAYS 
Cav-1 was first identified as one of the main tyrosine-phosphorylated proteins in 
Rous sarcoma virus-transformed fibroblasts (Glenney & Soppet, 1992). Further 
studies reported that Cav-1 can be phosphorylated at Tyr14 or Ser80 in a cell 
type-specific manner, following stimulation by, for example, the mitogens 
Epidermal growth factor (EGF), the Platelet-Derived growth factor (PDGF) and 
insulin (Fielding, Chau, Liu, Spencer, & Fielding, 2004; H Lee et al., 2000) or 
cellular stress signals (Sanguinetti & Mastick, 2003; Volonté, Galbiati, Pestell, & 
Lisanti, 2001); Cav-1 phosphorylation may be important in determining overall 
Cav-1 functionality. Mediated primarily through the CSD, Cav-1 has been shown 
to regulate the function of a wide variety of signalling molecules, including 
glycosyl-phosphatidylinositol (GPI)-linked proteins, Src-family tyrosine kinases, 
H-Ras, heterotrimeric G-protein subunits, protein kinase C (PKC) isoforms, and 
endothelial nitric oxide synthase (eNOS). These findings led to the proposal of 
the “Caveolae Signalling Hypothesis” whereby caveolae function as 
compartmentalisers of signalling molecules and regulators of signal transduction 
(Lisanti, Scherer, Tang, & Sargiacomo, 1994). 
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1.3 CAV-1 INVOLVEMENT IN CANCER 
Cav-1 is known to directly interact via its scaffolding domain with multiple 
signalling proteins and to regulate their activity. These proteins include important 
regulators of cell transformation and growth (van Golen, 2006). Furthermore, 
whilst the signal regulatory actions of Cav-1 are mostly recognised as resulting 
from its plasma membrane location, there is evidence that its soluble and 
secreted forms are also involved in modulating cancer cell growth and 
metastasis (Parat, 2009). 
 
In a number of tumour types, Cav-1 expression has been found to be associated 
with tumour grade and stage (Senetta et al., 2013). Depending upon the tumour 
type and the particular point in tumour development, Cav-1 has been shown to 
act variously as both a tumour suppressor and tumour promoter. There is 
evidence both in vitro and in vivo of the variable role of Cav-1 in cancer initiation 
and progression (Lloyd & Hardin, 2011). For example:  
 Cav-1 expression has been found to be inversely associated with the 
transformation of breast cancer cell lines (S. W. Lee, Reimer, Oh, 
Campbell, & Schnitzer, 1998). Overexpression of human Cav-1 represses 
the transformed phenotype, in terms of a decrease in proliferation, 
reduced anchorage-independent colony formation in soft agar, reduced 
matrix invasion, and inhibition of matrix metalloproteinase (MMP)-2 
collagenolytic activity (Engelman et al., 1997; Fiucci, Ravid, Reich, & 
Liscovitch, 2002). Consistent with this, Cav-1 appears to increase 
apoptosis of breast cancer cells in vitro (Sloan, Stanley, & Anderson, 
2004), and the recombinant expression of murine Cav-1 in the breast 
cancer metastatic cell line, Met-1, suppresses experimental metastasis in 
vivo, with the CSD peptide alone sufficient to inhibit invasion (Williams et 
al., 2004). 
 In renal cell carcinoma, the expression of Cav-1 in clinical tumour 
samples has been repeatedly observed to positively correlate with 
aggressive disease and represents a poor prognostic marker for patient 
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survival. In vitro studies in renal cancer cells has shown the expression of 
Cav-1 to drive tumour cell invasion and promotion of angiogenesis 
(Campbell et al., 2013). Moreover, RNA interference-directed Cav-1 
knockdown sensitises renal carcinoma cells to doxorubicin-induced 
apoptosis and reduces metastasis to lung (Park et al., 2010). 
 In prostate cancer, Cav-1 expression positively correlates with advanced 
disease in both human tumours and in experimental in vivo models of 
prostate cancer (Gould, Williams, & Nicholson, 2010). Cav-1 is released 
from tumour cells and acts in an autocrine and paracrine manner upon 
tumour and endothelial cells, respectively to promote cell proliferation and 
angiogenesis, in vitro, and lung metastases, in vivo (Tahir et al., 2006). In 
an in vivo prostate cancer model, lung metastases displayed increased 
expression of Cav-1. Furthermore, secreted Cav-1 levels has been found 
significantly higher in men with prostate cancer than in men with benign 
prostatic hyperplasia (Tahir et al., 2006) and elevated pre-operative levels 
of secreted Cav-1 predict a decreased time to cancer recurrence after 
radical prostatectomy (Tahir et al., 2006).  
 Cav-1 levels are also increased in drug-resistant carcinomas, such as in 
vitro lung carcinoma cells, (Engelman et al., 1997; Ho et al., 2002) with 
Cav-1 also recognised to promote chemoresistance in lymph node 
metastasis of non-small cell lung cancer (M. Li et al., 2010), and with 
Cav-1 silencing arresting the proliferation of metastatic lung cancer cells 
through the inhibition of signal transducer and catalyst of transcription 
(STAT)-3 signalling (Pancotti, Roncuzzi, Maggiolini, & Gasperi-Campani, 
2012). 
 In human astrocytoma cell line 1321N1, G protein-coupled P2Y2 
nucleotide receptor (P2Y2R) interaction with Cav-1 in membrane-raft 
caveolae has been reported to modulate the receptor coupling to its 
downstream signalling machinery (Martinez et al., 2016). P2Y2R is a 
mediator of pro-inflammatory responses, neurotransmission, apoptosis, 
proliferation, and cell migration (Abbracchio & Ceruti, 2006).  
The above data indicate a complex role for Cav-1 in tumorigenesis and 
progression with Cav-1 expression pattern (Parat & Riggins, 2012) and function 
appearing to vary with cell oncogenic stage (Figure 1.5); it could be possible that 
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during the first stages of the oncogenic transformation Cav-1 may be 
downregulated in order to promote proliferation and anchorage-independent 
growth, whilst in the later stages, when a tumour has to adapt to the 
environment, e.g. increased interstitial pressure, hypoxia and challenge with 
chemo- and radio-therapies, Cav-1 is overexpressed (Quest et al., 2013). 
 
 
Figure 1.5 Caveolin-1 (Cav-1) may function both as a tumour suppressor and as an oncogene, 
depending on the stage of oncogenic transformation and the extent of tumour progression.  
 
1.4 BRAIN TUMOURS 
There are a variety of different types and grades of brain tumours 
(approximately 130 different types) (D. N. Louis et al., 2007). Up to 2016, brain 
tumours have been classified according to their cellular origin, the tumour 
growth pattern and whether they are benign or malignant. In 2016, a new 
classification system has been proposed, that takes into consideration clusters 
of genetic and molecular markers for the new stratification system. This 
classification is currently under review by the scientific community so, for this 
work, the 2007 classification will be firstly described. The World Health 
Organization (WHO) 2016 classification will be discussed in 1.4.3. Between the 
two classifications, a further approach was adopted with the molecular profiling, 
which will be described in 1.4.2. 
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1.4.1 WHO 2007 CLASSIFICATION 
According to the WHO 2007 classification, a brain tumour is graded by its ability 
to grow and spread. The grade is most commonly defined by the criteria of the 
World Health Organization (WHO)(D. N. Louis et al., 2007) (Table 1.1). Such 
criteria include atypia (similarity to normal cells), mitotic index (rate of growth), 
indications of uncontrolled growth, necrosis (mostly in the centre of a tumour), 
infiltration ability (reflecting invasiveness and/or ability to migrate), margins 
(diffuse or focal) and vascularity.  
 
Table 1.1 Criteria used to define brain tumours by the WHO 2007 (D. N. Louis et al., 2007) 
grading classification 
 
 
A tumour whose origin is in the brain, i.e. from brain cells, is termed a primary 
brain tumour and can be distinguished as either benign (low-grade) or malignant 
(high-grade). Benign tumours are characterised by a slow growth rate, a distinct 
border (which helps surgical resection) and a rare propensity to spread. In 
contrast, malignant tumours usually grow very fast and display the ability to 
invade surrounding tissue thus impairing the correct functioning of the brain with 
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physical and psychological consequences; malignant brain tumours are also 
called brain cancers. Secondary brain tumours can be defined as primary brain 
tumours which have progressed to a more malignant grade. Most typically, 
these are grade II gliomas which progress to GBM and are distinguished from 
de novo GBMs. Secondary brain tumours can be also the result of a peripheral 
tumour that has metastasised into the brain. The most common peripheral 
primary cancers metastasising to the brain origin from lung (50%), breast (15%–
20%), unknown (10%–15%), melanoma (10%), and colon (5%) (Mehta M, 
Vogelbaum MA, Chang S, 2011; Patchell, 2003). Approximately 80% of brain 
metastases occur in the cerebral hemispheres, 15% occur in the cerebellum, 
and 5% occur in the brain stem (Mehta M, Vogelbaum MA, Chang S, 2011). 
Metastases to the brain are multiple in more than 70% of cases (Patchell, 2003).  
A particular note should be reserved for paediatric brain tumours, which are rare 
but represent the most common form of solid tumour in patients less than 15 
years of age. They display some different characteristics to adult tumours in that 
they have the propensity to arise from different cellular origins and exhibit 
different behaviours. The therapeutic approaches can also be quite different and 
depend not only on the tumour type but also on patient age (Karajannis, Allen, & 
Newcomb, 2008). 
Primary brain tumours are named after the cellular origin from which they arise, 
as shown in (D. N. Louis et al., 2007) and Figure 1.6.  
Gliomas include a range of different tumour types, arising from glial cells in the 
brain, i.e. gliomas include astrocytomas, oligodendrogliomas and ependymomas 
(Table 1.2). They are the most common type (86%) of primary malignant brain 
tumours (McKinney, 2004)  with a combined five-year survival for the high-grade 
tumours (III and IV) that only approximates to 14.5 % for men and 16.1 % for 
women (Goggins & Wong, 2009). 
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Table 1.2 Brain tumours classification 
 
 
Figure 1.6 Glial cells include several cell types, which give rise to distinct brain tumour types, all 
of which are classified as gliomas. 
 
Specifically, the following are the major types of glioma recognised: 
Astrocytomas are derived from astrocytes, star-shaped glial cells the general 
function of which includes the provision of support for neurons, e.g. in the supply 
of nutrients and removal of neuronal waste products or cellular material (S. K. 
CHAPTER 1: GENERAL INTRODUCTION 
 
14 
Kim, Nabekura, & Koizumi, 2017).  Astrocytes are key mediators of brain 
development, function, and plasticity (Guizzetti, Zhang, Goeke, & Gavin, 2014). 
They coordinate neuronal development and synapse formation and function 
through the release of trophic factors and synthesis of extracellular matrix (ECM) 
(Christopherson et al., 2005; Pascual et al., 2005). Moreover, astrocytes 
express numerous receptors, such as receptors for neurotransmitters and 
neuromodulators, that allow inter-cellular communication with neurons (Clarke & 
Barres, 2013) and other cell types. Astrocytomas represent the most frequent 
type of glioma in both adults and children (34% of the brain tumours) (D. N. 
Louis et al., 2007). They can initially form in any part of the brain or spinal cord, 
they can be focal (mostly diagnosed in children) or diffuse. Anaplastic 
astrocytoma (or Grade III astrocytoma) and glioblastoma multiforme (GBM or 
Grade IV astrocytoma) are the most common in adults and represent high-grade 
gliomas reflective of their malignant characteristics, such as the ability to spread 
to other parts of the brain. Glioblastomas’ cell types are all highly malignant and 
characterized by an abnormal vascularization and a high proliferative rate. In the 
centre of the tumour, it is possible to find necrosis, surrounded by a 
pseudostratified layer (pseudo-palisading). Glioblastomas are most commonly 
found in the cerebral hemispheres, but they can arise also in other parts of the 
brain and the spinal cord. Primary GBM defines a grade IV glioblastoma that 
lacks any clinical or histological evidence of a lower grade malignant precursor, 
whilst secondary GBM displays clinical or histologic evidence of having 
progressed from low-grade (grade II) diffuse astrocytoma or grade III anaplastic 
astrocytoma (Parat, 2009). 
 
Oligodendrogliomas are derived from oligodendrocytes, which are specialised 
glial cells that provide support and insulation to axons in the central nervous 
system. Oligodendrocytes create the myelin sheath around nerve axons 
providing axonal protection and improving the speed of the electrical signals 
(action potentials) within the axons (Jäkel & Dimou, 2017). Only the 3% of brain 
tumours are oligodendrogliomas (D. N. Louis et al., 2007). They are most often 
found in the cerebrum, in the temporal or frontal lobes where they can be fast or 
slow growing. They are more frequent in adults although they do occur also in 
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young children. Oligodendrogliomas sometimes display the ability to spread 
within the central nervous system towards the cerebrospinal fluid. 
Ependymal cells constitute a polarised epithelial-like cellular barrier lining the 
ventricles of the brain and lining the central canal of the spinal cord (Jiménez, 
Domínguez-Pinos, Guerra, Fernández-Llebrez, & Pérez-Fígares, 2014). Their 
function is to separate the cerebrospinal fluid from brain parenchyma. 
Ependymal cells give rise to ependymomas which are relatively rare low-grade 
tumours (J. Wu, Armstrong, & Gilbert, 2016).  
1.4.2 GLIOMAS MOLECULAR PROFILING 
Several attempts of molecular profiling have been proposed since 2006 for 
diffuse gliomas (gliomas with diffuse infiltrative nature, such as astrocytomas 
and oligodendrogliomas) (Huse, Phillips, & Brennan, 2011). They were inspired 
by the successful advancement in lung cancer clinical trial results of adjuvant 
Gefitinib after selection of patients with tumours bearing a mutation of epidermal 
growth factor receptor (EGFR) (Giaccone et al., 2004; Herbst et al., 2004; 
Sequist et al., 2008). The authors believed that a molecular stratification would 
allow bringing to light the therapeutic potential of some of the small molecule 
kinase inhibitors tested for glioma and rejected in clinical trials (De Witt Hamer, 
2010). 
The first attempt was published in 2006 with three subgroups, proneural, 
proliferative and mesenchymal (Phillips et al., 2006). This study associated 
molecular markers with the patients’ survival. It included previously reported 
markers, such as the Chitinase-3-like protein 1 (CHI3L1 or YKL40) and vascular 
endothelial growth factor (VEGF), that were used to discriminate between GBM 
and lower-grade tumours, and new ones like Mindbomb homolog 1 (MIB-1). In 
the same time, the classification has been enriched by other studies (Karcher et 
al., 2006; Tso et al., 2006). 
The proneural group is the one with the highest survival rate and thus the better 
prognosis, while the mesenchymal one is the most aggressive and 
characterized by worst outcome (Huse et al., 2011). 
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Four years later, Verhaak et al. used the data from The Cancer Genome Atlas 
Project (TCGA) to identify markers for the sub-classification of four GBM 
subtypes, Proneural, Neural, Mesenchymal, and Classic (Verhaak et al., 2010a). 
According to this classification, the proneural group this time is the one that does 
not benefit from a more aggressive therapeutical approach. This group is 
composed by tumours with Isocitrate dehydrogenases (IDH) mutations or 
Platelet Derived Growth Factor Receptor Alpha (PDGFRA) amplification, the 
classical subtype exhibits EGFR mutation and/or amplification whilst the 
mesenchymal one loss and/or mutation of Neurofibromin 1 (NF1). This study, in 
particular has received some critical comments (Huse et al., 2011) since it used 
“an unsupervised approach to classify data” and it presented a “lack of 
methodological uniformity” between studies.  
Anyway, the distinction between the proneural and mesenchymal group in both 
studies seems to be robust enough to allow a legitimate stratification. In Figure 
1.7 it is reported a schematic comparison between the two studies, the WHO 
classification and other marker-related studies previously reported.  
 
Figure 1.7 Schematic representation of the relationships between genetic markers and expression 
subgroups in diffuse gliomas. The areas are indicative of the incidence in adults (Central Brain 
Tumor Registry of the United States). Adapted from (Huse et al., 2011) with permission. 
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1.4.3 WHO 2016 CLASSIFICATION 
Recent technological advancements and the consequent reduction in genomic 
sequencing costs made the shifting from a histological to molecular-based brain 
tumours classification a reality. In the last ten years, a variety of large-scale 
molecular profiling efforts have highlighted possible new biomarkers that allow 
the distinction of tumours similar form a microscopic point of view into more 
reproducible and objective subgroups.  
Many of these efforts have been used to update the new WHO CNS 2016 
classification (Louis, 2016). The new classification indeed is not based solely on 
tumours microscopic similarities with different putative cells of origin and their 
presumed levels of differentiation (Louis et al., 2016b). Despite the advances of 
this new system, like the increased objectivity given by the integration of 
genotypic and phenotypic parameters (Table 1.3), the authors still auspicate a 
further classification based only on the genetic characteristics, when a better 
stratification will be possible.  
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Table 1.3 The WHO CNS 2016 classification (D. N. Louis et al., 2016b) 
 
 
The main genetic markers involved in this new classification are the IDH status 
and the 1p/19q deletion. Among other markers, there are Alpha-
Thalassemia/Mental Retardation Syndrome, Non-deletion Type, X-Linked 
(ATRX) and tumour protein 53 (TP53). 
In this work, only glioblastoma characteristics will be discussed. 
Glioblastoma has been divided into two subgroups (Table 1.4), the IDH wild-type 
and the IDH mutant. The first one is mostly comprised by the de novo GBMs 
and represents the majority (90%) with an incidence more common in the age 
range >55 years old, whilst the second one represents around 10% of the cases, 
is more common in young people and is secondarily derived mostly by lower 
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grade gliomas. A third group is represented by those GBMs whose IDH status 
was not assessable. 
The somatic IDH mutations correspond basically to the point mutation R132H of 
IDH1, or the mutually exclusive analogous residue in IDH2 (R172). These are 
enzymes part of the Krebs cycle, therefore relevant for the metabolic activity of 
the cells. Both the mutations affect the catalytic activity of the enzymes, leading 
to a decreased metabolic activity and a relatively better prognosis. 
Table 1.4 Glioblastoma WHO 2016 classification (D. N. Louis et al., 2016b) 
 
 
Other genetic markers not reported in Table 1.4 are v-Raf murine sarcoma viral 
oncogene homolog B, (BRAF) V600E mutation, loss of Integrase Interactor 1 
(INI1) expression, chromosome 10 loss, hemizygous deletions of Teneurin 
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Transmembrane Protein 3 (ODZ3) and Avian Myelocytomatosis Viral Oncogene 
Homolog (MYC) or Neuroblastoma MYC Oncogene (MYCN) amplification. 
 
1.4.4 CURRENT THERAPEUTICAL OPTIONS FOR GBM 
Even with advanced surgical procedures and treatment regimens involving 
radiation therapy and chemotherapy (Stupp et al., 2005), high-grade malignant 
gliomas display a poor prognosis. This is due to the diffuse infiltrative capacity of 
any residual tumour cells remaining after incomplete surgical resection, with the 
ability to spread to distant sites within the brain and undergo self-renewal and 
growth. High-grade tumours can also display resistance to chemo- and 
radiotherapy. The most aggressive form of glioma, GBM (grade IV), displays a 
median survival of two years (Parker, Khong, Parkinson, Howell, & Wheeler, 
2015). Even the lower-grade gliomas that appear less aggressive at the time of 
diagnosis eventually progress into a malignancy. In addition, the destructive 
effect of such tumours on brain function often leads to cognitive and emotional 
deficits for patients. The treatment of high-grade gliomas represents a truly 
unmet medical need with improved genetic diagnosis and curative therapeutic 
strategies needed that target the cell of origin (Zong, Verhaak, & Canoll, 2012). 
Upon initial diagnosis of GBM the standard treatment (Olar & Aldape, 2014) 
consists of maximal surgical resection, radiotherapy, and concomitant and 
adjuvant chemotherapy with Temozolomide (TMZ), an oral alkylating agent that 
was found to extend median survival to 15 months and with a 2-year survival in 
26% of patients (Furnari et al., 2007; Stupp et al., 2009). This survival increase 
is, however, restricted to patients with tumours displaying an epigenetic 
silencing of the DNA repair gene methyl guanine methyl transferase (MGMT). 
Only when MGMT is methylated the survival is extended (Stupp et al., 2009). 
Another example is represented by MutS Homolog 6 (MSH6) gene mutations, 
which are not present in untreated GBM but are induced by TMZ treatment 
causing resistance to the therapy (Cahill et al., 2007; Yip et al., 2009). 
Despite the new advances in target discovery and molecular classification 
described in glioma, very few markers passed the trial phase and are used in 
clinical practice. Indeed, apart from MGMT (which incidentally is not included in 
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the new classification but is already part of the routine diagnostic carnet), the 
only molecular marker in clinical practice for diffuse gliomas is the combined 
loss of chromosomes 1p and 19q, which is routinely tested in many centres as a 
prognostic and therapeutic indicator (Huse et al., 2011).  
In the UK, the National Institute for Health and Care Excellence (NICE) (2007) 
guideline for newly diagnosed high-grade gliomas still advises Temozolomide as 
primary drug treatment, with the possible association of Carmustine implants, if 
more than 90% of a tumour has been removed (Price, Whittle, Ashkan, Grundy, 
& Cruickshank, 2012). Carmustine implants are biodegradable polymers 
impregnated with the alkylating agent Carmustine, that are implanted in the 
resection cavity at the time of the surgery. As an alkylating agent, Carmustine is 
able to bind DNA and prevent cell proliferation. The implants are in addition to 
surgery and radiation therapy. 
 
1.4.5 CAV-1 AND GBM AGGRESSIVENESS 
Cav-1 biology in glioma, by comparison to other tumour types, is poorly 
understood. There are a few limited studies of Cav-1 expression in clinical 
samples. These have reported positive correlations between Cav-1 expression 
and increased tumour grade (Barresi et al., 2009; Cassoni et al., 2007). Cav-1 
expression has also been reported to independently predict shorter survival in 
oligodendrogliomas (Senetta et al., 2013), although this finding is not consistent 
with other studies that found no difference in Cav-1 expression in 
oligodendrogliomas or anaplastic astrocytomas (Barresi et al., 2009). It is clear 
however that Cav-1 positive and negative tumour cells co-exist in high-grade 
glioma. The potential role of Cav-1 in GBM has been reviewed by Parat (Parat & 
Riggins, 2012). 
Whilst there are several possible single-nucleotide polymorphisms (SNPs) in the 
Cav-1 gene, only one has been related to cancer. Specifically in breast cancer 
(Hyangkyu Lee et al., 2002) in an in vitro and in a preclinical in vivo model, but 
there seems to be no clinical evidence of the association of Cav-1 mutations and 
brain tumours. Clearly, this is an area that needs further investigation. 
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In preclinical models, the work of Li and colleagues (Y. Li et al., 2011) has 
shown Cav-1 expression to promote astroglial differentiation of neural progenitor 
cells (NPCs), an outcome mediated through increased Notch1 signalling; the 
same workers showing Cav-1 to inhibit neuronal differentiation from NPCs (Y. Li 
et al., 2011) via inhibitory effects on VEGF, phosphor-Extracellular Signal-
Regulated Kinase (pERK), AKT, Signal Transducer and Activator of 
transcription-3 (STAT3) pathways. Annabi and co-workers (Borhane Annabi, 
Thibeault, Moumdjian, & Béliveau, 2004) have proposed plasma membrane 
caveolae domains in glioma cells to serve as sites for the positive regulation of 
Cluster of Differentiation-44 (CD44) functional activity in respect to pro-invasive 
characteristics. Similarly, Strale’s group (Strale et al., 2012) showed 
sequestration of Connexin43 in Cav-1 rich domains increased the invasive and 
clonogenicity of U251 glioma cells. Stanimoirovic’s laboratory (Abulrob et al., 
2004) reported Cav-1 in U87MG to serve as a molecular break for EGF receptor 
(EGFR) signalling, diminishing aggressive features of U87MG cells.  
Cav-1 effects upon the glioma microenvironment have been studied: Régina et 
al. (Régina et al., 2004) reported angiogenic factors and hypoxia to 
downregulate Cav-1 in tumour brain microvasculature and to be associated with 
a less differentiated endothelial cell type. Kucharzewska et al. (Kucharzewska et 
al., 2013) reported hypoxia to induce Cav-1 levels in glioma cells and with Cav-
1, amongst other molecules, to be secreted in exosomes from the glioma cells 
leading to promotion of angiogenesis during tumour development. Shimato et al 
(Shimato et al., 2013) reported that Cav-1 expression in brain tumour 
monocyte/microglia cells populations suppresses their immune-stimulatory 
functions and thus undermines immunotherapeutic strategies.  
The more rigorously conducted studies focusing on Cav-1 biology in glioma are 
represented by three papers that have come from the laboratory of Sophie 
(Cosset et al., 2012; Martin et al., 2009) and from the one of Micheal Lisanti 
(Quann et al., 2013). 
The group of Sophie Martin published two papers (Cosset et al., 2012; Martin et 
al., 2009) about Cav-1 and GBM, both using the astroglial cell line U87MG as 
the model of interest. They silenced Cav-1 with a shRNA approach and 
determined the genes affected by Cav-1 silencing. In particular, they focused on 
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integrins, more specifically on integrin α5β1; they found its expression increased 
with a knockdown of Cav-1, i.e. negative regulation of α5β1 by Cav-1. Cav-1 
knockdown was also associated with an increase in cell proliferation, 
clonogenicity and adhesion to fibronectin. The tumour suppressor effects of 
Cav-1 were found to be integrin α5β1-mediated, as partly evidenced by the 
enhancement of Cav-1 silencing using an integrin antagonist.  
They went on to explore how the expression of α5β1 integrin increased after the 
depletion of Cav-1. They found that Cav-1 caused transcriptional repression of 
α5β1 integrin. They showed that depletion of Cav-1 led to the activation of the 
Transforming growth factor (TGF) β/ TGFβ Receptor 1 (TGFBRI)/Smad2 
pathway, which in turn induced the expression of α5β1 integrins.  
They also examined human glioma biopsies and were able to identify isolated 
subgroups with either low levels of Cav-1/high levels of α5β1 and TGFβRI or 
high levels of Cav-1/low levels of α5β1 and TGFβRI. There were, however still a 
proportion of tumours in which Cav-1 and α5β1 expression were not inversely 
related. They concluded the status of Cav-1/α5β1 integrins/TGFβR1 axis might 
be a useful marker of the tumour evolution/prognosis in GBM as well as a 
predictor of the effectiveness of anti-TGFβ or anti-α5β1 integrin therapies. 
The laboratory of Micheal P. Lisanti focused on the overexpression of Cav-1 in 
an in-vivo model. Using U87MG overexpressing Cav-1 through a lentiviral-based 
system, they observed a decrease of tumorigenicity (in an ectopic xenograft 
mouse model) with Cav-1 overexpression and an increase in Temozolomide 
sensitivity, the most commonly used chemotherapy agent for GBM. These 
effects (included Cav-1 overexpression) were associated with a decrease in the 
activity of the Phosphatidylinositol-4,5-Bisphosphate 3-Kinase (PI3K)/ 
Mechanistic Target Of Rapamycin Kinase (mTOR) pathway, metalloproteases 
and Cyclin D1, and an increase of P53, Phosphatase And Tensin Homolog 
(PTEN) (both negative modulators of the PI3K/mTOR pathway), factors 
responsible for cell cycle and transcription stop (FOXN3, HDAC, VHL and 
CDKN1C) and apoptosis-involved players. 
Together the data indicate that Cav-1 serves as a putative tumour suppressor in 
GBM. 
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1.5 STEMNESS IN CANCER  
There are multiple theories and models about tumour evolution and 
heterogeneity (Figure 1.8) (Parker et al., 2015). One of these is the “clonal 
evolution theory”, according to which somatic alterations occurring in the initial 
cell of origin lead to multiple cancer cell clones of differing chemo-sensitivities, 
survival and proliferative ability. These genetically unstable clones undergo 
successive genetic alterations and tumour cells with the most aggressive 
phenotype are selectively enriched.  
In contrast, the “cancer stem cell theory” views that a tumour comprises a small 
percentage of the cells, known as cancer stem cells (CSC), which display the 
classic stem properties such as the ability to self-renew, to continuously 
proliferate, to give rise to genetically different clones, and display resistance to 
therapy. It is the sustained survival of these CSC that affords the persistence of 
the primary and secondary tumours.  
Finally, the “theory of inter-clonal cooperativity” suggests that tumour evolution 
and heterogeneity is induced by interactions between tumour cell clones and the 
microenvironment. 
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Figure 1.8 Models for the origin of intra- (A-C) and inter- (D-F) tumour heterogeneity. A. 
Clonal evolution model.  From a common founder cell, different subclones emerge due to 
selection and distinct mutations.  B. Cancer Stem Cells (CSCs) model. According to this model 
clonal evolution only happens for the CSCs. Different lienages are able to arise from different CS 
clones. C. Interclonal cooperativity model. The interaction with the microenvironment drives the 
phenotype of plastic cancer cells. D. Different subtypes of cancer can arise from different 
mutations occurring in different parts of the same organ. E. signals from the microenvironment can 
trigger the activation of specific CSCs clones.  F. Gene expression can be used to identify patients 
with different survival probability. Adapted from (De Sousa E Melo et al. 2013) with permission. 
 
While Figure 1.8 shows the three theories (Inda, Bonavia, & Seoane, 2014), 
Figure 1.9 shows how these three theories may give rise to GBM (Parker et al., 
2015). The significant clonal diversity within tumours may explain the lack of 
effectiveness of the molecular target therapies in GBM patients. According to the 
theory of clonal evolution, one single cell affected by somatic alterations can 
give rise to multiple cancer clones each one displaying a different sensitivity to 
therapy and behaviour, such as the ability to survive and proliferate. These 
clones are genetically unstable and undergo successive waves of genetic 
alterations, and the ones with the most aggressive phenotype are advantaged. 
For example, cells displaying inhibiting methylation of the promoter in the 
MGMT gene (i.e. suppressing MGMT functional repair of damaged DNA) are 
more sensitive to the alkylating agent Temozolomide (TMZ) (Figure 1.9A). On 
the other hand, with the cancer stem cell theory, only a single subset of cells 
(CSCs) display the ability to self-renew, to endlessly proliferate and to give rise 
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to genetically variable clones, that are intrinsically resistant to therapy (Figure 
1.9B). The theory of interclonal cooperativity views that the evolution and the 
heterogeneity of tumours are promoted by the interaction between tumour cell 
clones and the microenvironment with which they are in contact, including both 
immune and stromal factors (Figure 1.9C). Indeed, the reality will be more 
complex and likely involve elements of at least all three models.  
 
 
Figure 1.9 Glioblastoma tumour heterogeneity theories: tumour evolution and tumour 
heterogeneity may be promoted by clonal evolution (A), cancer stem cells (B) and inte rclonal 
cooperativity (C). Adapted from (Parker et al., 2015). 
 
The properties that tumour cells are characterised by in terms of stem-like 
properties are:  
Self-renewal (Figure 1.10A) – the ability of cells to continuously self-renew 
through symmetrical (both daughter cells the same as parent cell) and 
asymmetrical (daughter cells differing with only one daughter exactly the same 
as the parental one) cell divisions. Self-renewal is considered a characteristic of 
crucial importance for stem cells because it is the only way to ensure that at 
least one of the progenies display the same molecular characteristics as the 
parental stem cell. In terms of cancer, it is the mechanism that sustains over 
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multiple generations the cells whose characteristics underpin CSC populations 
(Suksuphew & Noisa, 2015).  
Multipotency (Figure 1.10B) - the property of cells to retain the potential for cell 
differentiation to give rise to specialized and/or terminally differentiated cells. 
Stem cell plasticity is progressively restricted as differentiation advances, such 
that whilst the early stem cell generation(s) can give rise to a broad range of cell 
types, the latter more differentiated progeny have a more limited capacity, for 
example, able to give rise to only one or two different, but more closely related, 
cell types (Suksuphew & Noisa, 2015). 
Tumorigenicity (Figure 1.10C)- the property of a cell or collection of cells to give 
rise to tumours. It does not, however, mean that tumorigenicity is explained only 
by the cancer stem cell theory (Sampetrean & Saya, 2013). 
Chemo- and radio-resistance (Figure 1.10D)- this is the ability of tumour cells to 
possess or develop mechanisms that reduce the effectiveness of therapies and 
has direct clinical relevance. For example, the expression of efflux transporters 
in tumour cells, like P-glycoprotein, that export cytotoxic agents from the cell 
(Filatova, Acker, & Garvalov, 2013), or the expression of enzymes that repair 
DNA alkylation damage e.g. the enzyme MGMT removing methylation of DNA 
induced by TMZ.  
Invasion and metastatic ability (Figure 1.10E) - invasion is the ability to 
overcome the ECM and the microenvironment to migrate and invade through 
tissue, to escape the confines of the primary tumour. This translates into 
metastasis when the invading cells reach blood or lymphatic vessels, overcome 
the vessel barrier and travel through the blood or lymphatic system to establish 
as a secondary tumour within a new microenvironment at a distant site. This 
ability requires the cells to display the property of plasticity to adapt its functions 
to meet changing needs and changing environments, a property that makes 
cells extremely aggressive (Beck & Blanpain, 2013). The same processes are 
also observed in a variety of physiological conditions, such as in development 
where differentiated cells may dedifferentiate, move towards a distant site, and 
differentiate again to form a new structure. This phenomenon is known as 
epithelial-mesenchymal transition (EMT) and is a natural physiologic 
characteristic, that can be observed during development but also in adult life 
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whilst e.g. wound healing is necessary (Kerosuo & Bronner-Fraser, 2012; 
Savagner, 2010); EMT is currently studied for the onset of cancer cell migration, 
invasion and metastatic spread (Yilmaz & Christofori, 2009). 
Neo-angiogenesis (Figure 1.10F) - the ability of parenchymal cells to sense a 
decrease in the oxygen tension of their microenvironment and activate 
mechanisms that lead to the secretion of molecular signals stimulating the 
formation of new blood vessels. This ability is also connected to the theory of 
interclonal cooperativity, since newly-formed blood vessels may represent an 
ideal niche for cancer cells, particularly for GMB, whose cells in contact with the 
endothelial perivascular cells can exchange growth and survival factors (Folkins 
et al., 2007; Persano, Rampazzo, Basso, & Viola, 2013). 
 
Figure 1.10 Stem cell-like properties of cancer: A- self-renewal, B- Multipotency, C- 
Tumorigenesis, D- Chemo- and radio-resistance, E- Invasion and metastasis, F- Angiogenesis. 
 
1.5.1 CLONOGENICITY 
1.5.1.1 CLONOGENICITY AND STEM CELL PROPERTIES 
Clonogenicity is a stem cells property that can be distinguished in two and 
interconnected capabilities (Lewis & Petritsch, 2013). Stem cells, under physical 
and/or molecular stimuli, can start proliferating and undergo symmetrical or 
asymmetrical division. As a result of the symmetrical division, the daughter cells 
are exactly identical to the parental one. After the asymmetrical division, on the 
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contrary, the resulting daughter cells are different from each other. One of them 
is exactly the copy of the parental cell (according to the self-renewal ability 
principle). The other, on the other hand, is different from the previous two, 
reflecting a more committed phenotype; it will be potentially able to differentiate 
in all the different phenotypes that the committed cell is able to give rise to (in 
this case we can refer to the multipotency ability principle). 
It can be thus inferred that clonogenicity is an essential property in stem cells 
that have to repair tissues damages. They need to differentiate and to give rise 
to new specialized cells but, in the meantime, it is important to maintain the stem 
phenotype for future needs. 
Clonogenicity is of course also tightly connected to proliferation since the latter 
represents the first responder to the stimulation of the stem cell and it is also 
necessary for the generation of enough specialized cells for the complete 
repairing of the damage. Furthermore, clonogenic cells can proliferate whilst, 
e.g., invasive cells stop their proliferation and activate their motility mechanisms. 
Molecularly this is reflected in the passage between different phenotypes, 
among which the EMT is the most studied (De Sousa E Melo et al., 2013). 
1.5.1.2 CLONOGENICITY AND CANCER 
According to the CSC theory, within a tumour, most cells are non- tumorigenic 
and are characterized by limited self- renewal ability. The only subpopulation 
able to self-renew and initiate tumours is the one represented by the CSCs, also 
called tumour- initiating cells. This small group of cancer cells are believed to be 
able to hibernate during radiotherapy and chemotherapy, saving in this way their 
genetic and structural integrity (chemo- and radio-resistance), and to re-activate 
when the environmental conditions change, displaying both self- renewal and 
multipotency ability, in order to recapitulate a tumour (relapse and metastatic 
potential). 
1.5.1.3 CLONOGENICITY AND GLIOMA 
There are several signalling pathways that have been identified as shared 
between stem cells and Glioma stem cells (GSCs.) Among these, the most 
important are the Notch, Sonic Hedgehog (Shh), Bone morphogenetic proteins 
(BMPs) and Wingless-Type MMTV Integration Site Family (Wnt) signalling 
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pathways (Figure 1.11), that are believed to be essential for the maintenance of 
multipotency and self-renewal (Liebelt et al., 2016). In particular Notch signalling 
is important for regulating multiple cellular processes, including proliferation, 
differentiation, apoptosis, and cell lineage commitment in neural stem cells 
(NSCs), (Lasky & Wu, 2005). Recent studies have reported the implication of 
Notch signalling to be highly active in GSCs in the suppression of differentiation 
and in the maintenance of stem-like properties. Downregulation of Notch and its 
ligands, i.e. Delta-like-1 and Jagged-1, determines a decrease of the GSC 
oncogenic potential, implicating that Notch plays an important role in GSC 
survival and proliferation (Purow et al., 2005).  
BMPs participate to the regulation of proliferation, differentiation, and apoptosis 
in NSCs through their interaction with various signalling molecules among 
which, for example, the hypoxia-inducible factor-1α (HIF-1α) (Pistollato et al., 
2009). Wnt signalling induces BMP expression, which redirects NSCs toward an 
astroglial lineage (Kasai, Satoh, & Akiyama, 2005). In the same way, BMPs 
expression is shown to play an important role in directing glioma stem cells 
(GSCs) astroglial differentiation, inhibiting in this way their tumorigenic potential 
(Piccirillo et al., 2006). Moreover, BMP-2 reduces GSCs proliferation and 
sensitizes them to TMZ through destabilization of HIF-1α(Persano et al., 2013), 
while in vivo delivery of BMP-4 decrease brain tumour growth with a consequent 
reduction in mortality (Piccirillo et al., 2006). Finally, a BMP antagonist, 
Gremlin1, prevents differentiation of GSCs confirming the role of endogenous 
BMP in the maintenance of GSC self-renewal and tumorigenic potential (Yan et 
al., 2014).  
As mentioned, Wnt signalling is important for the regulation of neural stem cells 
expansion and the promotion of astroglial lineage differentiation (Pei et al., 
2012). Downstreamβ-Catenin is a critical factor for proliferation and 
differentiation of GSCs. An aberrant activation of Wnt signalling in GSCs 
induces tumour growth through nuclear localization of stabilized β-Catenin. 
FoxM1/β-Catenin interaction induces the transcription of Wnt target genes like c-
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Myc promoting glioma formation (N. Zhang et al., 2011). Finally, Wnt/β-Catenin 
signalling influences the expression of PLAGL2 leading to the suppression of 
GSCs differentiation and the maintenance of their stem phenotype (Zheng et al., 
2010).  
The EGFR signalling pathway influences NSCs proliferation, migration, 
differentiation, and survival (J. Wang & Yu, 2013). EGFR activation promotes 
GSC proliferation and tumorigenesis by transactivation of β-Catenin, whilst its 
overexpression increases the self-renewal capability of GSCs and consequently 
their tumorigenic potential (W. Yang et al., 2011).  
Sonic hedgehog (Shh) signalling is essential for proliferation, differentiation, and 
survival of NSCs in the subventricular zone (SVZ). Recent studies reported that 
the Shh pathway is highly important in the maintenance of self-renewal and the 
induction of tumorigenesis through the regulation of stemness genes (Ihrie et al., 
2011). Suppression of Shh signalling impairs in vitro self-renewal and in vivo 
tumorigenicity, confirming the dependency of GSCs on Shh signalling for their 
survival. 
 
Figure 1.11 Key molecular pathways regulating steps in glioma stem cell self -renewal, 
differentiation, and gliomagenesis (Liebelt et al., 2016) 
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1.5.1.4 CAV-1 GLIOMA AND CLONOGENICITY 
As previously discussed in 1.4.5, the group lead by Sophie Martin reported that, 
after manipulation of the levels of Cav-1 in a GBM cell line (U87MG), they 
observed that its reduction shifted cells towards a more aggressive phenotype 
whilst the forced expression of caveolin-1 slowed down not only proliferation and 
invasion but also clonogenicity (Martin et al., 2009). They then related this 
phenotype to the interference with a mechanism driven by secreted TGF 
(Cosset et al., 2012). 
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INVASION 
1.5.1.5 INVASION AND STEM CELL PROPERTIES 
Adult stem cells usually reside in the so-called stem cell niche, a physical 
environment, composed of cellular and non-cellular components, which provide 
nutrients and soluble factors and allow stem cells to maintain their quiescent 
status. In the brain, the stem cell niche has been demonstrated to reside in the 
perivascular environment, where NSCs can, in physiological conditions, receive 
nutrients and maintain their undifferentiated and quiescent status. In 
pathological conditions, they can instead receive activating signals in a prompt 
manner if their contribution is required for the production of new neurons or new 
macroglia components (astrocytes and oligodendrocytes) (Ottone et al., 2014). 
Adult stem cell niche effectors originate from the vascular endothelium, the 
molecules that are carried by the circulation, the ECM deposition, and the 
perivascular cell types (Figure 1.12) (Goldberg & Hirschi, 2013).  
In the striatum it has been demonstrated that astrocytes are able not only to give 
rise to other astrocytes but also to de-differentiate in neural stem cells and 
produce new neurons, in response to injuries like stroke  (by the downregulation 
of Notch signalling) or injury (by downregulation of Notch-mediated transcription 
factor Rbpj or overexpression of Sox2) (Magnusson & Frisen, 2016). 
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Figure 1.12 Putative vascular–derived regulators of the adult neural stem cell niche in a brain 
cross-section. With the permission of (Goldberg & Hirschi, 2013). 
 
1.5.1.6 INVASION AND CANCER 
Invasion in cancer is tightly related to EMT. EMT concept has been defined in 
chick embryos for the first time in 1968 by Elizabeth Hey, from Harvard Medical 
School (Hay, 1995). She defined it as a process, essential in embryos, during 
which cells with an epithelial phenotype loose contact with the surrounding cells 
and acquire a mesenchymal phenotype, which enables them to break through 
the basement membrane that separates the different tissues of the embryo, 
allowing the formation of new sub-tissues and, later on, organs (J. Zhang et al., 
2015). Subsequently, researchers connected aberrant reactivation of EMT to 
tumour cell migration and invasion.  
Several distinct molecular processes are required in order to initiate an EMT. 
These include activation of transcription factors for the expression of specific 
cell-surface proteins, cytoskeletal proteins and ECM-degrading enzymes. Some 
of these factors are often used as biomarkers to demonstrate the passage of a 
cell through an EMT, like for example the loss of E-Cadherin and the expression 
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of N-Cadherin, Vimentin, the nuclear localization of β-Catenin and the 
expression of transcriptional markers (summarized in Figure 1.13) (J. M. Lee, 
Dedhar, Kalluri, & Thompson, 2006).  
 
Figure 1.13 EMT markers 
 
1.5.1.6.1 PATTERNS OF INVASION 
The different tumours histological patterns and their behaviour in experimental 
conditions suggest that tumour cells can employ different ways of invasion. 
These molecular mechanisms translate then in cellular mechanisms, depending 
on the cell type and on the interaction with the local microenvironment. 
Tumour cell invasion can be distinguished by two mechanisms: single and 
collective migration (Figure 1.14) (Friedl, Locker, Sahai, & Segall, 2012). Single-
cell migration pattern includes the amoeboid and the mesenchymal sub-
patterns. Amoeboid-like cells can invade as single cells, without interacting with 
the environment, but simply modulating their cytoskeleton in order to adapt their 
shape and access to the available parts of the surrounding tissue. 
Mesenchymal-like cells have a more defined shape and so need to interact with 
the ECM and the other cellular components, through the expression of adhesion 
and proteolytic molecules. They can invade as single cells or as strains, with the 
leading cells creating a path for the other cells.  
The collective migration is typical of mesenchymal-like cells crossing the tissue 
in an organized manner, with the cells in front degrading the matrix and 
interacting with the other elements and the cells in the middle creating a supra-
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cellular contractility system that allows a group of cells to move in a concerted 
manner (Friedl et al., 2012). 
 
Figure 1.14 Patterns of Cancer Cell Invasion. Adopted from (Friedl et al., 2012) with permission. 
 
1.5.1.7 INVASION AND GLIOMAS 
Invasive behaviour is a critical prognostic factor for primary brain tumours. 
Glioma cells display a highly invasive behaviour that leads to the quick 
spreading of a tumour throughout both hemispheres (Brösicke & Faissner, 
CHAPTER 1: GENERAL INTRODUCTION 
 
37 
2015). This feature causes a dramatically shortening of glioma patients lifespan 
(Adamson et al., 2009).  
The peculiarity of glioma cells invasion is their ability to migrate as single cells 
even to distant parts of the brain. Despite precise and accurate surgical 
procedures, the removal of all malignant cells is impossible and the relapsing 
tumours exhibit high resistance to chemotherapy and radiation approaches (Bao 
et al., 2006; Giese, Bjerkvig, Berens, & Westphal, 2003).  
Regarding migration pathways, tumour cells display a tendency for blood vessel 
basement membranes, white matter tracts (such as the corpus callosum) and 
sub-ependymal layers as leading structures (Claes, Idema, & Wesseling, 2007). 
Although their migration along blood vessels, primary brain tumours are not able 
to invade into blood vessel walls. Neither do they invade into the braincase 
(Esiri, 2000). The vascular invasion capacity is a primary requisite for wide 
haematogenous metastasis of malignant neoplasms. This explains the very low 
propensity of primary brain tumours to metastasize outside of the brain to 
systemic organs (Bellail, Hunter, Brat, Tan, & Van Meir, 2004). 
Usually, malignant cell types follow a three-step model of invasion. At the 
invasive front, tumour cells:  
1. detach from the growing primary tumour bulk,  
2. adhere, via specific receptors, to the ECM and  
3. degrade the local ECM components progressively forming a pathway for 
the migration into adjacent tissues.   
Brain tumours follow this model in some ways, even if their peculiar histologic 
pattern of invasion and the unique brain ECM composition, suggest that some 
glioma-specific mechanisms might also be involved (Bellail et al., 2004). 
 
1.5.1.7.1 ECM IN GLIOMAS 
The intercellular space occupies the 20% of the adult brain volume. This volume 
is filled for a further 20% with ECM (Nicholson & Syková, 1998). It is organized 
differently according to the three principal compartments: the basement 
membrane, the perineural nets and the neural interstitial matrix (Figure 1.15) 
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(Lau, Cua, Keough, Haylock-Jacobs, & Yong, 2013). The basement membrane 
is a layer that surrounds and is part of the vasculature and serves as a bridge 
between the endothelial cells and the brain parenchyma; it is composed by 
laminin-nidogen complexes (or entactin), collagen, fibronectin, dystroglycan 
complexes and perlecan. The perineural nets surround neuronal cell bodies 
participating in the maintaining of cellular health and synaptic plasticity; they are 
composed by proteoglycans, tenascins ad other link proteins. The neural 
interstitial matrix is formed by ECM molecules that are dispersed in the 
parenchyma, not associated with basal membranes nor perineural nets; it is 
composed by proteoglycans, hyaluronan, tenascins and link proteins associated 
in a dense network together with small amounts of collagen, elastin and 
adhesion molecules (like laminin and fibronectin). 
 
 
Figure 1.15 The three major compartments of the ECM in the CNS. Adopted from (Lau et al., 
2013) with permission. 
 
Hyaluronan (or hyaluronic acid, HA, Figure 1.15) is the major component of the 
brain ECM. Its high anionic property allows attracting high levels of cations, 
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which bring a high osmotic flux, ensuring an environment rich in water (Alberts 
et al., 2002). Through specific receptors, HA is non-covalently bound to other 
components of ECM, like the proteoglycans belonging to the family of lecticans 
(versican, aggrecan, neurocan, brevican) (Bignami, Hosley, & Dahl, 1993). HA is 
upregulated in tumour stroma and in the advancing edges of a tumour within the 
brain parenchyma. Interestingly, HA has been implicated in the stimulation of 
tumour proliferation and invasion and inhibition of apoptosis (S. H. Cho et al., 
2012), but apparently according to his molecular weight. Indeed, Hirose et al. 
reported that, following Stabili-2 inhibition, HA levels were increased, and 
tumour metastasis was inhibited. However, this tumour suppressor function was 
limited only on small-sized HA (about 40kDa) suggesting a differential role of the 
different sizes of HA (Hirose et al., 2012). Proteoglycans consist of a protein 
core that can be chondroitin-, heparin-, keratin- or dermatan-sulphate. Up to 
now, 25 different proteoglycans have been identified, some of which exclusively 
present in the brain (like the brain-enriched hyaluronic acid binding protein or 
BEHAB, which is expressed only in malignant brain tumours). Important ECM 
components for brain tumour invasion are SPARC (Secreted Protein Acidic And 
Rich In Cysteine Or Osteonectin), that normally works as de-adhesive protein 
and cell cycle inhibitor, Thrombospondin-1 (TSP-1) that has a role in migration, 
invasion, adhesion, angiogenesis inhibition and activation of TGF- β and 
Tenascin C (TN-C), normally present in the white matter, that is upregulated in 
tumour (with increased expression associated to the increase of tumour grade) 
as well as in embryogenesis and wound healing. It is also inversely correlated 
with the expression of fibronectin (Higuchi, Ohnishi, Arita, Hiraga, & Hayakawa, 
1993). 
The lack of fibrillar components, such as collagen (with the exception of the 
perivascular niche), makes brain ECM softer in consistency, in comparison with 
other tissues ECM. (Bellail et al., 2004) 
Hyaluronan has been proven to promote primary brain tumour invasion in vivo 
and migration in vitro through its binding to its two cellular receptors, CD44 and 
RHAMM (Akiyama et al., 2001). Further investigations anyway seem necessary, 
since glioma has been proven to invade along blood vessels, where hyaluronan 
is not present (Bellail et al., 2004). 
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Vitronectin, Osteopontin, REHAB, Tenascin C, Thrombospondin-1 and SPARC 
are upregulated in gliomas, and the last three have been suggested to play a 
role in the promotion of angiogenesis (Higuchi et al., 1993). 
Versican is downregulated in some primary brain tumours and it seems to inhibit 
brain development, even if its mechanisms are unknown (Paulus, Baur, Dours-
Zimmermann, & Zimmermann, 1996).  
 
 
Figure 1.16 Schematic representation of the heterogeneity of the distribution of the various matrix 
proteins in normal brain ECM and in glial tumours 
 
1.5.1.7.2 PROTEASES IN GLIOMAS 
Proteases are secreted by glioma cells, glioma-associated macrophages or 
endothelial cells. They can degrade brain ECM or blood vessels basal lamina 
allowing glioma cell invasion through the brain parenchyma or along blood 
CHAPTER 1: GENERAL INTRODUCTION 
 
41 
vessels. They can also regulate growth and chemotactic factors (or their 
receptors) produced in the normal brain tissue or within a tumour (Mentlein, 
Hattermann, & Held-Feindt, 2012). 
Proteases can be classified according to their mechanism of catalysis (e.g. 
metallo-, serine and cysteine proteases) or according to their molecular structure 
(e.g. the Metzincin proteases share a conserved Met at their active site and a 
Zinc ion at their enzymatic domain). They may be also distinguished, according 
to their protein target, in endopeptidases, specific in targeting internal peptide 
bonds, and exopeptidases, which target the last amino acids of the protein 
chains (aminopeptidases for the N-terminal and carboxypeptidases for the C-
terminal). Whilst cysteine, serine and threonine proteases are named according 
to their target amino acid, matrix metalloproteinases (MMPs) are named after 
their localization (they are secreted in the ECM) and the presence of the Zinc ion 
(they are part of the Metzincin family) in their enzymatic domain, surrounded by 
the three Hys residues that contribute to their function (Nagase et al., 2006). 
Proteases can be also distinguished according to their localization (Figure 1.17): 
intracellular proteases are located in the cytoplasm and intracellular organelles 
and can modulate the cytoskeleton and the intracellular responses; the 
extracellular cell surface-bound proteases are attached to the cell membrane 
and are able to activate receptors (like Notch, ErbB4 and Angiopoietin receptor 
Tie-1) (Gridley, 2007; Sato et al., 1995), cleave adhesion molecules (like MT1-
MMP for CD44), release cytokines or growth factors (like MMP7 for pro-tumour 
necrosis factor- (TNF-) α) and activate other proteases (like plasminogen) 
(Nagase et al., 2006); extracellular secreted proteases in gliomas include 
MMPs, ADAMTS (a disintegrin and metalloproteinase with thrombospondin 
motifs) and serine proteases (like the urokinase/plasmin-type) and Cathepsins; 
they can be secreted as their active form or in a pro-active form that has to be 
activated by other proteases, to consequently cleave and activate other pro-
proteases (typical of the MMPs) (Nagase et al., 2006).  
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Figure 1.17 Example of different types of proteases on tumour (or tumour-associated) cells. 
(Mentlein et al., 2012) 
 
MMPs (Table 1.5) are distinguished in collagenases, stromelysins, gelatinases 
(according to their substrate) and MT-MMPs (bound to the external cell surface). 
Interstitial collagenases cleave preferentially different interstitial collagen 
subtypes. Stromelysins digest basement membrane proteins as substrates, 
whereas gelatinases process primarily cleaved matrix proteins into smaller 
fragments (Herouy, 2004). While the first three categories are secreted as 
inactive forms and then activate by other proteases, the MT-MMPs are cleaved 
and activated into the Golgi and then expressed as functional on the cell 
membrane (Rivera, Khrestchatisky, Kaczmarek, Rosenberg, & Jaworski, 2010).  
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Table 1.5 Selected substrates of different matrix metalloproteinases (MMPs).(Herouy, 2004) 
 
 
The remodelling of the ECM as result of the action of MMPs is actually due to 
the balance between the action of the MMPs and their endogenous 
counterparts, α2-macroglobulin and the tissue inhibitors of metalloproteinases 
(TIMPs). The first one is a big plasma glycoprotein (725 kDa) composed of 4 
identical subunits, that adsorbs and entraps the proteinases, carrying them with 
itself during its specific endocytosis process; the action of this protein is mostly 
carried out in the fluid compartments. TIMPs bind to MMPs and inhibit them. 
They can have different affinity for each MMP but generally, they can inhibit all 
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MMPs. Other proteins that have been reported to inhibit MMPs but their 
mechanisms are not clear yet and sometimes their action is controversial 
(Nagase et al., 2006). 
ADAMs (a disintegrin and metalloproteinases) are members of a family of cell-
surface metalloproteinases. They have to be activated by cleavage and they can 
digest and activate cell surface receptors (Edwards, Handsley, & Pennington, 
2008). An example is ADAM10 that is able to cut and activate HER2 (P. C. C. 
Liu et al., 2006). 
ADAMTs (a disintegrin and metalloproteinases with thrombospondin motifs) are 
able to process procollagen and von Willebrand factor, but also cleave versican, 
aggrecan, brevican and neurocan, thus contributing to the remodelling of the 
ECM (Kelwick et al., 2015). They act basically like members of the ADAM family 
but they have in their structure also the presence of a thrombospondin motif (Le 
Goff & Cormier-Daire, 2011). 
Urokinase-type plasminogen activator (uPA) is a serine-protease produced and 
secreted in the extracellular compartment, where it binds its receptor uPAR 
(uPA Receptor) and is activated by plasmin (J. S. Rao, 2003). uPA is able to 
activate plasminogen in plasmin and to inhibit its inhibitor PAI-1 (plasminogen 
activator inhibitor-1) and consequently is able also to start a positive feedback 
loop of its activation (Mentlein et al., 2012). uPA and Plasmin promote tumour 
growth and invasion through the activation of growth factors, the conversion of 
other proteases (especially MMPs) and by direct degradation of the ECM 
components. It is believed that their action is regulated by growth factors bFGF, 
TGF-α and -β, or chemokines (Mori et al., 2000; Oh, Olman, & Benveniste, 
2009). 
Cathepsin B is a lysosomal cysteine protease that has been showed in glioma to 
degrade laminin and collagen, thus influencing invasion (Natasa Levicar et al., 
2002). High levels of Cathepsin B has been found in both in vitro cell lines and 
tumour samples, with an increased expression according to the tumour grade 
(and consequently it is inversely related to the patient’s overall survival) 
(Demchik, Sameni, Nelson, Mikkelsen, & Sloane, 1999; Strojnik, Kos, Zidanik, 
Golouh, & Lah, 1999). Downregulation of Cathepsin B inhibits invasiveness and 
tumorigenicity of human GBM cell lines (Lakka et al., 2004; Mohanam et al., 
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2001). At the present Cathepsin B is considered as a strong prognostic factor in 
malignant gliomas (Verbovšek, Van Noorden, & Lah, 2015). 
Cathepsin D is an aspartic-protease that has been shown to be linked to glioma 
invasion. Pro-cathepsin D, which is found in the Golgi complex, is enzymatically 
inactive, whilst the intermediate and mature forms are enzymatically active and 
are found in the endosomes and lysosomes, respectively. The latter are involved 
in autophagy and apoptosis pathways, thus playing a crucial role in the control 
of cell and tissue homeostasis (Tan, Peng, Lu, & Tang, 2013). It has been 
showed in glioma that an inhibition of lysosomes exocytosis does not allow its 
excretion of Cathepsin D in the ECM, thus inhibiting invasion (Y. Liu, Zhou, & 
Zhu, 2012).  
Cathepsin K is primarily responsible for the degradation of bone matrix by 
osteoclasts and plays a key role in osteoporosis (Tan et al., 2013). Like 
Cathepsin D it is expelled by the cells through lysosomes. It has been reported 
also that Cathepsin K is able to cleave SDF-1, thus inhibiting it and promoting 
migration of GBM stem-like cells out of their niche (Verbovšek et al., 2015). At 
last, Cathepsin K has been shown to be stimulated by cytokines 
communications, like IL-1 (Verbovšek et al., 2015). 
 
1.5.1.8 INVASION AND CAV-1 
As previously mentioned, Cav-1 is believed to interact with several proteins, 
regulating directly or indirectly their function. These proteins interact with Cav-1 
and with each other in a very articulate manner leading to completely different 
phenotypes, according to nuances in their expression or activation (Goetz, 
Lajoie, et al., 2008). For example (Figure 1.18) (Parat & Riggins, 2012), 
integrins, EGFR and uPA bind Cav-1, that compartmentalizes them into the 
caveolae. Cav-1 –mediated endocytosis regulate the presence of EGFR on the 
surface, but in the same time EGFR is activated by EGF when it is located in the 
caveolae (Senetta et al., 2013), and Cav-1 is phosphorylated by EGF induction 
(Y. N. Kim, Wiepz, Guadarrama, & Bertics, 2000). uPA is activated by the 
interaction of Cav-1, through β1-integrin, with uPAR, regulating both cell 
adhesion and signalling (Src and FAK, members of the Focal adhesion 
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signalling pathway). The formation of these complexes is relevant for migration 
and invasion in glioma. pCav-1 is able also to interact with MT1-MMP, inhibiting 
it, thus controlling its action in the direct ECM degradation and the activation of 
proMMP2. 
 
Figure 1.18 Multiple signalling pathways essential to GBM growth and invasion are controlled by 
Caveolin-1. Adapted from (Parat & Riggins, 2012). 
 
Src is able to phosphorylate Cav-1, in particular when cells are expressing 
mutant or high levels of EGFR (Y.-N. Kim, Dam, & Bertics, 2002). Cav-1 
phosphorylation has been associated also with EGF-mediated anchorage-
independent growth and migration (H Lee et al., 2000). 
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1.5.1.9 INVASION, BIOLOGICAL CONSIDERATIONS FOR ANALYSIS 
A wide range of animal models (zebrafish, mouse, rat) have been developed for 
the study of primary and metastatic tumours; those models included human 
tumour xenografts in immunocompromised mice, environmentally-induced 
models and genetically-engineered ones (Cekanova & Rathore, 2014; Denayer, 
Stöhr, & Van Roy, 2014; Katt, Placone, Wong, Xu, & Searson, 2016). While the 
advantage of the in vivo models is that they capture the complexity of the 
metastatic process in a living system (Figure 1.19), they present the obvious 
difficulty in visualizing the individual steps, making the extraction of quantitative 
mechanistic data very difficult. On the other hand, in vitro models recapitulate 
the physiological reality with less accuracy, with only limited aspects of the 
tumour microenvironment in evidence but make the control of the experimental 
variables easier and allow quantitative analysis. Another advantage of in vitro 
assays is that they are relatively easy handling and highly reproducible. They 
can be used to test cells invasive ability in correlation with genetic manipulation 
and with the interaction with their cellular, chemical, structural and metabolic 
environment (Hulkower and Herber, 2011; Wirtz et al., 2011; Infanger et al., 
2013; Vidi et al., 2013). They can also be used for high-throughput drug 
screening and drug delivery (Friedrich, Seidel, Ebner, & Kunz-Schughart, 2009; 
Weigelt, Ghajar, & Bissell, 2014), being easier (from a technical and 
bureaucratic point of view), cheaper and less controversial than the in vivo 
studies. 
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A 
 
B 
Figure 1.19 Different outcomes in the study of tumour growth in vitro vs in vivo. CalS and CalR cell 
lines growth in vitro (A) and in vivo (B). Adapted from ( Box et al., 2013) with permission. 
 
1.5.1.9.1 IN VITRO INVASION ASSAYS 
Several in vitro invasion assays have been developed. They differ in several 
aspects (economic, easy, representative of physiological condition) and they are 
summarized in Figure 1.20 (Kramer et al., 2013): 
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Figure 1.20 Schemes of commonly used invasion assays. An overview of the technical se tup is 
schematically drawn for each assay and a close-up view is given on its right (inside the circles). 
Arrows indicate the direction of cell movement. Hatched areas symbolize ECM Adapted from 
(Kramer et al., 2013) with permission. 
 
Figure 1.20A: Transwell invasion assay (or Boyden chamber assay). A thin ECM 
coating occludes the pores of the filter membrane. Cells are seeded on the top 
and their ability to overcome it and pass on the other side of the membrane is 
measured. 
Figure 1.20B: Platypus invasion assay. Cells are seeded on top of a thin ECM 
coated surface. In the centre, a silicone plug creates a cell-free exclusion zone. 
After the plug is removed, cells are overlaid by a second thicker layer of ECM. 
The ability of cells to migrate from an outer ring towards the centre is measured.  
Figure 1.20C: 3D cell tracking assay. An automated software coupled with 
optical microscope tracks cells moving through the ECM. The routes through 3D 
space can be recorded and measured. 
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Figure 1.20D: Gelatine degradation assay. Cells are seeded onto a thin 
fluorescently-labelled gelatine layer. Loss of gelatine fluorescence is an indirect 
measure of matrix degradation at the sites of invadopodia formation.  
Figure 1.20E: Vertical gel invasion assay (organotypic skin model). Cells are 
cultured on top of a collagen gel. Cells invading vertically into the collagen 
matrix are counted. 
Figure 1.20F: Spheroid/monodispersed cell invasion assay. A single cell 
suspension of a certain cell type is incubated with preformed non-invasive 
spheroids. Cells are tested for their ability to attach to and eventually invade into 
the spheroid. 
Figure 1.20G: Spheroid confrontation assay. Spheroids from different cell types 
are separately fluorescently labelled and placed next to each other. If one of the 
spheroids presents invasive nature, it will penetrate into the cell clusters of the 
non-invasive cells. 
Figure 1.20H: Spheroid gel invasion assay. Cellular spheroids are embedded 
into ECM gels. Invasive cells can detach from the spheroid and emerge to give 
rise to astral outgrowing structures. 
 
1.5.1.9.2 3D CELL SPROUTING ASSAY 
Of the assays just mentioned, the last one is the one that seems to have more 
potential and therefore it has been chosen for this work. When multicellular 
spheroids are embedded into a 3D ECM (Figure 1.20H), non-invasive cells 
remain compact spheroids with a border at the interphase with the ECM and 
with no sign of invasion even after 2 weeks of culture (Dolznig et al., 2011). 
Invasive cell lines, on the contrary, start to invade into the surrounding matrix 
and display astral outgrowth from the spheroid (Korff & Augustin, 1999). 
Invasion can be followed in time by live imaging. The gels with the invading 
structures can be fixed and processed for immunofluorescence staining and 
confocal microscopy (Sabeh, Shimizu-Hirota, & Weiss, 2009; Wolf et al., 2007; 
Ylivinkka et al., 2017). Alternatively, the gels can be enzymatically degraded, 
and the cells isolated for flow cytometry analysis or to make protein lysates and 
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perform Western blot analysis, but those two are subject to the quantity of 
cellular material that can be recovered. The main advantage of the 3D assay is 
that cells moving through a 3D matrix replicate invasion in vivo (Figure 1.21), not 
only because cells move through the ECM, but mostly because invasion occurs 
from a cell spheroid with well-established cell-cell interactions instead of single 
cells, as it is the situation in human cancers. A variety of different ECM gels 
(Matrigel, collagen I, other BMEs, fibrin, etc) can be commercially purchased as 
liquid forms able to quickly solidify both chemically and/or physically. Different 
substrates can then be chosen according to the study aim. Even without 
fluorescent labelling, the invasion can be followed since the outer border of 
spheroids placed in the gel can be easily detected in a standard inverted light 
microscope allowing kinetic measurements of cell invasion. Some researchers 
embed the spheroids at the gel-medium interface or at the bottom in contact with 
the tissue culture plate. In this case, care must be taken to distinguish real 
invasion from cell movement on the surface of the gel or on the bottom of the 
plate, which are the routes of least resistance preferred by the cells. This can 
falsely give the impression of rapid invasion. Furthermore, the assay requires a 
confident manual skill and some pre-acquired experience with 3D gel systems. 
This system has already been used to confirm essential molecular pathways 
during 3D invasive growth (Sabeh et al., 2009; Wolf et al., 2007) or to measure 
TGF induced invasion (H. P. H. Naber, Wiercinska, Ten Dijke, & van Laar, 
2011). So far there is no spheroid invasion assay commercially available. 
Spheroid formation proceeds from the initial seeding of single cells to 
aggregation. Due to the 3D nature of the growing aggregates, internal chemical 
gradients start building up. This leads to a typical stratification or zonation from 
the core to the spheroid surface as observed in growing tumours in vivo (M. Wu 
et al., 2014). An example can be the developing hypoxia gradient (Mueller-
Klieser, 1984). Due to the limited diffusion of oxygen, a hypoxic area forms at 
the centre of the spheroids, which can then turn into necrosis in larger diameter 
spheroids (Freyer & Sutherland, 1986; Mueller-Klieser, Freyer, & Sutherland, 
1986). When spheroids are small, for a low proliferation rate or at the initial 
formation stages, chemical factors can diffuse freely, and no zonation is 
observed. Further in the growth from small to medium-sized spheroids (with 
diameters of about 150–300 μm), a zonation starts to appear, with the surface to 
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the core being proliferative, the middle being normoxic and quiescent and the 
centre being hypoxic (Khaitan, Chandna, Arya, & Dwarakanath, 2006). The core 
of the hypoxic zone is in large spheroids can become, upon further growth, a 
necrotic zone (Figure 1.21) (Khaitan & Dwarakanath, 2006). From this, it is 
natural to derive that generating the optimal size, to investigate determinants of 
tumour biology, needs careful study of the growth properties and spheroid 
characteristics, considering also cell-type variables (Vinci et al., 2012). Indeed a 
small tight spheroid (200 μm) may already be hypoxic, whilst a loosely 
aggregated one (400-500 μm) may not (Hirschhaeuser et al., 2010). 
Comparative gene expression studies in cells from melanoma grown in 2D and 
3D confirmed the appearance of a hypoxic core through upregulation HIF 
pathway (Sourabh Ghosh et al., 2005). Furthermore, different studies show that 
an induction of secreted factors could potentially contribute to cross-talk 
between more zones within the spheroid (Eckes et al., 1992; Enzerink, 
Salmenperä, Kankuri, & Vaheri, 2009; Klapperich & Bertozzi, 2004). 
Tight control of spheroid size is, of course, necessary to obtain reproducible 
results. The choice of the size of the spheroid can depend also on the scientific 
question. For example, if the aim is the study of tumour initiation, small well-
oxygenated spheroids with a diameter of about 200 μm may be desirable, while 
for studies related to tumour enlargement, where the presence of the 
hypoxic/necrotic core is desirable for the study of the poorly vascularized 
regions, large spheroids are preferred (Thoma, Zimmermann, Agarkova, Kelm, 
& Krek, 2014). 
The field of 3D spheroid technology is rapidly advancing and is beginning to be 
important for both discovery and translational research related to cancer. 
Moreover, spheroids have the potential to become a superior system for drug 
target identification and validation and in general for drug development. 
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Figure 1.21 3D tumour spheroid size, chemical gradients and biological/phenotypical zonation: 
schematic of 3D tumour spheroid monoculture models illustrating how spheroid growth (top) 
generates gradients (middle; e.g. O 2) followed by typical zonation (bottom; yellow: proliferative 
zone, black: necrotic zone). 
 
1.6 THE STUDY OF PROTEIN FUNCTION THROUGH 
EXPRESSION MODULATION 
The key of cancer insurgence is in altered genes (D. D. Rao, Vorhies, Senzer, & 
Nemunaitis, 2009), in sequence (genomics) or in expression (epi-genomics), 
and in the percentage of neoplastic cells displaying such aberrations. The 
variety of possible genes that can be altered in neoplastic conditions increase 
the number of possible therapeutical targets that can be powerful tools for 
cancer treatment. Over the last decade, several new therapeutical approaches 
have been approved, that target aberrantly amplified genes or overexpressed 
proteins. 
The goal of the study of gene and protein expression is to push the 
characterization towards a stratification where groups of patients present altered 
groups of genes and a specific therapeutic sensibility, and ideally towards the 
personalized medicine, according which the stratification is so narrowed that 
every single patient can be associated with a specific therapeutical cocktail. 
Several tools are available for the study of genetic and epigenetic abnormalities 
(C. A. Stein & Cohen, 1988). One of them is based on the inhibition of the 
transcription of specific genes. This can be achieved in different ways.  
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Each patient's tumour genetics can be analysed in a variety of ways. The 
analysis’ goal is to quantitatively determine both gene and protein over- or 
under-expression. Furthermore, functional pathways can be tested and 
integrated into a collaborative network allowing for the identification of new key 
molecular indicators and targets. Such information can potentially allow medical 
carers to prioritize and optimize treatment for cancer patients, and to validate 
alternative biomarkers for prognosis, and therapy. The recent discovery of RNA 
interference (RNAi) presents an invaluable tool for personalized cancer therapy. 
RNAi is basically a natural process through which the expression of a targeted 
gene can be reduced in a highly specific and selective way. 
The idea of using antisense oligo-deoxy-nucleotides as modulators of gene 
expression in research and in cancer gene therapy development was introduced 
more than 30 years ago (Cech, 1986). It is based on the discovery of an 
evolutionarily conserved mechanism of gene silencing, consisting in small 
sequences of double-strand (ds) or single-strand (ss) RNA that recognize and 
complementary bind freshly transcribed mRNAs. This can result in an inhibition 
of the mRNA translation (siRNA) or in its total suppression (miRNA).  
The main steps of the process are summarized in Figure 1.22. miRNAs are 
genomically encoded and are transcribed as long primary double-stranded 
transcripts (pre-miRNAs). The dsRNA is recognized and loaded onto the RNase 
III enzyme Dicer to form the RNA-interfering silencing complex (RISC) (Ichim et 
al., 2004) that cut them in 65nt pre-miRNA first and 22nt miRNA then (H. Wu et 
al., 2011). The non-guide strand is then removed, and the RISC complex 
recognizes the mRNA target through the guide-strand complementarity. The 
target mRNA is finally cleaved at a single site at ca 10 nucleotides from the 5′ 
end of the antisense siRNA sequence and then degraded, whilst the released 
RISC complex is able to recognize a new sequence (Elbashir et al., 2001; J. Liu 
et al., 2004).  
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Figure 1.22 The RNA interference process in mammal cells.  
 
The RNAi process is well studied and generally considered reliable. The 
application of the system to research purposes though encountered some 
challenges, like the delivery way and the efficiency of gene silencing. While the 
first one led to the development of several delivery techniques with different 
degrees of complexity, reliability and effectiveness (that will be discussed further 
on in 1.6.1.3), the latter has been improved through the insertion of mismatches 
that increased the rapidity and the degree of degradation (H. Wu et al., 2011) 
and the developing of two different kind of miRNA precursors, a dsRNA that can 
be directly loaded in the RISC complex (siRNA) and a plasmid vector codifying 
for an hairpin that can be subsequently cleaved and loaded onto RISC. A 
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graphical summary of the different structures and approaches is reported in 
Figure 1.23. 
 
Figure 1.23 siRNA and shRNA approaches.  
 
1.6.1.1 siRNA KNOCKDOWN 
In fluorescence-mediated experiments, the intact siRNA was observed to pass 
into the nucleus within 15 min after the delivery and then to disseminate into the 
perinuclear region of the cytoplasm (Chiu, Ali, Chu, Cao, & Rana, 2004) within 
the next 4 hours. It is not clear however the mechanism that allows the siRNA to 
translocate into the nuclei (D. D. Rao et al., 2009). 
At 48h post-delivery, the majority of siRNA appeared to be degraded with only 
1% fluorescence remaining in the cell. This confirmed the siRNA methodology 
according which the effectiveness of the treatment reaches its peak at 24hours 
post-delivery and decreases after another 24 (Hammond, Caudy, & Hannon, 
2001). 
Duplex siRNA in association with the RISC complex. In the RISC complex, the 
two strands of the duplex are separated, resulting in the departure of the 
passenger strand. The RISC with single-stranded guide strand siRNA is then 
able to execute multiple rounds of RNA interference (Robb & Rana, 2007). 
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1.6.1.2 shRNA KNOCKDOWN 
shRNAs, unlike siRNAs, are synthesized in the cell nucleus, where they are also 
processed and transported to the cytoplasm for the incorporation into the RISC 
complex for activity. The shRNA design aim is to create a template that is 
compatible with the cellular machinery in order to be processed in the microRNA 
maturation pathways (D. D. Rao et al., 2009).  
shRNA is transcribed by the endogenous RNA polymerase II or III in the 
nucleus. The primary transcript contains a hairpin-like stem-loop structure that is 
processed by a complex containing Drosha, an RNase III and the double-
stranded RNA-binding domain protein DGCR8 (Y. Lee et al., 2003). The 
complex processes the long primary transcripts into individual shRNAs with an 
extra 2 nucleotides overhanging at the 3’ extremity (H. Zhang, Kolb, Brondani, 
Billy, & Filipowicz, 2002). The processed primary transcript is the pre-shRNA 
molecule which is transported to the cytoplasm by Exportin 5 (Cullen, 2004; Y. 
Lee, Jeon, Lee, Kim, & Kim, 2002). In the cytoplasm, the pre-shRNA is loaded 
onto Dicer and TRBP/PACT for the loop of the hairpin to be processed off to 
form a double-stranded siRNA the 2nt overhanging (Y. S. Lee et al., 2004; Lund, 
Güttinger, Calado, Dahlberg, & Kutay, 2004; Yi, Qin, Macara, & Cullen, 2003). 
The Dicer-containing complex then coordinates loading onto the Ago2 protein 
containing RISC as described earlier for siRNA. After loading onto RLC and 
passenger strand departure; both siRNA and shRNA in the RISC, in principle, 
should behave the same. 
The advantage of shRNA is in efficiency of the loading onto the RISC complex, 
which is approximately 10x more efficient than the siRNA system (Sano et al., 
2008). Further on the gene silencing resulting from transfected synthetic siRNAs 
are usually transient whilst the shRNA sequence can be inserted in a plasmid 
carrying a drug resistance. In this way, the addition of the drug allows the 
survival only of cells that contain and are actually transcribing the plasmid and 
therefore the cells that express the shRNA sequences, making this a step 
towards a more durable silencing effect. Of course, on the other hand, the 
continuous pharmacological stimulus of the cells can induce phenotypes that are 
dissimilar from the normal physiological conditions, so it’s important to plan 
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carefully a negative control, whose aim is to exclude every phenotypical change 
that doesn’t derive from the silencing.  
 
1.6.1.3 RNAI DELIVERY METHODS 
Not only the efficiency of processing of the siRNA/shRNA and their chemical 
and biological stability is important, but also the efficiency in the entry of the 
molecules into the target cells. Nucleic acids, indeed, have a net negative 
charge and, in order to enter the cell, they must come into contact with a lipid 
bilayer of the cell membrane, whose head groups are also negatively charged 
(Dalby et al., 2004). Three major technologies have been established to 
introduce siRNA into target cells. 
 
1.6.1.3.1 TRANSFECTION 
The siRNA molecules can be complexed with carriers that allow them to cross 
cell membranes in a process called transfection. Typical carriers are packaging 
particles called liposomes, that facilitate the cellular uptake of siRNA, through 
cationic lipids mimicking the physical characteristics of natural phospholipids. 
The siRNA-lipid complexes protect siRNA from enzymatic degradation and allow 
efficient endocytosis by the cell (W. J. Kim, Chang, Lee, & Kim, 2007; Love, 
Moffett, & Novina, 2008). 
Recently, they have been introduced synthetic cationic polymer-based 
nanoparticles, with a size of  100nm. They have been developed to enhance 
the transfection efficiency with the combined reduction of cytotoxicity, in 
comparison with the liposomes used so far (Aigner, 2006). They are composed 
of more than one layer of lipid molecules, each with different physical and 
chemical characteristics which allow a  better fusion with the cell membrane and 
entry into the cell, an enhanced release of RNAi molecules inside the cell, and a 
reduced intracellular degradation of RNAi-nanoparticle complexes (Dalby et al., 
2004). A further advantage of polymer nanoparticles consists in their ability to be 
modified with certain ligands for the increased stability in vivo, the reduce 
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immunogenicity and the delivery to specific cell types, (Aigner, 2006; Behlke, 
2006). 
siRNA/shRNA can be conjugated also with other hydrophobic molecules, such 
as cholesterol, that seems to improve in vitro cellular uptake and in vivo 
pharmacological properties of siRNA (C. Zhang et al., 2006). Another method 
involves the use of cationic cell-penetrating peptides (CPPs), such as MPG, 
transportan or penetratin, to the siRNA by covalent or electrostatic interactions. 
The strong positive charge on these peptides promotes the condensation of 
negatively charged siRNA, allowing their delivery with high efficiency and 
minimal toxicity (C. Zhang et al., 2006). Highly branched histidine-lysine polymer 
peptides, dedrimer molecules and artificial virus particles, have also been 
applied for the self-assembly of siRNA into nanoscale particles that are able to 
transport siRNA into the cells with high efficiency, low cell toxicity and enhanced 
cellular internalization (Patil et al., 2008). 
 
1.6.1.3.2 ELECTROPORATION 
Cell membranes, with their negatively charged phospholipids both outside and 
inside the bilayer, are susceptible to influence by an applied electric field. A brief 
but powerful electric pulse can reorient the lipid molecules and provoke a 
thermal phase transition, that creates transient hydrophilic pores. The temporary 
loss of the semi-permeability of cell membranes allows the escape of 
intracellular ions and metabolites, and the simultaneous uptake of drugs, 
molecular probes, and nucleic acids from the outside. 
The cell delivery of siRNA based on electroporation has been developed to 
resolve some limitations of the liposome-based transfection associated with the 
specific cell line, such as primary and suspension cells. Despite the high 
efficiency of nucleic acid transfer, electroporation can induce high cell death 
(Tsong, 1991). Therefore, the individual parameters of electroporation (such as 
voltage, length of the electric pulse, and the number of pulses) must be 
optimized for each cell types. 
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1.6.1.3.3 VIRAL GENE TRANSFER 
As reported earlier on, the gene silencing resulting from transfected synthetic 
siRNAs is usually transient. To increase the effect of the gene silencing and 
allow semi- and long-term experiments, an RNAi approach based on DNA 
expression plasmids (shRNA) can be used to stably express siRNA in cells. 
(Rutz & Scheffold, 2004). 
The delivery of siRNA from DNA templates can be carried out by both liposomes 
and electroporation. However, the most efficient way seems to be the use of 
several recombinant viral vectors based on retrovirus, adeno-associated virus, 
adenovirus, and lentivirus. These vectors have been engineered and optimized 
to allow the easy entry of siRNA into cells that are difficult to transfect. Also, 
some synthetic viral vectors, like the lentiviral and adenoviral ones possess an 
ability to integrate the shRNA into the cell genome, thereby leading to stable 
siRNA expression and long-term knockdown of a target gene, with virtually no 
need for a continuous pharmacological treatment (Y. Shi, 2003). 
One of the most popular is the lentiviral system, which aims to integrate anti-
target gene shRNA coding DNA into the genetic patrimony of the cellular host. 
The sequences are inserted together with a puromycin resistance-carrying gene 
that allows the selection of the successfully transfected cells. (see map in Figure 
1.23).  
The plasmid is packaged into viral particles by lipo-transfecting the plasmid into 
so-called packaging cells, together with other plasmids necessary for the 
assembly of the viral particles. The plasmid carrying the shRNA sequence is 
replication incompetent, if not together with the other plasmids, making it “self-
inactivating” once it is integrated. The lentiviral systems still used derive from the 
HIV-1 genome and are the 2nd and the 3rd generation ones. In both systems, 
the lentiviral genome has been split in separate plasmids, to neutralize the 
uncontrolled-replication risk.  
In the 2nd generation vectors, a single packaging plasmid encodes Gag and Pol 
(for the viral structure) and Rev and Tat (essential regulatory elements) genes. 
The transfer plasmid contains the viral LTRs (long-term repeats that allow the 
insertion in the genome) and psi packaging signal. Unless an internal promoter 
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is provided, gene expression is driven by the 5'LTR, which is a weak promoter 
and requires the presence of Tat to activate expression. The envelope protein 
Env (usually VSV‐G due to its wide infectivity) is encoded on a third, separate, 
envelope plasmid. 
After the packaging of the viral particles containing the transfer vector, they are 
released into the medium and collected. When added to the target cell culture 
(or in vivo system) they penetrate the cells with high efficiency and release the 
transfer plasmid that is then able to integrate into the genome of the cells. The 
plasmid is carrying a resistance for puromycin, which allows the selection of the 
cells whose genome contains the integrated transfer vector. After the selection, 
the puromycin administration is suspended, the CMV promoter allows a high 
transcription of the inserted DNA and cells are tested for the expression of the 
silencing-targeted protein. 
 
1.6.1.4 CRISPR KNOCKDOWN/KNOCKOUT 
Concomitant to the development of RNAi, several other techniques for stable 
gene expression modifications have also been developed, in the branch so-
called “gene editing techniques” (Boettcher & McManus, 2015). One of these 
approaches is based on the use of prokaryotes Clustered Regularly Interspaced 
Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) 
systems for nucleic acid editing. The application of CRISPR/Cas9 was 
established very recently (2012–2013), but it has revolutionized the entire field 
(Cong et al., 2013; Jinek et al., 2012; Mali et al., 2013), starting replacing the 
RNAi system, that dominated the mammalian gene manipulation field for more 
than 15 years (Unniyampurath, Pilankatta, & Krishnan, 2016).  
The CRISPR/Cas systems is a natural immune defence strategy in prokaryotes 
against the invasion of non-self-DNA, like viruses and plasmids and it occurs in 
a sequence-specific manner (Barrangou et al., 2007; Sorek, Kunin, & 
Hugenholtz, 2008).  
The CRISPR/Cas system (Figure 1.24) is composed by several DNA repeats 
fragmented by spacers derived from foreign DNA, and multiple Cas genes, that 
can be nucleases or not (Haft, Selengut, Mongodin, & Nelson, 2005). The 
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spacer represents the code for the recognition of the foreign genetic element, 
and so for the identification of foreign DNA entering the host cell. 
 
Figure 1.24 CRISPR structure and function (Sorek et al., 2008). 
 
In the CRISPR/Cas system can be distinguished three steps (Jiang & Marraffini, 
2015; van der Oost, Jore, Westra, Lundgren, & Brouns, 2009). During the 
“spacer acquisition” step, the cell recognises foreign DNA and incorporates it 
among the CRISPR loci to for the spacers (Garneau et al., 2010). Then, during 
the “crRNA maturation” step, the prokaryotic organism will transcribe and 
generate mature CRISPR RNA (crRNA) containing the CRISPR repeats 
integrated with the spacers (Brouns et al., 2008; Carte, Wang, Li, Terns, & 
Terns, 2008; Deltcheva et al., 2011; Gesner, Schellenberg, Garside, George, & 
MacMillan, 2011). Finally, in the “target interference step”, the crRNA will detect 
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homologous DNA sequences when newly introduced, for example during the 
infection of another virus having the same sequence. Once the foreign DNA is 
recognized by the crRNA, the extra genetic material will be degraded by a 
cellular machinery, determining protection against the foreign DNA (Barrangou 
et al., 2007; Garneau et al., 2010; Semenova et al., 2011; Wiedenheft et al., 
2011).  
The 10 superfamilies of Cas proteins participate differently in all the steps of the 
CRISPR/Cas system (Makarova et al., 2011). Cas1 and 2 are involved in the 
spacer acquisition (Datsenko et al., 2012; Yosef, Goren, & Qimron, 2012), Cas6 
and 5d in the crRNA maturation (Carte et al., 2008; Haurwitz, Jinek, Wiedenheft, 
Zhou, & Doudna, 2010; Naito & Ui-Tei, 2013), while several others are part of 
the interference complex.  
The classification of the CRISPR/Cas systems has been structured in three 
types according to the conservation and composition of the Cas genes 
(Makarova et al., 2011; Tsui & Li, 2015). Type II is only present in bacteria, 
whilst types I and III are present in both bacteria and archaea. The two main 
differences between the three types of CRISPR/Cas systems are: 
- the target: Type I targets only DNA while Type II and III can target both 
DNA and RNA;  
- and the subunit composition: Type II system has two different RNA 
subunits in complex with a single Cas9 protein whilst Type I and III have 
multiple Cas proteins in complex with a single RNA. 
Since Type II is the simplest of the three systems, with for instance only Cas9 
necessary for the recognition and the incorporation of the foreign DNA into the 
spacers, it is the one that has been widely adapted for eukaryotic gene editing 
(Cong et al., 2013; Jiang & Marraffini, 2015; Mali et al., 2013). Furthermore, the 
type II CRISPR/Cas system requires only the tracrRNA cofactor, the crRNA and 
Cas9 to induce gene editing, while all others need multiple components, whose 
regulatory mechanisms are still not fully understood (Haft et al., 2005; Sorek et 
al., 2008; Tsui & Li, 2015). 
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1.6.1.4.1 CRISPR EFFICIENCY 
Different technologies can be used to insert the CRISPR/Cas9 system into the 
target cells/tissues (Figure 1.25). DNA codifying for all the components can be 
transfected in a plasmid vector. The DNA must be transported in the nucleus, 
transcribed (for the tracrRNA and the crRNA) and translated for the Cas9 and 
the machinery has to be assembled to achieve its active function. Due to its 
length and articulation, this process is not very efficient, with only 1% of the cells 
targeted successfully, and can lead to off-targets. This has led to the 
development of systems that can allow the skipping of some of those steps. In 
particular, it is possible to transfect cells with mRNA codifying for the Cas9 
protein and the other components, so to jump the transcription system, and also 
to introduce (generally by electroporation) the Cas9 protein ready to work into 
the cells associated already with the tracrRNA and the crRNA in 
ribonucleoproteins (RNPs), in order to allow its immediate functionality. Of 
course, those systems have as an advantage a higher efficiency and specificity 
in the gene manipulation but also a higher cost, as shown in Figure 1.25.  
 
Figure 1.25 CRISPR/Cas9 delivery systems. 
 
1.6.1.5 RNAI VERSUS CRISPR 
The CRISPR/Cas9 system has been recently and widely accepted as a reliable 
and powerful tool for gene editing, both because of its simplicity and wider 
potential. So far, RNAi has been the major tool for several genetic applications 
requiring gene expression modulation, but the rapid growth and use of 
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CRISPR/Cas9 in mammalian systems certainly implies the possibility for this 
system to integrate, if not replace, the RNAi technology. 
RNAi represented a revolution for reverse genetic screens, leading to an 
explosion of gene-function studies number and variety, including cell signalling, 
host-pathogen interactions, immune response, and cancer mechanisms. Many 
reports indicate now that a CRISPR/Cas9 based technology could also be used 
for this purpose (Parnas et al., 2015; Shalem, Sanjana, & Zhang, 2015; T. Wang 
et al., 2015; Tim Wang, Wei, Sabatini, & Lander, 2014). However, there are still 
several advantages to RNAi over CRISPR/Cas9 that makes the latter in need of 
further development. 
Even if both technologies have comparable delivery efficiency for in vitro cell 
culture systems, in terms of efficiency in altering gene expression, both may 
perform differently. RNAi has a relatively very high transfection efficiency in 
suppressing gene expression with >70% knockdown of the intended target 
mRNAs. CRISPR/Cas9 efficiency is instead in the range of 1% to 79% (Duda et 
al., 2014; Liang et al., 2015; Swiech et al., 2014). Such a heterogeneous 
efficiency means that CRISPR/Cas9 transfected cells should be selected 
according to their gene modification before application for genetic screens. 
RNAi has another advantage, which is that it can be used for genetic screening 
in both immortalized cell lines, and short-living primary cells (that often do not 
live longer than a week ex vivo), whilst the use CRISPR/Cas9 systems in short-
living primary cells will be less practical because there may not be enough time 
for selecting the modified-gene population before performing the phenotypic 
assays. 
Furthermore, another limitation of CRISPR/Cas9 system is that both the alleles 
in the targeted cells must be targeted in order to completely modify the 
expression of one gene, which reduces the efficiency of the process. If one 
considers that most of the widely used immortalized human cell lines are 
aneuploidy (with more than two alleles) gene deletion process becomes even 
more complex. RNAi instead targets transcripts, so it can cause a uniform and 
efficient gene repression.  
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Also, the time both techniques need for the displaying of the intended effect 
varies greatly, and this may lead to different choices regarding specific 
applications. RNAi exhibits rapid effects on gene expression. RNAi treatment 
can result in significant attenuation of gene expression in around 24h. However, 
the need for a selection step for cells treated with CRISPR/Cas9 may take up to 
a month or more depending on the specific needs, the gene effect on cells 
proliferation and the cells proliferation tendency per se (Gilbert et al., 2013). 
The big advantage of CRISPR over RNAi is that the first induces an absolute 
null phenotype that is irreversible (Jiang & Marraffini, 2015), while the second 
produces a reversible and incomplete modification of gene expression (Bosher 
& Labouesse, 2000; Gilbert et al., 2014; Konermann et al., 2014; Qi et al., 
2013). From this point of view, CRISPR/Cas9 seems to be ideal for the 
systematic study of gene function. 
Moreover, the selection step of CRISPR allows an unequivocal phenotype to be 
studied whilst with the RNAi a polyclonal population is produced. This may mean 
different off-targets. Anyway, the basic CRISPR technology is not off-target risk-
free, as we discussed previously. 
The design of RNAi sequences need only information about the sequence of the 
gene transcript, with lower regard for information about the corresponding gene, 
whilst CRISPR, on the contrary, requires a full understanding of the gene 
sequence information, with exons and intron alternating and often promoters 
sequences (Cong et al., 2013; Jiang & Marraffini, 2015).  
Furthermore, the RNAi system can be literally used to target any protein-coding 
gene, whilst the CRISPR/Cas9 system requires a short proto-spacer-adjacent 
motif at the target gene site, that makes the application of CRISPR/Cas9 bound 
to the presence of this sequence (Jinek et al., 2012). 
As mentioned before, it is widely agreed that RNAi has off-target effects (Ui-Tei, 
2013). Even if the new design principles that have been elaborated have greatly 
reduced off-target effects, there is still no methodology that can completely 
eliminate the RNAi-induced off targets (Naito & Ui-Tei, 2013). Unfortunately, the 
CRISPR/Cas9 system in mammalian cells has not overcome the issue. There 
are indeed several reports that have recently identified the off-target potential of 
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the CRISPR technology (S. W. Cho et al., 2014; Frock et al., 2014; Fu et al., 
2013; Lin et al., 2014). The scientific community, both academy and companies, 
have modified the methodology in order to minimize the potential off-target risks 
(Ran et al., 2013). For instance, as mentioned earlier, Cas9 has been proposed 
to be delivered directly as mRNA, or coupled as gRNA-Cas9 in form of 
ribonucleoprotein complex; those systems should reduce off-target since they 
have a shorter cellular life in comparison to plasmid-based delivery (Chang et 
al., 2013; S. Kim, Kim, Cho, Kim, & Kim, 2014; Schumann et al., 2015). 
Moreover, a recent study reported a minimal off-target effect achieved through 
the generation of a mutant Cas9 (Kleinstiver et al., 2016).  
All of this indicates that the CRISPR/Cas9 system has room for technology 
implementation and refinement in order to reduce the disadvantages and 
improve the advantages that differentiate it from the RNAi approach. 
1.7 SCOPE OF THE PROJECT 
As mentioned in 1.4.5, there still a lack of understanding about the role of Cav-1 
in high-grade glioma. In light of the increasing molecular stratification, having a 
better understanding of the caveolae major component may contribute to the 
future classifications, with impact on both research and clinical practice. 
The hypothesis of the present work is that Cav-1 serves as a modulator of the 
functional properties of cancer stemness in high-grade glioma, grade IV 
astrocytomas, either in a suppressor or promoter manner dependent upon 
context.  
Specifically, that in sub-populations of glioma cells Cav-1 has a critical role in 
interplay with other pro-stemness molecules to impart cancer stem cell–like 
activity, including the ability for self-renewal and increased clonogenicity and the 
ability to migrate and invade tissue; particular attention is focused upon the 
impact of Cav-1 on invasion. The results may reveal Cav-1 protein to be a 
potential candidate target for therapy. The hypothesis will be tested through the 
following experimental objectives: 
Objective 1. Create stable Cav-1 knockouts and knockdowns of 
established glioma cell lines. Here we created a series of stably transfected 
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shRNA anti-Cav-1 glioma cell lines (shRNA plasmid and lentiviral transfection) 
and genetic knockouts (CRISPR technology) which allowed explicit 
understanding of the role of Cav-1 biology in glioma stem-cell phenotype and 
function (Chapter 3).  
Objective 2. Examine the impact of Cav-1 upon functional characteristics 
of cancer cell aggressiveness in vitro. Stem-like functionality has been 
analysed, which includes: self-renewal and clonogenicity (Chapter 3), and the 
ability to migrate and invade (Chapter 4 and 5).  
Objective 3. Explore the molecular mechanism involved in Cav-1-driven 
changes in invasion of cancer cells. This has been achieved through the 
study of molecular pathways in Cav-1 expressing and non-expressing cell lines, 
and in aggressive and non–aggressive samples (Chapter 5). 
Objective 4. Study the impact of Cav-1 expression in GBM patients within 
online dataset. The role of Cav-1 in GBM has been explored by accessing one 
of “The Cancer Genoma Atlas” datasets for GBM. The association between 
Cav-1 and molecules involved in GBM invasion have been also explored. This 
could be used to get an insight into mechanisms and confirm in vitro data. 
(Chapter 6). 
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This represents a brief summary of methods common across a number of 
chapters. Appendiced also provide detailed procedures and materials. When 
relevant, each chapter will also describe unique materials and methods pertinent 
to that work. 
 
2.1 CELL LINES 
Eight human GBM cell lines have been used in this project (Table 2-1). 
Specifically, the human adult GBM cell lines from Uppsala, U87Uppsala (=U87) 
and U373MG (=U373) (Pontén & Macintyre, 1968), three are adult GBM-derived 
cell lines isolated in SEBTA (South of England Brain Tumour Alliance) facility 
provided by Professor Geoff Pilkington, from Portsmouth University, UP007, 
UP019 and UP029, while the other three have been provided by the SEBTA 
facility and correspond to infra-tentorial paediatric brain tumours, IN699 (Ward et 
al., 2010), SF188 (Trent et al., 1986) and KNS42 (Iwao et al., 1987).  
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Table 2-1- Cell lines under examination  
 Cell Line Origin Patient details Type (Grade) Genetic information available Source 
1 U87 
U. Uppsala 
(SE) 
Adult Adult GBM (IV) 
TP53 wt/ PTEN mut/ p16 del/ p14ARF 
del/CDKN2A mut 
ECACC 
2 U373 
U. Uppsala 
(SE) 
Adult Adult GBM (IV) TP53 wt/ PTEN null/ p16 wt/ p14ARF wt ECACC 
3 UP007 SEBTA Adult Adult GBM (IV)  SEBTA 
4 UP019 SEBTA Adult Adult GBM (IV)  SEBTA 
5 UP029 SEBTA Adult Adult GBM (IV)  SEBTA 
6 IN699 
Institute of 
Neurology 
(London, UK) 
Adolescent 
(15-year-old male) 
Supratentorial 
paediatric GBM 
 SEBTA 
7 SF188 
U. Arizona 
(AZ, USA) 
Child 
(8-year-old male) 
Frontal paediatric 
GBM (IV) 
TP53 wt/ PTEN wt/ p16 wt/ p14ARF wt SEBTA 
8 KNS42 
U. Kyushu 
(JP) 
Adolescent 
(15-year-old male) 
Frontoparietal 
anaplastic 
astrocytoma (IV) 
TP53 mut/ PTEN wt SEBTA 
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2.2 GENERAL CONSUMABLES AND REAGENTS  
Unless otherwise stated tissue culture plastics were purchased from Corning 
Costar (Hemel Hempstead, UK); liquid materials for cell culture such as media, 
serum and antibiotics from Invitrogen Life Technologies, Thermo Fisher 
(Paisley, UK); chemicals and reagents of the highest grade from Fisher 
Scientific (Loughborough, UK) or Sigma (Poole, UK).  
 
2.3 ROUTINE CELL CULTURE 
All cell lines were grown on tissue-culture treated plastic in Dulbecco’s Modified 
Eagle Medium (DMEM) (supplemented with 10% Foetal Bovine Serum (FBS) 
and 1% antibiotics Penicillin/Streptomycin). Cells were seeded with a density 
comprised between 5,000 and 10,000 cells/cm2 and cultures were maintained in 
a humidified 5% CO2 atmosphere. Cells were passaged twice each week with a 
protocol that foresees Phosphate Buffer Saline (PBS) washing, trypsinization (1x 
Trypsin-EDTA for 5min at 37oC), inactivation by FBS addition, centrifugation at 
200g for 5 min and cell resuspension in an appropriate volume of medium for 
cell counting (Disposable FastRead Counting Slides - Immune Systems Ltd, 
Paignton UK) prior to re-seeding onto new plastic ware.  
 
2.4 WESTERN BLOT 
To generate cell lysates, pellets were first washed twice with PBS and an 
opportune volume of lysis buffer (see APPENDIX 1) was added and kept for 30 
min with vortexing steps every 5 min. At the end of the incubation, the mixture 
was centrifuged at 4°C for 7 min (10,000g). The supernatant was aliquoted and 
stored at -20°C until required.  
Total protein content in the cell lysates was quantified using the Coomassie Plus 
Protein Assay Reagent (Thermo Scientific cat. 1856210) The same procedure 
was followed for the construction of the BSA calibration curve (Albumin 
Standard- Thermo Scientific, cat. 23209). 
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All samples were incubated at 37°C and the absorbance of the resultant reaction 
at 30 min was measured at 495 nm with a LT5000MS ELISA reader (Labtech 
International Ltd, Uckfield UK). Using the calibration curve, the unknown protein 
concentrations were calculated.  
Gel electrophoresis was undertaken using the Mini-protean II apparatus 
(BIORAD, Hertfordshire, UK) and 10% precast Mini-PROTEAN® TGX™ Gels. 
Each gel was placed in the apparatus submerged in running buffer (see 
APPENDIX 1) and electrophoresed at 90V for 15 min and then at 150V for 2 h. 
Gel markers were added to monitor the run and to verify the bands molecular 
weight during the reading (Figure 2.1). 
 
 
Figure 2.1 Molecular weight markers used for the execution and the analysis of western blots. A: 
Bio-Rad Precision Plus Protein Kaleidoscope Standard (BIORAD- cat. 161-0375) B: SeeBlue® 
Plus2 Pre-Stained Protein Standard (Life Technologies- cat. LC5925). C: MagicMark™ XP 
Western Protein Standard (Life Technologies- cat. LC5602). A and B were interchangeably used 
for the monitoring of the execution of the Western Blot, while C for the reading and the following 
analysis. 
 
The blotting was undertaken using a semi-dry blotting approach (Bio-Rad 
Transblotting system). All the components had previously been submerged in 
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blotting buffer (see APPENDIX 1) and positioned into the chamber, in contact 
with the nitrocellulose membrane. The blotting was performed at 25V for 30 
minutes. 
The nitrocellulose membrane was then removed and washed in washing buffer 
(see APPENDIX 1) before being submerged in blocking buffer (see APPENDIX 
1) for 1 hour. The membrane was then washed briefly and incubated, with 
shaking, for 16 hr at 4°C in the presence of the primary antibody, following 
specifications of manufacture. After the incubation with primary antibody the 
membrane was washed three times for 10 minutes at room temperature and 
then incubated for 1 hr at room temperature with the HRP-linked anti-rabbit or 
anti-mouse IgG secondary antibody (#7074S or #7076P2, Cell Signalling) at a 
dilution of 1:10,000 in blocking buffer. Subsequently, the membrane was 
washed three times for 10 minutes each and the signal detected using 
SuperSignal™ West Dura Extended Duration Substrate (Life Technologies Ltd, 
Paisley UK) and imaged and quantified on a ChemiDoc XRS+ (BIORAD, 
Hertfordshire, UK). A mouse anti-human β-actin monoclonal antibody (#A1978, 
SIGMA) has been used as housekeeping to normalize the expression of the 
target protein. 
 
2.5 STATISTICAL ANALYSIS 
For comparisons between two experimental groups, a Student’s T-Test 
(unpaired two-tailed) was employed with statistical significance set at P < 0.05. 
For comparisons involving more than two experimental groups, a one-way 
ANOVA statistical analysis followed by an appropriate post hoc test was applied. 
When all possible pairwise comparisons have been made and the group sizes 
are equal then a Tukey’s multiple comparison test has been performed. If the 
groups are of unequal size a Tukey-Kramer test was used. When multiple 
groups were compared to a single control treatment, a Dunnett test was applied. 
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3.1 INTRODUCTION 
The study of gene and protein expression in cancer allows the determination 
and characterization of sub-groups of patients presenting altered sets of genes 
and a specific therapeutic sensitivity. This could potentially stimulate specific 
therapeutical approaches that do not refer only to the broad diagnosis but also 
to the specific gene set and heterogeneity of the single patients. 
Several tools are available for the study of genetic and epigenetic abnormalities 
(C. A. Stein & Cohen, 1988). One of them is based on the inhibition of the 
transcription of specific genes. This can be achieved in different ways, among 
which we selected, for this work, the RNAi-mediated gene knockdown and the 
CRISPR-mediated knockout. 
Both took inspiration from physiological cellular processes. The RNAi is an 
evolutionarily conserved mechanism of gene silencing (Cech, 1986), consisting 
in small sequences of double-strand (ds) or single-strand (ss) RNA that are able 
to recognize and complementary bind freshly transcribed mRNA. This can result 
in an inhibition of the mRNA translation (siRNA) or in its total suppression 
(miRNA). 
The RNAi process is well studied and generally considered reliable, with a 
variety of challenges that have been addressed and overcome in the past, like 
the delivery way and the efficiency of gene silencing. Several delivery 
techniques with different degrees of complexity, reliability and effectiveness 
(discussed in Chapter 1) have been developed, and the efficiency has been 
improved by the insertion of mismatches that increased the rapidity and the 
degree of degradation (H. Wu et al., 2011). Two different kinds of miRNA 
precursors can be used, a dsRNA that can act directly once inserted in the cell, 
and a plasmid vector codifying for a sequence that can be then cleaved and be 
functional.  
The delivery of siRNA from DNA templates can be carried out by both liposomes 
and electroporation. However, the most efficient way seems to be the use of 
several recombinant viral vectors based on retrovirus, adeno-associated virus, 
adenovirus, and lentivirus. These vectors have been engineered and optimized 
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to allow the easy entry of siRNA into cells that are difficult to transfect. Also, 
some synthetic viral vectors, like the lentiviral and adenoviral ones possess an 
ability to integrate the shRNA into the cell genome, thereby leading to stable 
siRNA expression and long-term knockdown of a target gene, with virtually no 
need for a continuous pharmacological treatment (Y. Shi, 2003). 
One of the most popular is the lentiviral system, which aims to integrate anti-
target gene shRNA coding DNA into the genetic patrimony of the cellular host. 
The sequences are inserted together with a puromycin resistance-carrying gene 
that allows the selection of the successfully transfected cells.  
CRISPR, on the other hand, is based on the use of prokaryotes Clustered 
Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-
associated protein 9 (Cas9) systems for nucleic acid editing. This system is a 
natural immune defence strategy in prokaryotes against the invasion of non-self-
DNA, like viruses and plasmids and it occurs in a sequence-specific manner 
(Barrangou et al., 2007; Sorek et al., 2008).  
The principle of the technology is that DNA sequences corresponding to the 
target gene are inserted among the spacers, so that the exogenous Cas9 can 
recognize it as foreign DNA and cut the genomic sequence, leading to a genetic 
knockout.  
Again, like for the RNAi, the sequences can be inserted in different ways, like as 
DNA plasmids codifying for Cas9, or mRNA ready to be translated or the Cas9 
protein itself. The last delivery methods allow increased efficiency and 
specificity. 
Once the genetic knockdown/knockout has been assessed, generally via 
Western Blot or Real-Time PCR, cell properties can be tested to determine if the 
genetic modification had an impact on the phenotype of the cells under 
examination. Basic tests include cell cycle and cell proliferation, but also a 
change in morphology can indicate a change in the phenotype. For example, if 
cells pass from a mesenchymal to an epithelial shape, it may mean that some 
pathways related to EMT have been indirectly manipulated. 
In terms of stem cell properties in cancer, clonogenicity is one of the main 
properties tested (Suksuphew & Noisa, 2015). As discussed in Chapter 1, this 
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property represents the ability of single cells to give rise to a new tumour in vitro 
or in vivo (Franken, Rodermond, Stap, Haveman, & van Bree, 2006). In case of 
high-grade gliomas, this would be particularly important since brain tumour cells 
display the ability to invade as single cells and to give rise to new tumours in 
other sides of the brain (Brösicke & Faissner, 2015).   
 
3.2 SCOPE OF THE CHAPTER 
The hypothesis of this thesis is that Cav-1 serves as a cancer stem cell tumour 
modulator able to influence cancer stem cell functions either in a suppressor or 
promoter manner dependent upon context. Ultimately the first milestone in the 
project was to evaluate in a panel of glioma cell lines (eight cell lines) the impact 
of a Cav-1 knockout (or Cav-1 knockdown) on cancer stem cell functions. 
The selection of a glioma cell panel and the establishment of the requisite 
assays underpin this milestone. Method development initially involved the 
commonly used U87 glioma cell line and two of its shRNA transformed 
derivatives.  
As extensively described in the General Introduction (Chapter 1), RNAi and 
CRISPR/Cas9 technologies both present advantages and disadvantages. 
In different moments of the project, different technologies were available. This 
allowed us to test their ability to inhibit Cav-1 expression on the same cell lines 
and to discriminate the impact of Cav-1 on cell phenotype, aside from the 
changes induced by the technologies. 
The effect of genetic modulation has been explored not only through the 
expression of the target protein but also cell line characterization, such as 
morphological changes, proliferation rate, cell cycle profile, clonogenic potential 
(both in 2D and in 3D format) and migration. 
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3.3 MATERIALS AND METHODS 
3.3.1 CELL LINES 
These have been described in Chapter 2. 
 
3.3.2 RNAi 
3.3.2.1 Lipid-based shRNA 
U87 have previously been transfected for the silencing of Cav-1 by using a 
FUGENE-based technique. The Cav-1 knockout, U87 shRNA CAV and the non-
target positive control counterpart, U87 shRNA CTRL were kept in the same 
culture condition but with the addition of puromycin 0.5μg/ml for the 
maintenance of the selection pressure.  
 
3.3.2.2 Lentiviral-mediated shRNA (pLKO.1) 
The Cav-1 knockdown, mediated by a lentiviral vector, has been obtained 
through the pLKO1 system (Figure 3.1), purchased from SIGMA-ALDRICH 
(MISSION® shRNA, SIGMA ALDRICH, Irvine, UK).  
 
Table 3.1 The five sequences used for Cav-1 lentiviral-mediated shRNA knockdown. 
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Five different active-predicted sequences have been selected on the Sigma 
website for the insertion in the plasmid (Table 3.1). One extra sequence, 
designed not to target any mammalian gene, was used as negative control for 
the silencing. 
 
Figure 3.1 pLKO.1 vector map showing the insertion point of the custom sequences (top) and the 
resulting shRNA hairpin.  
 
The pLKO.1 vector, however, is classified as third-generation since its safety is 
improved in key ways. First, the packaging plasmid is split into two separate 
plasmids, one encoding for Gag and Pol and the other for Rev. Tat is eliminated 
and replaced by a chimeric 5' LTR fused with a CMV promoter. 
The five shRNA sequences (Table 3.1) from the SIGMA website were blasted 
on the whole human transcript to check if they were not interfering with the 
expression of other genes and subsequently tested (example in Table 3.2) 
(Altschul, Gish, Miller, Myers, & Lipman, 1990).  
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Table 3.2 BLAST of three sequences on the whole human transcript.  
 
 
The transfection procedure was performed by Dr Giusy Tornillo in the School of 
Bioscience, Cardiff University. 
After the lipo-transfection into 293T cell lines, maintained in DMEM 10% FBS 
and 1% PS, the plasmid was packaged into viral particles, to be released from 
the packaging cells. The supernatant was replaced after 14-16 hours with new 
medium, which was collected after 8-9 hrs. It then was centrifuged for 5 min at 
1500 rpm to remove cell debris, filtered (0.22m) and transferred on the culture 
of target cells to allow the viral particles to infect the cells and release and 
integrate the plasmid carrying the shRNA sequences. Cells with the integrated 
plasmid and expressing the shRNA containing DNA sequence were selected by 
Puromycin administration after 24 hrs, at a concentration (Table 3.3) established 
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a the puromycin killing curve, that was performed on each target cell line 
(puromycin concentration 50nM-100M, timepoints 72 and 120 hrs- see Figure 
3.21).  
Table 3.3 Puromycin concentrations for Lentiviral transfection selection and maintenance  
 Cell Line 
Puromicin Concentration Selection and 
Maintenance (g/ml) 
1 U87 0.4 
2 U373 0.4 
3 UP007 0.3 
4 UP019* 0.4 
5 UP029 0.8 
6 IN699* 0.3 
7 SF188 0.5 
8 KNS42 0.5 
 
Cell lines after selection were cultured in normal medium or in medium 
supplemented with half of the selecting concentration of Puromycin and Cav-1 
expression was tested by Western Blot. 
 
3.3.3 CRISPR/Cas9 
CRISPR engineering was performed by Miss Catia Neto as part of her PhD 
project. 
 
3.3.3.1 Plasmid delivery 
Plasmids U6gRNA-Cas9-2A-GFP (Figure 3.2) were bought from Sigma-Aldrich, 
already engineered with the sequences for the recognition of CAV-1 target 
sequences (Table 3.4).  
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Figure 3.2 U6gRNA-Cas9-2A-GFP map (Sigma-Aldrich). 
 
They were replicated into MAX Efficiency DH5 competent cells (Invitrogen- 
Thermo Fisher Scientific- Waltham, MA, USA). 
Table 3.4 Sequences for the targeting of CAV-1 with CRISPR knockout system. 
Target ID Target site Blast CAV-1 gene 
HS0000173746 TTTAGGGTCGCGGTTGACCAGG 6860-6881 
HS0000173749 CATCCCGATGGCACTCATCTGG 39311-392990 
HS0000173747 AAACACCTCAACGATGACGTGG 6879-6900 
 
48 hours after the transfection with Oligofectamine, cells were sorted for GFP as 
single cells into 96-well plates and clones were expanded and checked for the 
expression of Cav-1 by Western Blot. 
 
3.3.3.2 RNP (Alt-R®) 
The RNP system was purchased from IDT (Integrated DNA Technologies- 
Coralville, Iowa USA). The system is based on a pre-assembly of the three 
components (crRNA, tracrRNA and fluorescent Cas9, Figure 3.3). The RNPs 
assembled were then delivered inside the cells’ nucleus by electroporation and 
sorted after 48hrs into 96-well plates for the selection and the assessment of 
Cav-1 expression via Western Blot. 
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Figure 3.3 RNP assembly steps for the ALT-R CRISPR system. 
 
3.3.4 CELL PROLIFERATION - MICROSCOPY; 
U87 cells were seeded at three different seeding concentrations (5,000, 15,000 
and 50,000 cells/cm2) in a 24-well plate format (Figure 3.4). This included the 
non-transfected wild-type cells (U87-WT), the plasmid shRNA scrambled control 
cells (U87- shRNA CTRL) and the plasmid shRNA Cav-1 knockdown cells (U87- 
shRNA CAV). These transfectants were previously established in the laboratory 
by Ms Fang Zhang [between 2013 and 2014]. Together we refer to the different 
U87 cell lines described above as U87 shRNA.  
 
Figure 3.4 Cell growth seeding scheme for U87-WT and U87-shRNA CTRL. With a separate plate 
created for U87-shRNA CAV. 
 
CHAPTER 3: CAV-1 GENETIC KNOCKDOWN/KNOCKOUT APPROACHES 
 
85 
In each plate, three wells were used as replicates for the cell counting while a 
fourth well was reserved for staining with Crystal Violet (0.5% in Met OH) to 
allow the morphological characterization. Cells were counted and stained every 
day for seven days by haemocytometer-based methods. The cell counts were 
plotted as cells/cm2 by GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, 
CA USA). 
 
3.3.5 CELL PROLIFERATION - FLUORESCENCE 
Cell growth was assessed for all cell lines. Cells were seeded at the density of 
5,000-15,000 cells/cm2 in a 96 well-plate format and maintained in normal cell 
culture medium. At discrete time points for 144 hrs (6 days) cell counting was 
undertaken using the CyQUANT® Direct Cell Proliferation Assay Kit (Invitrogen, 
Life Technologies Ltd, Paisley UK). This assay quantifies DNA content and 
involves the addition of a nucleic stain, CyQuant® Direct nucleic acid stain, to 
the cells for an incubation period of 60 min at 37oC. It does not require the prior 
washing of the cells in culture. The fluorescence was read at 480/535 nm with 
detection on a FLUOstar OPTIMA plate reader (BMG LABTECH Ltd, Bucks UK). 
For each cell line, at least 12 replicates were tested.  
The doubling time was analysed by using the viability data corresponding to the 
log phase of the plots and an online tool for the calculation of the doubling time 
(Roth V., 2006). 
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3.3.6 SELF-RENEWAL CLONOGENIC ASSAYS  
Three clonogenic assays were explored (Figure 3.5).  
 
Figure 3.5 Graphical representation of the three-clonogenic assays. A. Colony-forming assay. B. 
Free-floating assay. C. Soft agar assay. 
 
3.3.6.1 2D Colony-forming assay (Figure 3.5.A) 
Cells from normal culture conditions were seeded at a density of 500 cells in 
each well (6 well-plate format) in normal culture medium and left to form cell 
colonies in 5% CO2 at 37°C, over 14 days, but with the culture medium 
replenished at 7 days. At the end of the experiment (day 14), the medium was 
removed, the cells briefly washed (PBS) and the colonies stained with 500μl 
solution of Crystal Violet (0.5% w/v in Met OH 20% v/v). After 2 minutes of 
submersion of plates in tap water, the staining was terminated. The dried plates 
were imaged, and colonies captured on a ChemiDoc XRS+ (BIORAD, 
Hertfordshire, UK), using a modified copper staining protocol from the machine 
standard software, and a cell culture microscope. Colonies were counted with 
the Cell Counter plugin of FIJI (Schindelin et al., 2012a). 
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3.3.6.2 3D Free-floating assay - materials (Figure 3.5.B) 
Stem cell medium used was DMEM-F12 (Gibco, Life Technologies Ltd, Paisley 
UK); 2% B27 (Gibco, Life Technologies Ltd, Paisley UK); 1% 
Penicillin/Streptomycin; 20ng/ml EGF (Gibco, Life Technologies Ltd, Paisley 
UK); 20ng/ml bFGF (Gibco, Life Technologies Ltd, Paisley UK). 
Cells were seeded at a density of 1000 cells/well (flat-bottomed-96 well-plate 
format) suspended in 100 μl of stem medium. After 7 days, the number of 
cellular spheres in each well were counted using a standard inverted light 
microscope. These spheres, when used in the context of a self-renewal 
clonogenicity assay, will be termed “neurospheres” in the following sections. 
The same assay was performed as above but seeding a single cell into each 
well using the FACSaria III (BD Biosciences, Oxford UK) in Central 
Biotechnology Services (Cardiff University).  
3.3.6.3 3D Soft agar assay (Figure 3.5.C) 
Soft agar colony-forming assays were carried out by seeding 1000 cells 
between two layers of agar with a 24-well plate format. The top layer of agar 
comprised 0.3% v/v agar (SeaPlaque Agarose, Basel, Switzerland) in stem 
medium (as described before), while the bottom layer comprised 0.4% v/v agar 
in stem medium. Cells were incubated at 37 °C for up to 21 days. Colonies from 
at least 8 replicate wells were stained with Crystal Violet (0.01% in 20% Met 
OH), visualised and quantified as above (see 2D Colony-forming assay). 
 
3.3.7 SCRATCH ASSAY 
After trypsinization of normal cell culture, 100,000 single cells were counted and 
seeded in a 24-well plate and grown until confluent (on average two days). Wells 
were then scratched with a 200l tip in both horizontal and vertical directions 
(see Figure 3.6). Wells were then washed to eliminate the floating scratched 
cells. Pictures were taken on cell culture microscope immediately after the 
scratch (0 hrs) and after 8 hours (8 hrs). The pictures were taken at the centre of 
the crossing, to replicate as much as possible to the position of the picture at 0 
hrs. 
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Figure 3.6 Graphical representation of the scratch assay methodology. 
 
For the quantification, wells’ pictures were loaded on ImageJ FIJI software and 
analysed with a procedure reported in detail in Appendix. Briefly, images were 
sharpened to highlight contrast and binarized, to allow the selection of the area 
not covered in cells. 
After the analysis of all the areas (A), the At8 were normalized on the At0 (set as 
100). The result is the percentage of area occupied by the migrated cells. 
 
3.3.8 CELL CYCE ANALYSIS 
1 million cells were resuspended in 1ml ice-cold PBS and then added delicately 
to 9 ml ice-cold Ethanol 70% for fixation. 
Cell suspension was centrifuges and and supernatant discarded. After a was 
with PBS 5%FBS cells were resuspended in 5ml of PI staining solution (PBS, 
0.1% Triton X-100, 2% PI 1mg/ml, 0.02% RNase) and incubated at RT for 30 
min in the dark. 
After resuspension and eventual filtering to eliminate clusters cells were 
analysed by flow citometry according to PI spectrum of excitation (536nm) and 
emission (617nm). 
Cell cycle analysis was performed with FlowJo univariate analysis. 
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3.4 RESULTS AND DISCUSSION 
In the table below (Table 3.5), all the cell lines under examination and the 
genetic modification are reported.  
U87 and U373 were commercially obtained by ECACC, while the other cell lines 
were gently provided by Professor Geoff Pilkington, from the University of 
Portsmouth, School of Pharmacy and Biomedical Sciences. Among them three 
cell lines, UP007, UP019 and UP029 were isolated in Professor Pilkington’s lab 
(Brain Tumour Research Centre). 
In total 5 adult and 3 paediatric GBM cell lines were obtained. For some of them, 
it was possible to retrieve from the literature some genetic information, like the 
TP53 and the PTEN status. 
After the first experiments, unfortunately, it was acknowledged that IN699 was 
indeed not derived from GBM but from rhabdomyosarcoma, while the UP019 
cell line was cross-contaminated with UP007 before the aliquot was shipped to 
the group. Instead of manipulating the images of the first panel experiments 
containing those two cell lines, a choice was made of keeping them in (with an 
asterisk indicating them) and they were not furtherly part of the experimental 
plan. 
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Table 3.5 Cell lines under examination with available information and genetic modifications 
 Cell Line Origin 
Patient 
details 
Type (Grade) 
Genetic information 
available 
Source shRNA 
Lentiviral 
knockdown 
CRISPR 
knockout 
1 U87 
U. Uppsala 
(SE) 
Adult Adult GBM (IV) 
TP53 wt/ PTEN mut/ p16 
del/ p14ARF 
del/CDKN2A mut 
ECACC   
 
(plasmid) 
2 U373 
U. Uppsala 
(SE) 
Adult Adult GBM (IV) 
TP53 wt/ PTEN null/ p16 
wt/ p14ARF wt 
ECACC  
 
 
3 UP007 SEBTA Adult Adult GBM (IV)  SEBTA    (RNP) 
4 UP019* SEBTA Adult Adult GBM (IV)  SEBTA    
5 UP029 SEBTA Adult Adult GBM (IV)  SEBTA    (RNP) 
6 IN699* 
Institute of 
Neurology 
(London) 
Adolescent 
(15-year-old 
male) 
Supratentorial 
paediatric GBM 
 SEBTA    
7 SF188 
U. Arizona 
(AZ, USA) 
Child 
(8-year-old 
male) 
Frontal 
paediatric GBM 
(IV) 
TP53 wt/ PTEN wt/ p16 
wt/ p14ARF wt 
SEBTA    
8 KNS42 
U. Kyushu 
(JP) 
Adolescent 
(15-year-old 
male) 
Frontoparietal 
anaplastic 
astrocytoma (IV) 
TP53 mut/ PTEN wt SEBTA    
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3.4.1 LIPOSOME-MEDIATE SHRNA KNOCKDOWN  
The U87 glioma cell line has been extensively used by the research community, 
including two laboratories in their study of the impact of Cav-1, as previously 
mentioned (Cosset et al., 2012; Martin et al., 2009; Quann et al., 2013). 
Preliminary studies were undertaken with this cell line served for methodological 
development prior to use a wider panel of glioma cell lines.  
The laboratory held stocks of the U87 cell line (U87WT) (Cav-1 +) and derivative 
cells that had been stably transduced (lipid-based system) with: a shRNA anti-
Cav-1 sequence generating a Cav-1 protein knockdown cell line (U87 shRNA 
CAV) (Cav –); and a parallel line transduced with a scrambled shRNA sequence 
(U87 shRNA CTRL) (Cav+) [Work of Ms Fang Zhang– Visiting Scholar in 
Gumbleton laboratory 2013-14]. The use of U87 within the pilot methodological 
experiments was decided also to allow initial testing of the impact of Cav-1 
status upon function and further comparison to already-published work.  
A western blot analysis of the U87 cells showed that the shRNA knockdown was 
intact with no Cav-1 protein expression observed in the shRNA Cav-1 cell line 
while expression was evident in the U87WT and shRNA CTRL cell lines (Figure 
3.7).  
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Figure 3.7 shRNA (plasmid) mediated Cav-1 silencing. Densitometry analysis of bands 
corresponding to Cav-1 molecular weight, 22 kDa, was performed and compared to the 
corresponding band density of the housekeeping gene -Actin (46 kDa). The resulting folds were 
normalized on the shRNA CTRL, in order to evaluate the knockdown efficiency.  Experiment was 
repeated once. 
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The pattern of growth (Figure 3.8B) of the U87 revealed that all three-cell lines 
(even when growing in standard cell culture medium) were able to establish 
sphere-like outgrowths of cells distinct from the adherent cell monolayer. This 
capacity to establish sphere-like cellular outgrowths may be regarded as a crude 
measure of clonogenicity. During the cell proliferation assay, where the actual 
cell count was monitored by microscopy and haemocytometer (Figure 3.8C- 
manual count), it was noted that the U87 cells not expressing Cav-1 protein 
(shRNA Cav) were always the first to form spheres, and these spheres were 
consistently smaller in size (qualitative assessment) compared to those seen in 
U87 CTRL and U87 WT cell lines. In the entire U87 a proportion of these 
spheres detached from the monolayer retaining the ability to grow while floating 
free in suspension. Figure 3.8C shows growth on a semi-log plot with a lag 
phase for all three U87 lines of 1-2 days. The exponential phase of cell growth 
indicated that the knockdown of Cav-1 had no impact upon U87 cell proliferation 
rate, with the rate of cell growth appearing to plateau at around day 8. This 
method of cell counting by microscopy did, however, require the initial washing 
of the cultures, which inevitably caused the release of some of the attached 
spheres. Figure 3.8D (linear scale) and Figure 3.8E (semi-log scale) show the 
growth pattern of the U87 as assessed over 6-days by a fluorescence DNA 
based assay. Here the assay did not involve a washing step of the cells, but 
simply the addition of the cell-permeable fluorescent label. The transfected cell 
lines, shRNA CTRL and shRNA Cav-1, are associated with a higher Level of 
fluorescence than the WT cells which is an expected outcome given that they 
bear additional recombinant DNA from the transformation shRNA process. 
However, the overall rate of proliferation across the cell lines appears to be 
unchanged by the loss of Cav-1, a consistent finding between the microscopy 
and fluorescence-based approaches to cell counting. 
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Figure 3.8 Growth pattern of U87: A non-magnified images of the U87 grown in a 24-well format 
and stained with crystal violet which highlights the size of the cellular spheres. B: 4x 
magnification of the spheres. C Cell counting-based proliferation assay (semi-log plot). The arrows 
indicate the time to the first appearance of the spheres/aggregates in the culture. D DNA content -
based proliferation assay (linear plot) and E (semi-log plot). The transfected cell lines display an 
increased DNA content, but the Cav-1 knockdown appears not to have affected U87 cell growth 
rates. 
 
3.4.1.1 U87 SELF-RENEWAL AND CLONOGENICITY: FREE-FLOATING NEUROSPHERE 
ASSAY 
Using the U87, a method was developed to establish a clonogenic assay. A 
clonogenic assay assesses the capacity for a single cell to undergo a process of 
self-renewal giving rise to a distinct cell population. This population may or may 
not contain members that have the capacity to undergo further differentiation, 
but the point is that a self-renewal process must have occurred to initiate the 
population. The ability to survive and undergo a self-renewal process under 
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environmental pressure is one of the characteristics of cancer stemness and an 
aggressive cancer phenotype.  
The clonogenic assay initially chosen was the ‘free-floating’ assay (Table 3.6 
below). It is a relatively quick (7-days) suspension-based assay testing the 
ability of an individual cell to undergo self-renewal in an environment where 
anchorage-dependent growth is prevented (i.e. using cell culture plasticware 
that prevents cell adhesion) and where the culture medium is minimal, i.e. 
lacking serum but comprising select ‘stem cell’ growth factors. It is termed ‘free-
floating’ as the cells that survive are literally free to float in suspension, i.e. they 
are not embedded in any matrix, and as they divide they will give rise to ‘tumour-
like’ cellular neurosphere.  
A set of criteria was used to count the neurospheres at the end of the 7-day 
assay:  
 a mass of cells has been considered a neurosphere if it contained at least 
50 cells (evaluated by optical microscopy). This criterion sets a certain 
demand on the replicative capacity of the cells comprising the neurosphere, 
e.g. discounting ‘neurospheres’ that may contain only a handful of cells after 
7 days of culture– here the assay conditions will have imposed a significant 
challenge to particular cells in their capacity to undergo self-renewal and 
proliferation;  
 to be considered as a neurosphere derived from a common initiator cell then 
the neurosphere must have a rounded and compacted structure (judged 
qualitatively by microscope). This criterion is aimed at distinguishing 
between a ‘true’ neurosphere and an aggregate of cells. This is particularly 
important in a ‘free-floating’ assay design as while it is easy to implement, 
the individual neurospheres that form have the potential to adhere to each 
other to form larger aggregates. An outcome not truly reflective of self-
renewal capacity.  
To establish an appropriate cell number for seeding into the low adherence 96-
well format an initial cell seeding study was undertaken using U87 WT cells, with 
cell seeding varied between 100 to 1000 cells per well. Figure 3.9A shows after 
7 days the number of neurospheres that had grown per well. Figure 3.9B shows 
the same data but expressing neurosphere growth as a % of original cell 
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seeding. While this pilot study represents only a single experiment the 
coefficient of variations for any of the seeding was no greater than 22%. The 
outcome of the pilot determined that 500 cells per well to be the basis for future 
U87 ‘free-floating’ clonogenicity assays. This choice was based on the minimum 
cell seeding number associated with the maximal observed % neurosphere 
formation.  
 
Figure 3.9 Establishing the seeding concentration for the free-floating assay for the U87. A: 
absolute number of neurospheres per well; B: number of neurospheres per well expressed as a % of 
original seeding number. Data represent a single experiment (mean ± SD) with n=10 wells for each 
seeding density 
 
The pilot experiment above allowed application of the ‘free-floating’ clonogenic 
assay to the U87 of cells. Figure 3.10 shows the results of a free-floating 
clonogenic assay on the U87 across three different independent experiments. 
Despite what was considered careful adherence to the methodology, the 
outcome of each experiment produced entirely different findings with no 
consistent pattern. It was also noted that the yield of neurospheres was 
considerably reduced in these latter series of experiments (e.g. U87 WT ca. 0.5 
to 1.6% neurosphere growth when expressed as % of the 500 cells seeded) 
compared to the pilot investigation (U87 WT ca. 7%, Figure 3.9). Nevertheless, 
despite the high variable outcomes in terms of the number of neurospheres 
formed, one consistent finding was that Cav-1 negative cells, (U87 shRNA CAV-
1) displayed neurospheres that were smaller in size, indicating that the 
expression of Cav-1 expression is important for the growth of the neurosphere in 
the context of this self-renewal assay.  
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Figure 3.10 Free-floating assay on U87: U87 wild-type (U87 WT) cells, U87 shRNA CTRL cells 
and U87 shRNA Cav-1 cells. 500 cells seeded into each well of a 96-well format. A. shows three 
separate experiments (mean ± SD with n=10 replicates within each experiment). Statistical ana lysis 
by one-way ANOVA with Tukey’s multiple comparison test. B. Representative images (4x 
magnification) of spheres formed for each cell line.  
 
Although the ‘free-floating’ neurosphere culture has been widely used there are 
several limitations to the method. In particular, it is highly sensitive to cell 
density, different constituents or concentrations of factors in the media as well 
as the very real problem of distinguishing aggregates of cells from ‘true 
neurospheres’. Further, when the repeated passages undertaken influence the 
composition of the individual passaged dissociated neurospheres themselves 
(e.g. differentiation status) and naturally lead to different outcomes. As a 
consequence of this, the cellular sphere formation saw in the U87 grown in 
standard 2D- culture conditions (Figure 3.8) might reflect the extent of the 
spheres present in the cells harvested from the standard 2D- cultures. Once 
harvested to seed into the self-renewal assay, they may represent a significant 
source of variation contributing to the findings in Figure 3.9 and Figure 3.10. 
Further, the U87 cells in such spheres maybe functionally/phenotypically 
different to those that had grown as part of the monolayer ‘carpet’ attached to 
the plastic. 
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3.4.1.2 ‘U87 CELL PANEL’- VARIABLE CELL PHENOTYPES WITHIN STANDARD 2D CELL 
CULTURE  
The above data led to a series of experiments aimed at testing if in standard 2D- 
cultures the U87 cells growing within spheres behaved differently from the cells 
growing as part of the monolayer ‘carpet’ attached to the plastic. Figure 3.11 
shows the experimental scheme for the harvesting of U87 cells that effectively 
represented sub-populations of cells from within a standard 2-D culture. The 
sub-populations tested were: adherent to the plastic in a monolayer culture; both 
adherent cells and cells weakly attached to the monolayer as spheres; and 
finally, as spheres or cell aggregates floating freely in suspension. The cells 
harvested under the different conditions were subjected to cell cycle analysis, 
Western Blot for Cav-1 and a self-renewal clonogenic assay. 
 
The U87 cells were all seeded at a density of 5x103 cells/cm2 and were collected 
at three different time points, either prior to sphere formation (day 3) or at a 
sufficient time (day 7) that allowed the cell spheres/aggregates to detach from 
the monolayer and exist in sufficient numbers in suspension. The cells 
harvested as a monolayer only were easier to handle in comparison to the 
mixed population and the floating aggregates. Specifically, the cellular 
aggregates were difficult to dissociate especially as they became more compact.  
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Figure 3.11 Experimental scheme within the standard 2-D culture to test if subpopulations of U87 
cells were functionally different. Use was made of the U87 (U87 WT, U87 shRNA CTRL and U87 
shRNA CAV-1. Cells were seeded at 5 x 103 cells/cm2 onto standard tissue culture plastic 
containing full medium replete with serum. In total 9 T-flasks were seeded. The U87 cultures were 
harvested at different time points, specifically: Day 3 post -seeding– a time point at which the only 
cells present were those adhering to the plastic in a monolayer culture; Day 5 post-seeding– a time 
point where both adherent cells and cells contained in weakly attached spheres could be found; 
Day 7 post-seeding- a time point that allowed harvesting of spheres or cell aggregates floating in 
suspension. 
 
Figure 3.12 shows the Western blot of the various sub-populations. The blots 
were difficult to conduct for the free-floating suspension spheres alone, reflecting 
a relatively low Level of protein material. These cell aggregates were difficult to 
process for the Western Blot being less susceptible to mechanical disruption 
and osmotic and chemical lysis. The resulting protein lysate was very poorly 
concentrated, and its consistency was jelly-like indicating nucleic acid 
contamination. Nevertheless, but not surprisingly, the expression of Cav-1 is 
maintained in the WT and CTRL cells for both the monolayer and mixed 
populations, and at least for the WT cells the expression of Cav-1 appears to be 
relatively stable.  
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Figure 3.12 Cav-1 Western blot analysis of the three sub-populations. Image of bands 
corresponding to Cav-1 molecular weight, 22 kDa, was compared to the corresponding image of 
the housekeeping gene -Actin (46 kDa).  
 
Cell cycle analysis of the individual populations is shown in Figure 3.13. The cell 
cycle methodology essentially quantifies the amount of DNA each cell line 
possessed against a mathematical model. The method requires cells to be 
stained with a fluorescent dye, propidium iodide (PI), which binds to DNA in a 
manner that reflects directly and accurately the amount of DNA present; a flow 
cytometer is used to analyse the amount of fluorescence associated with each 
cell. As the cells start replicating (S-phase of the cell cycle) the amount of DNA 
increases to become double (at the point of cell division G2/M) that observed in 
the non-replicative phase of the cell cycle (G0/G1). The staining of the DNA 
allows calculation of the proportions of cells that are in the G0/G1 phase (first 
peak, the DNA content is defined as 1n), G2/M phase (second peak, the DNA 
content is now 2n) and in S phase (the transition between the two peaks) – see 
Figure 3.18 for an example. The modelling of the cell cycle is undertaken by flow 
cytometer software, FlowJo.  
The cell cycle analysis (Figure 3.13) was able to model all the data for the 
monolayer sub-populations. However, the shRNA transfection process appeared 
to modify the cell cycle profiles, apparent from the comparison of the WT data to 
that of the shRNA CTRL (both Cav-1 +); this is likely a reflection of the additional 
DNA that the transfectants bear. When comparing the transfectants alone the 
shRNA CTRL (Cav-1 +) displayed a higher percentage of cells in the G0/G1 
phase in comparison to cells with the shRNA Cav-1 (Cav-1-ve) knockdown. This 
result is consistent with previous studies reporting that the expression of Cav-1 
induces G0/G1 arrest in breast and lung cells through a p53-dependent 
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mechanism (Galbiati, Volonté, et al., 2001; Torres et al., 2006). The shRNA 
Cav-1 (Cav-1–) cells (monolayer subpopulation) displayed a reduced G2/M 
phase compared to the shRNA CTRL, i.e. Cav-1 +ve cells have a longer 
duration G2/M phase. This is consistent with Quann et al. (Quann et al., 2013) 
who reported that Cav-1 expression inhibits cyclin D1, a factor promoting the cell 
to cycle rapidly through G2/M phase, i.e. high Cav-1 extends residence time in 
G2/M phase. Cell cycle analysis of the other sub-populations was more 
challenging. Specifically, the shRNA Cav-1 cells could not be adequately 
modelled. Again, the shRNA CTRL cells showed a different profile to the WT 
cells. Interestingly the cell cycle for the WT cells was modelled across all three 
subpopulations with the cells in the isolated spheres showing a distinctly lower 
fraction of cells in the resting phase (Go/G1) and a greater number in the S-
phase.  
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Figure 3.13 Cell cycle univariate analysis of the three sub-populations. Cells harvested for cell 
cycle from the monolayer state only; from a mixed state comprising monolayer and spheres 
attached to the monolayer, and finally, just spheres floating freely in suspension. Experiment was 
repeated once. 
 
With regards to the self-renewal clonogenicity assay, it was determined that due 
to the continuing lack of reliability of the neurosphere free-floating assay to 
adopt an alternative self-renewal clonogenic assay based on a matrix approach 
with soft-agar, the ‘Soft agar assay’ (Table 3.6 below.) In this assay colonies of 
neurospheres are formed between two layers of agar within a 24-well plate 
format. With this approach, the issue of the aggregate formation between 
neurospheres is decreased significantly.  
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Figure 3.14 shows the results of the sub-population analysis using the ‘soft agar’ 
neurosphere assay. The same cell seeding was applied to each of the three 
different types of sub-population and it was clear that irrespective of the 
particular U87 cell line, i.e. either WT, CTRL or Cav-1 knockdown, that the 
monolayer adherent cell populations were always the most clonogenic with a 
significant difference observed between the other sub-population types. This 
was not a reflection of the cell viability at the point of seeding as all cells whether 
from the adherent monolayer or from the mixed or floating sphere populations 
displayed cell viability > 95% based on trypan blue exclusion microscopy 
conducted in parallel with cell counting. The differences in clonogenic capacity 
between the different sub-populations indicate that the composition of the cells 
used to seed any self-renewal assay will be an important consideration, at least 
for the U87 cell line which displays sphere formation even in standard 2D-culture 
– an observation not previously made in the literature. The U87 cells in the 
spheres while viable may be in a more differentiated state with less plasticity to 
adopt a phenotype able to survive the clonogenic assay.  
It was also noted that within any given sub-population (e.g. adherent monolayer, 
mixed or suspension cells) that the Cav-1 knockdown cells showed the trend for 
the lowest self-renewal capacity, i.e. Cav-1 may be a mediator of neurosphere 
self-renewal.  
Nevertheless, the above experiments suggested that any self-renewal assay 
involving U87 cells should be conducted only with cells from the adherent 
monolayer sub-population, i.e. strict consideration given to the point of harvest in 
the feeder cell cultures, i.e. the 2D standard cultures used as the source of cells.  
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Figure 3.14 Soft agar neurosphere assay on the three subpopulations. U87 wild -type (U87 WT) 
cells, U87 shRNA CTRL cells and U87 shRNA Cav- cells. 1000 cells seeded between two layers of 
soft agar within a 24-well plate format. Data represent mean±SD with n=8 replicates from a single 
experiment. Statistical analysis is represented by one-way ANOVA with Tukey’s test between each 
sample and the respective monolayer counterpart * p≤0.05, § p≤0.01, ¶ p≤0.001].  
 
3.4.1.3 ‘U87 CELL PANEL’ SELF-RENEWAL AND CLONOGENICITY: SOFT AGAR ASSAY AND 
COLONY FORMATION  
As mentioned in the Introduction, Cav-1 knockdown in U87 cells has previously 
been associated with an increase clonogenicity using an in vitro 2D colony 
forming assay (Cosset et al., 2012; Martin et al., 2009), i.e. expression of Cav-1 
serving as a tumour suppressor. Adopting ‘soft-agar’ clonogenic assay (Figure 
3.5) we explored the capacity for neurosphere formation in U87 cells where the 
seeding cells were all obtained from the adherent monolayer cell populations. 
Figure 3.15 shows the outcome of this assay across four independent 
experiments. A consistent finding was that Cav-1 knockdown in the soft-agar 
assay decreased clonogenic potential, i.e. expression of Cav-1 mediates 
neurosphere self-renewal in the soft-agar assay with approximately half the 
capacity for self-renewal lost when Cav-1 is knocked down (shRNA CTRL vs. 
shRNA Cav-1; Figure 3.15A-B). Another finding from this study and one 
consistent to the qualitative findings of the free-floating assay (Figure 3.10B) is 
that the neurospheres formed in the Cav-1 knockdown cells were always greatly 
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reduced in size (Figure 3.15D) compared to the U87 cells expressing Cav-1, i.e. 
Cav-1 expression is important for the growth of a neurosphere in soft-agar self-
renewal assay. Further, in the Cav-1+ve cells (notably shRNA CTRL) an 
increased migration of cells away from the formed neurosphere, i.e. Cav-1 may 
appear to promote cell migration.  
The results of clonogenicity assay based in soft agar are in contrast with the 
clonogenic data reported by Martin et al. (Martin et al., 2009) who used an in 
vitro 2D colony-forming assay, where they reported Cav-1 in U87 cells to serve 
as a suppressor of clonogenic capacity.  
 
Figure 3.15 Soft agar assay neurosphere assay on U87. A. Cumulative graph of four separate 
experiments (means±SEM). B. Non-magnified images of the U87 grown in a 24-well format and 
stained with crystal violet which highlights the size of the cellular neurospheres C 4x 
magnification of the neurospheres. One-way ANOVA statistical analysis with Tukey’s multiple 
comparison test has been performed.  
 
In Figure 3.16 the results of an in vitro 2D colony-forming assay, similar to that 
undertaken by Martin et al. (Martin et al., 2009), are shown. The results of this 
type of assay are more difficult to interpret as demonstrated in the images in 
Figure 3.16C; it should be noted that the work of Martin et al. (Martin et al., 
2009) did not publish images of their colony-forming assay.  
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Figure 3.16 Colony-forming assay on the U87. A. Cumulative graph of the three separate 
experiments (means±SEM). B. Non-magnified images of the U87 grown in a 24-well format and 
stained with crystal violet, which highlights the size and number of colonies formed. C. 
Representative 4x magnification images of the colonies. One-way ANOVA statistical analysis with 
Tukey’s multiple comparison test has been performed.  
 
Specifically, we found the U87 cells displayed a tendency to spread across the 
plastic surface merging in instances with cells from an adjacent colony (Figure 
3.16C). Nevertheless, the quantitation of colony formation in this study was 
undertaken based upon observing a regular concentric pattern of cell growth 
surrounded by what appeared to be a belt of clear plastic bearing no attachment 
of cells. We found that in contrast to our soft agar assay (Figure 3.15), but in 
agreement with the report of Martin et al. (Martin et al., 2009), that Cav-1 
appears to serve as a suppressor of clonogenicity in the 2D colony-forming 
assay. Consistent with our free-floating and soft agar data we noted that the 
colonies formed in the Cav-1 knockout cells were always more defined and 
reduced in size (Figure 3.16C, D) compared to the U87 cells expressing Cav-1, 
i.e. in the context of the 2D assay Cav-1 expression is important for the growth 
of a colony or the migration of cells away from the colony.  
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Clearly, each of the three clonogenic assays is able to challenge different 
aspects of cellular biology.   
The colony-forming assay is a very simple and cheap assay that tests the ability 
of an isolated cell to survive, and for such a cell to undergo division under 
normal cell culture conditions including the presence of a plastic support for cell 
adherence and generally with media comprising rich in mitogenic stimuli, i.e. 
containing FBS. It is the assay that least resembles physiological tumour growth.  
The free-floating assay is also relatively easy to undertake. The isolated cells 
need to survive and proliferate in the absence of a plastic substratum for cell 
adherence (use is made of ultra-low attachment tissue culture plates), and in 
media that generally lacks FBS but contains specific growth factors in “Stem 
Media”(Dontu, Al-Hajj, Abdallah, Clarke, & Wicha, 2003), which is a basic 
medium deprived of FBS but containing EGF, bFGF and B27(Gu, Y., Fu, J., Lo, 
P-K., Wang, S., Wang, Q., Chen, 2011) as growth stimuli. The isolated cells 
need to adapt to the poor growing conditions and then proliferate within 
progressively expanding spheres, which float freely in suspension. Here the 
survival and expansion of the floating colony will depend upon anchorage-
independent survival and cell-cell interactions.  
The soft agar assay is complex and time-consuming, but it also is the one that 
more closely resembles physiological tumour growth. The isolated cells are 
placed between two layers of agarose gel prepared in ‘stem medium’. The cells 
need to survive in stem conditions and also to overcome the physical barrier 
imposed by the gel matrix surrounding if the colony is to expand in size. Here 
cell-cell interactions and the ability to migrate or invade through the matrix will 
be important. The principal characteristics of each of the three assays are 
highlighted in Table 3.6.  
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Table 3.6 Three clonogenic assays and their characteristics 
 
COLONY 
FORMING ASSAY 
FREE-FLOATING ASSAY SOFT AGAR ASSAY 
Conditions Culture medium Stem medium Stem medium 
Type of growth Adherence Suspension Semi-solid matrix (3D) 
Testing 
Ability to undergo 
“unlimited” 
divisions in normal 
culture conditions 
Ability to undergo 
“unlimited” divisions in a 
deprived medium and 
without the assistance of 
an anchorage surface. 
Ability to undergo “unlimited” 
divisions in a deprived 
medium, without the 
assistance of an anchorage 
surface and inside a 3D 
system that subject cells to 
external pressure. 
Advantages 
Easy 
Chip 
Quite easy 
Quick: only 7 days 
Deprived medium and 
non-adherent conditions 
make it more similar to 
physiology. 
More similar to physiology 
thanks to the medium and to 
the presence of the 3D 
environment. 
Cells are stuck inside the 
matrix, so they cannot 
aggregate. 
Useful to study also invasion 
ability. 
Disadvantages 
In vitro culture 
conditions (less 
physiological) 
Low seeding 
density can 
decrease the 
colony-forming 
ability. 
Since cells are free to 
move inside the well, 
aggregation may occur, 
thus altering the result 
(high intra and inter-
experimental variability). 
Not all cell lines grow in this 
kind of assay. 
 
The divergent outcome between the 2D colony forming assay (Figure 3.16) and 
the 3D soft agar assay (Figure 3.15) leads to the question of the differing biology 
that these two assays depend upon to assess self-renewal capacity.  
The 2D colony-forming assay essentially addresses the ability of the cells to 
initially (however transiently) survive in the absence appropriate cell-cell 
interactions but where extracellular matrix (ECM) interactions are more readily 
established and in a medium promoting cell proliferation. Using a 2D colony 
forming assay Martin et al (Cosset et al., 2012; Martin et al., 2009) reported the 
increased clonogenicity of U87 cells when cellular Cav-1 levels were knocked 
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down. This reflected an increased U87 cell attachment to fibronectin ECM via 
α5β1 integrin, the expression of which was upregulated in the U87 cells as the 
Cav-1 protein was downregulated. Both the expression of β1 integrin, important 
in adhesion and mesenchymal-type cellular movement (Friedl, 2004), and the 
reported formation of co-operative plasma membrane complexes (Preissner, 
Kanse, & May, 2000) comprising Cav-1, the GPI-anchored urokinase receptor 
(uPAR) and β1 integrins, are consistent with the Cav-1 positive cells displaying 
greater adhesion and colony formation in the 2D assay and with the observation 
that the respectively formed colonies showed a more widespread migration of 
cells. 
 
The 3D soft-agar assay while also testing the above is also examining the ability 
of the cells to overcome the process of anoikis (or cell-detachment-induced 
apoptosis) and it does so in a ‘nutrient-poor’ environment, i.e. one deficient in 
serum but supplemented with ‘stem media’. Only cells possessing high plasticity 
will be able to survive and proliferate to form neurospheres. The soft agar assay 
requires the cells to survive the external pressure represented by the matrix and 
be able to break down the surrounding matrix in order that the neurosphere can 
expand through by proliferation (Friedl, 2004).  
The process of anoikis eliminates cells that are not receiving the correct signals 
from the ECM (Grossmann, 2002). If the cells are able to adapt to their ‘new 
environment’ then anchorage-independent growth (AIG) is possible and is 
indeed one of the hallmarks of cancer. Resistance to anoikis and the ability of 
tumour cells to display AIG allows them to expand and potentially invade 
adjacent tissues. The ability to avoid anoikis is a critical transformation that a 
tumour cell undergoes during malignancy (Guadamillas, Cerezo, & Del Pozo, 
2011; Paoli, Giannoni, & Chiarugi, 2013). Overcoming anoikis and exhibiting 
AIG ultimately requires a bypass of integrin-mediated signals, which in the 
absence of ECM would trigger cell death. This bypass may be through a variety 
of mechanisms including the cell adaptation such as undergoing EMT or an 
alteration in expression of the cell’s integrin repertoire of proteins. There may 
also be compensatory mechanisms such as activation of pro-survival pathways 
such as PI3K, Ras-ERK etc. The role of Cav-1 in AIG has not been shown to be 
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consistent with studies in the lung cancer, reviewed in (Chunhacha & 
Chanvorachote, 2012). These studies reported that Cav-1 levels positively 
correlate with increased AIG, while in breast cancer (Fiucci et al., 2002) and 
indeed in transformed fibroblasts (Cerezo et al., 2009) decreased levels of Cav-
1 favour AIG. Mechanistic studies are clearly needed, and future 
experimentation of self-renewal would use both assays as they clearly can 
reflect different biology.  
 
3.4.2 ‘PANEL OF GLIOMA CELL LINES’ – PROLIFERATIVE 
CAPACITY AND CAV-1 STATUS 
As mentioned in the Introduction, one of the early milestones in the project is to 
evaluate in a panel of glioma cell lines (six cell lines) the impact of a Cav-1 
knockdown (or Cav-1 knockdown) upon classical cancer stem cell functions, 
specifically with a focus upon self-renewal (clonogenicity). This milestone is 
underpinned by the selection of a glioma cell panel and the establishment of the 
requisite assays. The U87 studies described above in this report contributed to 
method development for self-renewal (clonogenicity) outcomes. Next step was 
to apply these methods to a selected panel of glioma cell lines.  
Next, the Cav-1 status and proliferative capacity of the cell lines in the panel was 
assessed before the establishment of stable Cav-1 knockdowns. 
Figure 3.17A shows the expression of Cav-1 with all cell lines displaying a 
relatively high expression of Cav-1 with the exception of IN699 that displayed 
negligible expression and also happened to have the highest rate of 
proliferation. The Western blot confirmed that seven of these cells are suitable 
for shRNA Cav-1 knockdown whereas a knock-in strategy might have been 
more appropriate for the IN699 cells. The cell doubling times for the panel of the 
six selected glioma cell lines are shown in the Figure 3.17B, where the doubling 
times were determined by monitoring cell proliferation rates using both the 
microscopy cell counting procedure and by the fluorescence-based assay; the 
latter is shown in Figure 3.17C. Importantly the microscopy approach allows 
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confirmation that from the six cell lines panel only the U87 cells formed the 
previously described spheres in 2D standard culture conditions.  
The high proliferative rate of the IN699 is reflected also in the cell cycle analysis 
(Figure 3.18) where the G2/M phase of the IN699 is too small to allow a cell 
cycle profile to be adequately fit the data.  
 
Figure 3.17 Panel of glioma cell lines’. A Protein expression of Cav-1 in the six glioma cell lines. 
β-Actin has been used as the housekeeping gene. B Characteristics of the six cell lines including 
doubling time derived from proliferation assays, an example of which  is shown in C. Asterisks 
indicate cell lines that were subsequently excluded from the experimental plan for cross-
contamination of the original stocks. 
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Figure 3.18 Panel of glioma cell lines’, cell cycle analysis. Cells have been harvested, fixed and 
stained with Propidium Iodide. The DNA staining profiles have been obtained by flow cytometry 
and then analysed by FlowJo v10, using the Watson model (except for the IN699 whose G2/M 
peak was too low for the model). Asterisks indicate cell lines that were subsequently excluded 
from the experimental plan for cross-contamination of the original stocks. 
 
3.4.2.1  ‘PANEL OF GLIOMA CELL LINES’ – SELF-RENEWAL AND CLONOGENICITY: SOFT 
AGAR ASSAY AND COLONY FORMATION  
Shown in Figure 3.19 are the results of soft agar self-renewal and clonogenicity 
assay. The capacity to form neurospheres varied from SF188 (highest capacity 
ca. 16% of cells seeded were able to give rise to neurospheres) to UP029 
(lowest capacity < 1% of cells seeded giving rise to neurospheres). The UP029 
cell line may simply be usable in this experiment without seeding a higher 
number of cells, which is not a desirable approach for such an assay.  
The results of the 2D colony-forming assay are shown in Figure 3.20. The IN699 
and the SF188 still retain the highest clonogenic potential (in agreement with the 
soft agar assay) while the UP007 and U87 cells now display the lowest 
clonogenic potential.  
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Figure 3.19 Panel of glioma cell lines’. 3D Soft agar neurosphere clonogenicity assay. The plot 
graph neurosphere growth per well expressed as a % of cells seeded (1000 cells seeded per well) 
for the six cell lines in the expanded glioma panel. The data represent means±SEM of at least three 
experiments with n=8 replicates in each experiment. Surrounding the plot is the non-magnified 
images of the glioma panel neurospheres grown in a 24-well format and stained with crystal violet 
which highlights the size of the cellular neurospheres. Asterisks indicate cell lines that were 
subsequently excluded from the experimental plan for cross-contamination of the original stocks. 
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Figure 3.20 Panel of glioma cell lines’. 2D Colony-forming assay Plot shows outcome for three 
separate experiments for colony formation per well expressed as a % of cells seeded (500 cells per 
well seeded). The data represent means± SEM of at least three experiments with n=6 replicates in 
each experiment. Surrounding the plot is the non-magnified images around the graph the non-
magnified images of the glioma panel colonies formed in 6-well format and stained with crystal 
violet, which highlights the size of the cellular colonies . Asterisks indicate cell lines that were 
subsequently excluded from the experimental plan for cross-contamination of the original stocks. 
 
3.4.3 LENTIVIRAL TRANSFECTION 
To test the effect of Cav-1 on the cell line panel, a lentiviral-based shRNA 
approach was adopted. The system is more stable and doesn’t require the 
addition of puromycin to the culture medium, except for the initial selection 
stage. 
To avoid misinterpreting a transfection-related phenotype with a knockdown-
related one, another transfection was taken in parallel with a vector containing 
shRNA unable to target any mammalian gene.  
Cell lines were tested first for their sensitivity to Puromycin (50ng/ml-100µg/ml) 
in order to determine the concentration to be used for the subsequent selection 
(Figure 3.21 and Table 3.3). 
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Figure 3.21 Viability curve for all the cell lines under examination ( see legend) at different doses 
of Puromycin (50nM-100M) after 120 hours post-treatment in order to establish the IC50 and 
then the puromycin concentration ideal for the selection of every cell line transfected.  Asterisks 
indicate cell lines that were subsequently excluded from the experimental plan for cross-
contamination of the original stocks. 
 
The first cell line to be transfected was SF188, one of the paediatric cell lines. 
Among the five sequences tested, sequence number 5 was not producing cells 
able to survive, while sequence number 3 was not producing Cav-1 knockdown 
so they were not used for the transfection of the other cell lines (Figure 3.22). 
Three sequences, 1, 2 and 4 produced a substantial knockdown on SF188, so 
they were used for the lentiviral transfection of other cell lines (Figure 3.23). 
Unfortunately, a western blot for the SF188 cell line was repeated and this time 
the expression of Cav-1 for sequence number 1 was restored (if not increased in 
comparison with the positive control). 
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Figure 3.22 SF188 Lentiviral-mediated Cav-1 KD, following the transfection and after 4 passages 
in culture. Densitometry analysis of bands corresponding to Cav-1 molecular weight, 22 kDa, was 
performed and compared to the corresponding band density of the housekeeping gene -Actin (46 
kDa). The resulting folds were normalized on the shRNA CTRL, in order to evaluate the 
knockdown efficiency. 
 
That is why only sequence 2 and 4 were used for the transfection of UP007 and 
UP029. Sequence 4, however, showed a residual expression of Cav-1, that kept 
the interpretation of further experiments doubting, and it was excluded too. This 
left only one sequence-derived knockdown to be analysed. Furthermore, due to 
the re-expression of Cav-1 by the sequence 1-mediated knockdown, it was 
decided to keep the puromycin-selecting presence in the culture medium. This 
allowed more reliability in the knockdown maintenance during further 
experiments but cast also the same doubts about the reliability of the phenotype 
as the previous genetic modification approach. 
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Figure 3.23 Quantification of Cav-1 expression after lentiviral transfection. U87, U373, UP007 and 
UP029 were transfected for the lentiviral-mediated knockdown of Cav-1. On the top the Western 
Blot bands with Cav-1 expression in wild-type cells, in the positive control (CAV+-NT) and in 
three of the 5 sequences. Densitometry analysis of bands corresponding to Cav-1 molecular weight, 
22 kDa, was performed and compared to the corresponding band density of the housekeeping ge ne 
-Actin (46 kDa). The resulting folds were normalized on the shRNA CTRL, in order to evaluate 
the knockdown efficiency. 
 
After the assessment of the knockdown achievement, cells were tested for 
phenotypical changes, first of all, proliferation. As shown in Figure 3.24, when 
Cav-1 is knocked-down, U87, UP007 and UP029 reach the same Level of 
fluorescence as their control, while the U373 reach the plateau at a lower Level. 
On the other hand, while the U87 and the U373 do not display a significant 
difference in both proliferation rate and doubling time, UP007 and UP029 
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knockdowns are able to proliferate faster than their controls, suggesting that 
Cav-1 may be involved in limiting the proliferation mechanisms. 
 
 
Figure 3.24 Effect of Cav-1 Knockdown on proliferation. A. proliferation plots for U87 (red), 
U373 (blue), UP007 (green), and UP029 (brown), after transfection for Cav-1 knockdown. The 
black lines refer always to the control (CAV+) samples. B Doubl ing time derived from the 
proliferation plots analysed on viability values corresponding to the log phase.  Statistical analysis 
was performed with T-TEST and p value was reported when significant. 
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As for the cell cycle analysis (Figure 3.25), the transfected UP007 displayed no 
significant change in the portions of cells belonging to each cell cycle 
subpopulation (G0/G1, S and G2/M phases) in comparison with the wild-type 
reference, except for an increase of cells in S phase. The U87 and UP029, on 
the contrary, displayed a peculiar change. The control cells, like the UP007, 
were composed by an increase in the cells in S phase. The CAV-1 knockdown 
displayed three peaks, each one localized at the double of the previous one on 
the PI axis, indicating the double of the DNA. This may be due to the presence 
of different clonal subpopulations, some with a diploid and a quadruploid asset. 
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Figure 3.25 Effect of Cav-1 knockdown on cell cycle. A. Plots of U87, UP007 and UP029 WT, 
CAV+(NT) and CAV-(KD) with highlighted cell cycle subpopulations. B. Table reporting, for each 
cell line, the percentages of cells belonging to each cell cycle subpopulation.  
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In terms of clonogenicity, cells have been tested for colony formation (U87 in 
Figure 3.26, U373 in Figure 3.27 and UP007 and UP029 in Figure 3.28A) and 
for soft agar clonogenic assay (U87 in Figure 3.26, U373 in Figure 3.27 and 
UP007 and UP029 in Figure 3.28B). For all the cell lines the loss of Cav-1 (sq.2) 
resulted in a decrease of the ability of the cells to form colonies.  
 
Figure 3.26 Effect of U87 Cav-1 knockdown on clonogenicity. Plots show the outcome of Soft agar 
assay (A) and colony formation assay (B). Data were expressed as a percentage of Cav+ cells (NT) 
and represent mean ±SD of at least three experiments with n=8 replicates for soft agar and n=6 
replicates for colony formation in each experiment. Representative pictures for each sample on the 
bottom. 
 
CAV-( sq.4) on the other hand, determined a decreased spheres formation only 
for the U87 cell lines. As mentioned before, the sq.4 did not produce a complete 
knockdown. One hypothesis is that this could be the reason why the clonogenic 
phenotype is not absolute for all the cell lines. 
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Figure 3.27 Effect of U373 Cav-1 knockdown on clonogenicity. Plots show the outcome of Soft 
agar assay (A) and colony formation assay (B). Data were expressed as a percentage of Cav+ cells 
(NT) and represent mean ±SD of at least three experiments with n=8 replicates for soft agar and 
n=6 replicates for colony formation in each experiment. Representative pictures for each sample on 
the bottom. 
 
Figure 3.28 Effect of UP007 and UP029 Cav-1 knockdown on clonogenicity. Plots show the 
outcome of colony formation assay on UP007 (A) and UP029 (B). Data were expressed as a 
percentage of Cav+ cells (NT) and represent mean ±SD of at least three experiments with n=6 
replicates in each experiment. Representative pictures for each sample on the bottom.  
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The use of puromycin for normal cell culture conditions cast a doubt of the 
validity of those assays and a confirmation was necessary. This came through 
the use of CAV-1 knockouts (KO). 
 
3.4.4 CRISPR 
3.4.4.1 Plasmid CRISPR-Cas9 System  
Cav-1 CRISPR KO for the U87 has been obtained through a plasmid system 
described in materials and methods (3.3.3.1). After obtaining and testing the 
CRISPR U87 cell lines, we obtained also the CRISPR UP007 and UP029, with a 
ready RNP system as described in Materials and Methods (3.3.3.2). Together 
with the CAV-(KO) a positive control was produced and named CAV+(BB). Cav-
1 expression was tested via Western Blot ( 
Figure 3.29). 
 
Figure 3.29 CRISPR-mediated Cav-1 Knockout of U87, UP007 and UP029. Densitometry analysis 
of bands corresponding to Cav-1 molecular weight, 22 kDa, was performed and compared to the 
corresponding band density of the housekeeping gene GAPDH (37 kDa). The resulting folds were 
normalized on the CAV+(BB) cells, in order to evaluate the knockout efficiency.  
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In terms of proliferation (Figure 3.30), U87 and UP029 show no difference 
between the CAV+(BB) and the CAV-(KO) while the plateau of the UP007 CAV-
(KO) was reached at a lower fluorescence Level than the CAV+(BB) 
counterpart, leading to a longer doubling time.  
 
 
Figure 3.30 CRISPR U87 cell line proliferation assay. Cell fluorescence intensity was followed in 
time and plots were obtained for the calculation of the doubling time during the exponential phase, 
reported in the tables. 
 
The cell cycle analysis, on the contrary, showed an increased portion of cells in 
the G0/G1 phase when Cav-1 is knocked out (Figure 3.31). As for the cell cycle, 
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on the other hand, UP007 do not show any significant difference with the wild-
type and positive. Control, while both Cav-1 KO and CRISPR control display a 
shift in PI intensity and the presence of additional peaks. 
 
Figure 3.31 CRISPR cell lines cell cycle assay. A. Plots of U87, UP007 and UP029 CAV+(BB) and 
CAV-(KO) with highlighted cell cycle subpopulations. B. Table reporting, for each cell line, the 
percentages of cells belonging to each cell cycle subpopulation. 
 
A colony formation was chosen as a phenotypical assay to test whether the new 
Cav-1 manipulation was able to confirm the results of the lentiviral-mediated 
shRNA. For both U87 and UP029, the number of colonies was decreased when 
Cav-1 was knockdown, while the UP007 CAV-(KO) displayed a significant 
increase in the number of colonies. 
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In particular, again for the U87 colonies were reduced visually in number but 
especially in colony density, indicating that not only fewer cells are able to start a 
colony, but that also the number of divisions that cells undergo are less.  
 
Figure 3.32 CRISPR cell lines colony formation assay. Plots show the outcome of colony 
formation assay on U87, UP007 and UP029. Data were expressed as a percentage of Cav+ cells 
(BB) and represent mean ±SD of at least three experiments with n=6 replicates in each experiment 
(Statistical analysis: T-test). Representative pictures for each sample on the side.  
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3.4.5 CAV-1 GENE MANIPULATION IMPACT ON MIGRATION 
A second assay was performed to test whether Cav-1 was impacting on GBM 
cell lines phenotype, namely the scratch assay. This assay was chosen after the 
observation that U87 CAV+ cells in soft agar start to leave the neurospheres and 
to spread within the matrix (Figure 3.15D). cells tested were the lentiviral-
mediated shRNA UP007, UP029 and U373. The U87 could not have been used 
since, as mentioned before, they do not grow in a carpet until confluency (which 
is essential for the scratch assay since cells must feel pressure to fill up only the 
gap left by the scratch) but start forming spheres that tend to float. 
Both UP007 and UP029 displayed a significant decrease in migration velocity, 
while the U373 displayed a poor migration capacity in the CAV+ cells, thus not 
allowing a comparison with the CAV- counterpart. 
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Figure 3.33 Scratch migration assay on UP007, UP029 and U373. A. Representative pictures of 
samples at 0 and 8 hours after the scratch. The area non-occupied by cells after eight hours from 
the scratch was quantified and normalized on the corresponding area immediately after the scratch. 
Plots represent one example experiment (mean  SD). A T-test was used to compare the samples. 
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3.5 SUMMARY OF KEY FINDINGS  
In this chapter, we focused on the creation of stable cell lines bearing a 
downregulation of Cav-1. These cell lines would serve for the evaluation of Cav-
1’s role in terms of a cancer stem cell modulator. Several genetic modifications 
have been used for the obtaining of the modified cell lines, and the confirmation 
of the genetic manipulations was evaluated via Western Blot assay. The impact 
of a Cav-1 knockout (or Cav-1 knockdown) was investigated upon morphological 
changes, proliferation, cell cycle and classical cancer stem cell functions, such 
as self-renewal (clonogenicity) and migration.  
Distinct approaches for the stable suppression of Cav-1 gene expression were 
explored (RNAi and CRISPR/Cas9 technologies, as discussed in Chapter 1). 
Table 3. 7 reports a summary of all the cell lines used for the perfomed assays. 
 
Table 3. 7 Experimental plan  
 shRNA Knockdown CRISPR Knockout 
 Liposome Lentiviral  
Proliferation U87 U87, U373, UP007, UP029 U87, UP007, UP029 
Cell Cycle U87 U87, U373, UP007, UP029 U87, UP007, UP029 
Clonogenicity 
2D 
U87 U87, U373, UP007, UP029 U87, UP007, UP029 
Clonogenicity 
3D 
U87 U87, U373,  
Migration  U373, UP007, UP029  
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3.5.1 Cell lines and experimental plan 
In the beginning of this project, the lab had already produced genetic 
knockdowns of Cav-1 in at least one cell line, through the liposome-mediated 
transfection of a plasmid codifying for shRNAs directed against the Cav-1 
transcript. Initial studies have been performed with this technology, which 
required the persistent presence of puromycin to drive Cav-1 knockdown. 
However, the necessity for antibiotic for the continuous selection of the cells 
expressing the plasmid can modify the cells phenotype in unpredictable ways 
(Llobet, Montoya, López-Gallardo, & Ruiz-Pesini, 2015). Our own inconsistent 
results reported after replicate experiments led to the decision of finding a more 
stable system for the study of Cav-1 function in GBM cell lines. 
A lentiviral system for the transfection and the stable insertion of shRNA 
codifying sequences in the genome of the target cells was chosen. However, 
after a period in culture without puromycin, some of the cell lines started 
expressing Cav-1 again. This forced the reintroduction of the puromycin in 
culture. 
Later the development of Cav-1 knockouts by CRISPR/Cas9 technology allowed 
the use of an alternative technology that was able to confirm the findings. 
With the exclusion of one of the three paediatric cell lines (IN699), a decision of 
focusing only on the adult GBM-derived cell lines have been made, leaving in 
the experimental plan the U87, U373, UP007 and UP029.  
 
3.5.2 RNAi knockdown vs. CRISPR knockout 
As previously discussed in Chapter 1, RNAi modifications result in a genetic 
knockdown (reduction of protein expression), while CRISPR technology allows 
also to obtain genetic knockouts (total protein production suppression) 
(Unniyampurath et al., 2016). It is possible, as a result of that, to understand that 
CRISPR technology allows linking a particular phenotype unequivocally to the 
genetic knockout (Bosher & Labouesse, 2000; Gilbert et al., 2014; Jiang & 
Marraffini, 2015; Konermann et al., 2014; Qi et al., 2013). The use of the RNP 
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system reduces drastically the off-target risk and there is no need for selection 
antibiotics, that could induce further cellular modifications. CRISPR efficiency 
though is much lower than shRNA since both alleles have to be targeted and 
require the clonal selection of the modified cells. This means that after the 
treatment, single cells are isolated and allowed to grow. The few, if any, clones 
succeeding in starting a colony then have to be tested for the knockout. This 
results in a time-consuming process that can take up to several months. shRNA, 
on the contrary, is quite quick, and cells can be started to be stored and tested 
for the genetic knockdown a couple of weeks from the transfection (both lipid-
based and lentiviral transfection). On the other hand, though, the shRNA 
technology relies on antibiotics for the selections, that can be virtually removed 
from the medium once the culture is started, but that in reality have to be 
maintained in order to preserve the genetic selection. In fact, for the SF188 cell 
line (Figure 3.22) a genetic knockdown that looked successful after two weeks 
after the transfection (less than 50% reduction in comparison with the control), 
after a further month was not only not significant anymore, but even reverted. 
This led to the necessity of having to select the best knockdown (sequence 2 
was chosen) and to keep the puromycin selective presence in culture.   
 
3.5.3 Proliferation and cell cycle 
Both the Knockdown (KD- lentiviral shRNA) and knockout (KO- CRISPR) 
systems produced cell lines with a slightly reduced or equivalent proliferation 
rate to their respective Cav-1 positive controls. At the same time they produced 
cell lines with a different distribution of cell cycle sub-populations. Specifically, 
for: 
- U87: both knockdown and knockout approaches did not change U87 
proliferation profiles or rates, while at the same time increasing the G0/G1 
subpopulations (Figure 3.24 and Figure 3.30 for proliferation and Figure 
3.25, Figure 3.31 for cell cycle), 
- UP029: this cell line presented a mixed picture, with the shRNA 
knockdown producing a cell line with delayed proliferation start and 
reduced G0/G1 population (Figure 3.24 and Figure 3.30), while the 
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CRISPR knockout did not present any difference in terms of both 
proliferation and cell cycle (Figure 3.25 and Figure 3.31). 
- UP007: this cell line also presented a mixed picture, with the shRNA 
knockdown producing a cell line with delayed proliferation start and 
increased G0/G1 population (Figure 3.24 and Figure 3.30), while the 
CRISPR knockout did not present any difference in proliferation and cell 
cycle (Figure 3.25 and Figure 3.31). 
It is possible that differences between KD and KO derived from the intrinsic 
nature of the two technologies. The knockdown produces a reduction of the 
protein expression while the KO approach aim to completely cancel the 
expression of the target. At the same time, the lentiviral KD technology  stably 
insert the shRNA-codyfing plasmid in random regions in each cell targeted, 
creating a polyclonal population that can interact with other genes’ expressiona 
dn regulation. The CRISPR system aim to inibit block the expression of the 
mRNA, acting on the gene promoter, thus creating potentially no cross-
interactions. 
Overall with the CRISPR technology,little to no effect of Cav-1 KO was seen in 
cell proliferation profiles or rates, nor in cell cycle. The comments below 
represent the integrationof results from both platforms. 
The general proliferation results contrast with the work of Quann et al (Quann et 
al., 2013) who found, overexpressing Cav-1 in vivo, that it inhibit proliferation in 
the U87. As mentioned in the General Introduction (Chapter 1), Cav-1 role in 
cancer has been associated with different phenotypes, tissues, and stages of 
cancer development (Parat & Riggins, 2012; Senetta et al., 2013). As such, the 
differences in the impact of Cav-1 on cellular proliferation rate may be due to 
distinct molecular GBM subtypes associated with the cell lines. 
In more than one cell line anyway the typical observation was that Cav- cells 
tend to delay their proliferation log phase, but then reach the same Level of the 
plateau than the Cav+ counterparts. This may be because, when Cav-1 is not 
expressed, the cell-cell and cell-environment communication is not efficient, and 
single cells may take more time to realize if the space around them has to be 
filled, resulting in a slower proliferation. At the same time, when the number of 
cells increases, and cell-cell communications focal points are increased too, 
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cells can trigger the proliferation pathway and start expanding quickly, filling in 
this way the gap with the Cav+ samples. Indeed, if Cav-1 is involved in cell-cell 
and cell-matrix interactions, it can also lead to a more committed phenotype, 
resulting in a reduced proliferation, like for the UP007 KO.  
In previous reports, Cav-1 has been associated with induction of apoptosis and 
promotion of cell cycle arrest (Quann et al., 2013). In the same year Quest et al 
reported that Cav-1 promotes cell cycle arrest and decrease the number of cells 
going through the S phase by inhibiting the expression of Cyclin D1 (Quest et 
al., 2013). But also, as explored in the introduction, Cav-1 expression is thought 
to have a double role as both a tumour suppressor and an oncogene according 
to the tumour stage (Senetta et al., 2013). 
Generally speaking, an increase in the G0/G1 cell fraction is generally 
associated with a delay of the proliferation and possibly the induction of 
differentiation (Zarrilli et al., 1999). Anyway, other reports indicate that the block 
of G0/G1 phase can be unrelated to a decrease of proliferation. For example, 
Perna et al reported that a block in the cell cycle was not accompanied for their 
cell lines by a reduction in the proliferation rate (Perna et al., 2017). In their 
case, in fact, a DNA damage caused by therapeutical treatment was altering the 
cell cycle plot.  
It is then possible to hypothesize that a change in the cell cycle can be due, as 
for the proliferation, to a defect of the communication systems, due to the 
absence of Cav-1. Nuclei not receiving straightforward signals are not able to 
activate their cell cycle machine in a synchronized way, resulting in a delay in 
the cell cycle progression and in an accumulation of cells in the G0/G1 phase. 
It has also to be noted the presence of three peaks in the Cav- UP029 cell lines 
(both KO and KD, but not the positive controls) and U87 KD. In the beginning, 
we considered the possibility of a contamination. However, we then realized that 
the peaks are localized on three positions on the x-axis that are each one the 
double of the previous one. This corresponds to a cell line with a mixture of 
diploid and polyploid cells (Kuo et al., 2014). This may be correlated to the 
defect of communication derived from the absence of Cav-1. The cells fail to 
receive all the right stimuli and the activation of a new DNA replication may start 
before the previous cycle is completed. 
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Finally, we can’t fail to consider that the presence of three peaks makes it 
difficult to analyse the cell cycle status, and this may have led to the striving in 
the interpretation of the results.  
 
3.5.4 Clonogenicity 
In terms of clonogenic analysis, both the KD and KO produced cell lines with a 
reduced capacity of colony formation in 2D colony forming assay and 
neurosphere formation in 3D soft agar assay. Specifically, for: 
- U87: both the shRNA KD and CRISPR KO produced a cell line with a 
reduced clonogenic potential (Figure 3.26 and Figure 3.32); 
- UP007: this cell line presented a mixed picture, with the shRNA 
knockdown producing a cell line with a reduced clonogenic potential and 
the CRISPR KO producing a cell line with and increased clonogenic 
potential(Figure 3.28 and Figure 3.32); 
- UP029: as for the U87, both the shRNA KD and CRISPR KO produced a 
cell line with a reduced clonogenic potential (Figure 3.28 and Figure 
3.32); 
 
In Table 3.8 the summary of the effects of Cav-1 expression modification in the 
three major cell lines upon clonogenicity. 
 
Table 3.8 Effects of Cav-1 genetic Knockdown and knockout on GBM cell lines clonogenicity.  
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The general positive effect of Cav-1 on clonogenic potential (the reduction of 
Cav-1 expression correlates with a reduction in the clonogenic potential) may 
suggest that Cav-1 has an oncogenic role. These results included both the 
plastic condition (colony forming assay) and the 3D stem system (soft agar 
assay), meaning that the effect of Cav-1 expression on clonogenicity is not 
dependent on the cells environmental conditions. Moreover, in every assay, it is 
possible to observe that spheres/colonies produced by Cav+ cells are always 
consistently larger than the negative counterpart, and the colonies are also 
always less dense. This could confirm the hypothesis of Cav-1 absence as a 
difficulty for cells that have to start proliferating. In this sense, cells may start 
proliferating later and produce smaller and sparser colonies when Cav-1 is 
depleted.  
It is possible to infer that the negative modulation of Cav-1 leads to a disrupted 
signal communication, resulting in cells delaying their proliferation rate with 
smaller colonies and sphere resulting in the clonogenicity assays, and cell cycle 
un-synchronicity which may lead to the reduced clonogenic potential of the Cav- 
cells. 
Lastly, the Cav-1+ cells appeared to display increased migration of cells away 
from the formed neurosphere, i.e. Cav-1 appeared to promote cell migration. 
This observation would be important and concordant with the in vitro invasion 
studies reported in the next chapters.  
 
3.6 CONCLUSIONS  
The hypothesis of the work is that Cav-1 serves as a modulator of the functional 
properties of cancer stemness in high-grade glioma, grade IV astrocytomas, 
either as a suppressor or promoter. Specifically, that in sub-populations of 
glioma cells Cav-1 has a critical role in interplay with other pro-stemness 
molecules to impart cancer stem cell (CSC)–like activity, including the ability for 
self-renewal and increased clonogenicity and the ability to migrate and invade 
tissue.  
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The first objective was to create a series of stable glioma Cav-1-depleted cell 
lines, to understand the role of Cav-1 biology in glioma stem-cell phenotype and 
function. The initial lentiviral knockdown (KD) was compared to the newly 
developed technology CRISPR knockout (KO). The conclusion of the study is 
that they both present advantages and disadvantages. The RNAi KD is easier, 
cheaper and quicker to achieve and can be applied to a variety of difficult 
conditions (i.e. primary cell cultures) but it still produces only a reduction of the 
protein expression; moreover, its dependence on antibiotic selection contribute 
to its reduced reliability. The CRISPR KO produces straightforward phenotypes 
that can be related directly to the protein absence and doesn’t need antibiotic 
selection; on the other hand, it is more complicated to achieve, it’s expensive 
and not very efficient, and requires a clonal selection that is slow to achieve and 
must be confirmed by more than one clone. In the end, we must conclude 
anyway that, we feel more comfortable with the results of the cell lines derived 
by CRISPR KO than the RNAi technique.  
The knockdown/knockout techniques partially showed that Cav-1 has a positive 
impact on glioma cell lines clonogenicity and enhance cell cycle progression. 
From the study, however, it was not possible to observe consistent results 
across the cell lines. This may be due to cell lines heterogeneity. Some cell lines 
may have indeed other activated/suppressed pathways that attenuate the 
impact of Cav-1 on the cell lines phenotype. 
In the future, Cav-1 could be confirmed as driver of clonogenicity with in vivo 
tumourigenicity. Orthotopic injection of Cav+ and – cells could help 
understanding if Cav-1 is relevant for the tumour formation in vivo, thus 
confirming the clonogenicity results.  
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4.1 INTRODUCTION 
Cancer invasion is a complex process that needs in vitro and in vivo assays 
able to capture all its features. Among all the possible in vitro invasion assays 
available, the 3D invasion assay most likely captures the complexity of the 
phenomenon. Cells are first grown in a spheroidal state, under non-adherent 
conditions, and then surrounded by a matrix recalling the ECM. Invasion 
through the matrix can be followed in time by optical microscopy, or other 
imaging techniques. 
It is clear from the literature that the 3D spheroid technology is taking the place 
of the classic transwell-based invasion assay, and the field is rapidly advancing 
and expanding toward both discovery and translational cancer research, with 
potential in drug development and testing. 
However, when the project was started, there was a lack of a tool for the 
unequivocal quantification of the assay. 
Spheroid integrity and cellular invasion in the 3D invasion assay system can 
easily be visualized by phase-contrast imaging (manual or automated), which 
can be applied for recording spheroid volume growth and invasion kinetics. 
If from a qualitative point of view the interpretation of the 3D invasion assay is 
mainly straightforward and allows several kinds of studies and considerations, a 
quantitative point of view is also necessary to establish the reproducibility and 
the statistical significance of the qualitative observations. Many steps have 
been made in order to produce a satisfactory methodology for this necessity, 
but up to now, there is no standard system that is approved and shared among 
the scientific community. 
Two main difficulties to overcome for an effective invasion analysis of 2D bright 
field greyscale images, which can be inferred by observing Figure 4.1 were 
addressed. The first problem is intrinsic of the quality of pictures from inverted 
phase-contrast microscopes; in this kind of images the object, i.e. the spheroid 
with its invasive protrusions must be distinguished from the background. When 
the spheroid is compact and intact (like during the spheroid formation, before 
the embedding in the 3D matrix, or if the spheroid is formed by non-invading 
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cells) the compactness of the cellular material results in an optical dense 
aggregate, which can be distinguished easily from the background (Figure 
4.1A) even if the latter is dark. When the spheroids are invading (Figure 4.1), on 
the contrary, the finger-like projections are not uniformly dense anymore (Figure 
4.1C) and are lighter than the background. While the operator can easily 
understand between the background and the invading structures, an automated 
software that uses pixel density to distinguish the background from the cellular 
material will start including outside pixels before including the finger-like 
projections’ ones.  
 
Figure 4.1 2D greyscale images of 3D spheroids embedded in BME. A- Day 0, after embedding. 
B- Day 2 after the invasion. C- Enhanced image of field of view highlighted in B. 
 
The second problem is the need to distinguish the core of the spheroid from the 
invasive edges. Figure 4.2 reports three exemplified spheroids with the same 
invasive ability (traced by the red line and the number 100). On the other hand, 
the three spheroids occupy three different areas of the total image. This is 
because their cores, which are the parts of the spheroids that are not invading, 
behave differently in time. They, in fact, start all with the same size at Day 0 but 
then evolve differently. The first one increases in size more rapidly than the 
others (rapid proliferation), the second one is maintaining more or less the 
same size (the cells abandoning the core for the invasion process are replaced 
by cells proliferating at a lower rate than the ones of the first spheroid) and the 
third one is shrinking (cells are not proliferating enough/at all). This means that 
the invasion ability of the three spheroids is the same, while other processes 
are active or not, and they have to be taken into consideration. This results in 
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operators classifying spheroids invasion differently even if their net extent of 
protrusions is the same. 
This important aspect is often underestimated since few image analysis 
algorithms can distinguish the spheroid core (i.e. the original cellular mass that 
may have undergone varying extents of proliferation) and the spheroid invasive 
edge (representing motile cells invading the ECM).  
 
 
Figure 4.2 Considerations about the influence of the Core area over the total invading spheroid 
area. 1- Spheroid with high proliferation rate. 2- Spheroid with low or non-proliferating Core. 3- 
Spheroid with reducing core over time. The schematic comparisons are referred to a Day n 
spheroids. 
 
In the next part the main attempt at a quantification of the 3D invasion assay 
based on 2D grayscale phase-contrast images. The studies are summarised 
schematically in Table 4.1.  
 
 140 
Table 4.1 Methods for quantifying 3D spheroids and invasion in literature, with a preview of 
INSIDIA ability.  
Reference 
Geometric 
Parameters 
Isolation 
of Core 
and 
Invasion 
Specific 
Surface 
Open 
Source 
Software 
Semi-
/Automated 
Image 
Processing 
Stein 2007       
Friedrich 
2009  
     
De Wever 
2010  
     
Naber 2011       
Vinci 2012       
Blacher 2014       
Vinci 2015       
Solomon 
2016  
     
Ivanov 2014       
INSIDIA       
 
The first one is by an American group, led by Andrew M. Stein. Their 
mathematical model consists in quantifying the radius of the invasion in an 
image I. They calculated the magnitude of the gradient of the image, G =|I| 
and averaged it over the azimuthal angle to find (r). Then they defined the 
radius of invasion to be the distance farthest from the centre where (r) was 
half its maximum. The radius of the core was scored attributing at the darkest 
pixel (centre of the spheroid) the value 0 and the lightest pixel (background) 
value 1. The core was identified as the set of pixels with an intensity of <0.12. 
They chose this value because it corresponds to a region of the image where 
the pixel density is still high, but it is also rapidly decreasing, as for the passage 
from the core to the invasive edges, and also because it corresponded the core 
boundaries established by an operator in an experimental situation. Typical 
results are reported in Figure 4.3  
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The system is interesting even if not reproducible without the software. 
Moreover, it is important to point out, even from the representative results 
(Figure 4.3) that the algorithm seems not to be able to capture the total extent 
of the cells invading, which can result in an underestimation of the invasion 
process. 
 
Figure 4.3 Mathematical model that quantifies the distance of the invasion from the Core. 
Adopted from (A. M. Stein, Demuth, Mobley, Berens, & Sander, 2007)  with permission. 
 
The second work reported is from a Friedrich et al, published in 2009 (Friedrich 
et al., 2009). They didn’t actually quantify invasion but only the spheroids in 
suspension. Anyway, their important work provides multi-parameters for the 
interpretation of the assay outcome and also in a context of the semi-automated 
environment, not only in terms of image analysis but also for the setting of the 
assay (Figure 4.4). The group used a collaboration with Zeiss (Echingen, 
Germany) to image the spheroids and then to analyse them, through image 
processing algorithms implemented in the Zeiss AxioVision 4.5 Software. They 
reported that the software allows reliable and reproducible area selection to 
determine spheroid diameter and volume. Among the generated data there was 
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morphometric information, such as spheroid area, mean spheroid diameter, 
spheroid volume, minimum diameter, maximum diameter, circularity.  
They then focused on the analysis of tumour volume in different cells lines. 
Even if not relevant for the discussion of the invasion analysis it seems 
important to point out their observation that a certain size has to be reached by 
all spheroids to allow a drug treatment that can be reproducible and comparable 
within a range of different samples. 
 
Figure 4.4 Spheroid assay setting and analysis by. Adopted from (Friedrich et al., 2009) with 
permission. 
 
The third work reported is from a Belgian group, that analysed invasion in 
Collagen 3D matrices, by the use of ImageJ (NIH, Bethesda, MD, USA), an 
open-source software for image analysis (De Wever et al., 2010).  
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After converting the image in 8-bit type, they used ImageJ manual threshold to 
highlight the areas interest and convert them into black areas (Figure 4.5B) for 
a resulting binary (black/white) image. They subsequently manually “cleaned 
up” the images by excluding all particles less than three pixels in size and 
removing any artefacts (by comparison of the binary image with the phase- 
contrast pictures). At this point, they used the analyse particle to measure all 
remaining particles in the images in terms of area and perimeter of individual 
particles and recorded the area of the sum of individual particles. Other 
parameters (Figure 4.5C) included the shape factor, which refers to the ratio 
between perimeter and area and gives an idea of how the shape of the 
spheroid is close to a perfect circle (shape factor equal to 1) and the percent 
fragmentation, which is calculated as the percent of single or clustered cells 
released from the total spheroid area. 
This system is interesting for its use of ImageJ as image analysis software. 
However, all the work on every single picture is manual and laborious. 
Moreover, the manual threshold of ImageJ, being operator-dependent, is not 
precise and does not discriminate all the cellular material present in the image 
(see Figure 4.1). 
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Figure 4.5 Representative data of a heterotypic spheroid collagen invasion assay. (A) GFP -phase 
contrast pictures of a representative GFP-colon cancer cell spheroid followed at different time 
intervals under control conditions and myofibroblast coculture conditions. (B) Computerized 
binary image processing of GFP-phase contrast pictures. (C) Factor shape (S) is calculated from 
perimeter2/4π area and is shown in red +/-SEM. A higher number means a more irregular, 
infiltrating spheroid structure. Fragmentation (%) is calculated from released cells or clusters/total 
area x100 and is shown in black +/-SEM. Adopted from (De Wever et al., 2010) with permission. 
 
Further on, a group from Leiden (Netherlands) in 2011 used Adobe Photoshop 
Extended (San Jose, CA, USA) and its “quick selection tool” to manually select 
the area occupied by the cellular material, and then measure the total area and 
subtract the area at Day 0 (Figure 4.6). This method (H. Naber, Wiercinska, ten 
Dijke, & Laar, 2011) is straightforward and easy for the user to understand, and 
can reach a high Level of accuracy. Anyway, it is also extremely laborious, 
especially when cells are invading in highly ramified projections and when a lot 
of replicates and time points have to be analysed at once. The fact that the 
Photoshop software is not free-licenced is another disadvantage, even if it is 
possible to do the same process with the drawing tool in ImageJ. The 
laboriousness, however, would force the users to look for other solutions. 
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Figure 4.6 Quantification of the area of the spheroids using Adobe Photoshop Extended. (A)  The 
picture of the spheroid is opened in Adobe Photoshop Extended (B) Selection of the Quick 
Selection tool (C) Dragging the cursor over the spheroid to select the area of the spheroid (D) 
Removal of a wrongly included area using the negative Quick Selection tool (E) Adjustment of 
the brush size of the Quick Selection tool to more accurately select the area (F) Selection of the 
measurement command to record (G) Example of a measurement record. Adopted from (H. Naber 
et al., 2011) with permission. 
 
In 2012 a group from London (Vinci et al., 2012) published a paper for the high 
throughput study of spheroids, both in terms of drug screening and invasion.  
Image analysis is performed this time on a Celigo cytometer (Nexcelom, 
Lawrence, MA, USA) by using the Cell Counting Confluence application, which 
calculates the area occupied by individual or groups of cells, after manual 
image segmentation around the invading cells (Figure 4.7). Even here, apart 
from the advantage of using a high-throughput machine that allows the 
automatic record of each time point and replicates, the segmentation (the 
drawing of the interphase between the cellular material and the background) 
can be done with a licenced software or manually if a free-tool is the only one 
available. 
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Figure 4.7 Schematic overview of 3D tumour spheroid invasion assay analysis. On the left U87 
invading in the surrounding BME. On the right the same image a fter segmentation by Image Pro 
Analyser software (Vinci et al., 2012). 
 
Moreover, Vinci decided to calculate invasion by simply reporting the total area 
occupied by the cellular material, without taking into consideration different 
densities of invasion (few cells creating an extensive net are not the same as 
many more cells invading altogether) or any change in the core. 
One of the works that appear to be more accurate among the so far published 
ones, is the one of a Belgian group, led by Agnès Noel (Blacher et al., 2014). 
The group smartly recognised the importance of good segmentation and core 
thresholding (distinguishing the core from the invasive edge). They decided to 
use an algorithm developed for the highlight of blood vessels in angiograms, so-
called Frangi filter (Frangi, Niessen, Vincken, & Viergever, 1998), for a spheroid 
segmentation that allows the accurate reconstructions of all the finger-like 
projections emanating from the spheroid (Figure 4.8D and E). Plus, they used 
pixel density, like Stein (A. M. Stein et al., 2007), to distinguish the Core from 
the invasive edges. They essentially drew a sequence of concentric circles, 
starting from the centroid (Figure 4.8K), and recorded the average pixel density 
along the circles and then plotted them against the distance from the centroid 
(Figure 4.8M). They then use the resulting profile to select the average distance 
from the centroid to the end of the Core (as the one where the pixel density is 
arriving at 0.8, where 1 is the darkest pixel and 0 the lightest). From that they 
could calculate the radius of the Core and the extension of the invasive edges 
plus, through integrals, they could take into consideration also the density of the 
cells invading and the spheroids proliferating. The system is very clever and 
potentially perfect for quantifying invasion in a 3D context, if it were not for the 
fact that the software that they used is a MATLAB-based script, not provided 
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with the paper, so virtually not useful for the common average operators. Plus, 
MATLAB (MATLAB and Statistics Toolbox Release 2012b, The MathWorks, 
Inc., Natick, Massachusetts, United States) is not only a licenced tool, but also 
a software that requires a certain amount of experience in programming and in 
script composition, with its specific language, which is not applicable in projects 
that are not purely models but includes an extensive experimental plan other 
than the 3D invasion assay.  
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Figure 4.8 Description of the spheroid assay and the method of quantification (Blacher et al., 
2014). (a) Schematic representation of spheroid evolution during cell culture. (b -e) Spheroid Day 
0-n, greyscale and segmented. (f–i) Decomposition of the binarized image into spheroid core (f), 
edging cells (g) and detached cells (h) and composite (i). (j) Illustration of the parameters used for 
global measurements: convex envelope (green) and the total distance of cell invasion starting from 
the spheroid centre (d1) or border (d2). (k) The grid used for local measurements: a circular grid 
is superimposed on the coloured spheroid representation. (l) Comparison of global and local 
measurements at t = 0 and t = 24 h. (m) Graph representing the cell density distribution measured 
from the image. The colours of the curves correspond to the different spheroid components 
described in the other panels (a, i and k). Bars = 500 mm.  
 
Finally, in 2014 a group composed a macro on FIJI (Schindelin et al., 2012b) 
platform for the segmentation of spheroids in suspension and the computation 
of geometrical parameters (Ivanov et al., 2014). Their segmentation was 
obtained by the Yen thresholding algorithm (Jui-Cheng Yen, Fu-Juay Chang, & 
Shyang Chang, 1995), present in the FIJI package, while the geometrical 
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parameters include Area and Ferret min and max diameter. The measured area 
was then used to retrospectively calculate the radius and volume of an 
equivalent sphere, and consequently to compare volumes of different time 
points.  
The advantage of this approach is their effort to automatize the analysis 
process in a FIJI macro (the updated version of ImageJ) that they make public 
for the scientific community. On the other hand, the Yen segmentation algorithm 
is not as accurate as the manual outline performed by the other group. This is 
of course still acceptable for the Nottingham’s group because they are 
analysing spheroids in suspension, and not invading ones. 
 
4.2 SCOPE OF THE CHAPTER 
In this chapter, cell lines characterized in the previous chapter have been 
analysed for their invasion ability, through the use of the 3D invasion assay. 
An optimization of the protocol has been performed, as well as an effort for a 
reproducible, efficient and easy to use tool for the analysis. In fact, while image 
analysis software capable of detailed quantitative analysis of 3D spheroid 
assays are available, they are mostly licensed for a particular microscope 
platform, or are limited in terms of calculable parameters and not customisable 
by the end-user, for this reason we developed a new tool, based on ImageJ, for 
invasion assay analysis.  
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4.3 MATERIALS AND METHODS 
4.3.1 CELL LINES AND TREATMENTS 
U87, U373, UP007 and UP029 transfected for the lentiviral-mediated shRNA 
silencing of Cav-1, have been used for the analysis of in vitro invasion, as well 
as U87, UP007 and UP029 genetically modified by CRISPR technique. 
 
4.3.2 METHODS- INVASION ASSAY (3D CELL SPROUTING 
ASSAY) 
4.3.2.1 ASSAY SETTING 
The invasion assay was performed according to Vinci et al (Vinci et al., 2012) 
and is summarized in Figure 4.9. Cells were seeded in a 96-well plate, treated to 
obtain ultra-low adherence conditions (ULA) and round-bottomed (COSTAR-ref. 
7007). The optimal seeding concentration was established experimentally as 
1000 cells/well for the U87 and 5000 cell/well for the other cell lines. After the 
seeding, cells were gently centrifuged (300g - 1 min) and incubated for four days 
at 37° C 5%pCO2 to allow the formation of tight aggregates. After that half of the 
medium was replaced with growth growth factorreduced MATRIGEL™ (Corning, 
ref. 354230) on ice and the plate was left on ice for one hour to allow the 
homogeneous diffusion of the Matrigel and the medium and then incubated 
again at the same conditions to allow the jellification of the matrix around the 
aggregates. After one hour, new medium was added to the jellified wells and 
pictures were taken immediately after and every 24 hours for 2-4 days 
(according to the invasive ability of the cell line under examination). 
The analysis of the 2D grey scale projection pictures was obtained by the use of 
a customizable script in FIJI, reported in the appendix 5 (Moriconi et al., 2017). 
 
 
 
 
 151 
 
Day	0	 Day	2-4	
 
Figure 4.9 Invasion assay- experimental procedure. Cells are seeded in a low-adherence round 
bottom multi-well plate and after four days one single sphere per well can be observed. Half of the 
medium is then replaced with Matrigel and the cells can be followed in time.  
 
 
Figure 4.10 Invasion assay. Acquisition of images procedure. After the gelification (D0) of 
Matrigel, each well is imaged at 5x magnification and stored in separate folders. Every day and at 
the end of the assay (D2-4) the procedure is repeated, and images are stored in the corresponding 
folders. 
 
 
Figure 4.11 Matrigel diffusion study. Half of the spheroid phenol red-free medium was replaced 
with matrigel, as described in previous protocols (Vinci et al., 2012) and the plates were kept on 
ice until a homogeneous distribution of colour was achieved. Time reported in the pictures is in 
minutes. 
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4.4 RESULTS AND DISCUSSION 
4.4.1 ASSAY SETTINGS 
From a qualitative point of view, many features can be observed, like single cell 
leaving the spheroid (Figure 4.12A), starting replicating in the MATRIGEL™ 
(Figure 4.12B) and collective invasion (Figure 4.12C). 
 
 
Figure 4.12 Time lapse pictures of spheroid embedded in Matrigel with single cells leaving to 
invade (white arrow in A) and starting to divide outside the spheroid (grey arrow in B). In C it is 
possible to observe chains of cells (white arrows) leaving the spheroid in an organized structure.  
 
In this chapter, we focused on the 3D invasion assay of wild-type GBM cells and 
their quantification. 
 
4.4.2 INSIDIA 
Considering all the efforts formulated in the past for the quantification of the 
invasion that have been described in the introduction section, we decided to 
elaborate a new tool for the purpose that would be free to use, would use the 
useful features from past attempts and that would allow quantifying invasion in 
the most efficient, automatized and quick way. To do that we chose FIJI, the 
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new version of ImageJ, an open-source platform with a user-friendly interface, 
and the help of Dr Valentina Palmieri, as an expert in FIJI coding language. 
We wrote a script with the ImageJ language, that we called INSIDIA (Invasion 
SpheoID Invasion Analysis) and published in 2017 on Biotechnology journal 
(Moriconi et al., 2017). INSIDIA code is reported on Appendix 5. 
As mentioned before, two steps are important for the quantification of invasive or 
non-invasive spheroids. The first is the distinguishing of the cellular mass from 
the background, the so-called spheroid segmentation, while the second one is 
the ability to establish the point of transition between the core and the invasive 
edges, the Core thresholding. Both can be done manually and arbitrarily, or 
with the help of software tools. 
4.4.2.1 PRE-ANALYSIS: SEGMENTATION 
As shown in Figure 4.13, and as described in the introduction for the spheroid 
segmentation, a classic ImageJ thresholding method (not to be mistaken with 
the Core thresholding, described later), based on pixel density is not able to 
include all the invasive ramifications (Figure 4.13 middle). On the contrary, the 
Frangi filter, described by Blacher et al. (Blacher et al., 2014) is able to capture 
effectively all of them, as shown in Figure 4.13 (right). Since this filter is 
available for the ImageJ platform, we decided to use it as our tool for spheroid 
segmentation.  
 
Figure 4.13 Comparison between two thresholds (middle and right), on the same picture (left). 
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4.4.2.2 PRE-ANALYSIS: CORE THRESHOLDING 
As for the core selection, we had to understand how to establish the 
thresholding. We tried first arbitrarily to select a pixel density value but there was 
a necessity for a more universal method that would be adequate for different 
illumination methods and different cell lines. We then tried to select a pixel 
density that would represent a percentage of decrease of pixel density from the 
darkest pixel, that in theory is in the centre of the core (an example in Figure 
4.14). However, this method doesn’t’ take into consideration the heterogeneity in 
core pixel density displayed by some cell lines. For those cell lines, the resulting 
possible cores are very fragmented, and it is not possible to find a core 
threshold that is unequivocally mirror of the real Core.  
 
 
Figure 4.14 3D spheroid image segmented for three possible cores based on pixel density 
percentage decrease. Each line represents a possible core outline. Red 10%, Green 20% and Blue 
30% from the maximum pixel intensity. 
 
We applied both the arbitrary pixel density value and the percentage of 
decrease of the Blacher Core thresholding method (Blacher et al., 2014). As 
reported before the method consists in drawing concentric circles on a 2D 
picture from the spheroid (Figure 4.15B). Each circle is bigger than the previous 
one of 1 pixel. The recorded average pixel density is then plot for each circle 
against the distance from the centroid of that specific circle. The result is a 
density profile (Figure 4.15C) where the pixel density starts from the maximum 
value, which represents the core and then goes down when the circles pass 
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from the core to the invasive edges and the to the lower point when they reach 
the background.  
 
Figure 4.15 Core thresholding method. A- original 8-bit picture. B- Concentric circles are drawn 
from the centroid for recording average pixel density. C- Circle average pixel density plotted 
against distance from the centroid to get density profile, for the calculation of parameters, among 
which the Core thresholding density value, that is used to differentiate Core and Invasive edges on 
both the profile and the density map (D).  
 
We then studied the best way to calculate the point in the density profile where 
the core was transforming in invasive edges. Blacher et al (Blacher et al., 2014) 
set the pixel scale as a max density of 1 and a minimum density as 0 (Figure 
4.17A) and then decided that the Core would have ended when the pixel density 
would reach on the plot the value of 0.8. After manually studying several 
pictures at day 0, we established that at the transition the pixel values are 
decreasing rapidly but as an intermediate point in our scale (255 to 0) 100 could 
be chosen as an arbitrary point. 
4.4.2.3 PRE-ANALYSIS: NORMALIZATION 
in order to normalize and allow comparison of images acquired with different 
illumination settings we needed to adopt a new normalization standard. The 
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classic normalization process consists in stretching the pixel density so the 
darkest pixel is 255 (black in the pixel intensity value scale- Figure 4.16D) and 
the lightest 0 (white- Figure 4.16B). This resulted in the flattening of differences 
between spheroids with different core densities, which reflects the compactness 
of the cellular material. Our solution was to normalize only on the lightest pixel. 
The lightest pixel density value was then subtracted to all the image pixels 
(Figure 4.16C). This resulted in images that can be compared because they 
have the same value of background, but their core differences are maintained 
(Figure 4.16F). 
 
Figure 4.16 Image normalization options. A- Original pictures with values representing darkest and 
lighter pixel density. B- Classic normalization. Pixels area stretched to 255 and 0, black and white. 
C- New normalization. Only the lightest pixel is subtracted to all pixels. D- Pixel density scale 
with the values of the two original pictures. E- Density profile after classical normalization. F- 
Density profile after new normalization. 
 
4.4.2.4 ANALYSIS: CORE THRESHOLDING 
After the new normalization, however, the use of an arbitrary value was not 
possible anymore, because some spheroids with light cores do not reach a 
density of 100 after the normalization process. So, we used a value of 
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decreased pixel density (Figure 4.17C). In the beginning, we thought it would be 
better to have a user-customizable method and we decided to let the user 
decide the percentage of pixel density decrease to be used for all spheroids (an 
example in Figure 4.14). But that posed two problems, of which the most 
important was again the heterogeneous cores. They can indeed reach the 
designated pixel density decrease because of a reflection phenomenon and not 
because the invasive edges already started; that would result in a core 
thresholding that is valid for some replicates but not for others. And from this, it 
derived the second problem, which is that all the system was becoming time-
consuming, the decision of the most suitable Core thresholding.  
The final method we adopted (Figure 4.17D) is based on the software drawing a 
square that encapsulates the two axes on the left and bottom, touches the 
maximum pixel density on the top and starts from the end of the density profile 
on the right. By moving to the left until the area under the curve of the density 
profile corresponds to at least the 90% of total area of the square, the value of 
pixel intensity that intercepts the square is set as core thresholding value. This 
guarantees that the software can capture the darkest part of the profile, without 
the interference of lightest aberrations in the core. This can also be customised 
in the code, for users that have very dense (>90%) or light (<90%) replicates. 
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Figure 4.17 Core thresholding attempts in chronological order. A- Core threshold is established 
when pixel density reaches 100. B- Core threshold is set when pixel density decreases of 30% from 
the maximum pixel density. C- Core threshold is set as the pixel density of a box encasing the two 
axes, the maximum pixel density and the point of the profile that makes the area under the curve 
occupying at least 90% of the box area.   
 
4.4.2.5 ANALYSIS: DENSITY MAP 
Finally, once established the Core thresholding, the pixel intensity value is 
applied to the segmented picture (cellular mass without background) and the 
area corresponding to the range of pixels with an intensity higher than the core 
thresholding intensity value is considered as the Core of the Spheroid, while the 
remaining part is considered the Invasive edges (Figure 4.15D). The area in 
pixel2 is then converted in m2. Here the technical issue to be solved involves 
the size of the Cores, which has been demonstrated earlier in the Introduction 
(Figure 4.2), as a determinant of misinterpretation of the net invasion. We solved 
this issue by normalizing the area of the invasive edges on the perimeter of the 
core. 
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4.4.2.6 SUMMARY OF OVERCOME TECHNICAL ISSUES 
In Table 4.2 the main technical issues for the analysis of 2D images of 3D 
invading spheroids have been summarized.  
Table 4.2 Technical issues related to the computed analysis of the 2D pictures of 3D invading 
spheroids. 
N° CATEGORY ISSUE SOLUTION FIG. 
1 
Image 
processing 
Large number of images. 
Laborious. 
Batch mode  
2 
Image 
processing 
Intercellular differences 
depending on patterns of 
invasion 
Customizability  
3 
Image 
normalization 
The classic 225-0 
normalization method 
flattens the differences of the 
cores, which are due not 
only on illumination but also 
on actual cellular density. 
New method in which the lightest 
pixel intensity value is subtracted 
from every other pixel value. 
Figure 4.16 
4 
Image 
segmentation 
The classic pixel intensity 
ImageJ threshold is not able 
to capture completely the 
invasive edge, resulting in 
an underestimation of the 
invasion area. 
Frangi filter Figure 4.13 
5 
Density 
profile 
A single pixel intensity value 
for all the images is not able 
to reflect the real end of the 
core. The result can be a 
core that is too big (e.g. part 
of the core in the invasive 
edge) 
“Red box” method: a box is drawn 
around the plot. The right side is 
intercepting the coordinate with 
which the box area is represented 
by at least 90% of the area under 
the curve of the plot. The pixel 
intensity value of that coordinate 
is used then as core threshold in 
both density profile and map. 
Figure 4.17 
6 Density map 
Invasive edge area is 
different in spheroids with 
same invasive capacity but 
with different core sizes. 
Normalization of invasion area on 
perimeter core derived from 
density map. 
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4.4.2.7 INSIDIA PARAMETERS 
The analysis of INSIDIA can calculate and make available 3 categories of 
parameters, summarized in Table 4.3: 
-  The segmentation parameters are essentially geometrical parameters 
that can be derived from the geometric analysis of the image after the 
segmentation. As already described in the previous works presented in 
the introduction they can give a rough tool of comparison for highly 
invading cell lines versus poorly invading ones, like the total area, and the 
shape-specific parameters (such as Circularity, SpecSurf, ShapeF and 
Env Area). However, they can be also used for the derivation of other 
categories’ parameters, like the centre of mass and the maxRadius for 
the density profile. 
- The density map parameters are the ones derived from the pixels 
highlighted after the Core thresholding. They are represented by the area 
of the core and the invasive edges, the percentage of the total area 
represented by those areas and the perimeter of the core after the 
density map, that serves as normalization tool for the net invasion area. 
- The density profile parameters consist of the parameters derived from 
the analysis of the density profile and the Core thresholding. They are 
represented by the distances between the Centre of mass and the end of 
the Core and the one from the end of the core and the end of the invasive 
edges, and the areas under the curves (obtained by integrals) that belong 
to one or the other cellular compartment. They give not only information 
about the distance of invasion but also information about the density of 
that invasion, since cells invading for the same length may invade in few 
strings or in large numbers, as mentioned previously. 
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Table 4.3 INSIDIA parameters 
VARIABLE SEGMENTATION PARAMETERS 
Areatotal Area of the Spheroid 
Perimeter Perimeter of the Spheroid 
Xc, Yc Centre of Mass Coordinates 
maxRadius 
Maximum Radius of the Spheroid, calculated as half of max Feret’s diameter 
(The longest distance between any two points along the selection boundary, also 
known as maximum calliper) 
minRadius 
Minimum Radius of the spheroid, this is calculated as half of the min Feret’s 
diameter (minimum calliper) 
Circularity 
The circularity of the SS calculated with the formula 4π*Area/Perimeter2 with a 
value of 1.0 indicates a perfect circle. As the value approaches 0.0, it indicates 
an increasingly elongated shape. 
RadiusE Radius calculated using the best fit ellipse (half of the major axis) 
SpecSurf 
Specific surface: the ratio of the perimeter over its total area, is employed to 
quantify the degree of “fingering” of the growing tumour. For a perfectly circular 
shape with radius R, the associated s is given by 2/R, which is the minimum 
value among all shapes with the same area. The specific surface of a tumour in 
excess of that of a circle provides a measurement of the roughness of the 
tumour surface and thus, the degree of “fingering”. The formula used is 
s/(2/maxRadius). 
ShapeF 
The shape factor is calculated using the following formula (perimeter)2/4π(area). 
It gives a minimum value of 1 for a perfect circle and larger values for shapes 
having a higher ratio of perimeter to area. 
EnvArea 
the envelope area, defined as the area of the minimal convex polygon containing 
the whole spheroid 
 DENSITY MAP PARAMETERS 
AreaCore Area of pixel with intensity>CT 
AreaInvasion Area of pixel with intensity<CT 
PercCore AreaCore /AreaTotal*100 
PercInvasion AreaInvasion /AreaTotal*100 
PeriMap Perimeter of DensityMap Core 
 DENSITY PROFILE PARAMETERS 
Profiles.txt 
Coordinates of the profiles, conversion is applied to the X coordinates. Y 
coordinates represent normalized intensities 
ACMtotal Area under the density profile curve (arbitrary units) 
ACMcore Area under the density profile curve below the CT (arbitrary units) 
ACMinvasion Area under the density profile curve over the CT (arbitrary units) 
ACMPercCore (ACMcore/ACMtotal)*100 
ACMPercInvasion (ACMinvasion/ACMtotal)*100 
RadiusCore Core Radius obtained with CT 
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4.4.3 GLIOMA CELL LINES INVASION INHIBITION MEDIATED 
BY SRC INHIBITOR, SARACATINIB 
To test the new script, before applying it to the analysis of Cav-1 influence over 
GBM cell lines invasion in a 3D system, we tested two of the cell lines for their 
invasion, under the influence of the treatment with an inhibitor of Src, 
Saracatinib-AZD0530. Src has been proved as a mediator of cancer 
aggressiveness, both in terms of proliferation and invasion, with a particular role 
in adhesion, cytoskeletal reorganization and EMT (Green et al., 2009; Guarino, 
2010; Nam et al., 2013). Three concentrations of the drug were tested (500nM, 
1μM and 2μM). Representative pictures can be observed in Figure 4.18. 
The observed consistent decrease of the invasive edges, especially with the 
UP007 where this change was significant (Figure 4.18), proved the reliability of 
this assay in the invasion observation.  
 
 
 
 
CHAPTER 4: THE STUDY OF INVASION IN BRAIN TUMOURS 
 
163 
 
Figure 4.18 Src inhibition leads to a decrease in the invasion capacity in UP007. A: Representative 
pictures of UP007 at D0 and D4 treated or not with Src inhibitor at 3 three different concentrations, 
500nM, 1μM and 2μM. The experiment was performed three times with  n=3 replicates each time. 
CTRL represents cells treated with the same concentration of DMSO as the corresponding 
treatment. Scale bar 100μm. Graphs in B show the change of the Core, in terms of AUC of the 
Density profile, between D0 and D4 in all the conditions. Samples were compared using T-TEST 
between each corresponding CTRL and treatment. 
 
The UP029, on the other hand, showing a very small invasion propensity, make 
the observation of significant differences difficult (Figure 4.19). Interestingly 
when UP029 were treated with the Src inhibitor, they stopped invading and the 
formation of a cloudy material around the aggregates was observed. This 
material was thought to be the result of the production of other components of 
the ECM by the cells in the aggregate. Further studies may unravel interesting 
phenomena and mechanisms. 
 
CORE CHANGE NORMALISED INVASION 
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Figure 4.19 Src inhibition leads to a decrease in the invasion capacity in UP029. A: Representative 
pictures of UP029 at D0 and D4 treated or not with Src inhibitor at 3 three different concentrations, 
500nM, 1μM and 2μM. The experiment was performed three times with n=3 replicates each time. 
CTRL represents cells treated with the same concentration of DMSO as the corresponding 
treatment. Scale bar 100μm. Graphs in B show the change of the Core, in terms of AUC of the 
Density profile, between D0 and D4 in all the conditions. Samples were compared using T -TEST 
between each corresponding CTRL and treatment. 
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4.5 CONCLUSIONS 
The 3D invasion assay has been proven hard to quantify in a shared and 
unequivocal way. The necessity to compare experiments from different 
laboratories, with different cell lines and different imaging resources was 
addressed in this chapter. 
We developed a script, INSIDIA (INvasion SpheroIDImageJ Analysis), on the 
freeware software FIJI for the accurate high-throughput high-content analysis of 
3D cancer cell or organoid/spheroid invasion assays. This represents a step 
towards the collection of the analysis methods, that can be shared and 
implemented by the users, being the code made available (see Appendix 5). 
The macro can provide quantitative parameters about spheroids’ growth and 
invasive behaviour, and it can be easily adapted for both ﬂuorescent and bright-
ﬁeld greyscale images. 
Despite its efforts, INSIDIA is still not able to quantify the degree of invasion 
patterns, like single cells or collective invasion. This may need further research 
in the field, in order to get more information that can guide the implementation. 
Possible future applications could be the use of the assay, and therefore the 
INSIDIA tool, for the study of freshly-resected brain tumours samples, as a 
personalized tool for the therapeutical decision that can take into consideration 
also the invasive behaviour of the patients’ cancer. 
  
5 CHAPTER 5- MOLECULAR SIGNALING INVOLVED IN 
CAV-1 ROLE IN INVASION
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5.1 INTRODUCTION 
Cell movement is an important factor in the neural stem cell niche since 
quiescent cells can receive the signals to produce new neurons or new 
macroglia components and, after activation, start moving to restore the 
functionality of the damaged area. 
Invasion in cancer is tightly related to an aberrant EMT, the embryonic process 
during which cells pass from an epithelial to a mesenchymal phenotype, losing 
contact with the surrounding cells and breaking through different tissue 
components for the formation of new sub-tissues and, later on, organs (J. Zhang 
et al., 2015). Several distinct molecular processes are required to initiate an 
EMT as discussed in the introductory chapter. 
The invasion mechanism can differ from tissue to tissue, and from tumour stage 
to stage. For this reason understanding the patterns of invasion can help the 
understanding of the aggressiveness of the tumour, the patients’ prognosis and 
the therapeutical choices (Friedl et al., 2012). Cancer cells can invade as single 
or groups of cells and with an amoeboid or mesenchymal movement. Every 
pattern has specific molecular pathways involved, like the production of 
proteases or the cell-environment/cell contacts or the cytoskeletal 
rearrangements. 
Cancer invasion patterns are particularly relevant for high-grade gliomas, and in 
particular GBM, Glioma cells display a highly invasive behaviour that leads to 
the quick spreading of a tumour throughout both hemispheres (Brösicke & 
Faissner, 2015). This feature causes a dramatically shortening of glioma 
patients lifespan (Adamson et al., 2009), making it an important prognostic 
factor. 
The challenge for the surgical teams during GBM resection relies in the ability of 
cancer cells to migrate as single cells even to distant parts of the brain, following 
the perivascular niche or the white matter tracts. Despite precise and accurate 
surgical procedures, the removal of all malignant cells is impossible and the 
relapsing tumours exhibit high resistance to chemotherapy and radiation 
approaches (Bao et al., 2006; Giese et al., 2003).  
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The tumour has been 
removed
Surgery
Therapeutical 
failure
Therapy
A new brain tumour is 
diagnosed
 
Figure 5.1 The challenge of invasive brain tumours 
 
Invading cells contact both extracellular matrix and other cells and, according to 
the environment (the white matter tracts and the perivascular niche differ greatly 
in cellular and extracellular composition), different migration and invasion 
strategies are adopted for each barrier that have to be overcome. For example, 
the production of proteases for the digestion of the ECM, rearrangement of the 
cytoskeleton for the passage into narrow spaces, production and expression of 
adhesion molecules for the “grabbing” and “pulling” interactions necessary to 
move to distant sites. 
Cav-1 is believed to be part of all these processes since it is involved as a 
regulator of invasion major components, like proteases activation (Senetta et al., 
2013), signal molecules (Y. N. Kim et al., 2000), anchorage-independent growth 
and migration (H Lee et al., 2000). 
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5.2 SCOPE OF THE CHAPTER 
In this chapter, the analysis on migratory capacity (scratch assay) and the 3D 
invasion assay based on INSIDIA, are extended to the lentiviral-mediated Cav-1 
KD (U87, U373, UP007 and UP029) and the U87 CRIPSR knockdown (KO), for 
the exploration of the impact of Cav-1.  
Molecular mechanisms causing the phenotype modifications were also studied, 
using several tools, including protein arrays, PCR, Western blot and 
Immunofluorescence cells grown on plastic, on Matrigel and inside Matrigel, as 
single cells or invading spheres embedded in the ECM-mimicking material.
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5.3 MATERIAL AND METHODS 
5.3.1 EXPERIMENTAL CONDITIONS USED FOR EACH 
APPLICATION 
Cells were tested under different culture conditions, as shown in Figure 5.2. For 
Cav-1 modulation, both Lentiviral KD and CRISPR KO were tested on 2D plastic 
and in 3D spheres embedded in Growth growth factorreduced (GFR) Matrigel 
(Corning- cat. 354230). The CRISPR cell lines were also tested after growing on 
the top of 100% Matrigel or embedded as single cells in a layer of Matrigel 50%. 
 
Figure 5.2 Experimental conditions of cell lines adopted for each application described on the side. 
Cells have been grown in 2D plastic or on the top of a layer of undiluted Matrigel. In 3D cells were 
cultured as single cells embedded in 1:1 Matrigel:culture medium or as spheres in the ULA round 
bottom 96-well plates.  
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5.3.2 PROTEIN ARRAY 
Protein arrays kits (R&D Systems, Abingdon, UK) were used to explore the 
protein expression of human Oncology-related panel (Table 5.1), Angiogenesis-
related panel (Table 5.2), and human Phospho-kinases panel (Table 5.3). On 
each nitrocellulose membrane, antibodies directed against the target proteins 
were spotted in duplicate, together with positive (reference Spot) and negative 
control antibodies. 
 
Table 5.1 Proteome Profiler Human XL Oncology Array kit: Detectable proteins. The names of the 
proteins are accompanied by the duplicate coordinates of their targeting antibodies on the 
membranes. Reference spots are used as positive controls.  
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Table 5.2 Proteome Profiler Human Angiogenesis Array kit: Detectable proteins. The names of the 
proteins are accompanied by the duplicate coordinates of their targeting antibodies on the 
membranes. Reference spots are used as positive controls.  
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Table 5.3 Proteome Profiler Human Phospho-Kinase Array kit: Detectable proteins. The names of 
the proteins are accompanied by the duplicate coordinates of their targeting antibodies on the 
membranes. Reference spots are used as positive controls.  
 
 
The U87 CRISPR KO were cultured in 2D plastic and embedded in GFR 
Matrigel (Matrigel) as single cells, to select only cells interacting with the ECM. 
After four days, cells in 2D were lysed directly following the procedure already 
described in Chapter 2 (Western Blot section) and total protein amount was 
quantified, whilst Matrigel surrounding the 3D cell cultures was dispersed using 
Cell Recovery solution (Corning, REF. 354253). Wells were washed with ice-
cold PBS and the solution was applied for the resuspension of the 
cells/aggregates and the transfer in appropriate tubes. The suspension of 
CHAPTER 5: MOLECULAR SIGNALING INVOLVED CAV-1 AND INVASION  
 
174 
cellular material and Matrigel in the recovery solution was left on ice for one 
hour, with shaking, then cells were centrifuged at 200g for 10 minutes, washed 
with ice-cold PBS and centrifuged again. After recovering from Matrigel, cells 
were lysed, and total protein amount was quantified.  
 
A total amount of 200μg of protein lysate was loaded on each membrane and 
incubated on a rocking shaker over night at 4°C. The following day membranes 
were washed to remove the unbound material and incubated with the second 
set of biotinylated antibodies. Detection was mediated by Streptavidin-HRP 
incubation and chemiluminescent detection reagents application. The resulting 
signals in each spot were proportional to the protein expression of the markers 
under examination. Signals were detected and recorded by the same procedure 
as the Western Blot section in Chapter 2, following the kit instructions. 
Each signal was normalized to the negative and the positive control and only 
signals significantly higher than the negative control (>2 fold) were further used 
for the analysis. A fold-change value was derived by the ratio CAV+/CAV-, and 
ratios comprised between 0 and 1 were converted in a negative signal by the 
formula y=-1/x, where ‘x’ is the original ratio and ‘y’ the converted one. Only fold 
changes >1.25 and <-1.25 were then taken in further consideration. 
Fold changes were plotted in a heat map using Graph Pad Prism. 
Further studies about pathway and clustering of the significantly modulated 
proteins were conducted via KEGG Pathway 
(http://www.genome.jp/kegg/pathway.html), DAVID (https://david.ncifcrf.gov/), 
and MINT (http://mint.bio.uniroma2.it/HomoMINT/Welcome.do).  
Confirmation of protein expression data was obtained with Western Blot 
(described in Chapter 2 and in the following section). 
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5.3.3 WESTERN BLOT ANALYSIS 
U87 carrying the CRISPR-mediated Cav-1 KO were collected and processed 
following the procedure explained in Chapter 2. 
To assess the ability of cells to respond to stress, we obtained samples from 
serum-stimulated cells. Cell lines were seeded in normal conditions until they 
reached 80% confluence. Then the full medium was replaced with a serum-
deprived one. After 16 hrs serum was reintroduced for 10 minutes before 
collecting and lysing the cells, as usual. The serum stimulation procedure was 
used to test the expression of phospho-proteins in cells grown on plastic. 
Table 5.4 shows the antibody used for the protein expression detection and their 
dilution. 
The luminescent bands detected were quantified by FIJI software and plotted for 
comparison. Phospho-proteins were always normalized on their total form, while 
the total forms were normalised on the Housekeeping gene, like GAPDH, Beta-
Actin or Vinculin. 
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Table 5.4 Antibodies for the detection of target proteins and their use across applications, Western 
Blots (WB), Immunofluorescence (IF) on 2D plastic and on 2D Matrigel and in 3D Matrigel -
embedded spheroids. Suppliers for each antibody are indicated in the table.  
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5.3.4 RT-PCR FOR GENE EXPRESSION ANALYSIS 
The RT-PCR analysis was performed on CRIPSR-mediate Cav-1 KO U87 cell 
line and its positive control on cells growing in 2D on plastic and on a layer of 
Matrigel, as shown in Figure 5.2. 
5.3.4.1 TOTAL RNA EXTRACTION 
RNA extraction was obtained using TRIzol® Reagent (Life Technologies). Cells 
were collected in microcentrifuge tubes and resuspended in ice-cold PBS to 
eliminate any residual presence of medium. After pelleting at 300g for five 
minutes, cells were resuspended in TRIzol reagent and lysis was performed by 
repetitive pipetting.  
200µL of chloroform every 1mL of TRIzol were then added, samples were mixed 
by vortexing and then let incubate at room temperature (RT) for few minutes. 
After centrifugation (12,000g for 15 minutes at 4˚C), the aqueous top phase, 
containing RNA, was collected and combined with 500µL of isopropyl alcohol. 
Incubation at RT for 10 minutes was followed by a centrifugation step (12,000g 
for 10 min at 4˚C) for the precipitation of the isolated RNA. 
The supernatant was removed, and the RNA pellet was washed with 75% 
ethanol (1mL) and centrifuged (7500g for five minutes at 4˚). The last two steps 
were repeated twice. 
 RNA was let dry for 5-10 minutes at RT and then dissolved in DEPC-treated 
water. 
Isolated RNA was quantified by diluting it 1:40 in DEPC-treated water and 
analysing the solution with a spectrophotometer using absorbance at 260 and 
280. The ration 260/280 was considered acceptable when over 1.6, while the 
RNA concentration was derived by considering that 1OD at 260 equals 40µg/mL 
of RNA. Extracted RNA was labelled and stored at -80˚C. 
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5.3.4.2 REVERSE-TRANSCRIPTION 
The reverse-transcription step was performed using the High-Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems). This is based on the 
preparation of a 2x RT master mix that is diluted 1:1 with the RNA and amplifies 
the RNA using Random Primers. 
Before the reverse-transcription samples and kit components were defrosted on 
ice. 
The 2x RT master mix for the reaction was prepared as follow: 
Component Volume/Reaction (µL) 
10x RT Buffer 5 
25x dNTP Mix (100mM) 2 
10x RT Random Primers 5 
Multiscribe Reverse 
Transcriptase 
2.5 
RNase Inhibitor 2.5 
Nuclease-free H2O 8 
Total per reaction 25 
 
RNA was diluted to achieve 5µg each 25µL sample. The cDNA RT reaction was 
then prepared by pipetting 25µL of 2x RT Master mix in PCR tubes and adding 
25µL of RNA sample. After pipetting, tubes were sealed and placed in the 
thermal cycler for the following protocol: 
 Step 1 Step 2 Step 3 Step 4 
Temperature (˚C) 25 37 85 4 
Time (min) 10 120 5 ∞ 
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Reverse-transcribed samples were stored at -20˚C. 
 
5.3.4.3 PCR FOR THE ANALYSIS OF GENE EXPRESSION 
PCR was performed using a Hot-Start Taq DNA Polymerase (QIAGEN- cat. 
203205). A low amount of cycles doesn’t allow the amplicons to reach the 
plateau, therefore it is possible to compare gene expression in different 
samples. 
The PCR mix was assembled as follow: 
Component Volume (µL) 
10 PCR Buffer 2 
dNTPs (10mM) 0.4 
Hot-Start Taq Pol 0.1 
Forward-primer (10mM) 1 
Reverse-primer (10mM) 1 
cDNA 1 
Molecular Biology Grade Water 14.5 
Total Volume 20 
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The PCR mix freshly assembled is put on a thermocycler for the following steps: 
 STEP 
TEMPERATURE 
(˚C) 
TIME 
 Step 1 Enzyme Activation 95 15 minutes 
33 
CYCLES 
Step 2 DNA denaturing 94 30 seconds 
Step 3 Primers Annealing 56 45 seconds 
Step 4 Amplification 72 90 seconds 
 Step 5 Final Amplification 72 10 minutes 
 Step 6 Until analysis 4  
 
After the amplification samples were run on a 2% agarose gel. 2g of agarose 
(Thermo Fisher Scientific- cat. 16500500) was dissolved in 100 mL TBE 
(Thermo Fisher Scientific- cat. 15581044) by rapid heating. During cooling, 30µL 
of Ethidium Bromide (Thermo Fisher Scientific- cat. 15585011) were added and 
the solution was poured in a preformed cassette, with the appropriate gel comb, 
for the formation of the gelatinised block and the loading wells. 
After the complete set of the gel, this was removed from the cast, placed in an 
electrophoresis tank and submerged in TBE. PCR products were mixed with an 
appropriate amount of 5x Gel Loading Buffer (Thermo Fisher Scientific- cat. 
10482028) and loaded into the wells. One lane was reserved for the DNA ladder 
(Thermo Fisher Scientific- 10787018).  
The gel was allowed to run for 40 minutes at 90V to allow separation of the DNA 
bands.  
As soon as the electrophoresis run is complete, gels were imaged by ChemiDoc 
Scanner (Biorad), after applying a filter for Ethidium Bromide (580 nm). 
Bands were quantified for their integrated density with FIJI and plotted in Graph 
Pad. 
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In Table 5.5 it is reported all the genes of interest that have been investigated by 
PCR. 
Table 5.5 Genes whose expression has been investigated by PCR, and their main involvement in 
cellular processes. 
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Primers were designed using the NCBI tool “Pick Primers” 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi). Primers requisites 
were: 
 A melting temperature range between 57 and 63˚C; 
 A GC content between 45 and 60%; 
 A primer length between 18-25 bases; 
 A maximum product size of 1000 base pairs. 
Among the available resulting options, primers with an amplicon size between 
300 and 700 kb were selected and then blasted again on NCBI 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi) to detect eventual cross-matches that 
could allow non-specific amplification. The annealing temperature was obtained 
by a Thermo Fisher Scientific tool, Tm Calculator1 (Allawi & Santalucia, 1997).  
At the end of the validation process, final primers for the gene expression 
analysis were selected and are reported in Table 5.6 together with their 
predicted amplicon size and their annealing temperature. 
Other primers used during the validation properties are reported in Appendix 4. 
                                            
1 https://www.thermofisher.com/uk/en/home/brands/thermo-scientific/molecular-biology/molecular-biology-
learning-center/molecular-biology-resource-library/thermo-scientific-web-tools/tm-calculator.html 
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Table 5.6 List of validated pairs of primers for post-invasion analysis 
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5.3.5 IMMUNOFLUORESCENCE 
Immunofluorescence analysis was performed implementing the protocol 
described in Ylivinkka at al. (Ylivinkka et al., 2017).  
After the 3D invasion assay (day 2 for the U87 cell lines), blocks of  Matrigel 
containing invading/non-invading spheroids were transferred into 24-well plates, 
using a 1000mL pipette with a resected tip, to avoid damaging the 3D structure. 
This allowed an easier approach in the washing and staining process with a 
reduced risk of touching the samples and thus compromising their integrity. 
After transferring into the 24-well plate, blocks were washed with PBS and fixed 
with 4% formaldehyde for 30 minutes at room temperature. After fixation, 
formaldehyde was removed and blocks washed again with PBS twice. Blocking 
and permeabilization were performed simultaneously by incubating blocks in 
PBS 3% BSA 0.3% Tween-20 (Blocking Buffer) for one hour at room 
temperature and with a gentle shake. 
Incubation with primary antibodies was performed in Blocking Buffer overnight at 
4˚C with a gentle shake. The antibodies used and their dilutions for this 
technique are reported in Table 5.4. 
The blocks were then washed with PBS 0,1%Tween-20 three times for 10 
minutes at room temperature with a gentle shake and then incubated for one 
hour at room temperature with secondary antibody, Hoechst 33342 (Thermo 
Fisher Scientific- cat. 62249) and Alexa Fluor 647 phalloidin (Life Technologies- 
cat. A22287) all diluted in Blocking Buffer. 
After a further three PBS washings, the blocks were washed briefly with milli-Q 
water and then transferred onto the imaging slides.  
The imaging was achieved using Multispot Microscope Slides (Thermo Fisher 
Scientific- cat. 9991095). As shown in Figure 5.3, blocks were positioned at the 
centre of each spot and  Matrigel was cut away with a scalpel as much as 
possible, until only the  Matrigel containing the cellular material was left (Figure 
5.3B). This was a crucial step because an excess of  Matrigel results in a 
sample thickness unsuitable for confocal imaging. The multispot slides were 
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chosen because the thickness provided by the extra step created by the edge of 
the spot onto the glass provides help for the preservation of the spheroids 3D 
structure, while also allowing an easier localization of the samples during 
imaging. 
After this step samples were covered with ProLong™ Gold Antifade Mountant 
(Thermo Fisher Scientific- cat. P10144), covered with a coverslip and sealed 
with nail polish.  
 
Figure 5.3 Mounting steps for 3D spheres embedded in  Matrigel. A:  Matrigel blocks were 
transferred onto a Multispot slide, one every spot. B: Extra  Matrigel was trimmed with a scalpel. 
C: Mounting medium was applied to each block before covering with Cover slip and sealing with 
nail polish. 
 
For the immunofluorescence of 2D cells growing on plastic, cells were seeded, 
fixed, washed and stained on Black Clear Bottom 96-Well Polystyrene 
Microplates (Corning- cat. 3610), then imaged directly from the plates. Cells 
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growing on Matrigel were seeded on Chamber slides with a removable 12 well 
silicone chamber (IBIDI, cat. 81201) previously coated with 100%  Matrigel. After 
four days, cells were washed, fixed and stained as previously described. Before 
imaging the silicon chamber was removed, mounting medium applied and slides 
were covered with a coverslip and sealed with nail polish. 
 
Figure 5.4 Procedure for Immunofluorescence staining of cells growing on  Matrigel. A: Cell lines 
were seeded on the top of the Matrigel-coated wells formed by the silicon chamber.  Fixation, 
permeabilization and staining were performed in the chamber wells as well. B: Before imaging, the 
silicon chamber was removed, Matrigel layers coated with stained cells were covered with 
mounting medium, coverslip was applied, and nail polish was used for sealing  Adapted from 
https://ibidi.com/img/cms/products/labware/open_removable/E_8XXXX_Chamber_removable/IN_
80841_8Well_Chamber.pdf. 
 
The imaging was performed with a Leica SP5 inverted confocal laser scanning 
microscope. 40x and 63x oil-immersion objectives were used. Excitations of 405 
nm (Hoescht), 488 nm (mouse), 453 nm (rabbit) and 633 nm (647-Phalloidin) 
nm were chosen for each fluorophore under examination while gain and offset 
settings were optimized for each fluorescent channel within an experiment. 
Images were recorded and captured using two sequential scans to avoid 
fluorescence channel crosstalk. Images were scanned with a line average of 
three to reduce noise (100 Hz). 
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5.3.6 IMMUNOHISTOCHEMISTRY 
The immunohistochemistry protocol was prepared with the help of Christopher 
Von Ruhland PhD, from the School of Medicine, as an expert in sample 
processing for both optical and electron microscopy.  
After the invasion assay (2 days for the U87),  Matrigel blocks were washed and 
fixed in formaldehyde 4% glutaraldehyde 0.1% for one hour at room 
temperature. After the fixation blocks were transferred in 1.5 mL tubes, where a 
layer of liquified low-melting agarose had just been deposited. They were then 
covered with extra low melting agarose, to allow total embedding, and let gelify 
at room temperature overnight. After resuspension in PBS the newly formed 
blocks were processed as normal tissue samples: 
DEHYDRATION STEPS 
Solution 
Incubation Time 
(min) 
Solution 
Incubation Time 
(min) 
50% Ethanol 10 
2:1 Ethanol: 
Xylene 
10 
70% Ethanol 10 
1:1 Ethanol: 
Xylene 
10 
80% Ethanol 10 
1:2 Ethanol: 
Xylene 
10 
95% Ethanol 10 100% Xylene 10 
100% Ethanol 10 100% Xylene 10 
100% Ethanol 10 100% Xylene 10 
100% Ethanol 10 100% Xylene 10 
 
After all the incubations samples were embedded in Paraffin Wax overnight. 
Then the sample was positioned, and the paraffin was let harden in each block. 
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To enhance the outcome of the sectioning, the blocks were cut by 
ultramicrotome ad transferred onto slides and incubated overnight at 37˚C to 
allow the spreading of the paraffin and the firm adhesion to the microscope 
slides. 
Before proceeding with the staining protocol, slides were deparaffinized and 
rehydrated with the steps resumed in the following table. 
DEPARAFFINATION STEPS 
Solution Incubation Time (min) 
Xylene 100% 3 
Xylene 100% 3 
1:1 Ethanol: Xylene 3 
95% Ethanol 3 
70% Ethanol 3 
50% Ethanol 3 
Running cold tap water rinse 
 
Slides were kept in water until ready to perform antigen retrieval. 
Slides were placed in a beaker with Sodium Citrate pH 6.0, which was brought 
to boil, with a Bunsen flame. Once boiling, the flame was lowered, and the slides 
were left inside for 30 minutes. 
After 30 minutes, tap water was let run into the Becker to simultaneously cool 
down the solution and block the reaction. 
Once slides have been washed in Optimax washing buffer (Biogenex 
Laboratories- cat. HK5835K), they were partially dried with absorbing paper 
towel and samples areas were isolating using pap-pen (Abcam- cat. ab2601). 
Primary antibody diluted in 0.6% BSA in Optimax (Reagent diluent) were applied 
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on the samples and an incubation overnight at 4˚C in a humid chamber followed. 
Primary antibody was Beta-Actin (Sigma) diluted 1:100. 
The following day, slides were re-equilibrated at room temperature for one hour 
before washing again and applying the secondary antibody diluted in reagent 
diluent. After an incubation of one hour at room temperature, slides were 
washed again and then incubated in DAB solution. DAB solution is a mix of 
Diaminobenzidine dihydrochloride (DAB) and Hydrogen Peroxide (for the DAB 
activation). 10 ml of DAB 5g/L were dissolved in 90mL of Optimax washing 
buffer and the 8 drops of hydrogen peroxide were added before mixing. 
Incubation with DAB solution was performed for 5 minutes before blocking the 
reaction by transferring the slides into a container with tap water. 
Counterstain with Haematoxylin (Sigma- cat. GHS1128) was achieved by 
incubating a drop of the solution on each sample for 1 minute and then was in 
running tap water. 
After the counterstain slides were dehydrated again as follow: 
DEHYDRATION STEP 
Solution Incubation Time (min) 
50% Ethanol 3 
70% Ethanol 3 
80% Ethanol 3 
95% Ethanol 3 
100% Ethanol 3 
100% Ethanol 3 
1:1 Ethanol: Xylene 3 
100% Xylene Until ready for mounting 
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Slides were mounted on coverslips using DPX mounting medium (Sigma- cat. 
06552) and left overnight to dry in the dark. 
Images of the slides were taken using a Leica DMI6000 inverted microscope. 
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5.4 RESULTS AND DISCUSSION 
5.4.1 CAV-1 DRIVES INVASIVE PHENOTYPE ON 3D INVASION 
ASSAY MODEL 
As reported in Chapter 3, the scratch assay of the lentiviral transfected GBM cell 
lines revealed that Cav-1 can drive a migratory phenotype. In chapter 4 we 
developed a quantitative tool to measure invasion within a 3D matrix. 
Here, we explored the impact of Cav-1 genetic KD and KO upon invasion in the 
3D model. We tested the ability of the cells to move through an extracellular 
matrix using the 3D invasion assay, described in the previous chapter, and 
quantified results with INSIDIA (Moriconi et al., 2017). Typical images and the 
quantification of the invasion assay are reported in Figure 5.5 for U87 and U373, 
and Figure 5.6 for UP007 and UP029, these experiments conducted in cells 
carrying a lentiviral-mediated inhibition of Cav-1 expression.  
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Figure 5.5 Invasion assay on two cell lines transfected for the down-regulation of Cav-1. Seeding 
density: 1000 cells/well for the U87 (A, B), 5000 cells/well for the U373 (C, D). Experiments were 
repeated three times and replicates were analysed according to both density profile and density 
map.  A, C: Scale bar 100μm. B, D: Graphs represent the Change in the Core and the amount of 
invasive edges according to the density map analysis, normalised on the perimeter of the Core. 
Statistical analysis unpaired two-tailed T-Test (p-value is indicated when relevant). 
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Figure 5.6 Invasion assay on two cell lines transfected for the down-regulation of Cav-1. Seeding 
density: 5000 cells/well for both UP007 (A, B) and U373 (C,D). Experiments were repeated t hree 
times and replicates were analysed according to both density profile and density map.  A, C: Scale 
bar 100μm. B-D: Graphs represent the Change in the Core and the amount of invasive edges 
according to the density map analysis, normalised on the perimeter of the Core. Statistical analysis 
unpaired two-tailed T-Test (p-value is indicated when relevant). 
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In agreement with the scratch assay data, the 3D invasion data show UP007 
and UP029 to have a decreased invasion when Cav-1 is knocked down, while 
the U373 does not present a high invasive capacity and does not show a 
significant difference when Cav-1 is inhibited. The U87 CAV-(KD) on the other 
hand showed an apparent much-reduced invasion ability in comparison with 
their NT control. However, when the area of the invasion (density map data) 
normalized on the perimeter of the core (as justified and explained in Chapter 4), 
the difference in invasion is not significant. Nevertheless, it is interesting to 
observe that Cav+(NT) cells are still able to travel farther into the Matrigel from 
the edge of the Core (Figure 5.7), and this is evident, also for the other cell lines, 
the higher the invasive ability of the cell line is.  
The difference in the core areas at Day 0 for the U87 appears to be annulled 
when spheroids are surrounded by Matrigel. In fact, the ratio of the Core Area 
D2/D0 is similar between CAV+ and CAV- cells (Figure 5.5B). This suggests that 
CAV+ cells can survive and replicate better in an attachment-free environment 
than the CAV- ones, while when they are surrounded by the extracellular matrix, 
their ability to replicate is restored. 
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Figure 5.7 Maximum length reached by the invading/non-invading spheroids from the edge of the 
spheroid during 3D invasion assay on Matrigel for U87 (A), U373 (B), UP007 (C) and UP029(D) 
carrying the lentiviral-mediated KD of Cav-1. Parameters have been calculated with INSIDIA. 
Statistical analysis: unpaired T-Test (p-value is indicated when relevant). 
 
During experiments with the lentiviral-transfected cells, there was a loss in the 
consistency of the experimental outcomes. This was considered to reflect the 
polyclonal nature of the lentiviral cell lines and a change in the repression of 
Cav-1. As a result, the laboratory pursued the knockout of Cav-1 using a 
CRISPR approach.  
Figure 5.8 shows the 3D invasive characteristics of the CRISPR Cav-1 
modulated U87 cells. Figure 5.8A shows the Cav-1 KO confirmed by Western 
Blot. Figure 5.8B shows the 3D invasion in Matrigel for the CAV+ and the CAV-
(KO) cells. Figure 5.8C shows the INSIDIA analysis of the invasion assay of 
Figure 5.8B with the KO cells displaying essentially no expansion of the cells in 
the core of the sphere and also an essentially complete loss of invasion. 
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Figure 5.8 A- Western Blot analysis of U87 CRISPR expression of Cav-1. B U87 CRISPR Invasion 
assay on U87 cell lines transfected for the knockout of Cav-1. Seeding density: 1000 cells/well. 
U87. Experiments were repeated three times and replicates were analysed according to both density 
profile and density map. Scale bar 100μm. C- Graphs represent the Change in the Core between 
Day 0 and Day 2 and the amount of invasive edges according to the density profile analysis. 
Statistical analysis unpaired two-tailed T-Test (p-value is indicated when relevant). 
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In order to understand why the Cav-1 KO and its positive control presented 
different Core growth rate and motility, we tested if Cav-1 KO was affecting cells 
viability in 3D. We stained live floating spheroids with Hoescht for the 
visualization of all cell nuclei and Propidium Iodide (PI) for the identification of 
dead cells. The motionless of the KO spheroids was not related to an increased 
death (Figure 5.9), indicating that cells with the Cav-1 KO are not able to grow at 
high rates or to interact/ invade the extracellular matrix, but they are still able to 
survive. This suggests a less aggressive phenotype for the cells not expressing 
Cav-1.  
 
 
Figure 5.9 Live cell imaging on spheroids after four days in floating conditions. U87 CRISPR 
(CAV+ on the top, CAV- on the bottom) were stained with cell-permeable nuclei staining Hoechst 
33342 1g/ml (blue), and membrane impermeable dead cells staining Propidium Iodide 20g/ml 
(PI- red). Scale bar 100µm. 
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We next sought to develop an immunofluorescence approach that could allow 
the study of signalling molecules within the 3D invading spheres.  
Immunofluorescent staining for Cav-1 reveals that invading cells expressed a 
significant Level of Cav-1 (Figure 5.10B- green), while the KO spheroids in 
contact with the matrix do not show any expression of Cav-1, confirming the 
success of the KO and also corroborating the hypothesis that Cav-1 plays a role 
in invasion.  
 
Figure 5.10 3D Immunofluorescence analysis of U87 CRISPR expression of Cav-1. A. U87 CAV+ 
and CAV- spheres embedded in  Matrigel stained with Hoechst 33342 (blue: nuclei) and 
Phalloidin-Alexa647 (Red: Cytoskeleton). Scale bar 100µm. B- U87 CAV+ and CAV- spheres 
embedded in  Matrigel stained with Hoechst 33342 (blue), Phalloidin-Alexa647 (Red) and Cav-1 
(Green). Scale bar 50µm. C: indicative position (red square) of the pictures in B over whole sized 
bright field images of the invading/non-invading spheres. Scale bar 100µm. 
 
 
From the immunostaining for Cav-1 in CAV+ vs CAV- spheroids, no signal of 
Cav-1 could be detected in the spheroid core, while Hoechst (nuclei- blue) and 
Phalloidin (F-actin- red) could still be detected. The average size of an antibody 
(i.e. IgG2a) is 150’000 g/mole while Phalloidin is roughly 100 times smaller 
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(1528 g/mole). This led to the question of whether the antibody was physically 
able, despite the permeabilization step, to penetrate the spheroid and stain the 
core. In an attempt to address this, we stained U87 CAV+ and CAV- spheres 
with antibodies directed against housekeeping genes, including -Actin, GAPDH 
and Vinculin.  
First, we optimized the housekeeping genes staining on 2D cell cultures grown 
on plastic (Figure 5.11). 
 
Figure 5.11 2D Immunofluorescence analysis of U87 CRISPR expression of Cytoskeletal proteins. 
U87 CAV+ and CAV- grown on plastic and stained with Hoechst 33342 (blue: nuclei), Phalloidin -
Alexa647 (Red: Cytoskeleton) and, when indicated, GAPDH, Beta Actin and Vinculin 
(Cytoskeleton: Green). Scale bar 50µm. 
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After optimizing in 2D, we tested the housekeeping antibodies in 3D spheroids. 
The U87 CAV+ showed a signal for the antibodies in the invading edges and 
partially in the core (shown in Figure 5.12) while the CAV- spheroids, being 
more compact and lacking invasive edges, were stained only on their outer 
layers. This can be seen in comparing the confocal sections at the spheroid 
surface (Figure 5.12C) to the sections deep in the spheroid core (Figure 5.12D). 
Vinculin showed a higher signal in both CAV+ and CAV- cells, but it showed also 
several non-specific signals that make its use unreliable (despite its validation 
via western blot). 
 
Figure 5.12 3D Immunofluorescence analysis of U87 CRISPR expression of Cytoskeletal proteins. 
U87 CAV+ (A-B) and CAV- spheres (C-D), embedded in  Matrigel and stained with Hoechst 
33342 (blue: nuclei), Phalloidin-Alexa647 (Red: Cytoskeleton) and, when indicated, GAPDH, Beta 
Actin and Vinculin (Cytoskeleton: Green). B indicates the location of the correspondent picture in 
A. Images of the KO spheroids stained for the selected housekeeping antibodies are shown, 
representing their outer layer (C) and their core-level layer (D). Scale bar 50µm. 
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Given the challenge of antibody penetration into the spheroid core, we explored 
the fixing and embedding of the spheroids in paraffin wax, followed by physical 
sectioning and immunohistochemistry staining. However, while the sectioning 
was able to preserve the compact nature of the non-invading CAV- spheroids, 
the invasive edges of the CAV+ spheroids were not maintained (Figure 5.13). 
 
Figure 5.13 Paraffin-embedded sections of U87 CAV+ and CAV-. Spheroids embedded in Matrigel 
were fixed in formaldehyde 4% glutaraldehyde, washed, dehydrated and embedded in paraffin wax, 
then sectioned. 
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Due to the inefficiency of the antibody penetration in the intact spheroids, and 
the fragility of the paraffin-embedded sections, we decided to continue 
immunofluorescence investigations on 3D matrix-embedded spheroids only for 
the CAV+ cell lines and in particular their invasion projections. Any comparisons 
between CAV+ and CAV- cells were performed on cells in 2D growing on plastic 
or in 2D with cells growing upon a layer of Matrigel.  
We found the growth on Matrigel particularly interesting because cells are 
interacting with matrix which may cause different effects. For example, Figure 
5.14A and B shows the U87 CAV+ and CAV- cells grown on plastic. The images 
confirm similar morphology. In contrast, Figure 5.14C and D show CAV+ and 
CAV- cells grown on Matrigel. Here, the CAV+ cells started interacting with the 
matrix, sending projections and connecting with distant groups of cells. The 
CAV- cells, on the other side, grew as clusters with limited migratory movement 
and only after a four day delay small projections outside the clusters observable. 
The difference in matrix effects are thus exemplified, and the results with the 
cells grown on the matrix consistent with the observations seen in the 3D 
invasion assays (Figure 5.8B). Since the clusters of CAV-  cells are much 
smaller than the spheroids, it was possible to overcome the difficulty of the 
antibody penetration. 
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Figure 5.14 Culture conditions of U87 CRISPR. Both CAV+ and CAV- were cultured on 2D 
plastic (A and B) and on upon a layer of 100% Matrigel (C and D). Scale bar 250 µm.
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Figure 5.15 shows the staining of cells grown upon plastic or Matrigel in the 2D 
format. As expected Cav-1 staining is  clearly observed  in  the CAV+ cells but 
not the CRISPR knockout cells. The CAV+ cells expressed a high and 
distributed level of the protein confirming the validity of the 2D Matrigel culture 
condition (Figure 5.15). 
 
 
Figure 5.15 2D Immunofluorescence analysis of U87 CRISPR knockout cells for the expression of 
Cav-1. The U87 CAV+ and CAV- cells grown on plastic (top) were stained with Hoechst 33342 
(blue: nuclei), Phalloidin-Alexa647 (Red: Cytoskeleton) and, Cav-1 (Green). The U87 CAV+ and 
CAV- cells grown on Matrigel (bottom) were similarly stained except Phalloidin-Alexa647. Scale 
bar in all images 50µm. 
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To investigate invadopodia capacity in the 2D growth conditions we stained for 
cortactin, a marker of invadopodia (Kirkbride, Sung, Sinha, & Weaver, 2011; 
MacGrath & Koleske, 2012; Weaver, 2008). This staining is able to highlight  
membranes and cell projections. The expression of cortactin in glioma 
specimens has been  reported to be  significantly higher than in normal brain 
tissues (Spandidos et al., 1994). On 2D plastic (Figure 5.16A), cortactin 
expression appeared to be more diffuse in CAV+ cells while more localized in 
CAV- cells, with focal points on the membrane (Figure 5.16A). On 2D Matrigel 
again the protein was expressed by both cell lines, with a diffuse distribution of 
signal in both, even if for the small clusters of CAV- cells it was difficult to 
interpret localisation as they were in a compact multicellular cluster. Intense 
staining in the invadopodia arising from the CAV+ cells (Figure 5.16B) was 
evident. Similarly, for the 3D spheroid growth in Matrigel we saw for cells 
invading the matrix a high level of expression of cortactin throughout the cell 
body (Figure 5.16C). 
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Figure 5.16 Immunofluorescence analysis of U87 CRISPR cells for the expression of the 
cytoskeletal protein, cortactin.  A: U87 CAV+ and CAV- grown on plastic and stained with 
Hoechst 33342 (blue: nuclei), Phalloidin-Alexa647 (Red: Cytoskeleton) and, Cortactin 
(Cytoskeleton: Green). B: U87 CAV+ and CAV- grown on Matrigel and stained as previously. C: 
U87 CAV+ spheroids embedded in Matrigel and stained as previously. Scale bar 50µm for all of 
above.  Shown in the bright-field image (bottom right) the indicative position (red square) for the 
spheroid staining. Scale bar 100µm. 
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Another approach to staining invadopodia within the 3D spheroid model was 
undertaken using Concanavalin A. It is a lectin that binds glycoproteins and 
glycolypids on the cell plasma membrane. In vitro use of Concanavalin A has 
been shown in GBM cells to promote the activation of MT1MMP and 
consequently MMP2 (Annabi et al., 2001). 
In this current work the staining gave rise to significant signal of the Matrigel 
(Figure 5.17). However penetration of the matrix was sufficent to stain some of 
the cells, but interestlngly an absence of staining (Figure 5.17) the projections 
(red) into the Matrigel network.  
 
 
Figure 5.17 Immunofluorescence analysis of U87 CRISPR cell lines using ConcanavalinA. U87 
CAV+ sphere embedded in Matrigel and stained with Hoechst 33342 (blue: nuclei), Phalloidin -
Alexa647 (Red: Cytoskeleton) and, Concanavalin A (Green). Scale bar 25µm. 
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5.4.2 RT-PCR ANALYSIS FOR GENES ASSOCIATED WITH 
INVASION 
In order to explore the mechanisms involved in the Cav-1 pro-invasive 
phenotype, we examined by RT-PCR levels of transcripts for genes involved in 
adhesion, digestion of matrix and epithelial to mesenchymal transition. A list of 
all these genes and their main role is reported in Materials and Methods (Table 
5.5).  
Gene expression was compared between U87 CAV+ and CAV- cells grown in 
2D format on both plastic (Figure 5.18) and on Matrigel (Figure 5.19) with the 
results summarised in (Figure 5.20).  
Primers were first validated for their specificity with a high number of PCR cycles 
PCR (50, as shown in Appendix 4) to allow every band to eventually appear and 
determine if the primers were specific for the target. After the validation the PCR 
was run on 33 cycles, to allow comparison of gene expression between CAV+ 
and CAV- cells. 
 
Figure 5.18 RT-PCR analysis of 26 genes using validated primers on lysates from U87 CAV+ and 
CAV- cells grown on normal plastic culture conditions. 
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Figure 5.19 PCR analysis of 26 pairs of validated primers on U87 CAV+ (Dark Grey) and CAV-
(Light Grey) grown on a Matrigel layer.  
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Figure 5.20 is a summary of the RT-PCR study results for cells grown on plastic 
and on Matrigel. The expression comparison was reported as a fold-change 
between the CAV+ and CAV- cells, with the fold-change values ranked in 
decreasing order by the Matrigel data.  
Despite acknowledging that cells grown on plastic will synthesise their own 
ECM, the results with Matrigel maybe more pertinent since the immediate 
contact with Matrigel could stimulate earlier those pathways closer to the 
physiological conditions.  
 
Figure 5.20 Summary of results of RT-PCR analysis on lysates from U87 CAV+ and CAV- cells on 
cells grown on plastic (left) and on Matrigel (right). Values represent the fold-change of 
CAV+/CAV- gene expression. Results are ordered from higher to lower in respect to the Matrigel 
condition. Colour code bar is reported on the side. 
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A selection of molecules from the RT-PCR was chosen for further investigation 
by Western blot and immunofluorescence.  These molecules are acknowledged 
to have relevance to GBM pathophysiology and showed some significant fold-
changes in the RT-PCR data, cathepsins D (CATD/CTSD) and B (CATB/CTSB), 
UPAR and CD44. Further MMP1, a molecule related to pathology of GBM 
showed disparate outcomes on plastic and Matrigel, which warranted further 
study.    
 
5.4.3 WESTERN BLOT AND IMMUNOFLUORESCENCE OF 
SELECT MOLECULES FROM THE RT-PCR ANALYSIS 
The PCR results for the four most modulated markers was achieved by Western 
blot and immunofluorescence of cells in 2D plastic, 2D on Matrigel and 3D in 
Matrigel. The Western blot analysis was used to confirm the differences in the 
proteins expression both in plastic and on 2D Matrigel, while the 
immunofluorescence studies were useful to compare qualitatively the intensity of 
the signal (and thus of the protein expression), as well as the localization and 
distribution of the marker. In 3D spheroids embedded in Matrigel, the expression 
signal was evaluated only on invading cells, for the U87 CAV+. 
In particular, we analysed the expression of the matrix-digesting CTSB, CTSD, 
MMP1 and the adhesion UPAR and CD44. As a control, we also chose to 
analyse E-Cadherin (CDH1). 
 
5.4.3.1 MATRIX-DIGESTING ENZYMES 
The first protein analysed was CTSB (Figure 5.21, Figure 5.22, Figure 5.23). 
Cathepsin B is a lysosomal cysteine protease involved in intracellular 
proteolysis. In cancer it may increase the activity of other proteases, including 
CTSD, UPA and MMPs. 
Despite the inter-experimental variation, on Matrigel CATB is always more 
expressed in CAV+ than in Cav- cells, while on plastic the results of different 
experiments were not consistent (Figure 5.21). The results of the Western blot 
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showing increased CTSB in CAV+ cells when grown on Matrigel are consistent 
with the PCR analysis for similarly growth conditions (Figure 5.20). 
The immunofluorescence analysis for both CAV+ and CAV- cell lines grown in 
2D on plastic show that some cells displayed a high level of CTSB, while others 
could be observed displaying a low level of expression or indeed a complete 
absence (Figure 5.22A). In contrast, on 2D Matrigel, all cells expressed CTSB 
with peaks of intensity in CAV+ cells projections (Figure 5.22B). This latter point 
was further substantiated for the immunofluorescence of the invading spheroids 
which revealed CAV+ cells in the outer rim of the invasive edges to express high 
levels of CTSB, suggesting the molecule is at the forefront of the 
migratory/invasive process (Figure 5.23). 
 
Figure 5.21 A: Western blot analysis for the expression of Cathepsin B (CTSB) in U87 CAV+ and 
CAV- grown on plastic or on Matrigel. The antibody recognizes a mature form at 31kDa and a pro-
form at 43kDa. GAPDH (EXP 2 and 3) or Vinculin (EXP 1) were used as a housekeeping gene and 
the normalized quantification is reported in B. Three separate experiments are reported, each one 
from three different sets of samples. 
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Figure 5.22 Immunofluorescence of 2D cultures of U87 CRISPR and HeLa cell lines for the 
expression of Cathepsin B (CTSB). U87 CAV+ and CAV- grown on plastic (A) and on Matrigel 
(B) and stained with Hoechst 33342 (blue: nuclei), Phalloidin-Alexa647 (Red: Cytoskeleton) and, 
CTSB (Green). HeLa in A were used as a control. Scale bar 50µm.  
 
 
Figure 5.23 Immunofluorescence of 3D-spheroids (U87 CAV+ cell lines) embedded in Matrigel for 
the expression of Cathepsin B (CTSB). A: Spheres were embedded in Matrigel and stained with 
Hoechst 33342 (blue: nuclei), Phalloidin-Alexa647 (Red: Cytoskeleton) and CTSB (Green). Scale 
bar 50µm. B: Bright-field image of the indicative position (red square) for the spheroid staining. 
Scale bar 100µm. 
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We next analysed for CTSD (Figure 5.24, Figure 5.25, Figure 5.26). CTSD is an 
aspartyl-protease that appears to cleave a variety of substrates such as 
fibronectin and laminin. 
Here, CTSD Western blot analysis did not provide any consistent outcome, 
particularly when the cells were grown upon Matrigel, and certainly not 
demonstrating significantly higher expression for the CAV+ cells over CAV- cells 
(Figure 5.24). 
The immunofluorescence analysis for both 2D plastic and 2D Matrigel failed to 
show any difference between the CAV+ and CAV- cells, with a diffuse 
(distributed throughout the cell body) signal present in all. However, of note is 
the staining present in the membrane projections seen for CAV+ cells grown on 
Matrigel (Figure 5.25). This is consistent with the signals seen for CTSD in the 
invadopodia for CAV+ cells arising from 3D invading spheroids (Figure 5.26). 
 
Figure 5.24 A: Western blot analysis for the expression of Cathepsin D (CTSD) in U87 CAV+ and 
CAV- cell lines grown upon 2D plastic or upon 2D Matrigel. GAPDH or Vinculin were used as 
housekeeping genes and the normalized quantification is reported in B. Three separate experiments 
are reported, each one from three different sets of samples. 
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Figure 5.25 Immunofluorescence of 2D cultures of U87 CRISPR and HeLa cell lines for the 
expression of Cathepsin D (CTSD). U87 CAV+ and CAV- grown on plastic (A) and on Matrigel 
(B) and stained with Hoechst 33342 (blue: nuclei), Phalloidin-Alexa647 (Red: Cytoskeleton) and, 
CTSD (Green). HeLa in A were used as a control. Scale bar 50µm 
 
 
Figure 5.26 Immunofluorescence of 3D-spheroids (U87 CAV+ cell lines) embedded in Matrigel for 
the expression of Cathepsin D (CTSD). A: Sphere was embedded in Matrigel and stained with 
Hoechst 33342 (blue: nuclei), Phalloidin-Alexa647 (Red: Cytoskeleton) and CTSD (Green). Scale 
bar 50µm. B: Bright-field image of the indicative position (red square) for the spheroid staining. 
Scale bar 100µm. 
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We next analysed for MMP1 (Figure 5.27, Figure 5.28, Figure 5.29). MMP1 is 
involved in the breakdown of extracellular matrix, in particular interstitial 
collagens. 
The Western blot analysis of MMP1 was difficult to interpret because the signal 
from the MMP1 antibody was very weak, even when adjustments for the 
increase of sensitivity were made (Figure 5.27A). According to the quantification 
results on Matrigel, however, MMP1 appeared to some extent to be inhibited by 
Cav-1. This contrasts with the RT-PCR results, although the results for Matrigel 
were not clearly indicative of an up-regulation, whereas on plastic MMP1 
appeared to positively correlate with high Cav-1 levels. (Figure 5.27B and Figure 
5.20). 
Intriguingly, immunofluorescence staining for MMP1 in cells grown upon 2D 
Matrigel showed that MMP1 is expressed only by the Cav+ cells (Figure 5.28). 
The simultaneous conduct of these immunofluorescence studies gives some 
assurance that this result is real and not a technical artefact. The 
immunofluorescence results reinforced concerns of the suitability of the MMP1 
antibody for Western blot applications.  
The staining for MMP1 was also evident by immunofluorescence in the invading 
spheroids, which revealed CAV+ cells in the outer rim of the invasive edges to 
express levels of MMP1, again indicative that the molecule is important for 
migratory/invasive function in these cells (Figure 5.29). 
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Figure 5.27 A: Western blot analysis for the expression of MMP1 in U87 CAV+ and CAV- grown 
upon 2D plastic or upon 2D Matrigel. GAPDH was used as a housekeeping gene and the 
normalized quantification is reported in B. Three separate experiments are reported, each one from 
three different sets of samples. 
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Figure 5.28 Immunofluorescence of 2D cultures of U87 CRISPR and HeLa cell lines for the 
expression of MMP1. U87 CAV+ and CAV- grown on plastic (A) and on Matrigel (B) and stained 
with Hoechst 33342 (blue: nuclei), Phalloidin-Alexa647 (Red: Cytoskeleton) and, MMP1 (Green). 
HeLa in A were used as a control. Scale bar 50µm 
 
 
Figure 5.29 I Immunofluorescence of 3D-spheroids (U87 CAV+ cell lines) embedded in Matrigel 
for the expression of MMP1. A: Sphere was embedded in Matrigel and stained with Hoechst 33342 
(blue: nuclei), Phalloidin-Alexa647 (Red: Cytoskeleton) and MMP1 (Green). Scale bar 50µm. B: 
Bright-field image of the indicative position (red square) for the spheroid staining. Scale bar 
100µm. 
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5.4.3.2 ADHESION MARKERS 
We next analysed for UPAR (Figure 5.30, Figure 5.31, Figure 5.32). UPAR is 
the primary ligand of UPA but is also able to interact with a variety of proteins 
such as vitronectin in the ECM and integrins. 
Western blot for UPAR showed more consistent results, particularly when cells 
were grown on Matrigel (Figure 5.30). The results here showed the expression 
of UPAR to correlate with the expression of Cav-1, UPAR being higher in the 
CAV+ cells. These findings are consistent with the RT-PCR data (Figure 5.20). 
The data for cells growing on plastic showed essentially no difference in UPAR 
expression between CAV+ and CAV- cells. Again, this is entirely consistent with 
the respective RT-PCR results.  
Immunofluorescence staining for UPAR in cells grown upon 2D Matrigel showed 
that UPAR is highly expressed only by the CAV+ cells (Figure 5.31) while CAV- 
cells a weaker signal. Similarly to the studies with MMP1, the simultaneous 
conduct of these immunofluorescence studies gives some assurance that this 
result is real and not a technical artefact.  
The staining for UPAR was also evident by immunofluorescence in the invading 
spheroids, which revealed CAV+ cells in the outer rim of the invasive edges to 
express levels of UPAR, again indicative that the molecule is important for 
migratory/invasive function in these cells (Figure 5.32). 
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Figure 5.30 A: Western blot analysis for the expression of UPAR in U87 CAV+ and CAV- grown 
upon 2D plastic or upon 2D Matrigel. GAPDH or Vinculin were used as a housekeeping gene and 
the normalized quantification is reported in B. three separate experiments are reported, each one 
from three different sets of samples. 
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Figure 5.31 Immunofluorescence of 2D cultures of U87 CRISPR cell lines for the expression of 
UPAR. U87 CAV+ and CAV- grown on plastic (A) and on Matrigel (B) and stained with Hoechst 
33342 (blue: nuclei), Phalloidin-Alexa647 (Red: Cytoskeleton) and, UPAR (Green). Scale bar 
50µm 
 
 
Figure 5.32 Immunofluorescence of 3D-spheroids (U87 CAV+ cell lines) embedded in Matrigel for 
the expression of UPAR. A: Sphere was embedded in Matrigel and stained wi th Hoechst 33342 
(blue: nuclei), Phalloidin-Alexa647 (Red: Cytoskeleton) and UPAR (Green). Scale bar 50µm. B: 
Bright-field image of the indicative position (red square) for the spheroid staining. Scale bar 
100µm. 
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We next analysed for CD44 (Figure 5.33, Figure 5.34, Figure 5.35). CD44 is the 
primary ligand of Hyaluronic acid, involved in cell–cell interactions, cell adhesion 
and migration. 
The results for CD44 represents an anomalous finding in that the RT-PCR data 
(Figure 5.20), indicated that cells growing on 2D Matrigel showed significant 
reduction in CD44 transcript in the CAV+ phenotype. 
The Western blot analysis showed a very strong signal for CD44 expression in 
all samples, with a slight increase in CD44 expression in the CAV+ cells when  
growing on Matrigel (Figure 5.33). Interestingly, Experiment 2 showed a shift in 
the CD44 signal from a molecular weight of ca. 80 kDa to 220 kDa. This 
molecular weight shift was not replicated in the signals for other antibodies run 
simultaneneously on the same gel, such as GAPDH. A possiblility is that the 
boiling of the samples didn’t completely denature the 3D structure of the proteins 
and some glycosylation sites were still in their native conformation, making more 
difficult for CD44 to travel along the electrophoresis gel. 
The immunofluorescence on 2D showed no difference in CD44 expression, both 
on plastic and on Matrigel, with the images showing a strong and well-defined 
signal (Figure 5.34). CD44 was also abundantly expressed by CAV+ cells 
invading from spheroids embedded in the 3D Matrigel (Figure 5.35). 
 
 
CHAPTER 5: MOLECULAR SIGNALING INVOLVED CAV-1 AND INVASION  
 
223 
 
Figure 5.33 A: Western blot analysis for the expression of CD44 in U87 CAV+ and CAV- grown 
upon 2D plastic or upon 2D Matrigel. GAPDH was used as a housekeeping gene and the 
normalized quantification is reported in B. three separate experiments are reported, each one from 
three different sets of samples. 
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Figure 5.34 Immunofluorescence of 2D cultures of U87 CRISPR and HeLa cell lines for the 
expression of CD44. U87 CAV+ and CAV- grown on plastic (A) and on Matrigel (B) and stained 
with Hoechst 33342 (blue: nuclei), Phalloidin-Alexa647 (Red: Cytoskeleton) and, CD44 (Green). 
HeLa in A were used as a control. Scale bar 50µm 
 
Figure 5.35 Immunofluorescence of 3D-spheroids (U87 CAV+ cell lines) embedded in Matrigel for 
the expression of C44. A: Sphere was embedded in Matrigel and stained with Hoechst 33342 (blue: 
nuclei), Phalloidin-Alexa647 (Red: Cytoskeleton) and CD44 (Green). Scale bar 50µm. B: 
Indicative position (red square) of the picture in A over whole sized bright field images of the 
invading sphere. Scale bar 100µm. 
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Finally, we analysed for ECAD (Figure 5.36, Figure 5.37). ECAD is a cell-cell 
adhesion glycoprotein recognised as marker of epithelial differentiation and as a 
tumour suppressor. 
E-Cadherin displayed no signal in the RT-PCR but is a molecule of potential 
interest in terms of interaction with Cav-1. Hence, the correlation with Cav-1 was 
examined here by Western blot and Immunofluorescence (Figure 5.20).  
The Western blot data failed to reveal any further information, as ECAD 
appeared to be variously expressed depending on the experiment (Figure 5.36). 
Perhaps, the studies on Matrigel would indicate that Cav-1 has little effect on the 
expression of ECAD, but clearly further studies would be required to confirm this 
(Figure 5.36). On 2D plastic, we failed to obtain a signal, even with an increase 
in the primary antibody concentration (Figure 5.37); no staining for ECAD was 
perform in cells grown on 2D Matrigel or within Matrigel-embedded 3D spheres.  
 
Figure 5.36 A: Western blot analysis for the expression of E Cadherin (ECad) in U87 CAV+ (BB) 
and CAV- (KO) grown on plastic or on  Matrigel. GAPDH was used as a housekeeping gene and 
the normalized quantification is reported in B. three separate experiments are reported, each one 
from three different sets of samples. 
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Figure 5.37 Immunofluorescence of 2D cultures of U87 CRISPR and HeLa cell lines for the 
expression of E Cadherin (E Cad). U87 CAV+ and CAV- grown on plastic and stained with 
Hoechst 33342 (blue: nuclei), Phalloidin-Alexa647 (Red: Cytoskeleton) and, ECad (Green). HeLa 
in A were used as a control. Scale bar 50µm 
 
5.4.4 PROTEIN ARRAY ON CELLS INTERACTING WITH 
MATRIGEL: BUILDING A PUTATIVE SIGNALLING 
PATHWAY  
Given the findings from RT-PCR, Western blot and immunofluorescence studies 
for both cells grown on 2D Matrigel and for 3D spheroids embedded on Matrigel 
we next utilised a proteomic approach to examine molecules that may correlate 
with the changes in Cav-1 levels resulting from our CRISPR knockout model.  In 
particular this section of the work utlised an intermediate matrix model, i.e. 
intermediate between the 2D Matrigel and 3D spheroids, whereby individual 
cells were embedded in Matrigel for 4 days prior to using for proteomic array 
analysis. The advantages of this approach for the proteomic analysis over both 
the 3D spheroid model and the 2D model, are that all cells are interacting with 
the Matrigel rather than just the invading edge and hence bulk biochemical 
analysis may produce more consistent and meaningful data.  
The proteomic data also includes analysis of cells grown on 2D plastic, the 
comparisons between the plastic and Matrigel formats will not be the subject of 
extensive discussion but rather the focus will be what the collective findings may 
mean for potential hypotheses around Cav-1 interactions that promote invasion.  
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Figure 5.38 shows the results of the proteomic array analysis for U87 CAV+ and 
CAV- grown upon plastic and importantly embedded within Matrigel, and using  
commercially obtained oncology, angiogenesis and protein kinases platforms. 
From the combined platforms a selection of 16 molecules are shown in the 
heatmap (Figure 5.38C). These 16 molecules were the ones which showed a 
level of expression signficantly greater to background irrespective of the growth 
format, i.e. plastic or Matrigel.  
The molecules that showed a significant fold-change in expression  as a function 
of ratio be CAV+/CAV- included UPA, HSP27 S78/S82, IL8 all of which were 
positively correlated with Cav-1 expression in cells grown within Matrigel.   
Those molecules whose expression appeared negatively correlated with Cav-1 
expression included,  TSP-1 and Coagulation Factor III.  
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Figure 5.38 A:  Oncology, angiogenesis and protein kinases array analysis on U87 CAV+ and 
CAV- grown upon plastic and within Matrigel. Resulting pictures of the exposed Arrays for each 
cell line. B: Legend of the markers indicated in A.  C: Heat map of the significant protein 
expression modifications. Each value represents the fold change ratio CAV+/CAV-. 
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Some of the markers evidenced as correlating with Cav-1 from the protein array 
data have previously been linked with GBM invasion and/or with Cav-1 
signalling. A schematic summarizing the putative interactions  that involve some 
of our examined molecules shown in Figure 5.39, with a more simplified scheme 
presented in Figure 5.40. In constructing the schemes showing  putative Cav-1 
interactions we have brought information from the literature and focussed from 
the array on UPA,  HSP27 S78/S82  and TSP-1 interactions in particular. 
Interesting is the connection between TSP-1 and UPA (H. Li et al., 2017) since 
they inhibit each other but at the same time, they promote the activation of TGF-
1. The latter is able in return to promote the activation of TSP1 and indirectly 
inhibit the activation of PLS, through activation of PAI1, which inhibits UPA, 
consequently blocking the conversion from plasminogen (PLG) to plasmin 
(PLS). 
Cav-1 would have a role in this process since it is known to block TGF-1 
(Cosset et al., 2012). This would promote the activation of the proteases 
cascade and the enhancing of the invasion process (red circle in Figure 5.39B). 
TSP1 is also known for being able to behave as a tumour suppressor (Huang, 
Sun, Yuan, & Qiu, 2017) with the ability, against VEGF, to induce apoptosis 
(Figure 5.39C). When TSP1 overcomes VEGF, it allows the recruitment of FYN 
by CD36 and this activates the cascade for apoptosis, while when VEGF is 
higher CD36 recruits SRC and promotes survival. 
TSP1 expression has been related to increased survival (Elstner et al., 2011), 
but it has also been demonstrated that tumours can adapt to high levels of TSP1 
and bypass its inhibitory action (Filleur et al., 2001). 
Kinases HSP27 and AKT participate in the invasive process by activating UPA 
(Malinowsky et al., 2012). 
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Figure 5.39. Literature analysis of protein array. A. Main result of the invasion analysis. Cav -1 
appears to drive invasion in Matrigel in GBM cell lines. B: Connections between differentially 
expressed markers in the protein array, reviewed from the literature. The circle with the asterisk is 
reported enlarged in the bottom to show the activation cascade of the MMPs. C. Differential 
activation of CD36 by TSP-1 or VEGF leads to the recruitment of FYN or SRC and results in two 
phenotypical outcomes, apoptosis or survival. 
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Figure 5.40 Simplified conjectured pathway explaining the mechanism under Cav-1 stimulating 
invasion of GBM cell lines. 
 
The integration of the protein array results with the information provided by the 
literature allowed us to create a putative pathway that explains the mechanism 
according to which Cav-1 regulates 3D invasion (Figure 5.40). In CAV+ cells, 
Cav-1 activates HSP27 that promotes the activation of UPA through AKT. UPA 
converts PLG in PLS and activates the cascade of the proteases that leads to 
invasion. At the same time, Cav-1 inhibits TSP1, which is not able to inhibit both 
AKT, UPA and consequently invasion. 
 
To test our hypothesis, we decided to validate the markers selected in Figure 
5.40 via Western blot. Together with UPA, HSP27 and TSP1, we also decided to 
examine: 
 Activation of AKT, a key molecule in the putative scheme (Figure 5.40) 
 SRC, which is involved in the activation of AKT and it has been related to 
Cav-1 in the literature (Goetz, Lajoie, et al., 2008); 
 FAK, which is present at the focal adhesions (FAs) and it has been 
reported as stabilized by Cav-1, thus promoting FAs disassembling and 
cell movement (Goetz, Joshi, et al., 2008). 
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5.4.5 PROTEIN ARRAY PATHWAY VALIDATION 
The phosphokinases protein array analysis of U87 CAV+ and CAV- showed that 
on plastic the activation of HSP27 was inhibited to some extent by Cav-1 and on 
Matrigel driven by Cav-1 (Figure 5.38). The Western blot analysis was 
consistent with the results for plastic, but showed for cells on Matrigel that 
contrary to the proteomic array results Cav-1 appeared to inhibit the activation 
(phosphorylation) of HSP27 (Figure 5.41) when the quantification of the 
phosphorylated form was normalised on the total expression of HSP27. While 
the readout for the protein array was solely on the phosphorylated HSP27, 
examining the Western blot in Figure 5.41A for the Matrigel lanes fails to show a 
positive correlation with Cav-1 even based on the phosphorylated HSP27 form 
alone. A further point of note is that while the proteomic array was conducted 
with cells embedded within the Matrigel, the Western blot data was undertaken 
on cells growing on the surface of Matrigel in a simlar format to that described 
as the 2D Matrigel format in previous sections. The approach for the Western 
blot was out of necessity to harvest sufficient protein for the gel loading. The 
more intimate interactions of all of the cells when embedded in the matrix could 
well have impacts upon the signalling molecules.  A future study to consider is 
the use of the p38 MAPK inhibitor, SB202190 to see if effects on invasion can 
be seen to be mediated via HSP27.  p38 MAPK is one of the kinases 
responsible for the phosphorylation and activation of HSP27 (Malinowsky et al., 
2012) and has been used experimentally in cell culture at effective 
concentrations of 5M (Chen, Xie, & Xu, 2010; Nemoto, Xiang, Huang, & Lin, 
1998). Although any data from such experiment needs to be considered 
carefully as phosphorylation of HSP27 may be carried out by other kinases, not 
only p38 MAPK, e.g. PDK (Stetler et al., 2012).  
On the protein array we found TSP1 to be positively correleated with Cav-1 
levels in cells grown on plastic but signficantly downregulated in CAV+ cells 
embedded Matrigel (Figure 5.38). The Western blot analysis presented 
challenges in interpretation since the signals were very weak despite the use of 
ultra-sensitive developing agents and extended exposure times. Based on the 
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technical issues alone it was not so surprising that the Western blot did not 
reveal TSP1 to be influenced by changing Cav-1 levels (Figure 5.42).  
 
 
 
Figure 5.41 Western blot analysis for the expression of phospho HSP27 (Ser82) in U87 CAV+ and 
CAV- cells grown on plastic or on Matrigel. GAPDH was used as a housekeeping. The 
phosphorylated forms were normalized on their total form (B), while the to tal forms were 
normalised on GAPDH (C). 
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Figure 5.42 A: Western blot analysis for the expression of Thrombospondin-1 (TSP1) in U87 
CAV+ and CAV- grown on plastic or on Matrigel. GAPDH was used as a housekeeping gene and 
the normalized quantification is reported in B. three separate experiments are reported, each one 
from three different sets of samples. 
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UPA in the protein array was shown upregulated in CAV+ cells, both in cells 
growing on plastic and in cells embedded in Matrigel (Figure 5.38). Despite 
some interexperimental variation, two from three  Western blot experiments on 
cells grown on Matrigel showed an upregulation of UPA in CAV+ cells (Figure 
5.43), a result concordant with the protein array findings. The Western blot data 
for cells grown on plastic did not indicate any dependence as such for UPA 
expression upon Cav-1.  
To further clarify the relationship of UPA and Cav-1 in cells grown on Matrigel 
we undertook immunofluorescence for UPA (Figure 5.44) which revealed that 
UPA is ubiquitously expressed by CAV+ cells, while only some of the KO cells 
express the marker, with some groups of CAV- cells not showing any signal for 
UPA. This was in agreement with the protein array and western blot analyses. 
 
Figure 5.43 A: Western blot analysis for the expression of UPA in U87 CAV+ and CAV- grown on 
plastic or on Matrigel. GAPDH was used as a housekeeping gene and the normalized quantification 
is reported in B. three separate experiments are reported, each one from three different sets of 
samples. 
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Figure 5.44 Immunofluorescence analysis of U87 CRISPR expression of UPA. U87 CAV+ and 
CAV- grown on Matrigel and stained with Hoechst 33342 (blue: nuclei), Phalloidin-Alexa647 
(Red: Cytoskeleton) and, UPA (Green). Scale bar 50µm 
 
In an attempt to further understand the connection of Cav-1 with the markers 
studied in this chapter, we explored intracellular kinases involved in GBM 
aggressiveness and reported to be correlated with Cav-1 and their expression. 
These are AKT, SRC and FAK. 
In GBM, UPAR drives invasion also via key intracellular pathways, including 
PI3K/AKT. A large scale genomic analysis of GBM has demonstrated that this 
pathway is mutated in the majority of GBMs, with consequent high levels of 
phospho AKT. AKT can be phosphorylated in two sites, S473 and T308, both 
required for its activation. The phosphorylated form of AKT , detected at high 
levels in the majority of GBM samples, has been shown to help glioma cells to 
grow, evade apoptosis and enhance tumour invasion. 
AKT was analysed for two of its activated phosphorylation forms, Ser473 and 
Thr308. The samples on plastic were obtained from both normal culture 
conditions or from samples undergone serum stimulation. Serum stimulation 
consisted of removing the serum from the culture medium for 16 hrs and then 
reintroducing it for 10 minutes before lysing the samples. The procedure allows 
examination of how able the cells can react under stress conditions, and  is a 
common manipulation when observing phospho-proteins (Levin et al., 2010; 
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Levin, Panchabhai, Shen, & Baggerly, 2012). Serum stimulation is not a straight 
forward procedure for cells grown on Matrigel, as by the nature of the matrix 
itself growth factors will be present even in ‘growth factor reduced’ Matrigel. 
Experiments conducted in serum stimulation conditions are indicated as 
appropriate in the following series of figures. Quantification shows the 
phosphorylated forms normalised on the total expression of AKT. 
For AKT S473 two out of three experiments conducted on plastic  showed CAV+ 
cells to be associated with a greater degree of AKT phophorylation. The single 
experiment on Matrigel also showed the proportion of total protein that is 
phosphorylated on AKT Ser473 to be higher in the CAV+ cells (Figure 5.45). 
For AKT Thr308 we found upon serum stimulation the phosphorylation response 
in CAV+ cells to be very noticable indicating, as for the S483 site, a role of Cav-
1 in facilitating AKT activation (Figure 5.44).  Under the other conditions 
conducted in normal growth medium conditions, the signal for AKT T308 was 
very weak, although quantification where possible suggested that CAV+ cells 
even here worked to facilitate AKT Thr308 (Figure 5.46).  
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Figure 5.45 Western blot analysis for the expression of phospho AKT (Ser473) in U87 CAV+ and 
CAV- grown on plastic or on Matrigel. GAPDH was used as housekeeping. Three experiments are 
reported for the plastic condition, two of whom were conducted in serum reintroduction conditions. 
The phosphorylated forms were normalized on their total form (B), while the total forms were 
normalised on GAPDH (C). 
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Figure 5.46 Western blot analysis for the expression of phospho AKT (Thr 308) in U87 CAV+ and 
CAV- grown on plastic or on Matrigel. GAPDH was used as housekeeping. Two experiments are 
reported for the plastic condition, one of whom was conducted in serum reintroduction conditions. 
The phosphorylated forms were normalized on their total form (B), while the total forms were 
normalised on GAPDH (C). 
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Src is reported as a promising target for anti-cancer therapy. Elevated Src 
activity has been detected in GBM samples in comparison with normal brain 
tissue. Our pilot studies for the validation of INSIDIA (Chapter 4) showed that 
Src inhibition has an impact on the ability of GBM cell lines to invade in the 3D 
invasion model. 
Activated phosphoSrc (Tyr418) is able to phosphorylate Cav-1 on its Tyr14. 
The Src signal in the Western blot was extremely weak, consistent with the 
phospho protein array data for this molecule (not shown). For this reason, a 
quantification of the phosphorylated form was not performed and only the total 
Src is shown in Figure 5.47. Specifically, in Matrigel cav-1 apperas not to have 
any influence on total Src levels, whereas disparate effects on total Src could be 
seen on cells grown on plastic, with or without serum stimulation. 
 
Figure 5.47 Western blot analysis for the expression of phospho Src (Tyr417) in U87 CAV+ and 
CAV- grown on plastic or on Matrigel. GAPDH was used as housekeeping. Three experiments are 
reported for the plastic condition, two of which were conducted in serum reintroduction conditions 
(A). The total forms were normalised on GAPDH (B). 
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FAK, together with Src, regulate the focal adhesion turnover, migration and 
proliferation in GBM. As mentioned, Src phosphorylates Cav-1 on its Tyr14. The 
phosphorylated form of Cav-1 is required to stabilize the localization of FAK 
within focal adhesions. 
In the protein array the signal of phospho-FAK was very weak (data not shown). 
However, in Western blot experiments here we found that when cells underwent 
serum stimulation (plastic), a significant difference between CAV+ and CAV- 
cells was evident, with CAV+ cells having a higher proportion of FAK Tyr397. On 
Matrigel, under normal serum conditions, this difference in regulating the activity 
of FAK disappeared (Figure 5.48).  
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Figure 5.48 Western blot analysis for the expression of phospho FAK (Tyr397) in U87 CAV+ and 
CAV- grown on plastic or on Matrigel. GAPDH was used as a housekeeping. Two experiments are 
reported for the plastic condition, one of whom was conducted in serum reintroduction conditions. 
The phosphorylated forms were normalized on their total form (B), while the total forms were 
normalised on GAPDH (C). 
 
5.5 SUMMARY AND CONCLUSIONS 
Despite several decades of intensive research and improved diagnostic 
technology, the prognosis for patients with high-grade gliomas remains very 
poor.  
One of the main reasons for the lack of improvements is the highly invasive 
behaviour of glioma cells able to effectively spread from the tumour to both 
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hemispheres of the brain, along white matter tracts, subependymal layers and 
blood vessel basement membranes. Despite more precise surgery, the 
elimination of all malignant cells is improbable. Recurrent tumours exhibit 
resistance to both chemotherapy and radiotherapy.  
To initiate this migration process, glioma cells have to be able to degrade the 
extracellular matrix for the creation of a migration space. They also have to be 
able to detach from the tumour bulk, attach to the single components of the 
extracellular environment and modify their cytoskeletal structure to allow the 
movement.  
In this chapter we have shown that Cav-1 influences positively the invasive 
ability of GBM cell lines growing in spheroids surrounded by an extracellular 
matrix. When Cav-1 expression was inhibited by different techniques, cells all 
displayed a reduction of their invasive ability. The reduction in invasion was not 
related to an increase in cellular death, suggesting that cells with no or low 
expression of Cav-1 may not be able to interact effectively with the extracellular 
environment. This is consistent with reports in the literature relating to caveolae 
regulating communication between the extracellular and the intracellular 
environment, undertaking vesicular transport as well as cholesterol 
homeostasis, facilitating cell migration and cell cycle progression (Parat & 
Riggins, 2012). It also appears that Cav-1 itself is able to function outside the 
caveolae compartments, being secreted into the extracellular environment as 
part of membrane vesicles which are able to advance prostate cancer 
aggressiveness (Watanabe et al., 2009). 
In this work, the mechanistic insight of the Cav-1- driven invasion included the 
use of transcriptional (RT-PCR) and protein expression analysis (Protein array) 
with validation of the results by Western Blot and immunofluorescence studies. 
Most of the investigations we undertook in this chapter involved 2D model 
platforms, with cells growing on plastic, on Matrigel or, for the protein array work, 
as single cells embedded in Matrigel. The latter model more likely to align to the 
3D spheroid model we used in Chapter 4 and earlier parts of chapter 5 for the 
quantitative measure of invasion. The 3D spheroid model itself while excellent 
for the study of quantitative aspects of invasion did not lend itself to discreet 
measurements of biology happening at the cell-matrix interphase. Specifically, 
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the one approach we pursued to explore this, immunofluorescence 
investigations, presented significant technical challenges on the embedded 3D 
spheroid model. 
A summary of the results obtained for each of the molecules of interest and for 
each technique used is shown in Table 5.7. While CTSB and UPAR show 
consistent results among the experiments, with both of them being driven by 
Cav-1 in their expression, the other markers expression is less clear. One of the 
most interesting among them is MMP1, with Cav-1 driving its expression 
according to the PCR and the immunofluorescence on 2D Matrigel, as well as 
with a good expression in the CAV+ invading cells in 3D. The other interesting 
one is UPA, whose results on protein array, western blot and 
immunofluorescence on Matrigel confirm its expression to be concordant with 
Cav-1. 
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Table 5.7 Integrated results on markers expression from different techniques. The arrows indicate 
if the marker expression is concordant () or discordant () with the one of Cav-1.  
 
 
In 2010, a work published on the Annals of Biomedical Engineering (Demou, 
2010) connected Cav-1 as the orchestrator of the increased invasiveness of U87 
after increased compressive pressure. The work reported that, when 
compression is applied to GBM cells growing in 3D gels, invasion and cells 
detachment are enhanced. Cav-1 would be the first responder, by activating 
CD44, the complex UPAR-UPA, CTSB and MMP1, all promoting adhesion to 
contact and degradation of the extracellular matrix. Its action would also result in 
the activation, through integrins, of Src and FAK signalling and the regulation of 
cell cycle by the activation of the PI3K/AKT pathway (Figure 5.49). At the same 
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time, Cav-1 would stimulate the production of ITG1 and inhibit the expression 
of CDH1 (ECAD), leading to tumour progression. 
 
Figure 5.49 Figure from Demou et al 2010, with pathway led by Cav-1 after mechano-compression 
is applied to GBM cells. A. Cav-1 senses compression, together with other mechanosensors (B) 
and induces differential upregulation of Cav-1, which could affect adhesion, migration, and 
invasion (C). Molecules involved can localize at caveolae and enhance proteolysis, adhesion, 
migration, and invasion via: recruitment and activation of MMPs and cathepsins  (D), involvement 
of UPA (E), or integrin-mediated pathways, like Src, FAK, and PI3k/ Akt (F). PI3K/Akt pathway 
is involved in the control of cell cycle (G). CD44 localized in the caveolae of the invasive cells 
could promote recruitment of MMPs and other molecules that enhance migration and invasion (H). 
Image is reported with permission. 
 
This work is consistent with our findings. Cav.1 appears to drive UPAR, UPA, 
CTSB and partially MMP1 and CD44, which were all upregulated in Demou et al 
after compression. AKT phosphorylation forms and FAK were also upregulated 
in CAV+ cells. The influence of the PI3K/AKT pathway over cell cycle could be in 
the future investigated by the use of proliferation-specific staining, like Ki67 on 
invading spheroids or on cells on Matrigel. 
To be more specific on the single molecules that Cav-1 appears to modulate: 
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 UPAR is a negative prognostic factor for aggressive gliomas. It interacts 
with integrins and vitronectin and mediates a link between cell adhesion 
and chemotaxis (N. Levicar, Nutall, & Lah, 2003). 
 UPA when bound to UPAR in the caveolae, converts plasminogen to 
active plasmin, and induces the degradation of various ECM components 
such as fibronectin and laminin, while also contributing to the activation 
of the adhesive and invasive properties of glioblastoma cells (Vehlow & 
Cordes, 2013). 
 CTSB is physiologically an intra-lysosomal protease. In GBM it is 
secreted and helps degrading laminin and collagen. It activates UPA 
from its precursor (J. S. Rao, 2003). It is a negative prognostic factor for 
GBM patients (Natasa Levicar et al., 2002). 
 MMP1 is a collagenase that enhances both GBM tumorigenicity and 
tumour-related angiogenesis (Pullen, Anand, Cooper, & Fillmore, 2012) 
MMP1 has been shown to be upregulated in glioma specimens and to be 
related to increased invasiveness (McCready, Broaddus, Sykes, & 
Fillmore, 2005). 
 CD44 is the receptor for Hyaluronic acid. It is also overexpressed in 
GBM. Cells positive for CD44 are usually localized at the normal tissue-
tumour interface, suggesting that it causes them to be more efficient at 
invading the brain parenchyma (Rape, Ananthanarayanan, & Kumar, 
2014). CD44 has also been reported to activate intracellular signals that 
lead to the increase of glioma proliferation and invasion (Ponta, 
Sherman, & Herrlich, 2003; Xu, Stamenkovic, & Yu, 2010). 
 AKT is the downstream player of many pathways, among which CD44 
(Rape et al., 2014), EGFR and other receptors (Majewska & Szeliga, 
2017). It stimulates secretion of MMP2 and MMP9 (Claes et al., 2007) 
especially in cells at invasive edges, giving these cells enhanced 
proteolytic capacity. It has been reported that in breast cancer AKT is 
activated by Cav-1 and promotes invadopodia formation and metastasis 
(H. Yang et al., 2016). 
In summary, Cav-1 drives invasion in GBM cell lines, through the activation of 
UPA/UPAR, localized in the caveolae, which activate MMP1. At the same time, 
it induces the production of cathepsin B which contributes to the dismantling of 
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the extracellular matrix, and CD44, which helps cells recognizing hyaluronic acid 
and pathways triggered by the binding. AKT activation stimulates the regulation 
of cell cycle and contributes at different levels to GBM aggressiveness. 
Experiments such as chemical inhibition of these pathways would allow to 
confirm if Cav-1 is indeed responsible for driving the expression of these 
molecules and consequenty invasion or if a more complex relatioship is needed, 
with iother interactors and feedback loops. 
 
  
6 CHAPTER 6- THE CLINICAL IMPACT OF CAV-1 AND 
ASSOCIATED SIGNAL MOLECULES IN GBM 
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6.1 INTRODUCTION 
6.1.1 The study of survival in GBM- The Cancer Genome Atlas 
(TCGA)  
As mentioned in Chapter 1, high-grade gliomas present a very poor patient 
survival, which has not been improved in many decades of research (Ostrom et 
al., 2017). 
The high tumour heterogeneity among patients and even among different parts 
of the same tumour increases immeasurably the difficulty of finding common 
pathways and mechanisms that can be used as a therapeutical target (Inda et 
al., 2014). This is why GBM, in particular, was the first cancer to be adopted 
and studied by the Cancer Genome Atlas Project (McLendon et al., 2008). The 
Cancer Genome Atlas (TCGA) is a project that collected data from genomic, 
epigenomic, expression (microarray and recently RPPA) studies and combined 
them with the clinical information about the patients involved. TCGA started with 
GBM but it actually now comprises 33 different cancer types. 
In six years from the publication of the data in TCGA, the group has published 
significant results on GBM (Brennan et al., 2013; McLendon et al., 2008). 
These results included the establishment of new GBM subgroups that are 
characterized by different molecular expression profiles (Huse et al., 2011) and 
varying patient survival rates.  They also included the identification of mutations 
that can lead to GBM development and Temozolomide resistance (Yip et al., 
2009), as well as the association of different mutations by chromosomal 
proximity.  They confirmed the implication of five mutations (NF1, ERBB2, 
TP53, PIK3R1 and TERT) in GBM (Andersson et al., 2010; Verhaak et al., 
2010b), and the definition of a pattern of methylation predicting GBM 
aggressiveness (Noushmehr et al., 2010). 
At the same time, with the database currently available, researchers are able to 
verify if their genes of interest are related to GBM survival or other specific 
clinical features by comparing their expression across large datasets.  
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6.1.2 Cav-1 and GBM clinical samples  
The understanding of Cav-1 biology in glioma is by comparison to other tumour 
types poorly understood. There are only a few limited studies of Cav-1 
expression in clinical material. These have reported positive correlations 
between Cav-1 expression and increased tumour histological grade (Barresi et 
al., 2009; Cassoni et al., 2007). Cav-1 expression has also been reported to 
independently predict shorter survival in oligodendrogliomas (Senetta et al., 
2009), although this finding is equivocal (Barresi et al., 2009). It is clear 
however, that Cav-1 positive and negative tumour cells co-exist in high-grade 
glioma. 
 
6.2 SCOPE OF THE CHAPTER 
 
In this chapter, we investigated the relationship between Cav-1 transcriptional 
levels in GBM clinical samples and patient survival.  
Specifically, if Cav-1 served as an independent marker of survival and how 
Cav-1 may interact with other molecules associated with invasion to impact 
upon patient prognosis. 
The invasion-associated molecules explored in combination with Cav-1 in this 
chapter were those identified from Chapter 5 in the in vitro studies, and included 
molecules active in adhesion and digestion of the ECM and the EMT. 
We used two different platforms for the interrogation of the database. The first 
one is R, a software for statistical analysis, whereas the second one is R2, a 
web tool for the analysis of TCGA databases for scientists without programming 
experience, both described in the materials and methods section. 
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6.3 MATERIALS AND METHODS 
6.3.1 The Cancer Genome Atlas (TCGA) 
The Cancer Genome Atlas (TCGA) is provided by 
https://portal.gdc.cancer.gov/.  
The dataset used in this work is “Tumor Glioblastoma - TCGA - 540 - MAS5.0 - 
u133a”. It comprises information about 540 patients, including 85 samples sub-
classified in classical (n = 17), mesenchymal (n = 27), neural (n = 17) and 
proneural (n = 24) GBM. 
Whilst the number of the patients present in the dataset is quite large (540), 
only 152 patients’ samples have been analysed for gene expression. 
 
6.3.2 R2 Genomic platform for the analysis of TCGA database 
The R2 Genomics Platform is a free platform, where publicly accessible 
genomics can be analysed and visualized. This allows biomedical researchers 
without bioinformatics training, to study clinical and genomics data and to 
compare their own results to larger databases (Koster, 2016; Valentijn, Koster, 
& Versteeg, 2006). From 2006 the number of publications using the tool has 
increased exponentially up to reaching, in July 2018, 778 publications in 
different scientific journals. 
The dataset “Tumor Glioblastoma - TCGA - 540 - MAS5.0 - u133a” was added 
to R2 in 2011. It was used for Overall survival analysis and gene expression 
correlation using the scan cut-off mode based on median target gene 
expression and specifying different track subsets. 
R2 allows generating Kaplan Meier plots and provides a statistical comparison, 
expressed in p-value, based on the Log-Rank Scale. It does not provide Cox 
regression analysis nor median survival. 
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6.3.3 R project 
 R Project 3.5.0 (RCoreTeam, 2018) and RStudio, Version 1.1.423 
(RStudioTeam, 2018) were used for this study. 
The survival statistical analysis was performed by the use of Survminer 
package (Kassambara & Kosinski, 2017). The Survminer package provides 
functions for facilitating survival analysis and visualization. 
The optimal cut off point was calculated by maximally selected rank statistics 
(Delgado, Pereira, Villamor, López-Guillermo, & Rozman, 2014). This test can 
be easily applied using R (maxstat package- (Hassen et al., 2015)) and has two 
main advantages. The first is that there is no need for the time-dependent 
endpoint transformation, whilst the second is that the test calculates an exact 
cut-off point with a P value (type I error). (Lausen & Schumacher, 1992) 
The scripts used on R are available in the Appendix 6. The maxstat cutoffs for 
each gene analysed are in Appendix 9. 
 
6.3.4 Kaplan Meyer survival visualization and analysis 
Kaplan-Meier (KM) estimates represent effective measures of survival analysis 
and prognostic factors identification, thanks to their ability to analyse patients 
independently from their follow up (Kaplan & Meier, 1958). This method 
excludes (censors) patients whose survival status is unknown. This is the 
reason why KM is appropriate for the evaluation of the impact of a gene 
expression/mutation/epigenetic modification on the prognosis of patients with a 
determined disease. Disease-free or progression-free survival can also be 
calculated. Several tests can be used to compare different KMs, with the log-
rank test as the most popular (Klein, Rizzo, Zhang, & Keiding, 2001). 
The log-rank test verifies if the difference between two groups (or more) in 
terms of survival times is statistically significant or not. It does not allow us to 
test the impact of other independent variables (Kishore, Goel, & Khanna, 2010). 
The smaller the p-value, the more significant and reliable the difference 
between the groups. 
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6.3.5 COX regression and survival analysis 
The Cox proportional hazard regression model is very popular because allows 
evaluating continuous variables (e.g. age) without having to convert them into 
categorical variables, like when using the KM method. Furthermore, it is 
possible to evaluate variables that are unknown at Time 0 but become known 
later, in a time-dependent manner (Cox, 1972). 
The Cox regression elaborates a Hazard Ratio (exp(coeff)) that equals to 1 
when the expression of a marker has no effect on survival (no difference 
between the two groups) and increases or decreases together with the risk that 
the group in consideration will die in a determined time. For example, if the 
expression of a marker correlates with a positive prognosis and a delayed 
survival curve, the Hazard Ratio (HR) will be smaller than 1. Vice versa, if the 
marker increases the chances of those patients to die sooner, the hazard ration 
will be bigger than 1. To give a practical idea, if the HR is 0.5 only half of the 
patients will be likely to die at a certain time-point in comparison with the 
baseline (groups combined). On the other hand, if the HR is 2, at every time-
point the double number of patients will die in comparison with the baseline. 
 
6.3.6 Median Survival 
Median survival (in R, returned by Surv_median) provides data about the time 
by which it is more probable that a half of the group under examination will be 
still alive. It is coupled with a 95% confidence interval (95CI), which allows the 
comparison of different groups by verifying if the respective 95CIs present 
overlapping areas. 
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6.4 RESULTS AND DISCUSSION 
6.4.1 GBM survival and The Cancer Genome Atlas (TCGA) 
GBM survival has been extensively reviewed in the literature (D. N. Louis et al., 
2016a) but the impact of Cav-1 on GBM patient survival has not. Due to lack of 
surgical material, for this analysis, we decided to use a TCGA dataset, the 
TCGA 540-MAS 5.0- U133a. We chose this dataset, which is the largest of the 
TCGA datasets and it has been extensively studied (Y. W. Kim et al., 2013; Q. 
Wang et al., 2017).  
We first interrogated the TCGA database for Glioblastoma patients’ overall 
survival (Figure 6.1). It is clear from this analysis that the prognosis for the 
patients is not favourable, with as little as 20% of the whole GBM population 
achieving the 24-months survival and only 10% survival at 48 months. 
According to other sources, less than 3% of patients are still alive five years 
after diagnosis (Ohgaki & Kleihues, 2005). 
 
 
OVERALL SURVIVAL OF THE U133A TCGA 
DATASET 
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Figure 6.1 Overall survival curves for GBM patients. Plot represents all 540 patients present in  the 
dataset and was obtained through the R2 web tool.  
 
6.4.2 Impact of Cav-1 on GBM survival 
What is absent from the literature is the role that Cav-1 has in GBM patients’ 
survival. From the TCGA database analysis, it resulted that Cav-1 impacts 
significantly on survival (Figure 6.2). In particular, patients with a high 
expression of Cav-1 present a significantly shorter median survival (4.7 months 
for high Cav-1 expression whereas 14.2 months for low Cav-1 expression). 
 
 
Figure 6.2 Overall survival curves for GBM patients with a high and low expression of Cav-1. 
Vertical lines connect median survival time. The number of patients alive at each time -point is 
reported under the plot. The table shows Log Rank p-value for the evaluation of the curves 
statistical difference; median survival for each group is reported together with the confidence 
interval (CI), whilst Cox hazard ratio for the referring group is coupled with its p -value. Plot and 
analysis were obtained through R project. 
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This finding is in line with the previous chapter results, where Cav-1 was shown 
to drive invasion in GBM cell spheroids (Chapter 5). 
When looking at the overall survival the data showed no difference in gender 
(Figure 6.3A). When Cav-1 was introduced in the analysis, however, it emerged 
that this gene impacts on patients’ survival more significantly in female patients 
than in male ones (Figure 6.3B). Indeed, the median survival for female patients 
with a high expression of Cav-1 is of only three months - compared to 14 for the 
low-Cav-1 expressing female population. The male group survival, on the other 
side, is influenced by Cav-1 in a less significant way, having the MaleCav-1high 
subgroup 11 months median survival, versus the 14 months of the MaleCavlow 
subgroup.  
A quick analysis showed that the worst prognosis of Cav-1high female patients, 
compared to the Cav-1high male patients, was not due to a significant difference 
in age between the groups. 
However, differences in the degree of surgical resection (complete vs. partial) 
or performance status of patients cannot be ruled out. 
Furthermore, it may be possible that the worse overall survival in females 
whose tumours expressed Cav-1 has a biological basis. It is well established 
that Cav-1 is a regulator of ER signalling (Goetz, Lajoie, et al., 2008). More 
recent work has revealed that certain isotypes of ER, when activated, drive 
disease progression. Namely, ER1 is shown to be a tumour suppressor, whilst 
the ER5 isotype is oncogenic (Jinyou Liu et al., 2018). Therefore, the 
possibility exists that Cav-1 is driving disease progression in females through its 
potentiation of ER5 signalling. 
Further mechanistic studies to explore this possibility are necessary. It has not 
been done here because it would have been beyond the scope of this thesis. 
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Figure 6.3 Overall survival, gender and Cav-1. A. Survival curves for GBM patients belonging to 
the two different gender groups. B. Survival curves for GBM patients with high (Cav+) and low 
(Cav-) expression of Cav-1 in the two gender groups. Vertical lines connect median survival 
times. The number of patients alive at each time-point is reported under the plots. Tables show 
Log Rank p-value for the evaluation of the curves statistical difference; median survival for each 
group is reported together with the confidence interval (CI), whereas Cox hazard ratio for the 
referring group is coupled with its p-value. Plot and analysis were achieved through R project.  
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Patients appear to express an average higher Level of Cav-1 in the 
mesenchymal group, compared with the other molecular subgroups (Figure 
6.4). Despite the distribution is statistically different, the low number of patients 
in each group does not allow to draw conclusive results. The TCGA database 
indeed provides information about the molecular subtypes only for a limited 
number of patients (85 in total). An analysis of a larger group of classified 
patients would allow the confirmation of the different distribution of Cav-1 
expressing patients within the molecular subtypes. 
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Figure 6.4 Cav-1 expression in GBM subgroups (from left to right: classical, mesenchymal, neural, proneural). Patients are ordered within ea ch group by their Level of 
expression of Cav-1. Expression scale is 2Log, with each increment representing the double value of the precedent one. Red line represents cut off between Cav-1 high 
and low in Figure 6.2. R-value and p-value are reported on the top left. Gender is indicated in the bottom (female: red, male: green), together with MGMT methylation  
(methylated: red, un-methylated: green) and subtype (classical: red, mesenchymal: green, neural: blue, proneural: fuchsia). Plots were obta ined through R2. 
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The same patients have been also tested separately to understand if Cav-1 
expression has an impact on survival in different subgroups. Again, in the 
mesenchymal group, a higher expression of Cav-1 leads to a shorter patients’ 
survival (Figure 6.5).  
Interestingly, it appears also that in the proneural group a low expression of 
Cav-1 is related to a lower median survival. In Figure 6.4 the same proneural 
group was represented only by patients with an expression of Cav-1 that is 
under the cut off established for the general population. This could mean that in 
proneural GBMs Cav-1 has a different role in comparison with the 
mesenchymal ones. In a recently published thesis, it was reported that Cav-1 
was found inversely correlated with proneural markers in peri-necrotic areas of 
patients’ samples and that hypoxia was possibly related to the shift in Cav-1 
expression (Kundu, 2018). This would confirm the low expression of Cav-1 that 
we observed in the TCGA patients belonging to the proneural group and also 
the increased hazard of the Cavlow subgroup in comparison with Cavhigh in the 
same subtype. 
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Figure 6.5 Overall survival curves for GBM patients belonging to the four different GBM 
subgroups and divided into high (blue) and low (red) Cav-1 expression groups. Median survival 
for each group is reported. Log Rank p-value is reported on the bottom right of the plots. Each 
plot is coupled with the distribution of Cav-1 expression and the cut-off established by the 
software (R2). 
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Figure 6.6 Overall survival curves for GBM patients belonging to the four different GBM 
subgroups and divided into high (blue) and low (red) Cav-1 expression groups. Median survival 
for each group is reported. Log Rank p-value is reported on the bottom right of the plots. Each 
plot is coupled with the distribution of Cav-1 expression and the cut-off established by the 
software (R2). 
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Being the mesenchymal group the GBM subtype with a highest aggressive 
feature, Cav-1 higher expression and shorter survival supports the hypothesis 
of its oncogene function. This may be achieved by influencing invasion and 
facilitating relapse. 
 
6.4.3 Invasion-associated genes, Cav-1 expression and GBM 
In order to explore further the hypothesis generated in the previous section, we 
interrogated the database to understand if genes known to be related to 
invasion in GBM are related to Cav-1 expression. Results are reported in Table 
6.1. The XY expression correlation plots are reported in the appendix 8, while 
the highest 500-ranked proteins related to Cav-1 expression in GBM are in the 
Appendix 7. 
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Table 6.1 Genes previously of interest (CH.5) related to invasion: statistically significant 
relationship to Cav-1 expression in GBM TCGA dataset. The analysis was conducted through R2 
web tool. 
 
Required parameters are missing or incorrect. 
 
Most of the genes are positively related to Cav-1 expression. Two are inversely 
correlated with Cav-1 expression, with ECAD being already a marker of 
epithelial-differentiated phenotype (Hay, 1995) and thus its inverse correlation is 
in line with the hypothesis that Cav-1 is driving invasion. 
Proteins involved in invasion, like MMPs, Cathepsins and UPA, are positively 
correlated with Cav-1. At the same time, integrins and other adhesion 
molecules are related to Cav-1 expression as well. 
Interestingly, proteins recognized to be inhibitors of invasion like PAI1 and the 
TIMP family - through the inhibition of enzymes such as MMPs - are positively 
correlated to Cav-1 as well. 
ITGAV: Integrin Subunit Alph  V   ITGA3: Integrin Subunit Alpha 3 
ITGA5: Integrin Subunit Alpha 5   ITGB1: Integrin Subunit Beta 1 
ITGB3: Integrin Subunit Beta 3   ITGB5: Integrin Subunit Beta 5 
MMP2: Matrix Metallopeptidase 2   MMP9:Matrix Metallopeptidase 9 
MT1MMP: Membrane-Type-1 MMP   MMP7:Matrix Metallopeptidase 7 
MMP10: Matrix Metallopeptidase 10  MMP1:Matrix Metallopeptidase 1 
MMP8: Matrix Metallopeptidase 8   MMP3:Matrix Metallopeptidase 3 
CTSK: Cathepsin K    CTSB: Cathepsin B 
CTSL: Cathepsin L    CTSS: Cathepsin S 
CTSH: Cathepsin H    CTSD: Cathepsin D 
UPA: Urokinase Plasminogen Activator   UPAR: UPA Receptor  
TIMP1: TIMP Metallopeptidase Inhibitor 1  TIMP3: TIMP Metallopeptidase Inhibitor 3 
PAI1: Plasminogen Activ tor Inhibitor 1   VIM: Vimentin   
ECAD: E-Cadherin    PVRL4: Nectin 4 
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To test whether the correlation showed in Table 6.1 translates into an impact for 
patients we first interrogated the database for the impact of the single genes on 
GBM patients’ survival (Level 1). After which, we then examined the combined 
expression of both Cav-1 and the target genes upon patient survival (Level 2 
and Level 3). 
The aim of Level 1 analysis is to understand if the selected markers are 
independent prognostic markers in the selected GBM patient dataset. Level 2 
and Level 3 provide information regarding the correlation between the markers, 
Cav-1 and patient survival. Specifically, Level 2 is useful to determine if the two 
combined markers are correlated, i.e. acting in synergy. This would be the case 
if, for example, the median survival of the combined biomarkers would be 
shorter than the median survival of the single biomarkers analysis (Level 1). 
Level 3 clear further the relatioship between the two markers and the role that 
one marker could have in one of the subpopulations of the other marker. For 
example, whether Cav-1 acts as a tumour suppressor or oncogene in the 
subpopulation of patients expressing low levels of UPAR and vice-versa. 
The resulting analysis has been summarized in Figure 6.7. 
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Figure 6.7 Summarizing figure of the workflow of the three analyses conducted on the selected 
markers. Level 1 overall survival analysis was followed by the combination of patients with high 
levels of both Cav-1 and target genes. The split of the four possible combinations was performed 
as last. Analysis revealed differences that were significant (S) or non-significant (N). Genes 
belonging to each group of results are listed at the bottom.  
 
When commenting each of the genes analyses, the terms “drive” and “inhibit” 
indicate not a direct activation or inhibition of the target, but a positive or 
negative influence over the target expression. 
Figure 6.8 shows the impact of UPAR expression levels on survival. Figure 
6.8A shows UPARhigh tumours (UPAR+) to have a reduced survival (316 days 
vs 480 for the UPARlow group), paired with a significant HR of 2.457, suggesting 
that UPAR may be an independent negative prognostic biomarker. Figure 6.8B 
shows survival curves corresponding to the portion of the patients with high 
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levels of both Cav-1 and UPAR (CAV+UPAR+) and the remaining population 
(Others). The combination of the two biomarkers determines a shorter survival 
median time (146 days) than the others (419 days), indicating that the 
subpopulation of patients with UPARhighCAVhigh have a significantly worse 
outcome than the patients with UPARhigh but not a different outcome than the 
CAVhigh alone, whose median survival is 142 days. This could exclude a 
synergistic effect of Cav-1 and UPAR expression. Figure 6.8C shows the single 
stratifications with the two biomarkers reported as a significant negative 
prognostic factors (HR for Cav-1high is 2.294 and for UPAR high 2.123). Figure 
6.8C shows that, when Cav-1 is low expressed, UPAR drives the disease 
progression however, when Cav-1 expression is high, the UPARlowCAVhigh 
condition is met only by one patient so in this case, it is not possible to explore 
the relationship further, by checking if Cav-1 has more impact on survival than 
UPAR. 
 
Figure 6.9 shows the impact of CD44 expression levels on survival. Figure 
6.9A shows CD44high tumours (CD44+) to have a reduced survival (320 days vs 
419 for the CD44low group), paired with a significant HR of 1.536, suggesting 
that CD44 may be an independent negative prognostic biomarker. Figure 6.9B 
shows survival curves corresponding to the portion of the patients with high 
levels of both Cav-1 and CD44 (CAV+CD44+) and the remaining population 
(Others). The combination of the two biomarkers determines a shorter survival 
median time (142 days) than the others (427 days). This value corresponds to 
the median survival of Cav-1, suggesting that a synergistic effect in this case is 
not present. Figure 6.9C shows the single stratifications with only Cav-1 
confirmed as a significant negative prognostic factor (HR for Cav-1 high is 2.688). 
All patients with high levels of Cav-1 are also CD44high, while CD44high patients 
can be CAVlow, suggesting that CD44 is a pre-requisite for Cav-1 expression. 
Moreover, when Cav-1 is low there is no difference between CD44high and 
CD44low, whilst Cav-1 high expression in the CD44high subpopulation drives 
disease progression. This suggests that CD44 is able to drive disease 
progression, and thus act as an oncogene, only when Cav-1 is highly 
expressed as well. 
CHAPTER 6- TCGA ANALYSIS OF THE IMPACT OF CAV-1 ON GBM 
 
269 
 
Figure 6.10 shows the impact of ITGA3 expression levels on survival. 
Figure 6.10A shows ITGA3high tumours (ITGA3+) to have no significant impact 
upon patient survival (360 days vs 427 for the ITGA3low group), paired with a 
non-significant HR of 1.527. This suggests that ITGA3 is not a prognostic 
marker for GBM. Figure 6.10B shows survival curves corresponding to the 
portion of the patients with high levels of both Cav-1 and ITGA3 (CAV+ITGA3+) 
and the remaining population (Others). The combination of the two biomarkers 
determines a shorter survival median time (142 days) than the others (427 
days). This value corresponds to the median survival of Cav-1, suggesting that 
a synergistic effect in this case is not present. Figure 6.10C shows that the 
group CavhighITGA3low is not present, suggesting that all Cavhigh patients are 
also ITGA3high. The Level 3 stratifications confirmed Cav-1 as a significant 
negative prognostic factor (HR for Cav-1 high is 2.747) while ITGA3 is not. This is 
because, when Cav-1 is low, there is no difference between patients with high 
or low levels of ITGA3. However, in the subpopulation of ITGA3highCAVhigh the 
survival is greatly reduced. This indicates that is able to shorten patient survival 
only when it is co-expressed with Cav-1, and that Cav-1 can be highly 
expressed only when ITGA3 is highly expressed as well, thus ITGA3 is a pre-
requisite for Cav-1 expression. 
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Figure 6.8 Cav-1 and UPAR (adhesion 1). Overall survival curves of UPAR for GBM patients. A. Impact of high and low expression on survival ( Level 1). B. Survival 
curve for patients with high expression of both Cav-1 and UPAR was compared to the rest of the patients (Level 2). High or low expressions have been abbreviated to 
+/-. C. Comparison between the single combinations of a high and low expression of Cav -1 and the target gene (Level 3). Vertical lines connect median survival time. 
Tables show for each plot: Log Rank p-value for the evaluation of the curves statistical difference; median survival for each group, reported together with the con fidence 
interval (CI); Cox hazard ratio for the referring group, coupled with its p -value. Plot and analysis were achieved through R project. 
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Figure 6.9 Cav-1 and CD44 (adhesion 2). Overall survival curves of CD44 for GBM patients. A. Impact of a high and low expression on survival ( Level 1). B. Survival 
curve for patients with high expression of both Cav-1 and CD44 was compared to the rest of the patients (Level 2). High or low expressions have been abbreviated to +/-
. C. Comparison between the single combinations of a high and low expression of Cav-1 and the target gene (Level 3). Vertical lines connect median survival time. 
Tables show for each plot: Log Rank p-value for the evaluation of the curves statistical difference; median survival for each group, reported together with the con fidence 
interval (CI); Cox hazard ratio for the referring group, coupled with its p-value. Plot and analysis were achieved through R project.  
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Figure 6.10 Cav-1 and ITGA3 (adhesion 3). Overall survival curves of ITGA3 for GBM patients. A. Impact of a high and low expression on survival (Level 1). B. 
Survival curve for patients with high expression of both Cav-1 and ITGA3 was compared to the rest of the patients (Level 2). High or low expressions have been 
abbreviated to +/-. C. Comparison between the single combinations of a high and low expression of Cav-1 and the target gene (Level 3). Vertical lines connect median 
survival time. Tables show for each plot: Log Rank p-value for the evaluation of the curves statistical difference; median survival for each group, reported together  with 
the confidence interval (CI); Cox hazard ratio for the referring group, coupled with its p -value. Plot and analysis were achieved through R project.
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Figure 6.11 shows the impact of ITGA5 expression levels on survival. 
Figure 6.11A shows ITGA5high tumours (ITGA5+) to have a reduced survival 
(316 days vs 419 for the ITGA5low group), paired with a significant HR of 1.757, 
suggesting that ITGA5 is an independent prognostic biomarker for GBM. Figure 
6.11B shows survival curves corresponding to the portion of the patients with 
high levels of both Cav-1 and ITGA5 (CAV+ITGA5+) and the remaining 
population (Others). The combination of the two biomarkers determines a 
shorter survival median time (148 days) than the others (419 days), indicating 
that the subpopulation of patients with ITGA5highCAVhigh have a significantly 
worse outcome than the patients with ITGA5high but not a different outcome than 
the CAVhigh alone, whose median survival is 142 days. This could exclude a 
synergistic effect of Cav-1 and ITGA5 expression. Figure 6.11C shows the 
single stratifications with only Cav-1 reported as a significant negative 
prognostic factor (HR for Cav-1 high is 2.591). This suggests that ITGA5 is a poor 
driver of disease progression and that its oncogene properties are reduced in 
comparison with Cav-1. 
 
Figure 6.12 shows the impact of ITGAV expression levels on survival. 
Figure 6.12A shows ITGAVhigh tumours (ITGAV+) to have no significant impact 
upon patient survival (427 days vs 342 for the ITGAVlow group), with a non-
significant HR of 1.484 for ITGAVlow. This suggests that ITGAV is not an 
independent prognostic marker for GBM. Figure 6.12B shows survival curves 
corresponding to the portion of the patients with high levels of both Cav-1 and 
ITGAV (CAV+ITGAV+) and the remaining population (Others). The combination 
of the two biomarkers determines a shorter survival median time (138 days) 
than the others (419 days). The median survival for the combined biomarkers in 
this case is shorter than both the median survival times of ITGAVhigh (342 days) 
and CAVhigh alone (142 days), suggesting that some synergy may be present 
between them. Figure 6.12C for the Level 3 stratification shows, however, that 
Cav-1 is a significant negative prognostic factor (HR for Cav-1 high is 3.155) 
while ITGAV as a positive prognostic factor (HR for ITGAVlow is 1.589). This is 
because, whilst Cav-1 expression drives disease progression and shortens 
median survival, a high expression of ITGAV correlates with a longer survival, 
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even if the effect is not powerful enough to annul the oncogene effect of Cav-1 
high expression. This suggests that ITGAV is a tumour suppressor in GBM, but 
also that Cav-1 is able to override its action. 
 
Figure 6.13 shows the impact of ITGB1 expression levels on survival. 
Figure 6.13A shows ITGB1high tumours (ITGB1+) to have no significant impact 
upon survival (342 days vs 419 for the ITGB1low group), paired with a non-
significant HR of 1.344. this suggests that ITGB1 is not an independent 
prognostic marker for GBM. Figure 6.13B shows survival curves corresponding 
to the portion of the patients with high levels of both Cav-1 and ITGB1 
(CAV+ITGB1+) and the remaining population (Others). The combination of the 
two biomarkers determines a shorter median survival time (146 days) than the 
others (419 days), indicating that the subpopulation of patients with 
ITGB1highCAVhigh have a significantly worse outcome than the patients with 
ITGB1high but not a different outcome than the CAVhigh alone, whose median 
survival is 142 days. Figure 6.13C shows the single stratifications with Cav-1 
reported as a significant negative prognostic factor (HR for Cav-1 high is 2.865). 
when Cav-1 is low expressed, there is no difference between ITGB1high and 
ITGB1low patients. When Cav-1 is high the survival time decreases drastically, 
but the difference between ITGB1high and ITGB1low is not reliable. This is 
because the group CavhighITGB1low is comprised of only two patients, making a 
reliable statistical analysis for the impact of ITGB1 upoon CAVhigh patients 
impossible. A larger cohort would allow the unequivocal understanding of the 
role of ITGB1 in GBM patient survival. 
 
Figure 6.14 shows the impact of ITGB3 expression levels on survival. 
Figure 6.14A shows ITGB3high tumours (ITGB3+) to have no significant impact 
upon survival (485 days vs 359 for the ITGB3low group), paired with a non-
significant HR of 1.460. this suggests that ITGB3 is not an independent 
biomarker for GBM. Figure 6.14B shows survival curves corresponding to the 
portion of the patients with high levels of both Cav-1 and ITGB3 (CAV+ITGB3+) 
and the remaining population (Others). The combination of the two biomarkers 
determines a shorter survival median time (146 days) than the others (419 
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days), indicating that the subpopulation of patients with ITGB3highCAVhigh have a 
significantly worse outcome than the patients with ITGB3high but not a different 
outcome than the CAVhigh alone, whose median survival is 142 days. Figure 
6.14C shows the single stratifications with Cav-1 reported as a significant 
negative prognostic factor (HR for Cav-1 high is 2.710). The group 
CavhighITGB3low is comprised of only two patients, making a reliable statistical 
analysis impossible. A larger cohort would allow the unequivocal understanding 
of the role of ITGB1 in GBM patient survival. 
 
Figure 6.15 shows the impact of ITGB5 expression levels on survival. 
Figure 6.15A shows ITGB5high tumours (ITGB5+) to have a reduced survival 
(316 days vs 439 for the ITGB5low group), paired with an HR of 1.715. this 
suggests that ITGB5 is an independent prognostic marker for GBM. Figure 
6.15B shows survival curves corresponding to the portion of the patients with 
high levels of both Cav-1 and ITGB5 (CAV+ITGB5+) and the remaining 
population (Others). The combination of the two biomarkers determines a 
shorter survival median time (138 days) than the others (419 days). The median 
survival for the combined biomarkers in this case is shorter than both the 
median survival times of ITGB5high (316 days) and CAVhigh alone (142 days), 
suggesting that some synergy may be present between them. Figure 6.15C 
shows the single stratifications with only Cav-1 reported as a significant 
negative prognostic factor (HR for Cav-1 high is 2.611). This indicated that ITGB5 
is a poor driver of disease progression. 
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Figure 6.11 Cav-1 and ITGA5 (adhesion 4). Overall survival curves of ITGA5 for GBM patients. A. Impact of a high and low expression on survival ( Level 1). B. 
Survival curve for patients with high expression of both Cav-1 and ITGA5 was compared to the rest of the patients (Level 2). High or low expressions have been 
abbreviated to +/. C. Comparison between the single combinations of a high and low expression of Cav -1 and the target gene (Level 3). Vertical lines connect median 
survival time. Tables show for each plot: Log Rank p-value for the evaluation of the curves statistical difference; median survival for each group, reported together with 
the confidence interval (CI); Cox hazard ratio for the referring group, c oupled with its p-value. Plot and analysis were achieved through R project.  
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Figure 6.12 Cav-1 and ITGAV (adhesion 5). Overall survival curves of ITGAV for GBM patients. A. Impact of a high and low expression on survival ( Level 1). B. 
Survival curve for patients with high expression of both Cav-1 and ITGAV was compared to the rest of the patients (Level 2). High or low expressions have been 
abbreviated to +/-. C. Comparison between the single combinations of a high and low expression of Cav-1 and the target gene (Level 3). Vertical lines connect median 
survival time. Tables show for each plot: Log Rank p-value for the evaluation of the curves statistical difference; median survival for each group, reported together with 
the confidence interval (CI); Cox hazard ratio for the referring group, coupled with its p -value. Plot and analysis were achieved through R project.  
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Figure 6.13 Cav-1 and ITGB1 (adhesion 6). Overall survival curves of ITGB1 for GBM patients. A. Impact of a high and low expression on survival (Level 1). B. 
Survival curve for patients with high expression of both Cav-1 and ITGB1 was compared to the rest of the patients (Level 2). High or low expressions have been 
abbreviated to +/-. C. Comparison between the single combinations of a high and low expression of Cav-1 and the target gene (Level 3). Vertical lines connect median 
survival time. Tables show for each plot: Log Rank p-value for the evaluation of the curves statistical difference; median survival for each group, reported together with 
the confidence interval (CI); Cox hazard ratio for the referring group, coupled with its p -value. Plot and analysis were achieved through R project.  
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Figure 6.14 Cav-1 and ITGB3 (adhesion 7). Overall survival curves of ITGB3 for GBM patients. A. Impact of a high and low expression on survival ( Level 1). B. 
Survival curve for patients with high expression of both Cav-1 and ITGB3 was compared to the rest of the patients (Level 2). High or low expressions have been 
abbreviated to +/-. C. Comparison between the single combinations of a high and low expression of Cav -1 and the target gene (Level 3). Vertical lines connect median 
survival time. Tables show for each plot: Log Rank p-value for the evaluation of the curves statistical difference; median survival for each group, reported together with 
the confidence interval (CI); Cox hazard ratio for the referring group, coupled with its p -value. Plot and analysis were achieved through R project. 
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Figure 6.15 Cav-1 and ITGB5 (adhesion 8). Overall survival curves of ITGB5 for GBM patients. A. Impact of a high and low expression on survival ( Level 1). B. 
Survival curve for patients with high expression of both Cav-1 and ITGB5 was compared to the rest of the patients (Level 2). High or low expressions have been 
abbreviated to +/-. C. Comparison between the single combinations of a high and low expression of Cav -1 and the target gene (Level 3). Vertical lines connect median 
survival time. Tables show for each plot: Log Rank p-value for the evaluation of the curves statistical difference; median survival for each group, reported together with 
the confidence interval (CI); Cox hazard ratio for the referring group, coupled with its p-value. Plot and analysis were achieved through R project.  
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Figure 6.16 shows the impact of ECAD expression levels on survival. 
Figure 6.16A shows ECAD high tumours (ECAD +) to have an increased survival 
(441 days vs 231 for the ECAD low group), paired with an HR for ECADlow of 
2.431. This suggests that ECAD is and independent positive prognostic marker 
for GBM. Figure 6.16B shows survival curves corresponding to the portion of 
the patients with high levels of both Cav-1 and ECAD (CAV+ ECAD +) and the 
remaining population (Others). The combination of the two biomarkers 
determines a shorter survival median time (135 days) than the others (414 
days). The median survival for the combined biomarkers in this case is shorter 
than both the median survival times of ECADhigh (441 days) and CAVhigh alone 
(142 days), suggesting that some synergy may be present between them. 
Figure 6.16C shows the single stratifications with Cav-1 reported as a 
significant negative prognostic factor (HR for Cav-1 high is 2.674) while ECAD is 
a positive prognostic factor (HR for ECADlow is 1.652) even if not significant. 
Specifically, when Cav-1 is high, there is no difference between ECADhigh and 
ECADlow, while when Cav-1 is low ECAD inhibits disease progression, thus not 
allowing a significant statistical difference. This suggests that ECAD acts as a 
tumour suppressor, but also that Cav-1 is able to override its tumour suppressor 
abilities. 
 
Figure 6.17 shows the impact of VIM expression levels on survival. Figure 
6.17A shows VIMhigh tumours (VIM+) to have no significant impact upon patient 
survival (342 days vs 468 for the VIMlow group), paired with a non-significant HR 
of 1.328. This suggests that VIM is not a prognostic marker for GBM. Figure 
6.17B shows survival curves corresponding to the portion of the patients with 
high levels of both Cav-1 and VIM (CAV+VIM+) and the remaining population 
(Others). The combination of the two biomarkers determines a shorter survival 
median time (142 days) than the others (427 days). This value corresponds to 
the median survival of Cav-1, suggesting that a synergistic effect in this case is 
not present. Figure 6.17C shows the single stratifications. The group 
CavhighVIMlow is not present, indicating that all Cavhigh patients are also VIMhigh. 
Only Cav-1 reported as a significant negative prognostic marker (HR for Cav-1 
high is 2.890), while VIM is not. This is because, when Cav-1 is low, there is no 
CHAPTER 6- TCGA ANALYSIS OF THE IMPACT OF CAV-1 ON GBM 
 
282 
difference between patients with high or low levels of VIM. However, in the 
subpopulation of VIMhighCAVhigh the survival is greatly reduced. This indicates 
that is able to shorten patient survival only when it is co-expressed with Cav-1, 
and that Cav-1 can be highly expressed only when VIM is highly expressed as 
well, thus VIM is a pre-requisite for Cav-1 expression. 
 
Figure 6.18 shows the impact of PVRL4 expression levels on survival. 
Figure 6.18Figure 6.14A shows PVRL4high tumours (PVRL4+) to have a 
reduced survival (231 days vs 419 for the PVRL4low group), paired with a 
significant HR of 2.695. This indicates that PVRL4 is an independent negative 
prognostic marker for GBM. Figure 6.18B shows survival curves corresponding 
to the portion of the patients with high levels of both Cav-1 and PVRL4 
(CAV+PVRL4+) and the remaining population (Others). The combination of the 
two biomarkers determines a shorter survival median time (83 days) than the 
others (406 days). Figure 6.18C shows the single stratifications with both 
biomarkers reported as a significant negative prognostic factors (HR for Cav-1 
high is 2.833 and for PVRL4 high 2.494). The median survival of Level 1 PVRL4high 
and Level 1 CAVhigh are both longer than the PVRL4highCAVhigh group in Level 2, 
suggesting that Cav-1 and PVRL4 may sinergetically drive disease progression. 
 
Figure 6.19 shows the impact of CTSB expression levels on survival. 
Figure 6.19Figure 6.14A shows CTSBhigh tumours (CTSB+) to have a reduced 
survival (333 days vs 478 for the CTSBlow group), paired with an HR of 2.155, 
suggesting that CTSB may be an independent prognostic marker. Figure 6.19B 
shows survival curves corresponding to the portion of the patients with high 
levels of both Cav-1 and CTSB (CAV+CTSB+) and the remaining population 
(Others). The combination of the two biomarkers determines a shorter survival 
median time (142 days) than the others (427 days). This value corresponds to 
the median survival of Cav-1, suggesting that a synergistic effect in this case is 
not present. Figure 6.19Figure 6.14C shows that the group CavhighCTSBlow is 
not present, suggesting that all Cavhigh patients are also CTSBhigh. The Level 3 
stratifications confirmed Cav-1 reported as a significant negative prognostic 
factor (HR for Cav-1 high is 2.681) while CTSB wass not. This is because, when 
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Cav-1 is low, there is no significant difference between patients with high or low 
levels of CTSB. However, in the subpopulation of CTSBhighCAVhigh the survival 
is greatly reduced. This indicates that is able to shorten patient survival only 
when it is co-expressed with Cav-1, and that Cav-1 can be highly expressed 
only when ITGA3 is highly expressed as well, thus ITGA3 is a pre-requisite for 
Cav-1 expression. 
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Figure 6.16 Cav-1 and ECAD (EMT 1). Overall survival curves of ECAD for GBM patients. A. Impact of a high and low expression on survival ( Level 1). B. Survival 
curve for patients with high expression of both Cav-1 and ECAD was compared to the rest of the patients (Level 2). High or low expressions have been abbreviated to 
+/-. C. Comparison between the single combinations of a high and low expression of Cav-1 and the target gene (Level 3). Vertical lines connect median survival time. 
Tables show for each plot: Log Rank p-value for the evaluation of the curves statistical difference; median survival for each group, reported together with the con fidence 
interval (CI); Cox hazard ratio for the referring group, coupled with its p -value. Plot and analysis were achieved through R project.  
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Figure 6.17 Cav-1 and VIM (EMT 2). Overall survival curves of VIM for GBM patients. A. Impact of a high and low expression on survival (Level 1). B. Survival curve 
for patients with high expression of both Cav-1 and VIM was compared to the rest of the patients (Level 2). High or low expressions have been abbreviated to +/-. C. 
Comparison between the single combinations of a high and low expression of Cav-1 and the target gene (Level 3). Vertical lines connect median survival time. Tables 
show for each plot: Log Rank p-value for the evaluation of the curves statistical difference; median survival for each group, reported together with the confidence 
interval (CI); Cox hazard ratio for the referring group, coupled with its p -value. Plot and analysis were achieved through R project.  
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Figure 6.18 Cav-1 and PVRL4 (cell-cell adhesion). Overall survival curves of PVRL4 for GBM patients. A. Impact of a high and low expression on survival ( Level 1). 
B. Survival curve for patients with high expression of both Cav-1 and PVRL4 was compared to the rest of the patients (Level 2). High or low expressions have been 
abbreviated to +/-. C. Comparison between the single combinations of a high and low expression of Cav -1 and the target gene (Level 3). Vertical lines connect median 
survival time. Tables show for each plot: Log Rank p-value for the evaluation of the curves statistical difference; median survival for each group, reported together with 
the confidence interval (CI); Cox hazard ratio for the referring group, coupled with its p -value. Plot and analysis were achieved through R project. 
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Figure 6.19 Cav-1 and CTSB (invasion 1). Overall survival curves of CTSB for GBM patients. A. Impact of a high and low expression on survival ( Level 1). B. Survival 
curve for patients with high expression of both Cav-1 and CTSB was compared to the rest of the patients (Level 2). High or low expressions have been abbreviated to +/-
. C. Comparison between the single combinations of a high and low expression of Cav-1 and the target gene (Level 3). Vertical lines connect median survival time. 
Tables show for each plot: Log Rank p-value for the evaluation of the curves statistical difference; median survival for each group, reported together with the con fidence 
interval (CI); Cox hazard ratio for the referring group, coupled with its p-value. Plot and analysis were achieved through R project.  
CHAPTER 6- TCGA ANALYSIS OF THE IMPACT OF CAV-1 ON GBM 
 
288 
Figure 6.20 shows the impact of CTSD expression levels on survival. 
Figure 6.20A shows CTSDhigh tumours (CTSD+) to have a reduced survival 
(269 days vs 427 for the CTSDlow group), paired with an HR of 1.848, indicating 
that CTSD is an independent negative prognostic biomarker. Figure 6.20B 
shows survival curves corresponding to the portion of the patients with high 
levels of both Cav-1 and CTSD (CAV+CTSD+) and the remaining population 
(Others). The combination of the two biomarkers determines a shorter survival 
median time (151 days) than the others (414 days), indicating that the 
subpopulation of patients with CTSDhighCAVhigh have a significantly worse 
outcome than the patients with CTSDhigh but not a worse outcome than the 
CAVhigh alone, whose median survival is 142 days. This could exclude a 
synergistic effect of Cav-1 and CTSD expression. Figure 6.20C shows the 
single stratifications with only Cav-1 reported as a significant negative 
prognostic factor (HR for Cav-1 high is 2.451). The Level 3 analysis reveals that 
there is no difference in in survival rate between CTSDhigh and CTSDlow when 
Cav-1 is high as well. However, when Cav-1 expression is low, CTSDhigh drives 
disease progression. This suggests that CTSD is an independent negative 
prognostic biomarker but also that its effect is relatively small in comparison 
with the impact of Cav-1. 
 
Figure 6.21 shows the impact of CTSH expression levels on survival. 
Figure 6.21A shows CTSHhigh tumours (CTSH+) to have a increased survival 
(543 days vs 360 for the CTSHlow group), paired with an HR for CTSHlow of 
2.059, suggesting that CTSH is an independent positive prognostic biomarker. 
Figure 6.21B shows survival curves corresponding to the portion of the patients 
with high levels of both Cav-1 and CTSH (CAV+CTSH+) and the remaining 
population (Others). The combination of the two biomarkers determines a 
shorter survival median time (233 days) than the others (399 days) but the 
hazard is not significant. Figure 6.21C shows the single stratifications with Cav-
1 reported as a significant negative prognostic factor (HR for Cav-1 high is 3.311) 
and CTSH as a positive prognostic factor (HR for CTSH low is 2.332). Whilst 
Cav-1 high expression drives disease progression and shortens median 
survival, CTSHhigh correlates with a longer survival, even if not enough to 
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counterbalance the negative effect of Cav-1 (in fact CTSH HR is lower than 
Cav-1). This suggests that CTSH acts as a tumour suppressor but also that 
Cav-1 is able to partially override its tumour suppressor potential. 
 
Figure 6.22 shows the impact of CTSK expression levels on survival. 
Figure 6.22 shows CTSKhigh tumours (CTSK+) to have no significant impact 
upon patient survival (323 days vs 427 for the CTSKlow group), paired with a 
non-significant HR of 1.418. Figure 6.22B shows survival curves corresponding 
to the portion of the patients with high levels of both Cav-1 and CTSK 
(CAV+CTSK+) and the remaining population (Others). The combination of the 
two biomarkers determines a shorter survival median time (138 days) than the 
others (419 days). The median survival for the combined biomarkers in this 
case is shorter than both the median survival times of CTSKhigh (323 days) and 
CAVhigh alone (142 days), suggesting that some synergy may be present 
between them. Figure 6.22C shows the single stratifications with only Cav-1 
reported as a significant negative prognostic factor (HR for Cav-1 high is 3.096). 
This indicates that CTSK is not a driver of disease progression. 
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Figure 6.20 Cav-1 and CTSD (invasion 2). Overall survival curves of CTSD for GBM patients. A. Impact of a high and low expression on survival (Level 1). B. Survival 
curve for patients with high expression of both Cav-1 and CTSD was compared to the rest of the patients (Level 2). High or low expressions have been abbreviated to +/-
. C. Comparison between the single combinations of a high and low expression of Cav-1 and the target gene (Level 3). Vertical lines connect median survival time. 
Tables show for each plot: Log Rank p-value for the evaluation of the curves statistical difference; median survival  for each group, reported together with the confidence 
interval (CI); Cox hazard ratio for the referring group, coupled with its p -value. Plot and analysis were achieved through R project.  
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Figure 6.21 Cav-1 and invasion 3. Overall survival curves of CTSH for GBM patients. A. Impact of a high and low expression on survival ( Level 1). B. Survival curve 
for patients with high expression of both Cav-1 and CTSH was compared to the rest of the patients (Level 2). High or low expressions have been abbreviated to +/-. C. 
Comparison between the single combinations of a high and low expression of Cav-1 and the target gene (Level 3). Vertical lines connect median survival time. Tables 
show for each plot: Log Rank p-value for the evaluation of the curves statistical difference; median survival for each group, reported together with the confidence 
interval (CI); Cox hazard ratio for the referring group, coupled with its p -value. Plot and analysis were achieved through R project.  
CHAPTER 6- TCGA ANALYSIS OF THE IMPACT OF CAV-1 ON GBM 
 
292 
 
Figure 6.22 Cav-1 and invasion 4. Overall survival curves of CTSK for GBM patients. A. Impact of a high and low expression on survival ( Level 1). B. Survival curve 
for patients with high expression of both Cav-1 and CTSK was compared to the rest of the patients (Level 2). High or low expressions have been abbreviated to +/-. C. 
Comparison between the single combinations of a high and low expression of Cav-1 and the target gene (Level 3). Vertical lines connect median survival time. Tables 
show for each plot: Log Rank p-value for the evaluation of the curves statistical difference; median survival for each group, reported together with the con fidence 
interval (CI); Cox hazard ratio for the referring group, coupled with its p -value. Plot and analysis were achieved through R project. 
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Figure 6.23 shows the impact of CTSL expression levels on survival. 
Figure 6.23A shows CTSLhigh tumours (CTSL+) to have a reduced survival (316 
days vs 439 for the CTSLlow group), paired with an HR of 1.418, suggesting that 
it is an independent negative prognostic biomarker. Figure 6.23B shows 
survival curves corresponding to the portion of the patients with high levels of 
both Cav-1 and CTSL (CAV+CTSL+) and the remaining population (Others). 
The combination of the two biomarkers determines a shorter survival median 
time (142 days) than the others (427 days). This value corresponds to the 
median survival of Cav-1, suggesting that a synergistic effect in this case is not 
present. Figure 6.23C shows the single stratifications with only Cav-1 reported 
as a significant negative prognostic factor (HR for Cav-1 high is 2.632). The 
group CAVhighCTSLlow is not present, indicating that all Cavhigh patients are also 
CTSLhigh. All patients with high levels of Cav-1 are also CTSLhigh, while CTSLhigh 
patients can be CAVlow, suggesting that CTSL is a pre-requisite for Cav-1 
expression. 
 
Figure 6.24 shows the impact of CTSS expression levels on survival. 
Figure 6.24A shows CTSShigh tumours (CTSS+) to have no significant impact 
upon patient survival (342 days vs 468 for the CTSSlow group), paired with a 
non-significant HR of 1.506. This suggests that CTSS is not an independent 
prognostic biomarker for GBM. Figure 6.24B shows survival curves 
corresponding to the portion of the patients with high levels of both Cav-1 and 
CTSS (CAV+CTSS+) and the remaining population (Others). The combination 
of the two biomarkers determines a shorter survival median time (146 days) 
than the others (419 days), indicating that the subpopulation of patients with 
CTSShighCAVhigh have a significantly worse outcome than the patients with 
CTSShigh but not a different outcome than the CAVhigh alone, whose median 
survival is 142 days. This could exclude a synergistic effect of Cav-1 and CTSS 
expression. Figure 6.24C shows the single stratifications with only Cav-1 
reported as a significant negative prognostic factor (HR for Cav-1 high is 2.762). 
Figure 6.24 that, when Cav-1 is low expressed, CTSS drives the disease 
progression however, when Cav-1 expression is high, the CTSSlowCAVhigh 
condition is met only by three patients so in this case, it is not possible to 
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explore the relationship further, by checking if Cav-1 has more impact on 
survival than CTSS. 
 
Figure 6.25 shows the impact of MMP1 expression levels on survival. 
Figure 6.25A shows MMP1high tumours (MMP1+) to have a reduced survival 
(313 days vs 419 for the MMP1low group), paired with an HR of 1.672, 
suggesting that MMP1 may be an independent negative prognostic biomarker. 
Figure 6.25B shows survival curves corresponding to the portion of the patients 
with high levels of both Cav-1 and MMP1 (CAV+ MMP1+) and the remaining 
population (Others). The combination of the two biomarkers determines a 
shorter survival median time (149 days) than the others (414 days), indicating 
that the subpopulation of patients with MMP1highCAVhigh have a significantly 
worse outcome than the patients with MMP1high but not a different outcome than 
the CAVhigh alone, whose median survival is 142 days. This could exclude a 
synergistic effect of Cav-1 and MMP1 expression. Figure 6.25C shows the 
single stratifications with only Cav-1 reported as a significant negative 
prognostic factor (HR for Cav-1 high is 2.667). This indicated that MMP1 is a poor 
driver of disease progression. 
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Figure 6.23 Cav-1 and invasion 5. Overall survival curves of CTSL for GBM patients. A. Impact of a high and low expression on survival ( Level 1). B. Survival curve 
for patients with high expression of both Cav-1 and CTSL was compared to the rest of the patients (Level 2). High or low expressions have been abbreviated to +/-. C. 
Comparison between the single combinations of a high and low expression of Cav-1 and the target gene (Level 3). Vertical lines connect median survival time. Tables 
show for each plot: Log Rank p-value for the evaluation of the curves statistical difference; median survival for each group, reported together with the con fidence 
interval (CI); Cox hazard ratio for the referring group, coupled with its p -value. Plot and analysis were achieved through R project.  
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Figure 6.24 Cav-1 and invasion 6. Overall survival curves of CTSS for GBM patients. A. Impact of a h igh and low expression on survival (Level 1). B. Survival curve 
for patients with high expression of both Cav-1 and CTSS was compared to the rest of the patients (Level 2). High or low expressions have been abbreviated to +/-. C. 
Comparison between the single combinations of a high and low expression of Cav-1 and the target gene (Level 3). Vertical lines connect median survival time. Tables 
show for each plot: Log Rank p-value for the evaluation of the curves statistical difference; median survival for each  group, reported together with the confidence 
interval (CI); Cox hazard ratio for the referring group, coupled with its p -value. Plot and analysis were achieved through R project.  
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Figure 6.25 Cav-1 and invasion 7. Overall survival curves of MMP1 for GBM patients. A. Impact of a high and low expression on survival ( Level 1). B. Survival curve 
for patients with high expression of both Cav-1 and MMP1 was compared to the rest of the patients (Level 2). High or low expressions have been abbreviated to +/-. C. 
Comparison between the single combinations of a high and low expression of Cav-1 and the target gene (Level 3). Vertical lines connect median survival time. Tables 
show for each plot: Log Rank p-value for the evaluation of the curves statistical difference; median survival for each group, reported together with the confidence 
interval (CI); Cox hazard ratio for the referring group, coupled with its p -value. Plot and analysis were achieved through R project.  
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Figure 6.26 shows the impact of MMP2 expression levels on survival. 
Figure 6.26A shows MMP2high tumours (MMP2+) to have a reduced survival 
(357 days vs 543 for the MMP2low group), paired with an HR of 1.984, 
suggesting that MMP2 may be an independent negative prognostic biomarker. 
Figure 6.26B shows survival curves corresponding to the portion of the patients 
with high levels of both Cav-1 and MMP2 (CAV+ MMP2+) and the remaining 
population (Others). The combination of the two biomarkers determines a 
shorter survival median time (138 days) than the others (419 days). The median 
survival for the combined biomarkers in this case is shorter than both the 
median survival times of MMP2high (357 days) and CAVhigh alone (142 days), 
suggesting that some synergy may be present between them. Figure 6.26C 
shows the single stratifications with both markers reported as a significant 
negative prognostic factors (HR for Cav-1high is 3.356 whilst for MMP2high 
2.320). MMP2 impact upon survival is irrespective of Cav-1, suggesting that 
MMP2 is an independent prognostic marker. 
 
Figure 6.27 shows the impact of MMP3 expression levels on survival. 
Figure 6.27A shows MMP3high tumours (MMP3+) to have no significant impact 
upon patient survival (485 days vs 359 for the MMP3low group), paired with a 
non-significant HR of 1.460 for MMP3low. This suggests that MMP3 is not an 
independent prognostic marker for GBM. Figure 6.27B shows survival curves 
corresponding to the portion of the patients with high levels of both Cav-1 and 
MMP3 (CAV+ MMP3+) and the remaining population (Others). The combination 
of the two biomarkers determines a shorter survival median time (146 days) 
than the others (406 days), indicating that the subpopulation of patients with 
MMP3highCAVhigh have a significantly worse outcome than the patients with 
MMP3high but not a different outcome than the CAVhigh alone, whose median 
survival is 142 days. This could exclude a synergistic effect of Cav-1 and MMP3 
expression. Figure 6.27C shows the single stratifications with Cav-1 reported as 
a significant negative prognostic factor (HR for Cav-1high is 3.322) whereas 
MMP3 is a positive prognostic marker (HR for MMP3low is 1.641). This is 
because, whilst Cav-1 expression drives disease progression and shortens 
median survival, a high expression of MMP3 correlates with a longer survival, 
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even if the effect is not powerful enough to annul the oncogene effect of Cav-1 
high expression. This suggests that MMP3 is a tumour suppressor in GBM, but 
also that Cav-1 is able to override its action. 
 
Figure 6.28 shows the impact of MMP7 expression levels on survival. 
Figure 6.28A shows MMP7high tumours (MMP7+) to have a reduced survival 
(316 days vs 468 for the MMP7low group), paired with an HR of 1.645, 
suggesting that MMP7 may be an independent negative prognostic biomarker. 
Figure 6.28B shows survival curves corresponding to the portion of the patients 
with high levels of both Cav-1 and MMP7 (CAV+ MMP7+) and the remaining 
population (Others). The combination of the two biomarkers determines a 
shorter survival median time (146 days) than the others (419 days), indicating 
that the subpopulation of patients with MMP7highCAVhigh have a significantly 
worse outcome than the patients with MMP7high but not a different outcome than 
the CAVhigh alone, whose median survival is 142 days. This could exclude a 
synergistic effect of Cav-1 and MMP7 expression. Figure 6.28C shows the 
single stratifications with only Cav-1 reported as a significant negative 
prognostic factor (HR for Cav-1high is 2.625). ,When Cav-1 is low expressed, 
MMP7 drives the disease progression however, when Cav-1 is high almost all 
patients are MMP7high as well. A larger cohort would allow to include more 
patients CAVhighMMP7low and determine if MMP7 is actually a prognostic factor 
for gliomas. 
 
Figure 6.29 shows the impact of MMP9 expression levels on survival. 
Figure 6.29A shows MMP9high tumours (MMP9+) to have a reduced survival 
(359 days vs 737 for the MMP9low group), paired with an HR of 1.789, 
suggesting that MMP9 may be an independent negative prognostic biomarker. 
Figure 6.29B shows survival curves corresponding to the portion of the patients 
with high levels of both Cav-1 and MMP9 (CAV+ MMP9+) and the remaining 
population (Others). The combination of the two biomarkers determines a 
shorter survival median time (139 days) than the others (419 days). The median 
survival for the combined biomarkers in this case is shorter than both the 
median survival times of MMP9high (359 days) and CAVhigh alone (142 days), 
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suggesting that some synergy may be present between them. Figure 6.29C 
shows the single stratifications with both markers reported as a significant 
negative prognostic factors (HR for Cav-1high is 3.086 and for MMP9high 1.869). 
MMP9 impact upon survival is irrespective of Cav-1, suggesting that MMP9 is 
an independent prognostic marker.  
 
Figure 6.30 shows the impact of MMP10 expression levels on survival. 
Figure 6.30A shows MMP10high tumours (MMP10+) to have a reduced survival 
(320 days vs 427 for the MMP10low group), paired with an HR of 1.653, 
suggesting that MMP10 may be an independent negative prognostic biomarker. 
Figure 6.30B shows survival curves corresponding to the portion of the patients 
with high levels of both Cav-1 and MMP10 (CAV+ MMP10+) and the remaining 
population (Others). The combination of the two biomarkers determines a 
shorter survival median time (142 days) than the others (419 days). This value 
corresponds to the median survival of Cav-1, suggesting that a synergistic 
effect in this case is not present. Figure 6.30C shows the single stratifications 
with only Cav-1 reported as a significant negative prognostic factor (HR for Cav-
1high is 2.703). When Cav-1 is low there is no difference between MMP10high 
and MMP10low patients. When the expression of Cav-1 increases, however, 
only two patients corresponds to the phenotype CAVhighMMP10low. This makes 
not possible to explore the relationship further, by checking if Cav-1 has more 
impact on survival than MMP10. 
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Figure 6.26 Cav-1 and invasion 8. Overall survival curves of MMP2 for GBM patients. A. Impact of a high and low expression on survival ( Level 1). B. Survival curve 
for patients with high expression of both Cav-1 and MMP2 was compared to the rest of the patients (Level 2). High or low expressions have been abbreviated to +/-. C. 
Comparison between the single combinations of a high and low expression of Cav-1 and the target gene (Level 3). Vertical lines connect median survival time. Tables 
show for each plot: Log Rank p-value for the evaluation of the curves statistical difference; median survival for each group, reported together with the confidence 
interval (CI); Cox hazard ratio for the referring group, coupled with its p -value. Plot and analysis were achieved through R project.  
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Figure 6.27 Cav-1 and invasion 9. Overall survival curves of MMP3 for GBM patients. A. Impact of a high and low expression on survival ( Level 1). B. Survival curve 
for patients with high expression of both Cav-1 and MMP3 was compared to the rest of the patients (Level 2). High or low expressions have been abbreviated to +/-. C. 
Comparison between the single combinations of a high and low expression of Cav-1 and the target gene (Level 3). Vertical lines connect median survival time. Tables 
show for each plot: Log Rank p-value for the evaluation of the curves statistical difference; median survival for each group, reported together with the con fidence 
interval (CI); Cox hazard ratio for the referring group, coupled with its p -value. Plot and analysis were achieved through R project. 
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Figure 6.28 Cav-1 and invasion 10. Overall survival curves of MMP7 for GBM patients. A. Impact of a high and low expression on survival ( Level 1). B. Survival curve 
for patients with high expression of both Cav-1 and MMP7 was compared to the rest of the patients (Level 2). High or low expressions have been abbreviated to +/-. C. 
Comparison between the single combinations of a high and low expression of Cav-1 and the target gene (Level 3). Vertical lines connect median survival time. Tables 
show for each plot: Log Rank p-value for the evaluation of the curves statistical difference; median survival for each group, reported together with the con fidence 
interval (CI); Cox hazard ratio for the referring group, coupled with its p-value. Plot and analysis were achieved through R project.  
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Figure 6.29 Cav-1 and invasion 11. Overall survival curves of MMP9 for GBM patients. A. Impact of a high and low expression on survi val (Level 1). B. Survival curve 
for patients with high expression of both Cav-1 and MMP9 was compared to the rest of the patients (Level 2). High or low expressions have been abbreviated to +/-. C. 
Comparison between the single combinations of a high and low expression of Cav-1 and the target gene (Level 3). Vertical lines connect median survival time. Tables 
show for each plot: Log Rank p-value for the evaluation of the curves statistical difference; median survival for each group, reported together with the confidence 
interval (CI); Cox hazard ratio for the referring group, coupled with its p -value. Plot and analysis were achieved through R project.  
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Figure 6.30 Cav-1 and invasion 12. Overall survival curves of MMP10 for GBM patients. A. Impact of a high and low expression on survival (Level 1). B. Survival 
curve for patients with high expression of both Cav-1 and MMP10 was compared to the rest of the patients (Level 2). High or low expressions have been abbreviated to 
+/-. C. Comparison between the single combinations of a high and low expression of Cav -1 and the target gene (Level 3). Vertical lines connect median survival time. 
Tables show for each plot: Log Rank p-value for the evaluation of the curves statistical difference; median survival for each group, reported together with the confidence 
interval (CI); Cox hazard ratio for the referring group, coupled with its p -value. Plot and analysis were achieved through R project.  
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Figure 6.31 shows the impact of MT1MMP expression levels on survival. 
Figure 6.31A shows MT1MMPhigh tumours (MT1MMP+) to have a reduced 
survival (359 days vs 772 for the MT1MMPlow group), paired with an HR of 
2.451, suggesting that MT1MMP is a negative prognostic biomarker. Figure 
6.31B shows survival curves corresponding to the portion of the patients with 
high levels of both Cav-1 and MT1MMP (CAV+MT1MMP+) and the remaining 
population (Others). The combination of the two biomarkers determines a 
shorter survival median time (142 days) than the others (427 days). This value 
corresponds to the median survival of Cav-1, suggesting that a synergistic 
effect in this case is not present. Figure 6.31C shows the single stratifications 
with both biomarkers reported as a significant negative prognostic factors (HR 
for Cav-1high is 2.762 and MT1MMPhigh 2.212). All CAVhigh patients are also 
MT1MMPhigh whilst not all MT1MMPhigh patients were also CAVhigh. This 
suggests that MT1MMP is a pre-requisite for Cav-1 expression. Finally 
MT1MMP has an impact upon survival irrespective of Cav-1 expression, 
suggesting that MT1MMP is also an independent prognostic biomarker. 
 
Figure 6.32 shows the impact of UPA expression levels on survival. Figure 
6.32A shows UPAhigh tumours (UPA+) to have a reduced survival (320 days vs 
427 for the UPAlow group), paired with an HR of 1.580, suggesting that UPA is 
an independent negative prognostic biomarker. Figure 6.32B shows survival 
curves corresponding to the portion of the patients with high levels of both Cav-
1 and UPA (CAV+ UPA+) and the remaining population (Others). The 
combination of the two biomarkers determines a shorter survival median time 
(146 days) than the others (419 days), indicating that the subpopulation of 
patients with UPAhighCAVhigh have a significantly worse outcome than the 
patients with UPAhigh but not a different outcome than the CAVhigh alone, whose 
median survival is 142 days. This could exclude a synergistic effect of Cav-1 
and UPA expression. Figure 6.32C shows the single stratifications with only 
Cav-1 reported as a significant negative prognostic factor (HR for Cav-1high is 
2.667). this indicates that UPA is a poor driver of disease progression. 
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Figure 6.33 shows the impact of TIMP1 expression levels on survival. 
Figure 6.33A shows TIMP1high tumours (TIMP1+) to have a reduced survival 
(342 days vs 989 for the TIMP1low group), paired with an HR of 3.425, 
suggesting that TIMP1 may be an independent negative prognostic biomarker. 
Figure 6.33B shows survival curves corresponding to the portion of the patients 
with high levels of both Cav-1 and TIMP1 (CAV+TIMP1+) and the remaining 
population (Others). The combination of the two biomarkers determines a 
shorter survival median time (142 days) than the others (427 days). This value 
corresponds to the median survival of Cav-1, suggesting that a synergistic 
effect in this case is not present. Figure 6.33C shows the single stratifications 
with both biomarkers reported as a significant negative prognostic factors (HR 
for Cav-1high is 2.681 and TIMP1high 3.086). All CAVhigh patients were also 
TIMP1high whilst not all TIMP1high patients were also CAVhigh. This suggests that 
TIMP1 is a pre-requisite for Cav-1 expression. Finally TIMP1 has an impact 
upon survival irrespective of Cav-1 expression, suggesting that TIMP1 s also an 
independent prognostic biomarker. 
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Figure 6.31 Cav-1 and invasion 13. Overall survival curves of MT1MMP for GBM patients. A. Impact of a high and low expression on survival ( Level 1). B. Survival 
curve for patients with high expression of both Cav-1 and MT1MMP was compared to the rest of the patients (Level 2). High or low expressions have been abbreviated 
to +/-. C. Comparison between the single combinations of a high and low expression of Cav-1 and the target gene (Level 3). Vertical lines connect median survival time. 
Tables show for each plot: Log Rank p-value for the evaluation of the curves statistical difference; median survival for each group, reported together with the c onfidence 
interval (CI); Cox hazard ratio for the referring group, coupled with its p -value. Plot and analysis were achieved through R project.  
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Figure 6.32 Cav-1 and invasion 14. Overall survival curves of UPA for GBM patients. A. Impact of a high and low expression on survival (Level 1). B. Survival curve 
for patients with high expression of both Cav-1 and UPA was compared to the rest of the patients (Level 2). High or low expressions have been abbreviated to +/-. C. 
Comparison between the single combinations of a high and low expression of Cav-1 and the target gene (Level 3). Vertical lines connect median survival time. Tables 
show for each plot: Log Rank p-value for the evaluation of the curves statistical difference; median survival for each group, reported together with the confidence 
interval (CI); Cox hazard ratio for the referring group, coupled with its p -value. Plot and analysis were achieved through R project.  
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Figure 6.33 Cav-1 and invasion inhibition 1. Overall survival curves of TIMP1 for GBM patients. A. Impact of a high and low expression on survival ( Level 1). B. 
Survival curve for patients with high expression of both Cav-1 and TIMP1 was compared to the rest of the patients (Level 2). High or low expressions have been 
abbreviated to +/-. C. Comparison between the single combinations of a high and low expression of Cav -1 and the target gene (Level 3). Vertical lines connect median 
survival time. Tables show for each plot: Log Rank p-value for the evaluation of the curves statistical difference; median survival for each group, reported together with 
the confidence interval (CI); Cox hazard ratio for the referring group, coupled with its p -value. Plot and analysis were achieved through R project. 
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Figure 6.34 shows the impact of TIMP3 expression levels on survival. 
Figure 6.34A shows TIMP3high tumours (TIMP3+) to have a delayed survival 
(480 days vs 357 for the TIMP3low group), paired with an HR of 1.967, indicating 
that TIMP3 is an independent positive prognostic marker in GBM. Figure 6.34B 
shows survival curves corresponding to the portion of the patients with high 
levels of both Cav-1 and TIMP3 (CAV+ TIMP3+) and the remaining population 
(Others). The combination of the two biomarkers was present only in one patient 
(median survival NA days) so no statistical conclusions could be inferred. Figure 
6.34C shows the single stratifications with Cav-1 reported as a significant 
negative prognostic factor (HR for Cav-1high is 2.825) and TIMP3 as a significant 
positive prognostic factor (HR for TIMP3low is 1.838). The Level 3 analysis 
indicates that TIMP3 is a tumour suppressor in patients with low expression of 
Cav-1, whereas Cav-1 still drives disease progression in the TIMP3low patients. 
TIMP3 and Cav-1 appear to be mutually exclusive, with the exception of the only 
patient in the cohort that expressed high levels of both markers. 
 
Figure 6.35 shows the impact of PAI1 expression levels on survival. Figure 
6.35A shows PAI1high tumours (PAI1+) to have a reduced survival (231 days vs 
419 for the PAI1low group), paired with an HR of 1.715, suggesting that PAI1 
may be an independent negative prognostic factor for GBM. Figure 6.35B shows 
survival curves corresponding to the portion of the patients with high levels of 
both Cav-1 and PAI1 (CAV+ PAI1+) and the remaining population (Others). The 
combination of the two biomarkers determines a shorter survival median time 
(149 days) than the others (414 days), indicating that the subpopulation of 
patients with PAI1highCAVhigh have a significantly worse outcome than the 
patients with PAI1high but not a different outcome than the CAVhigh alone, whose 
median survival is 142 days. This could exclude a synergistic effect of Cav-1 
and PAI1 expression. Figure 6.35C shows the single stratifications with Cav-1 
reported as a significant negative prognostic factor (HR for Cav-1high is 3.215). 
The Level 3 analysis reveals that there is no difference in in survival rate 
between PAI1high and PAI1low when Cav-1 is high as well. However, when Cav-1 
expression is low, PAI1high drives disease progression. This suggests that PAI1 
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is an independent negative prognostic biomarker but also that its effect is 
relatively small in comparison with the impact of Cav-1. 
 
Figure 6.36 shows the impact of TSP1 expression levels on survival. Figure 
6.36A shows TSP1high tumours (TSP1+) to have a reduced survival (323 days vs 
648 for the TSP1low group), paired with an HR of 2.597, suggesting that TSP1 
may be an independent negative prognostic biomarker. Figure 6.36B shows 
survival curves corresponding to the portion of the patients with high levels of 
both Cav-1 and TSP1 (CAV+TSP1+) and the remaining population (Others). 
The combination of the two biomarkers determines a shorter survival median 
time (142 days) than the others (427 days). This value corresponds to the 
median survival of Cav-1, suggesting that a synergistic effect in this case is not 
present. Figure 6.36C shows the single stratifications with both biomarkers 
reported as a significant negative prognostic factors (HR for Cav-1high is 2.591 
and TSP1high 2.268). All CAVhigh patients were also TSP1high whilst not all 
TSP1high patients were also CAVhigh. This suggests that TSP1 is a pre-requisite 
for Cav-1 expression. Finally TSP1 has an impact upon survival irrespective of 
Cav-1 expression, suggesting that TSP1 s also an independent prognostic 
biomarker. 
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Figure 6.34 Cav-1 and invasion inhibition 2. Overall survival curves of TIMP3 for GBM patients. A. Impact of a high and low expression on survival ( Level 1). B. 
Survival curve for patients with high expression of both Cav-1 and TIMP3 was compared to the rest of the patients (Level 2). High or low expressions have been 
abbreviated to +/-. C. Comparison between the single combinations of a high and low expression of Cav -1 and the target gene (Level 3). Vertical lines connect median 
survival time. Tables show for each plot: Log Rank p-value for the evaluation of the curves statistical difference; median survival for each group, reported together with 
the confidence interval (CI); Cox hazard ratio for the referring group, coupled with its p -value. Plot and analysis were achieved through R project.  
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Figure 6.35 Cav-1 and invasion inhibition 3. Overall survival curves of PAI1 for GBM patients. A. Impact of a high and low expression on survival ( Level 1). B. 
Survival curve for patients with high expression of both Cav-1 and PAI1 was compared to the rest of the patients (Level 2). High or low expressions have been 
abbreviated to +/-. C. Comparison between the single combinations of a high and low expression of Cav -1 and the target gene (Level 3). Vertical lines connect median 
survival time. Tables show for each plot: Log Rank p-value for the evaluation of the curves statistical difference; median survival for each group, reported together with 
the confidence interval (CI); Cox hazard ratio for the referring group, coupled with its p -value. Plot and analysis were achieved through R project. 
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Figure 6.36 Cav-1 and invasion inhibition 4. Overall survival curves of TSP1 for GBM patients. A. Impact of a high and low expression on survival ( Level 1). B. 
Survival curve for patients with high expression of both Cav-1 and TSP1 was compared to the rest of the patients (Level 2). High or low expressions have been 
abbreviated to +/-. C. Comparison between the single combinations of a high and low expression of Cav -1 and the target gene (Level 3). Vertical lines connect median 
survival time. Tables show for each plot: Log Rank p-value for the evaluation of the curves statistical difference; median survival for each group, reported together with 
the confidence interval (CI); Cox hazard ratio for the referring group, coupled with its p-value. Plot and analysis were achieved through R project.  
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6.4.4 Level 1 analysis 
Refer to Figure 6.7. 
From the survival analysis of the studied biomarkers, Cav-1 is one of the 
strongest prognostic indicators. Only TIMP1 had a higher HR when analysed at 
Level 1 with TIMP1high having a median survival of 342 days, while Cav-1high 
median survival was 142 days.  
The analysis at the single-molecule level (Level 1) revealed that some of them 
are independent prognostic biomarkers. Specifically, as single biomarkers 
UPAR, PVRL4, TIMP1, TSP1, MT1MMP, MMP2, MMP9, CTSB, CTSD, CD44, 
ITGA5, ITGB5, PAI1, UPA, MMP10, MMP1 and  CTSL were all independent 
negative prognostic biomarkers, i.e. predictors of poor outcome, while ECAD, 
CTSH and TIMP3 were all independent positive prognostic biomarkers, i.e. 
predictors of improved outcome.  
 
6.4.5 Level 2 and 3 analysis 
Refer to Figure 6.7. 
Level 2 and Level 3 analysis seek to explore those biomarkers combined with 
Cav-1 in predicting poor outcome, and if such molecules have a positive 
relationship with Cav-1. 
Level 2 analysis indicated if the expression of high levels of Cav-1 together with 
the selected markers correlates with differences in survival in comparison with 
the rest of the population. This could indicate if specific genes are correlated 
with Cav-1 expression and may act in synergy with it (i.e. TIMP1 and PVRL4).  
Eight genes displayed coexpression pattern whereby Cavhigh only occurs in 
situations where the respective paired gene itself shows high expression, i.e. 
low expression of those genes was never co-present with Cavhigh. These genes 
were CD44, ITGA3, VIM, CTSB, CTSL, MT1MMP, TIMP1 and TSP1. This data 
strongly suggests that these eight genes are all upstream of Cav-1 with Cav-1 
serving as a downstream effector molecule.  
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In this context, Cav-1 may serve as a critical organization centre for multiple 
genes that make the biology of GBM more aggressive with respect to tumour 
invasion and spread, ultimately impacting upon patient survival. Consistent with 
this, is that none of the above genes appears to be interacting with Cav-1 to 
bring synergy in the survival data. 
Several genes present a shorter median survival when combined with CAVhigh 
than their high expression alone or CAVhigh alone, although not statistically 
significant. They are ITGAV, ITGB5, ECAD, CTSK, MMP2, MMP9. MMP2 and 
MMP9 displayed oncogene functions and therefore may be proposed to be Cav-
1 synergistic partners. It is, however, important to remember that the differences 
in the median survival are not significant. A study with a larger cohort of patients 
could be helpful in understanding if the connection is real. 
Both ECAD and ITGAV appear to be tumour suppressors when Cav-1 
expression is low, while CTSK and ITGB5 have no significant impact in the 
Level 3 analysis.  
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6.4.6 Biological implications of the survival analysis 
Figure 6.37 represents a hypothetical schematic derived from the current TCGA 
analysis that shows a putative relationship between Cav-1 and different gene 
sets studied. 
 
Figure 6.37 Conclusive summary of the chapter findings. A. Oncogenes minimised by Cav-1. B. 
Oncogene independently driving GBM progression. C. Oncogene whose expression is driven by 
Cav-1. D. Oncogenes able to drive disease progression only when co-expressed with Cav-1. E. 
Oncogenes expressed by patients with high levels of Cav-1, whose tumour promoter activity is 
enhanced by Cav-1 expression. Tumour suppressor TIMP1 and Cav-1 are mutually exclusive and 
able to inhibit each other. G. Tumour suppressors over-ridden by Cav-1. Markers not significant 
and not correlated with Cav-1 are reported in yellow. Green arrows indicate positive correlation. 
Red diamonds indicate negative correlation. Different arrow sizes indicate high or low correlation. 
Asterisks indicate a possible synergistic cooperation with Cav-1. 
 
From the survival analysis, it can be concluded that  (Refer to Figure 6.37): 
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[A]. Genes comprising CTSD, MMP2, MMP9 and PAI1 may serve as 
oncogenes. They drive disease progression, although not as effectively as Cav-
1  
[B]. The receptor for UPA, UPAR, and the cell-cell adhesion marker PVRL4 are 
powerful and independent negative prognostic factor. PVRL4 may act also in 
synergy with Cav-1 in driving disease progression. 
[C]. Genes represented in group C (ITGA3, CD44, VIM, CTSB and CTSL) only 
have an adverse impact on survival when co-expressed with Cav-1 in a double-
high phenotype. Cav-1 is not highly expressed when these genes are low or 
absent. Collectively, this data shows that Cav-1 is a critical downstream effector 
molecule for the genes present in group C. 
[D]. Genes represented in group D (MT1MMP, TIMP1 and TSP1) are similar to 
those in group C, in that is no high expression of Cav-1 when these genes are 
low/absent. These genes are also upstream of Cav-1. The survival analysis 
shows that these three genes adversely impact overall survival without the 
presence of Cav-1, i.e. independent biomarker of poor outcome. Although it 
must be stressed that the outcome is much worse when Cav-1 is co-expressed. 
Collectively, these data suggest that these three genes drive aggressiveness 
mainly through Cav-1, but may also activate other oncogene pathways 
independently of Cav-1. 
[E]. TIMP3 is a tumour suppressor. Cav-1 and TIMP3 are mutually exclusive. 
[F]. ECAD, ITGAV, CTSH and MMP3 are tumour suppressors that Cav-1 is able 
to override and overcome the tumour suppressor actions. 
 
6.4.6.1 Groups A-B (Figure 6.37) 
In vitro, in vivo and clinical studies, UPAR and MMP9 (Veeravalli & Rao, 2012), 
CTSD (Mallawaaratchy et al., 2017) and MMP2 (Ramachandran, Sørensen, 
Aaberg-Jessen, Hermansen, & Kristensen, 2017) have all been recognised as 
negative prognostic markers for GBM, confirming the results of the analysis in 
this current chapter. UPAR and CTSB have also been positively related to 
glioma-initiating cells and self-renewal (Gopinath et al., 2013). 
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From the current TCGA analysis, both PAI1 and UPAR serve as negative 
prognostic markers, whereas UPA does not. It is surprising that UPA does not 
serve as a negative prognostic marker in this dataset. UPA is a serine protease 
able to activate plasminogen in plasmin, which can then degrade the 
extracellular matrix (Irigoyen, Muñoz-Cánoves, Montero, Koziczak, & Nagamine, 
1999). Its catalytic-independent binding to UPAR triggers an intracellular 
pathway that leads to increased migration, growth and survival (Andreasen, 
Kjoller, Christensen, & Duffy, 1997). As PAI1 is the main inhibitor of UPA, it is 
similarly surprising that PAI1 in this analysis serves as a negative prognostic 
biomarker. PAI1 is an inhibitor of UPA catalytic activity, preventing plasmin 
activation while still allowing UPA to bind to UPAR. One possible reason for 
UPA not serving as a negative prognostic marker could be that the UPAR-UPA 
system can also be activated by other molecules, such as vitronectin in the 
extracellular space and integrins (Blasi & Carmeliet, 2002). It is not clear though 
if the presence of UPA is still required for this activation mechanism.  
Among the reported integrins interacting with UPAR, is the product of ITGA3 
and ITGB1, Integrin 31 (Supurna Ghosh et al., 2006). Indeed, UPAR is mostly 
localized with clustered- Integrin 31, in caveolae (Parat & Riggins, 2012). 
Integrin 3 has also been found overexpressed in glioma stem-like cells in vitro 
and acts as a promoter of invasion (Nakada et al., 2013). This is consistent with 
ITGA3 being a negative prognostic marker. Moreover, Cav-1 has been linked to 
the Integrin 1 subunit for the regulation of signalling and endocytosis (Hwang et 
al., 2016; F. Shi & Sottile, 2008). 
Cav-1 has also been reported to activate the UPAR-mediated activation of other 
Integrins, like Integrin 51 (Hwang et al., 2016), which is the integrin studied in 
relation to Cav-1 in GBM cells by Martin et al. (Martin et al., 2009). The in vitro 
interaction of Cav-1 and Integrin 51 is reported by these authors to prevent 
cell invasion and migration in vitro. Our clinical analysis does not confirm these 
studies in that ITGA5 and ITGB1 have no significant impact on GBM.  
PVRL4 has been described elsewhere as being highly expressed in lung, 
breast, colon, and ovarian tumours (Noyce & Richardson, 2012), but it has not 
been demonstrated in brain tumours. According to our analysis, PVRL4 is a 
powerful negative prognostic marker in GBM, that acts in synergy with Cav-1 
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expression. Nectin-4 is the product of the PVRL4 gene and is a cell-cell 
adhesion molecule, but also the receptor for the measles virus, which is being 
used in clinical trials against several types of cancer, including GBM. Moreover, 
PVRL4 is not expressed in the normal brain. Our data might suggest therefore 
that an in-situ therapy with a modified measles virus could be successful in 
targeting Cav-1 positive GBM cells.  
Of note, in early pilot proteomic studies with lentiviral-mediated Cav-1 KD of 
GBM cell lines, we did find Nectin-4 to be positively correlated with Cav-1 in 
UP007 and UP029. 
 
6.4.6.2 Group C and D (Figure 6.37) 
Of note, an extraordinary finding is that it is only when all eight genes in Groups 
C and D display high expression, will there be a high expression of Cav-1 and 
decreased survival. This may involve these markers clustering together and 
promoting Cav-1 expression. Cav-1 in return would allow the cross-activation of 
the markers and allow disease progression. 
CD44, together with Vimentin, is a molecular marker of the mesenchymal 
phenotype, which is the most aggressive GBM subtype (Phillips et al., 2006). 
Our analysis identified them as both negative prognostic markers, able to 
influence disease progression only when co-expressed with high levels of Cav-
1.  
CTSD and CTSB are shuttled from the endoplasmic reticulum to the caveolae 
where CTSD activates CTSB (Aghdassi et al., 2018) which in turn activates UPA 
(Kobayashi et al., 1993), MMPs and induces angiogenesis (Yanamandra et al., 
2004). In Inflammatory Breast Cancer, Cav-1 and CTSB co-expression has 
been reported, with Cav-1 unlocking CTSB proteolytic properties (Nouh et al., 
2011). Our analysis in GBM shows CTSD to be an independent prognostic 
factor, and CTSB being able to promote disease progression only when co-
expressed with Cav-1. 
CTSL has previously been reported as an independent negative prognostic 
marker promoting hepatocellular carcinoma aggressiveness (Ruan et al., 2014). 
Others have reported that CTSL expression is increased in GBM cell lines after 
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induction by VEGF (Keerthivasan, Keerthivasan, Mittal, & Chauhan, 2007). But 
the role of CTSL in GBM and its relationship with Cav-1 has not been previously 
described. Here we suggest that CTSL is able to promote tumour 
aggressiveness when co-expressed with Cav-1. 
Parat and Riggins published in 2012 a comprehensive review about Cav-1 in 
GBM (Parat & Riggins, 2012). This includes the description of molecules that 
cluster within the caveolae and their interactions. According to their work, Cav-1 
interacts directly and stabilizes not only UPAR but also MT1-MMP, which 
activates in turn other MMPs. MMPs can also be activated by Plasmin, whose 
activation from Plasminogen is catalysed by UPA. In our analysis, MT1MMP 
appears to serve as an oncogene whose tumour promoter effect is enhanced by 
Cav-1. This is consistent with the necessity of MT1MMP to be within the 
caveolae, in contact with Cav-1, in order to be activated by UPA and to activate 
the MMPs. 
MT1MMP has also the ability to cleave CD44, thus increasing cell motility. This 
shedding of CD44 allows to disconnect with degraded hyaluronic acid fibres and 
connect with new ones and is crucial for the CD44-dependent tumour migration 
process (Ulasov, Yi, Guo, Sarvaiya, & Cobbs, 2014).  
TSP1 expression and secretion are highly increased in GBM when compared to 
normal tissue (Naganuma et al., 2004). This protein is a known inhibitor of 
tumour growth and angiogenesis. However, it has also been reported that 
tumours are able to acquire a resistance to high levels of TSP1 (Filleur et al., 
2001). In pulmonary hypertension, it has also been reported that TSP1 is able to 
induce the expression of Cav-1 (Rogers, Ghimire, Calzada, & Isenberg, 2017). 
This is consistent with our analysis, which shows Cav-1 is only expressed in 
TSP1high patients meaning TSP1 is upstream and is able to drive the high 
expression of Cav-1. TSP1 could be then able to shorten patient survival, both in 
a Cav-mediated and -independent way. 
TIMP1 has already been described in the literature associated with a shortened 
survival in GBM (Aaberg-Jessen et al., 2009). According to our analysis, and 
consistent with what was reported, TIMP1 is a strong marker of aggressiveness, 
with 89% of the patients expressing high levels of the biomarker (Figure 6.33). 
The analysis also shows that co-expression of TIMP1 and Cav-1 further 
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shortens survival and that TIMP1 is pre-required for the expression of Cav-1. 
TIMP1, however, has been described as a bland inhibitor of MMP9 and that its 
overexpression in mice determines a reduction in cancer occurrence. At the 
same time, we also know that TIMP1 is not as an efficient inhibitor as the other 
TIMP family members, i.e. it is unable to inhibit MT1MMP or MMP2 (Sternlicht & 
Werb, 2009). Moreover, in patients samples, a positive correlation between 
MMP2 and TIMP1 expression has been reported, and the combination of high 
levels of MMP2 together with TIMP1 had a stronger prognostic value than 
MMP2 alone (Ramachandran et al., 2017). Further studies are needed in order 
to explain the controversial reports. 
 
6.4.6.3 Group E (Figure 6.37F) 
Unlike TIMP1, TIMP3 is a strong inhibitor of MMP9, but also of MT1MMP and 
the ADAMs/ADAMTs family (Sternlicht & Werb, 2009). TIMP3 is also able to 
bind directly to heparan-sulfate proteoglycans, thus concentrating its action on 
basement membranes (Langton, Barker, & McKie, 1998). TIMP3 activity has 
also been correlated in GBM with respect to the activity of MGMT (Saraiva-
Esperón, Ruibal, & Herranz, 2014). According to our analysis, TIMP3 serves as 
a tumour suppressor with only 4% of the patients (1/24) expressing both high 
levels of Cav-1 and TIMP3. To date, no studies have been conducted to 
investigate whether Cav-1 and TIMP3 functionally interact. 
 
6.4.6.4 Group F (Figure 6.37G) 
The most important epithelial-differentiation marker, E-Cadherin, is rarely 
expressed in glioma (Iwadate, 2016). Consistently, our analysis concluded that 
ECAD is a tumour suppressor, whose activity appears to be over-ridden by Cav-
1 oncogene activity. Collectively the Cav-1 data, when considered alongside 
with ECAD and VIM, suggest that Cav-1 may be important for the epithelial to 
mesenchymal transition process. 
Integrin V has been reported in GBM to help tumour cells to escape 
senescence (Franovic et al., 2015). According to our analysis, when Cav-1 is not 
expressed ITGAV acts as a tumour suppressor, possibly through the binding of 
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vitronectin and the anchorage to the basal membranes. However, this data 
interestingly shows that Cav-1 switches ITGAV from tumour suppressor to 
oncogene when co-expressed. This could be because Cav-1 is a strong driver of 
aggressiveness, overriding ITGAV tumour suppressor activity. Alternatively and 
consistently with published literature, when Cav-1 is expressed, ITGAV clusters 
in the caveolae and helps tumour cells to escape senescence (Franovic et al., 
2015). Further studies would be needed to confirm that. 
In pancreatic cancer, CTSH is reported to be a tumour promoter (Gocheva, 
Chen, Peters, Reinheckel, & Joyce, 2010). However, there are no studies about 
its role in GBM, with the exception of an in vitro study from 1996, where it has 
been reported that an antibody anti-CTSH was inhibiting invasion through 
Matrigel in three cell lines (Sivaparvathi, Sawaya, Gokaslan, Chintala, & Rao, 
1996). In our analysis, CTSH is a statistically significant tumour suppressor both 
alone and in combination with Cav-1. Further studies will be needed to identify 
the actual function of CTSH in GBM and its connection to Cav-1. 
A protective role of MMP3 has been reported in squamous carcinomas, in terms 
of papillomas insurgence and tumour growth (Shay, Lynch, Fingleton, & Moffitt, 
2015). Even if not reported in GBM, this finding is in line with our analysis. In the 
TCGA dataset indeed MMP3 displays a tumour suppressor activity when Cav-1 
is not expressed.  
CHAPTER 6- TCGA ANALYSIS OF THE IMPACT OF CAV-1 ON GBM 
 
325 
 
6.5 CONCLUSIONS 
 In this chapter, we interrogated the TCGA database to understand if Cav-
1 has an impact on the survival of patient suffering from GBM, and 
whether Cav-1 is related to any other biomarkers of tumour 
aggressiveness. 
 Significantly, in a population of 540 patients we found that a high 
expression of Cav-1 is related to a shorter survival, with a decrease from 
14.2 to 4.7 months (Figure 6.2). 
 Certain subgroups of patients were differentially affected. For example:  
o median survival in females displaying high Cav-1 levels was only 3 
months, whereas males displaying high Cav-1 had a median survival 
of 10.5 months; median survival for both male and females 
expressing low Cav-1 were not different from each other, ca. 14 
months (Figure 6.3B). 
o for 87 patients we had information on GBM molecular subtypes. Here 
we found high expression of Cav-1 appears to be more common in 
mesenchymal GBMs, a GBM subtype recognised to be one of the 
most aggressive forms (Figure 6.4) with a 7.3 months median survival 
for Cav-1high versus 17.6 months for Cav-1low (Figure 6.6). In the 
proneural subgroup of patients the expression of high Cav-1 
appeared to be associated with better prognosis. This may be in line 
with the theory that Cav-1 can have different roles in cancer 
progression. 
o Unfortunately, the TCGA dataset accessed via R project does not 
allow to discriminate between different subtypes, so it was not 
possible to verify if the markers selected were differentially related to 
Cav-1 and survival in specific molecular subtypes. This could be 
implemented in the future. 
 We then investigated whether Cav-1 expression is related to other 
aggressiveness markers (Table 6.1). We found that a high expression of 
Cav-1 is always associates with a high expression of certain markers of 
adhesion (CD44, ITGA3), certain markers of invasion (Vimentin, 
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Cathepsin B, Cathepsin L, MT1MMP) but also recognized inhibitors of 
invasion (TIMP1, TSP1) (Figure 6.37 C and D). 
 While CD44, ITAG3, VIM, CTSB and CTSL were able to serve as 
oncogenes only when Cav-1 was also highly co-expressed, TSP1, TIMP1 
and MT1MMP displayed oncogenic functions independently but also in 
synergy with Cav-1. 
 Some other markers, like UPAR, PVRL4, CTSD, MMP2, MMP9, PAI1 
predict poor survival independently of Cav-1 (Figure 6.37A and B). 
 We found the effect of some genes (ECAD, ITGAV, MMP3, CTSH) to act 
as tumour suppressors could only be observed when Cav-1 is not highly 
expressed. When Cav-1 is highly expressed the suppressor actions of 
these genes are no longer evident (ECAD, MMP3, CTSH) or indeed there 
appears to be a reversal of actions, with the molecule displaying 
oncogenic properties (ITGAV).  
 TIMP3 serves as a tumour suppressor mutually exclusive of Cav-1 
(Figure 6.37E). 
 The TCGA results in this chapter implicate Cav-1 as a potentially 
important therapeutic target in GBM. 
 
.
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The overall aim of the thesis was to explore the role of Cav-1 in the cancer-stem 
like properties, i.e. aggressiveness, of GBM.  Cav-1 is at the centre of the 
interaction between signals coming from the environment and their receptors, 
the consequent activation of intracellular pathways for the adaptation to the 
environment and the cell structure modification. For this reason, it could 
potentially be a major player in GBM aggressiveness (Parat & Riggins, 2012). 
 
The functional work was undertaken using in vitro cell lines, while work exploring 
the role of Cav-1 as an independent prognostic marker driving poor survival in 
GBM was undertaken using The Cancer Genome Atlas (TCGA) database, a 
repository of clinical data linking genomic patient information to clinical outcome. 
One of the major problems with the treatment of GBM is that cells can detach 
from the tumour bulk, as singles or small groups, and travel along the 
perivascular niche or the white matter tracts. These cells can reach other areas 
of the patients’ brain and form new tumours. This capacity reflects the ability of 
the cells to display invasive and self-renewal properties. Further, the re-
established tumours often become chemo and radio-resistant.  
We initially tested two key properties that are related to tumour aggressiveness, 
clonogenicity and invasion. 
Clonogenic assays (Chapter 3) showed a general trend with Cav-1 driving 
clonogenicity in a range of different models: cells bearing lipid-based shRNA 
knockdown of Cav-1, lentiviral-based shRNA knockdown of Cav-1 and CRISPR-
mediated knockout of Cav-1; and different model platforms, i.e. 2D colony 
formation, 3D free floating sphere formation, 3D soft agar sphere formation. 
The knockdown/knockout approaches partially showed that Cav-1 has a positive 
impact on in vitro GBM cell lines clonogenicity and enhanced their cell cycle 
progression.  
In Chapter 4, we developed a custom ImageJ-based script - INSIDIA - for the 
analysis of 3D spheroid invasion. The script represents a novel tool for the 
cancer biology community, enabling customizable quantitative processing of a 
large number of images for the quantification of 3D invasion assays undertaken 
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in vitro. Using this tool, together with other approaches we found (Chapter 5) 
that in a number of different GBM cell lines Cav-1 is unequivocally a factor in 
driving the invasion of the GBM model cells from a preformed spheroid through 
the extracellular matrix. Given the unequivocal data for the invasion studies, we 
focused attention, in the later part of Chapter 5, upon the biological mechanisms 
in respect to this particular phenotypic trait. 
From the in vitro studies, it appears that Cav-1 drives the expression of enzymes 
for the digestion of the matrix, i.e. Cathepsin B (CTSB), MMP1 and urokinase-
type plasminogen activator (UPA) and also expression of receptors i.e. UPAR 
and CD44, as well as increases in AKT activation. The context of these findings 
to the literature was discussed in detail in Chapter 5. 
A schematic showing how Cav-1 interactions with these components may give 
rise to altered function is shown in Figure 7.1. 
 
Figure 7.1 Markers putatively related to Cav-1-mediated increases in GBM invasion. Cav-1 
regulates the synthesis or turnover of UPA and UPAR, which together activate the collagenase 
MMP1. Cav-1 promotes the synthesis of CTSB, which is exposed inside the caveolae and 
contributes to the degradation of the matrix. An increased CD44 allows  the activation of 
intracellular pathways, among which AKT, promoting overall tumour progression.  
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Future in vitro studies to explore the mechanisms by which Cav-1 may be 
modulating the invasive phenotype should include: 
 Selective and sequential manipulation of molecules in the putative 
pathway(s) using genetic or chemical knockouts of, for example potential 
downstream molecules, e.g. MMP1. This would help to address whether 
the relationship with Cav-1 is direct or indirect in nature.  
 To support the above studies exploring if any physical interaction exists 
between Cav-1 with the respective molecules should be undertaken, 
using immunoprecipitation and immunofluorecence microscopy 
approaches.  
 Expanding the molecular biology knockout studies to include a broader 
range of GBM cell lines, including those with a known molecular-subtype. 
Ideally studies in primary tumour cells or at least lower-passage cells 
should be undertaken. Where genetic manipulations my not be possible 
to accommodate this, the use of siRNA or chemical inhibitors (notably for 
molecules other than Cav-1) should be explored.  
 The study of Cav-1 relationship with these molecules in an hypoxic 
environment, and in presence of endothelial cells for the study of neo-
angiogenesis. 
 The developing of a methodology that would allow the study of molecular 
expression in both core and invasive edges of a Matrigel-embedded 
spheroid, in an immunofluorescence context or using tools like micro-
dissectors for the isolation of the spheroid components and then a 
transcriptomic (PCR) or phosphoproteomic (WB) analysis. 
 The use of the 3D spheroid in vitro invasion assay for the study of the 
invasive behaviour of freshly resected GBM samples, in order to help the 
therapeutical decision.  
 To develop INSIDIA: Increasing of the power of INSIDIA by, for instance, 
allowing the detection of single cells invasion. Adapt INSIDIA script for 
the study of MRI scans, where the M1 and M2 projection, whose 
juxtaposition is commonly used to determine the rough tumour invasion, 
could be used to better quantify and study the invasive behaviour of every 
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single tumour before the surgical resection. This would allow to gain 
precious time that could help the prognosis of the patients. 
Reports about Cav-1 are conflicting, with different suggested roles attributed to 
the caveolae major component (Cerezo et al., 2009; Hnasko & Lisanti, 2003). 
Some reported that Cav-1 plays a tumour suppressor role, while others 
suggested Cav-1 to be an oncogene, according to cancer/tissue type and the 
patients (Senetta et al., 2013). As for GBM, the few studies published report 
Cav-1 as a tumour suppressor (Cosset et al., 2012; Martin et al., 2009; Quann et 
al., 2013; Shimato et al., 2013). An interesting hypothesis describes Cav-1 as 
playing a double role as a tumour suppressor in the early cancer stages and as 
an oncogene in the later aggressive and resistant stages (Quest et al., 2013). 
Due to GBM inter and intra-heterogeneity, the identification of a single 
unequivocal therapeutic target represents a significant challenge (Xie et al 
2014). Indeed, an effective therapeutic approach may have to involve targeting 
of multiple proteins simultaneously. Further, an understanding of the underlying 
molecular pathway physiology by patient subgroups will be critical. 
In Chapter 6, we interrogated “The Cancer Genome Atlas” (TCGA) and found 
that Cav-1 is a strong independent prognostic biomarker indicative of poor 
survival in GBM patients, i.e. median survival 4.7 months for patients expressing 
high levels of Cav-1 vs. 14.2 months for the general GBM population. We also 
noted a potential gender bias in that median survival in females displaying high 
Cav-1 levels was only 3 months, whereas males displaying high Cav-1 have a 
median survival of 10.5 months. At the same time, high expression of Cav-1 
appears to be more common in mesenchymal GBMs, a GBM subtype 
recognised to be one of the most aggressive forms. 
In Chapter 5, we explored the correlation between Cav-1 KO and the expression 
of a range of transcripts and proteins, that are associated with the invasion 
process per se, that are adhesion molecules, proteases, and receptors. 
Encouraged by some of the findings we then further interrogated the TCGA 
database to see if the selected genes were correlated to Cav-1 expression and 
ultimately GBM survival in the clinical material (Figure 7.2).  
The findings (Figure 7.2) were that markers comprising CD44, ITGA3, VIM, 
CTSB, CTSL, MT1MMP, TIMP1, TSP1 appeared to drive Cav-1 expression and 
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thus disease progression. While the high expression of CD44, ITAG3, VIM, 
CTSB and CTSL serves an oncogenic function only when Cav-1 was itself 
highly expressed. The molecules TSP1, TIMP1 and MT1MMP, when highly 
expressed, display oncogenic functions independently of Cav-1 but, when Cav-1 
itself is also highly expressed, these molecular pairings display synergistic 
outcomes. We also found Cav-1 to override the tumour suppressor ability of 
ECAD, CTSH, MMP3 and ITGAV. 
Further, TIMP3 appears to serve as a tumour suppressor mutually exclusive 
with Cav-1.  
Finally, UPAR and PVRL4 appear to drive disease progression independently 
from Cav-1, while MMP2, CTSD and MMP9 are independent negative 
prognostic biomarkers whose oncogenic effect is relatively minor compared to 
that attributed to Cav-1.  
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Figure 7.2 Summary of key findings in Chapter 6. A. Oncogenes independently driving disease 
progression. B Oncogenes driving disease progression and Cav-1 expression, which itself drives 
PVRL-4 and a shorter survival. C. Tumour suppressors inhibited by Cav-1 expression. 
 
Future studies exploiting the TCGA database and/or the use of clinical material 
in biomarker investigations would comprise: 
 Testing further the correlation between Cav-1 and the markers by 
combining multiple genes in the same survival analysis, e.g. high 
expression of three markers versus the rest of the population. 
 Testing the role on Cav-1 in a dataset containing more information about 
the molecular subtype of each tumour, in order to verify if Cav-1 has an 
impact on mesenchymal and proneural subtypes. 
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 Expanding the study of molecules that may interact with Cav-1 to include 
ones involved in processes such as survival, self-renewal and hypoxic 
responses. 
 
The most significant finding of this thesis is that from both the database analysis, 
and from the in vitro findings, Cav-1 is a molecule that strongly drives GBM 
aggressiveness through enhancing cell invasion. This includes the ability to 
establish contact and react to the extracellular environment, the production of 
matrix-degrading enzymes and the movement through the newly formed 
passages. Cav-1 appears to represent a good candidate for the targeting of 
invasion in high-grade gliomas. 
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APPENDIX 1: BUFFERS AND SOLUTIONS 
 
7.1.1 PBS (PHOSPATE BUFFER SALINE), 10mM 
NaCl   8 g 
KCl  0.2 g 
Na2HPO4 1.44 g 
KH2PO4 0.24 g 
ddH2O to 2 L 
 
pH 7.4 
 
 
7.1.2 LYSIS BUFFER 
5M NaCl     70 L 
Proteases inhibitor cocktail   10 L 
(Thermo Fisher Scientific cat. 1861281) 
0.5M EDTA     10 L 
(Thermo Fisher Scientific cat. 1861274) 
T-PER buffer     to 1 mL 
(Thermo Fisher Scientific cat. 78510) 
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7.1.3 ELCTROPHORESIS RUNNING BUFFER 
0.25M TRIS  6.06 g 
GLYCINE 28.8 g 
 
pH TO 8.3 
 
SDS  2 g 
ddH2O to 2 L 
 
 
7.1.4 BLOTTING BUFFER 
TRIS   6.06 g 
GLYCINE 28.8 g 
SDS  2 g 
METHANOL 400 mL 
ddH2O to 2 L 
 
 
7.1.5 WESTERNBLOT WASHING BUFFER 
TRIS   2.42 g 
 
pH TO 7.5 
 
NaCl  11.688 g 
Tween 20 2 mL 
ddH2O to 2 L 
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7.1.6 BLOCKING BUFFER 
Washing buffer 100 mL 
Powdered milk  5 g (5%)  or 1g (1%) 
 
 
 
7.1.7 ANTIBODY DILUENT FOR WESTERN BLOT 
Washing buffer 100 mL 
BSA    5 g (5%)  or 1g (1%) 
 
Filter before use 
 
 
7.1.8 PONCEAU 
Glacial acetic acid 0.5 mL 
Ponceau S  0.05 g 
ddH2O  to 50 mL 
 
 
 
7.1.9 IMMUNOHISTOCHEMISTRY REAGENT DILUENT 
0.6% BSA in Supersentisitive Wash Buffer 1x ( BioGenex- cat. HK583-5KE) 
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7.1.10 IMMUNOHISTOCHEMISTRY SODIUM CITRATE 
BUFFER 
10mM SODIUM CITRATE  1.47 g 
pH 6 
 
 
7.1.11 IMMUNOHISTOCHEMISTRY ACTIVE DAB SOLUTION 
5 g/L DAB (diaminobenzidine dihydrochloride) 10 mL 
Optimax 1x      90 mL 
H2O2       8 drops 
 
 
 
7.1.12 IMMUNOFLUORESCENCE BLOCKING BUFFER 
3% BSA 
0.3% TWEEN 20 
PBS  
 
 
7.1.13 IMMUNOFLUORESCENCE WASHING BUFFER 
0.1% TWEEN 20 
PBS  
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APPENDIX 2: SCRATCH ASSAY ANALYSIS PROCEDURE 
 Open pictures with ImageJ FiJi; 
 Image->type->8-bit; 
 Process-> Sharpen 
 Process -> find edges 
 Process -> make binary 
 Edit -> Invert 
 Process ->Binary ->Options 
- in "Options" select: 
 interations: 6 
 Do: dilate 
 Select "preview" 
 Select background picture with Magic wand 
 Analyse -> Measure (Area to be selected in "Analyse -> set measurements")  
 
After analysing all the areas (A) at t0 and t8, they have been compared, with A t0 =100%, 
with the formula: 
 
A t8(%) = 100 - ((A t8/A t0)*100) 
 
The result is the percentage of area occupied by the migrated cells. 
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APPENDIX 3: IF SECONDARY ANTIBODIES 
 
 
Figure 8.13D Immunofluorescence analysis of U87 CAV+(BB- first four images) and CAV- (KO- 
last image) expression of Cav-1, MMP1, CTSB, CTSD, CD44 and UPAR.  Sphere was embedded 
in  Matrigel and stained with Hoechst 33342 (blue: nuclei), Phalloidin -Alexa647 (Red: 
Cytoskeleton) and target genes (Green). Scale bar 50µm. 
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APPENDIX 4: PRIMERS VALIDATION 
Table 8. 1 Primers pairs sequences for primers validation 1 (Refer to Figure 8.2 Primers validation 
1- 25 pairs of primers were tested on U87 CAV+ (grey arrow) and MDA-231 (white arrow) 
isolated and retro-transcribed mRNA. PCR was conducted for 50 cycles at 56°C annealing 
temperature (sequences at Table 5.2).) 
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Table 8. 2 Primers’ pairs sequences for primers validation 3 (Refer to Figure 8.4) 
 
. 
Table 8. 3 Primers’ pairs remixed (Refer to Figure 8.5). 
 
 
Table 8. 4 Alternative primers for CDH1 (Refer to Figure 8.3) 
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MMP1 
513
MMP3
491
MMP7 
486
MMP9
681 
MMP10
443
MT1MMP
466
CATK 
367
CATB
462
CATL 
436
CATS 
524 
CATH 
538
CATD 
496
MMP2
406
MMP8
363
100
200
300
400
500
600
100
200
300
400
500
600
100
200
300
400
500
600
ITGA5 
548
UPA 
373
UPAR
502
ITGA3 
497
ITGAV
511 
VIM 
511
CDH1
463 
CD44
737 
TIMP1 
452
TIMP3 
543
PAI1 
500
 
Figure 8.2 Primers validation 1- 25 pairs of primers were tested on U87 CAV+ (grey arrow) and 
MDA-231 (white arrow) isolated and retro-transcribed mRNA. PCR was conducted for 50 cycles at 
56°C annealing temperature (sequences at Table 5.2). 
 
MCF7MDA-231U87 KOU87 BB
100
200
300
400
500
600
 
Figure 8.3 Primers validation 2- Three pairs of primers  directed to ECAD transcript were tested on 
mRNA isolated and retro-transcribed from U87 CAV+, U87 CAV-, MDA-231 and MCF-7 cell 
lines. PCR was conducted at 56°C annealing temperature for 40 cycles. Light grey arrow: alt1; 
white arrow: alt2; dark grey arrow: alt3 (Table 5.4). 
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UPAR1
291
ITGAV
671
ITGB1
252
ITGB3
526
ITGB5
504
MMP2
503
MMP8
110
MMP9
102
CD44
419
100
200
300
400
500
600
 
Figure 8.4 Primers validation 3- Nine pairs of primers were tested on U87 CAV+ (light grey arrow) 
U87 CAV- (KO- white arrow) and MDA-231 (dark grey arrow) isolated and retro-transcribed 
mRNA. PCR was conducted for 40 cycles at 56°C annealing temperature (Table 5.3). 
 
ITGAV 1
152
ITGAV 2
321
MMP8 1
671
MMP8 2
511
Reverse primer 1
Reverse primer 2Reverse primer 1
100
200
300
400
500
600
Forward primer 1 Forward primer 2
Reverse primer 2
Forward primer 1 Forward primer 2
100
200
300
400
500
600
MMP2 1
502
MMP2 2
407
 
Figure 8.5 Primers validation 4- ITGAV, MMP” and MMP8 primers from validation 1 and 3 were 
mixed. PCR conditions: 40 cycles, T°a 56°C. Sequences on Table 5.4 
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APPENDIX 5: INSIDIA CODE 
///////////////////////////////////////// 
////////////// FUNCTIONS//////////////// 
/////////////////////////////////////// 
////note: do not modify this part 
function closing(a) { 
run("8-bit"); 
run("Auto Threshold", 
"method=Default white"); 
run("Dilate"); 
run("Dilate"); 
run("Erode"); 
run("Erode"); 
run("Dilate"); 
run("Dilate"); 
run("Erode"); 
run("Erode"); 
run("Fill Holes"); 
run("Erode"); 
} 
function 
SSdialog(franginum,frangimin,frangi
max){ 
label=newArray(3); 
default=newArray(3); 
label[0]="accept segmentation"; 
label[1]="manual threshold"; 
label[2]="Frangi filter"; 
default[0]=true; 
default[1]=false; 
default[2]=false; 
Dialog.create("Spheroid 
segmentation"); 
Dialog.addCheckboxGroup(3,1,label
,default); 
Dialog.addNumber("number", 
franginum); 
Dialog.addNumber("minimum", 
frangimin); 
Dialog.addNumber("maximum", 
frangimax); 
Dialog.show(); 
} 
function printArray(a) { 
print(""); 
for (i=0; i<a.length; i++) 
print(a[i]); 
} 
function error(err) { 
Dialog.create("Error"); 
Dialog.addMessage(err); 
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Dialog.show(); 
} 
function largest(input,X,xc,yc){ 
run("Analyze Particles...", "size=0-
Infinity circularity=0.00-1.00 
show=Nothing display clear"); 
totalArea=0; 
for(j=0; j<nResults; j++){ 
current=getResult("Area",j); 
if(current>totalArea){ 
totalArea=current; 
xc[X]=round(getResult("XM",j)); 
yc[X]=round(getResult("YM",j)); 
} 
} 
run("Analyze Particles...", 
"size="+totalArea+"-Infinity 
show=Masks display clear"); 
run("Dilate"); 
run("Clear Results", ""); 
run("Grays"); 
run("Select None");} 
//////////////////////////////////////// 
//////////////////////////////////////// 
//////////////////////////////////////// 
///////////////////////////////////////// 
/////IMAGEJ SETTINGS//////////////////// 
/////////&ERRORS/////////////////////// 
////////////////////////////////////// 
////note: do not modify this part 
run("Close All"); 
run("Set Measurements...", "area 
mean min centroid center perimeter 
fit shape feret's redirect=None 
decimal=3"); 
setForegroundColor(0, 0, 0); 
run("Options...", "iterations=1 
count=1 black"); 
roiManager("reset"); 
getDateAndTime(year, month, 
dayOfWeek, dayOfMonth, hour, 
minute, second, msec); 
single="Please select a single 
option"; 
instr="Please follow the instructions 
to prepare your folders"; 
//////////////////////////////////////// 
//////////////////////////////////////// 
//////////////////////////////////// 
//////MENU 1 CHOOSE DIR//////////// 
/////MENU 2 SS Y/N//////////////// 
///////////////////////////////// 
////note: do not modify this part 
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maindir = getDirectory("Choose 
main folder"); 
do{ 
mode=newArray(2); 
Dialog.create("Are your spheroids 
segmented?"); 
Dialog.addCheckbox("Yes, proceed 
to density map & density 
profile",false); 
Dialog.addCheckbox("No, I want to 
do spheroid segmentation",true); 
Dialog.show(); 
mode[0]=Dialog.getCheckbox(); 
mode[1]=Dialog.getCheckbox(); 
mainlist = getFileList(maindir); 
nfolder=0;/// number of folder in the 
mainfolder 
for (i=0; i<mainlist.length; i++) { 
if (endsWith(mainlist[i], "/")){ 
nfolder=nfolder+1; 
} 
else 
mainlist[i] =""; ///removes image files 
from list 
} 
numbdir=0; 
for(G=0; G<nfolder;G++){ 
dir = maindir+mainlist[G]; 
list = getFileList(dir); 
c=list.length; 
tof=tof+c; 
for (i=0; i<c; i++){ 
if (File.isDirectory(dir+list[i])==true){ 
numbdir=numbdir+1;} 
}} 
tof=tof-numbdir; 
if (mode[1]==mode[0] ) { 
error(single); 
r=0;} 
else 
if(((mode[0]==true)&(numbdir!=nfold
er))||((mode[1]==true)&(numbdir>0))|
| (mainlist.length!=nfolder)){ 
error(instr); 
r=0; 
} 
else 
r=1; 
} while (r==0); 
//////////////////////////////////////// 
///////////////////////////////////////// 
/////FLUORESCENCE 
MENU/////////////////// 
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//////////////////////////////////////// 
Dialog.create("Do you work with 
fluorescence images?"); 
Dialog.addCheckbox("Yes",false); 
Dialog.addMessage("if you check 
Yes your images will be inverted"); 
Dialog.show(); 
fluo=Dialog.getCheckbox(); 
//////////////////////////////////// 
//////////INSIDIA PART 1/////////// 
//////SPHEROID 
SEGMENTATION/////// 
///////////////////////////////// 
if ((mode[1]==true) & 
(mode[0]==false)) { 
for(G=0; G<nfolder;G++){ 
dir = maindir+mainlist[G]; 
list = getFileList(dir); 
c=list.length; 
if (G==0) { 
xc=newArray(tof); 
yc=newArray(tof); 
} 
myDir = 
dir+"000results"+File.separator; 
File.makeDirectory(myDir); 
name=newArray(c); 
res=newArray(c); 
for (i=0; i<c; i++) { 
X=c*G+i; 
name[i]=replace(list[i],".tif","res"); 
res[i]=myDir+name[i]; 
open(dir+list[i]); 
run("Set Scale...", "distance=0 
known=0 pixel=1 unit=pixel"); 
run("8-bit"); 
if (fluo==true) 
run("Invert"); 
h=getHeight(); 
w=getWidth(); 
run("Select None"); 
selectWindow(list[i]); 
run("Duplicate...", "Duplicate.tif"); 
run("Auto Threshold", 
"method=[Default]"); 
rename(list[i]+"bw"); 
selectWindow(list[i]+"bw"); 
run("Fill Holes");////////////NEW 
largest((list[i]+"bw"),X,xc,yc); 
selectWindow("Mask of 
"+list[i]+"bw"); 
rename("Mask of "+list[i]); 
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selectWindow(list[i]+"bw"); 
run("Close"); 
selectWindow("Mask of "+list[i]); 
doWand(round(xc[X]), round(yc[X])); 
roiManager("Add"); 
selectWindow(list[i]); 
roiManager("Select",0); 
listisempty=0; 
menu=true; 
check=false; 
while (menu==true){ 
SSdialog(4,0.6,1); 
franginum=Dialog.getNumber(); 
frangimin=Dialog.getNumber(); 
frangimax=Dialog.getNumber(); 
check=Dialog.getCheckbox(); 
manual=Dialog.getCheckbox(); 
frang=Dialog.getCheckbox(); 
if(listisempty==0 && 
roiManager("count")!=0){ 
roiManager("delete");} 
segmcheck=check+manual+frang; 
if (segmcheck!=1){ 
error(single); 
listisempty=1; 
} 
else 
menu=false; 
if (check==false){ 
selectWindow("Mask of "+list[i]); 
run("Close"); 
selectWindow(list[i]); 
run("Select None"); 
/////frangi thresholding 
if (frang==true){ 
run("Frangi Vesselness (imglib, 
experimental)", 
"number="+franginum+" 
minimum="+frangimin+" 
maximum="+frangimax+""); 
closing("vesselness of "+list[i]); 
selectWindow("vesselness of 
"+list[i]); 
rename("Mask of "+list[i]);} 
////////manual thresholding 
else if (manual==true){ 
selectWindow(list[i]); 
run("Duplicate...", "title=Mask of 
"+list[i]); 
rename("Mask of "+list[i]); 
run("Threshold..."); 
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setOption("BlackBackground", true); 
title = "ManualThreshold"; 
msg = "Use the \"Threshold\" tool 
to\nadjust the threshold,click apply 
then click OK\"."; 
waitForUser(title, msg); 
run("Invert"); 
run("Fill Holes");////////////NEW 
} 
selectWindow("Mask of "+list[i]); 
largest(("Mask of "+list[i]),X,xc,yc); 
roicheck=roiManager("count"); 
if (roicheck!=0){ 
roiManager("reset"); 
} 
selectWindow("Mask of Mask of 
"+list[i]); 
doWand(xc[X], yc[X]); 
run("Clear Outside"); 
run("ROI Manager..."); 
roiManager("Add"); 
selectWindow("Mask of Mask of 
"+list[i]); 
run("Close"); 
selectWindow(list[i]); 
roicheck=roiManager("count"); 
if (roicheck!=0){ 
roiManager("Select", 0); 
} 
menu=true; 
listisempty=0; 
}} 
selectWindow(list[i]); 
run("Close"); 
roicheck=roiManager("count"); 
if (roicheck!=0){ 
roiManager("reset");} 
///// segmented images saving ///// 
selectWindow("Mask of "+list[i]); 
doWand(xc[X], yc[X]); 
run("Clear Outside"); 
run("Select None"); 
saveAs(".tif",res[i]); 
} 
run("Close All"); 
selectWindow("Results"); 
run("Close"); 
} 
} 
//////////////////////////////////////////////////////////
/ 
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////////////////////SS 
PARAMETERS////////////////////////// 
//////////////////////////////////////////////////////////
/ 
setBatchMode(true); 
for(G=0; G<nfolder;G++){ 
dir = maindir+mainlist[G]; 
analysisdir=maindir+"analysis"+day
OfMonth+"_"+month+1+"h"+hour+"-
"+minute+File.separator; 
File.makeDirectory(analysisdir); 
anSubdir=analysisdir+mainlist[G]; 
File.makeDirectory(anSubdir); 
list = getFileList(dir); ////list contains 
results folder in the first line 
c=list.length-1; 
name=newArray(c); 
res=newArray(c); 
myDir = 
dir+"000results"+File.separator; 
if (G==0){ 
xc=newArray(tof); 
yc=newArray(tof); 
AreaTotal=newArray(tof); 
Perimeter=newArray(tof); 
maxRadius=newArray(tof); 
minRadius=newArray(tof); 
coordinates=newArray(tof); 
circularity=newArray(tof); 
RadiusE=newArray(tof); 
SpecSurf=newArray(tof); 
ShapeF=newArray(tof); 
EnvArea=newArray(tof); 
//DM// 
AreaCore=newArray(tof); 
AreaInvasion=newArray(tof); 
PercCore=newArray(tof); 
PercInvasion=newArray(tof); 
PeriMap=newArray(tof); 
startx=newArray(tof); 
starty=newArray(tof); 
printnames=newArray(tof); 
//DP 
RadiusCore=newArray(tof); 
RadiusCoreII=newArray(tof); 
INTENSE=newArray(tof); 
ACMtotal=newArray(tof); 
ACMcore=newArray(tof); 
ACMinvasion=newArray(tof); 
ACMpercCore=newArray(tof); 
ACMpercInvasion=newArray(tof); 
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} 
for (i=0; i<c; i++) { ////for all the 
images in each folder 
roicheck=roiManager("count"); 
if (roicheck!=0){ 
roiManager("reset"); 
} 
X=c*G+i; 
name[i]=replace(list[i+1],".tif","res.tif"
); 
res[i]=myDir+name[i]; 
open(dir+list[i+1]); 
if (fluo==true) 
run("Invert"); 
run("Set Scale...", "distance=0 
known=0 pixel=1 unit=pixel"); 
printnames[X]=list[i+1]; 
printnames[X]=replace(printnames[X
]," ","_"); 
run("8-bit"); 
h=getHeight(); 
w=getWidth(); 
run("Select None"); 
image="current"+i; 
bw="bw"+i; 
selectWindow(list[i+1]); 
rename(image); 
open(res[i]); 
run("Select None"); 
rename(bw); 
run("Set Scale...", "distance=0 
known=0 pixel=1 unit=pixel"); 
run("Analyze Particles...", "size=0-
Infinity circularity=0.00-1.00 
show=Nothing display clear"); 
totalArea=0; 
for(j=0; j<nResults; j++){ 
current=getResult("Area",j); 
if(current>totalArea){ 
totalArea=current; 
AreaTotal[X]=getResult("Area",j); 
Perimeter[X]=getResult("Perim.",j); 
xc[X]=round(getResult("XM",j)); 
yc[X]=round(getResult("YM",j)); 
maxRadius[X]=(round(getResult("Fe
ret",j)))/2; 
minRadius[X]=(round(getResult("Min
Feret",j)))/2; 
RadiusE[X]=(round(getResult("Major
",j)))/2; 
circularity[X]=(getResult("Circ.",j)); 
} 
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} 
run("Clear Results", ""); 
run("Set Scale...", "distance=0 
known=0 pixel=1 unit=pixel"); 
run("Analyze Particles...", 
"size="+totalArea+"-Infinity 
show=Masks display clear"); 
run("Grays"); 
run("Select None"); 
doWand(xc[X],yc[X]); 
doWand(xc[X],yc[X]); 
run("Convex Hull"); 
run("Measure"); 
EnvArea[X]=getResult("Area",0); 
run("Clear Results", ""); 
run("Select None"); 
selectWindow(bw); 
run("Close"); 
selectWindow("Mask of "+bw); 
rename(bw);RadiusCore=newArray(t
of); 
RadiusCoreII=newArray(tof); 
INTENSE=newArray(tof); 
ACMtotal=newArray(tof); 
ACMcore=newArray(tof); 
ACMinvasion=newArray(tof); 
ACMpercCore=newArray(tof); 
ACMpercInvasion=newArray(tof); 
 
//////////////////////////////////////////////////////////
// 
//////////////////////////////////// 
//////////INSIDIA PART 2/////////// 
///////////////////////////////// 
////IMAGE NORMALISATION///////// 
/////////////////////////////// 
selectWindow(image); 
run("Macro...", "code=v=(-v+255)"); 
/////////image inverted 
selectWindow(bw); 
run("Select None"); 
doWand(xc[X],yc[X]); 
doWand(xc[X],yc[X]); 
roiManager("Add"); 
selectWindow(image); 
run("Select None"); 
roiManager("Select",0); 
run("Make Inverse");///area external 
to spheroid selected 
run("Measure"); 
bg=getResult("Mean",0); 
run("Clear Results", ""); 
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roiManager("reset"); 
selectWindow(image); 
run("Select None"); 
run("Subtract...", "value="+bg+""); 
/////////////////////////// 
selectWindow(bw); 
run("Select None"); 
run("Divide...", "value=255"); 
imageCalculator("Multiply create", 
image,bw);///only greyscale spheroid 
in the image 
selectWindow(image); 
run("Close"); 
///////////density file/////////////////// 
selectWindow("Result of "+image); 
run("Select None"); 
run("Duplicate...", "Duplicate.tif"); 
saveAs(".tif",anSubdir+"density"+i); 
selectWindow("density"+i+".tif"); 
run("Close"); 
selectWindow(bw); 
run("Close"); 
selectWindow("Result of "+image); 
run("Close"); 
} 
} 
////////////////////////////////// 
//////Pixel Conversion Menu////// 
//////////////////////////////// 
Dialog.create("Convert values in 
microns?"); 
Dialog.addNumber("pixel to micron", 
2.09); 
Dialog.addCheckbox("convert",true); 
Dialog.show(); 
pixel=Dialog.getNumber(); 
convert=Dialog.getCheckbox(); 
xaxisunits="(um)"; 
if (convert==false) { 
xaxisunits="(pixel)"; 
pixel=1;} 
run("Close All"); 
selectWindow("Results"); 
run("Close"); 
//////////////////////////////// 
/////////////////////////////// 
////////INSIDIA PART 3///////// 
/////////DENSITY PROFILE////////// 
///////////////////////////// 
//Profile Table// 
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title1 = "Profiles"; 
f="["+title1+"]"; 
run("New... ", "name="+f+" 
type=Table"); 
//////////////// 
for(G=0; G<nfolder;G++){ 
dir = maindir+mainlist[G]; 
list = getFileList(dir); 
c=list.length-1; 
myDir = 
dir+"000results"+File.separator; 
profileth=newArray(c); 
anSubdir=analysisdir+mainlist[G]; 
for (i=0; i<c; i++) { 
X=c*G+i; 
densitysave=anSubdir+"density"+i+"
.tif"; 
//////////////////DM file //////////////////////// 
open(densitysave); 
run("Median...", 
"radius=4");////////////////// 
rename("density"+i+".tif"); 
run("Duplicate...", "Duplicate.tif"); 
rename("profile"+i); 
sumy=0; /// to calculate the integral 
of the whole curve 
selectWindow("profile"+i); 
run("Concentric Circles", 
"circles="+maxRadius[X]+" line=1 
x="+xc[X]+" y="+yc[X]+ " inner=1 
outer="+maxRadius[X]+" measure"); 
y=newArray(nResults); 
for(a=0; a<nResults; a++){ 
y[a]=getResult("Mean",a); 
sumy=sumy+y[a]; 
} 
////x coordinates for plot//// 
Xplot=newArray(y.length); 
for(xx=0;xx<Xplot.length; xx++){ 
Xplot[xx]=(xx+1)*pixel; 
} 
print(f,printnames[X]); 
for (p=0; p<y.length; p++){ 
print(f,y[p]); 
} 
print(f," "); 
ACMtotal[X]=pixel*sumy; ////integral 
of the curve 
max=(y[3]+y[5]+y[7]+y[9])/4; 
ylength=y.length; 
counter=0; 
if(i!=0){ 
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for (inte=5;inte<ylength; inte+=5){ 
sumapp=0; 
for(in=0; in<y.length-inte; in++){ 
sumapp=sumapp+y[in]; 
} 
THEORY=max*(y.length-inte); 
delta=sumapp/THEORY*100; 
counter=counter+1; 
if (delta>89){ 
RadiusCoreII[X]=ylength-inte; 
CT=(ylength-(counter*5)); 
INTENSE[X]=round(y[CT]); 
inte=ylength; 
} 
} 
} 
else 
RadiusCoreII[X]=maxRadius[X]; 
/////////////////////////////////////////////////// 
////////////Profile Plot 
Creation///////////////// 
//plot creation 
xaxis="Distance from centre of 
mass"+xaxisunits; 
Plot.create("Circle profile", xaxis, 
"Intensity"); 
Plot.setLimits(0, 1000, 0, 255); 
Plot.setFormatFlags("110011000011
11"); 
Plot.setLineWidth(i+1.5); 
Plot.add("line",Xplot, y); 
Plot.show(); 
///plot legend 
setColor(0, 0, 0); 
drawString(printnames[X],350,50+11
*i); 
run("Set Scale...", "distance=0 
known=0 pixel=1 unit=pixel"); 
setLineWidth(i*1); 
drawLine(330,40+11*i,340,40+11*i); 
rename("plot"+i); 
////create empty plot//// 
if (i==0){ 
hp=getHeight(); 
wp=getWidth(); 
newImage("Plot", "8-bit white", wp, 
hp, 1);} 
///sum the two plots before drawing 
the line 
imageCalculator("AND", "Plot", 
"plot"+i); 
////draw the line ///// 
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selectWindow("plot"+i);///axis origin 
is 60,510 
saveAs("tiff",anSubdir+"plot"+i); 
open(anSubdir+"plot"+i+".tif"); 
rename("plot"+i+".tif"); 
selectWindow("plot"+i+".tif"); 
run("Clear Results"); 
run("Select None"); 
////////////////// 
run("16 colors"); 
if(i!=0){ 
setLineWidth(2); 
newnumberII=(((9*RadiusCoreII[X])/
10)+60); 
setColor(255, 0, 0); 
drawLine(newnumberII, hp, 
newnumberII, 0); 
setColor(0, 0, 0); 
///integral of curve below core 
for (gg=0;gg<RadiusCoreII[X];gg++){ 
ACMcore[X]=ACMcore[X]+pixel*y[gg
]; 
} 
} 
else{ 
ACMcore[X]=ACMtotal[X]; 
} 
ACMinvasion[X]=ACMtotal[X]-
ACMcore[X]; 
ACMpercCore[X]=((ACMcore[X])/(A
CMtotal[X]))*100; 
ACMpercInvasion[X]=((ACMinvasion
[X])/(ACMtotal[X]))*100; 
drawString("core",70,200); 
selectWindow("plot"+i+".tif"); 
saveAs("tiff",anSubdir+"plot"+i); 
///////////NEW DENSITY 
MAP////////////////////// 
selectWindow("density"+i+".tif"); 
run("Duplicate...", "Duplicate.tif"); 
rename("green"+i); 
selectWindow("green"+i); 
for(sss=0;sss<w;sss++){ 
for(jjj=0;jjj<h;jjj++){ 
test=getPixel(sss,jjj); 
if(test>INTENSE[X]){ 
setPixel(sss,jjj,255); //pixel is set in 
white 
} 
} 
} 
run("Subtract...", "value=254"); 
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run("Multiply...", "value=255.000"); 
setOption("BlackBackground", true); 
run("Make Binary"); 
run("Dilate"); 
run("Fill Holes"); 
run("Erode"); 
run("Analyze Particles...", "size=0-
Infinity circularity=0.00-1.00 
show=Nothing display clear"); 
apptotalArea=0; 
for(jjj=0; jjj<nResults; jjj++){ 
current=getResult("Area",jjj); 
if(current>apptotalArea){ 
apptotalArea=current; 
} 
} 
run("Analyze Particles...", 
"size="+apptotalArea+"-Infinity 
show=Masks display clear"); 
AreaCore[X]=getResult("Area",0); 
PeriMap[X]=getResult("Perim.",0); 
AreaInvasion[X]=AreaTotal[X]-
AreaCore[X]; 
run("Clear Results", ""); 
run("Dilate"); 
run("Clear Results", ""); 
run("Grays"); 
run("Select None"); 
imageCalculator("Add create", 
"Mask of green"+i,"density"+i+".tif"); 
selectWindow("Mask of green"+i); 
run("Close"); 
selectWindow("green"+i); 
run("Close"); 
selectWindow("density"+i+".tif"); 
run("Close"); 
selectWindow("Result of Mask of 
green"+i); 
rename("density"+i+".tif"); 
doWand(xc[X],yc[X]); 
run("Measure"); 
selectWindow("density"+i+".tif"); 
run("Red/Green"); 
saveAs(".tif",anSubdir+"density"+i); 
run("Close"); 
} 
selectWindow("Plot"); 
saveAs("tiff",anSubdir+"Plot"); 
run("Close All"); 
} 
///////////// 
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//montage/// 
//////////// 
run("Close All"); 
for(G=0; G<nfolder;G++){ 
dir=maindir+mainlist[G]; 
list=getFileList(dir); 
c=list.length; 
newImage("HyperStack", "RGB 
color-mode", w, h, 1, 1, 4); 
open(dir+list[1]); 
selectWindow(list[1]); 
run("Select None"); 
run("Copy"); 
selectWindow("HyperStack"); 
Stack.setFrame(1); 
run("Paste"); 
close(list[1]); 
open(dir+list[c-1]); 
selectWindow(list[c-1]); 
run("Select None"); 
run("Copy"); 
selectWindow("HyperStack"); 
Stack.setFrame(2); 
run("Paste"); 
close(list[c-1]); 
anSubdir=analysisdir+mainlist[G]+"/"
; 
open(anSubdir+"density0.tif"); 
selectWindow("density0.tif"); 
run("Select None"); 
run("Copy"); 
selectWindow("HyperStack"); 
Stack.setFrame(3); 
run("Paste"); 
close("density0.tif"); 
open(anSubdir+"density"+(c-
2)+".tif"); 
selectWindow("density"+(c-2)+".tif"); 
run("Select None"); 
run("Copy"); 
selectWindow("HyperStack"); 
Stack.setFrame(4); 
run("Paste"); 
close("density0.tif"); 
run("Make Montage...", "columns=2 
rows=2 scale=1 first=1 last=4 
increment=1 border=0 font=12"); 
selectWindow("Montage"); 
saveAs("tiff",anSubdir+"Montage"); 
run("Close All"); 
} 
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/////////////////////////////// 
////////INSIDIA PART 6///////// 
////////OUTPUT//////////////// 
///////////////////////////// 
for(G=0; G<nfolder;G++){ 
anSubdir=analysisdir+mainlist[G];} 
print("This macro has been run on 
"+dayOfMonth+"/"+month+1+"/"+yea
r+" at "+hour+":"+minute+" with"); 
if (mode[0]==true){ 
print("thresholded images."); 
} else 
{ 
print("unthresholded images."); 
} 
print("The pixel value conversion 
used is "+pixel); 
print("SS Parameters"); 
print("\\file AreaTotal Perimeter 
MaxRadius MinRadius Circularity 
RadiusE SpecificSurf ShapeF 
EnvArea "); 
for (b=0; b<tof; b++){ 
////////pixel conversion//////// 
///SS parameters/////// 
coordinates[b]=maxRadius[b]; 
maxRadius[b]=maxRadius[b]*pixel; 
minRadius[b]=minRadius[b]*pixel; 
RadiusE[b]=RadiusE[b]*pixel; 
AreaTotal[b]=AreaTotal[b]*pixel; 
Perimeter[b]=Perimeter[b]*pixel; 
EnvArea[b]=EnvArea[b]*pixel; 
SpecSurf[b]=(Perimeter[b]/AreaTotal
[b])/(2/maxRadius[b]); 
ShapeF[b]=(Perimeter[b]*Perimeter[
b])/(4*PI*AreaTotal[b]); 
/////density profile parameters//// 
RadiusCoreII[b]=RadiusCoreII[b]*pix
el; 
////density map parameters/////// 
AreaCore[b]=AreaCore[b]*pixel; 
PeriMap[b]=PeriMap[b]*pixel; 
AreaInvasion[b]=AreaInvasion[b]*pix
el; 
PercCore[b]=(AreaCore[b]/AreaTotal
[b])*100; 
PercInvasion[b]=(AreaInvasion[b]/Ar
eaTotal[b])*100; 
print(printnames[b]+" 
"+AreaTotal[b]+" "+Perimeter[b]+" 
"+maxRadius[b]+" "+minRadius[b]+" 
"+circularity[b]+" "+RadiusE[b]+" 
"+SpecSurf[b]+" "+ShapeF[b]+" 
"+EnvArea[b]); 
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} 
b=0; 
print("DM and DP parameters"); 
print("\\file PeriMap AreaCore 
AreaInvasion %Core %Invasion 
ACMTotal ACMCore ACMInvasion 
%ACMcore %ACMinvasion 
RadiuscoreII"); 
for (b=0; b<tof; b++){ 
print(printnames[b]+" "+PeriMap[b]+" 
"+AreaCore[b]+" 
"+AreaInvasion[b]+" "+PercCore[b]+" 
"+PercInvasion[b]+" "+ACMtotal[b]+" 
"+ACMcore[b]+" "+ACMinvasion[b]+" 
"+ACMpercCore[b]+" 
"+ACMpercInvasion[b]+" 
"+RadiusCoreII[b]); 
} 
///search for largest maxradius and 
print x coordinates for profiles, if 
conversion is not selected values 
are in pixel 
largR=0; 
for(iii=0; iii<tof; iii++){ 
current=coordinates[iii]; ///in pixel 
if(current>largR){ 
largR=current; 
}} 
XCoord=newArray(round(largR)); 
print(f,"X coordinates"); 
for(i=0;i<XCoord; i++){ 
XCoord[i]=(1+i)*pixel; 
print(f,XCoord[i]); 
} 
//////////////////////////////// 
/////////CLOSE&EXIT//////////// 
////////////////////////////// 
setBatchMode(false); 
selectWindow("Results"); 
run("Close"); 
selectWindow("Log"); 
saveAs("Text", analysisdir+"output"); 
run("Close"); 
selectWindow(title1); 
saveAs("Text", 
analysisdir+"Profiles"); 
run("Close"); 
waitForUser("Finish","Click OK to 
exit"); 
exit(); 
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APPENDIX 6: R CODE 
7.1.14 SURVIVAL 
SINGLE GENE 
 
# installation 
source("https://bioconductor.org/bioc
Lite.R") 
biocLite("RTCGA.clinical") 
biocLite("RTCGA.rnaseq") 
install.packages("devtools") 
library(devtools) 
 
 
library(tidyverse) # pipes (%>%) and 
dplyr data munging 
library(RTCGA.clinical) # survival 
times 
library(RTCGA.rnaseq) # genes' 
expression 
library(RTCGA) ##access library 
library(devtools) 
infoTCGA()  ##see names of cohorts 
(brca, gbm, etc) 
 
 
GBM.surv<-
survivalTCGA(GBM.clinical) 
 
#head(GBM.surv) 
GBM.expressions<-
expressionsTCGA(GBM.rnaseq) 
#head(colnames(GBM.expressions[, 
3021], 50)) 
 
#head(GBM.expressions) 
#nrow(GBM.expressions) 
 
expressionsTCGA( 
  GBM.rnaseq, 
  extract.cols = c("CAV-1|857")) 
%>% 
  rename(cohort = dataset, 
         CAV-1 = `CAV-1|857`) %>% 
  filter(substr(bcr_patient_barcode, 
14, 15) == "01") %>%  
  # only cancer samples 
  mutate(bcr_patient_barcode =  
           substr(bcr_patient_barcode, 
1, 12)) -> GBM.rnaseq_v2 
 
GBM.surv %>% 
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  left_join(GBM.rnaseq_v2, 
            by = "bcr_patient_barcode") -
> 
  GBM.surv_rnaseq 
 
 
GBM.surv_rnaseq <- 
GBM.surv_rnaseq %>% 
  filter(!is.na(cohort)) 
 
 
 
library(survminer) 
 
GBM.surv_rnaseq.cut <- 
surv_cutpoint( 
  GBM.surv_rnaseq, 
  time = "times", 
  event = "patient.vital_status", 
  variables = c("CAV-1", "cohort") 
) 
summary(GBM.surv_rnaseq.cut) 
 
plot(GBM.surv_rnaseq.cut, "CAV-1", 
palette = c("#000000","#000000")) 
 
GBM.surv_rnaseq.cat <- 
surv_categorize(GBM.surv_rnaseq.c
ut)  
 
 
library(survival) 
 
fit <- survfit(Surv(times, 
patient.vital_status) ~ ITGB1 + 
cohort , 
               data = 
GBM.surv_rnaseq.cat) 
 
ggsurvplot( 
  fit,                     # survfit object with 
calculated statistics. 
  risk.table = TRUE,       # show risk 
table. 
  pval = TRUE,             # show p-
value of log-rank test. 
  conf.int = FALSE,         # show 
confidence intervals for  
  # point estimaes of survival curves. 
  xlim = c(0,1750),        # present 
narrower X axis, but not affect 
  # survival estimates. 
  break.time.by = 250,    # break X 
axis in time intervals by 500. 
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  surv.median.line = "v", 
  ggtheme = theme_light(), # 
customize plot and risk table with a 
theme. 
  palette = c("#000000","#000000"), 
  risk.table.y.text.col = T, # colour 
risk table text annotations. 
  risk.table.y.text = FALSE # show 
bars instead of names in text 
annotations 
  # in legend of risk table 
) 
 
surv_median(fit) #returns median 
survival with upper and lower for 
each curve 
survdiff(Surv(times, 
patient.vital_status) ~ CAV-1, data = 
GBM.surv_rnaseq.cat) #log rank test 
coxph(Surv(times, 
patient.vital_status) ~ CAV-1, data = 
GBM.surv_rnaseq.cat) 
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7.1.15 SURVIVAL 
DOUBLE POSITIVE VS 
OTHER 
 
# installation 
source("https://bioconductor.org/bioc
Lite.R") 
biocLite("RTCGA.clinical") 
biocLite("RTCGA.rnaseq") 
install.packages("devtools") 
library(devtools) 
 
 
library(tidyverse) # pipes (%>%) and 
dplyr data munging 
library(RTCGA.clinical) # survival 
times 
library(RTCGA.rnaseq) # genes' 
expression 
library(RTCGA) ##access library 
library(devtools) 
infoTCGA()  ##see names of cohorts 
(brca, gbm, etc) 
 
 
GBM.surv<-
survivalTCGA(GBM.clinical) 
 
#head(GBM.surv) 
GBM.expressions<-
expressionsTCGA(GBM.rnaseq) 
#head(colnames(GBM.expressions[, 
3021], 50)) 
 
#head(GBM.expressions) 
#nrow(GBM.expressions) 
 
expressionsTCGA( 
  GBM.rnaseq, 
  extract.cols = c("SPP1|6696", 
"CAV-1|857")) %>% 
  rename(cohort = dataset, 
         TSP1 = `SPP1|6696`, 
         CAV-1 = `CAV-1|857`) %>% 
  filter(substr(bcr_patient_barcode, 
14, 15) == "01") %>%  
  # only cancer samples 
  mutate(bcr_patient_barcode =  
           substr(bcr_patient_barcode, 
1, 12)) -> GBM.rnaseq_v2 
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GBM.surv %>% 
  left_join(GBM.rnaseq_v2, 
            by = "bcr_patient_barcode") -
> 
  GBM.surv_rnaseq 
 
 
GBM.surv_rnaseq <- 
GBM.surv_rnaseq %>% 
  filter(!is.na(cohort)) 
 
 
 
library(survminer) 
 
GBM.surv_rnaseq.cut <- 
surv_cutpoint( 
  GBM.surv_rnaseq, 
  time = "times", 
  event = "patient.vital_status", 
  variables = c("TSP1", "cohort", 
"CAV-1") 
) 
summary(GBM.surv_rnaseq.cut) 
 
 
GBM.surv_rnaseq.cat <- 
surv_categorize(GBM.surv_rnaseq.c
ut)  
GBM.surv_rnaseq.cat <- 
GBM.surv_rnaseq.cat %>%  
  mutate(group = ifelse(TSP1 == 
'high' & CAV-1 == 'high', 
'TSP1+/CAV-1+', 'other')) 
 
library(survival) 
 
fit <- survfit(Surv(times, 
patient.vital_status) ~ group, 
               data = 
GBM.surv_rnaseq.cat) 
 
ggsurvplot( 
  linetype = c(1,4),          # change 
linetypes, the first element is for first 
group, the second for the 2nd group 
  pval.coord = c(470, 0.7),    # 
coordinates of the p-value 
apperance 
  censor = FALSE,              # should 
censoring be included in survival 
plots 
  pval.method = TRUE,          # 
should the p-value method name be 
plotted 
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  pval.method.coord = c(470, 0.8),  # 
coordinates for the test for which the 
p-value was calculated 
  fit,                     # survfit object with 
calculated statistics. 
  risk.table = TRUE,       # show risk 
table. 
  pval = TRUE,             # show p-
value of log-rank test. 
  conf.int = FALSE,         # show 
confidence intervals for  
  # point estimaes of survival curves. 
  xlim = c(0,1750),        # present 
narrower X axis, but not affect 
  # survival estimates. 
  break.time.by = 250,    # break X 
axis in time intervals by 500. 
  surv.median.line = "v", 
  ggtheme = theme_light(), # 
customize plot and risk table with a 
theme. 
  palette = c("#000000","#000000"), 
  risk.table.y.text.col = T, # colour 
risk table text annotations. 
  risk.table.y.text = FALSE # show 
bars instead of names in text 
annotations 
  # in legend of risk table 
) 
 
surv_median(fit) #returns median 
survival with upper and lower for 
each curve 
survdiff(Surv(times, 
patient.vital_status) ~ group, data = 
GBM.surv_rnaseq.cat) #log rank test 
coxph(Surv(times, 
patient.vital_status) ~ group, data = 
GBM.surv_rnaseq.cat) 
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7.1.16 SURVIVAL FOUR 
GROUPS 
 
# installation 
source("https://bioconductor.org/bioc
Lite.R") 
biocLite("RTCGA.clinical") 
biocLite("RTCGA.rnaseq") 
install.packages("devtools") 
library(devtools) 
 
 
library(tidyverse) # pipes (%>%) and 
dplyr data munging 
library(RTCGA.clinical) # survival 
times 
library(RTCGA.rnaseq) # genes' 
expression 
library(RTCGA) ##access library 
library(devtools) 
infoTCGA()  ##see names of cohorts 
(brca, gbm, etc) 
 
 
GBM.surv<-
survivalTCGA(GBM.clinical) 
 
#head(GBM.surv) 
GBM.expressions<-
expressionsTCGA(GBM.rnaseq) 
#head(colnames(GBM.expressions[, 
3021], 50)) 
 
#head(GBM.expressions) 
#nrow(GBM.expressions) 
 
expressionsTCGA( 
  GBM.rnaseq, 
  extract.cols = c("SPP1|6696", 
"CAV-1|857")) %>% 
  rename(cohort = dataset, 
         TSP1 = `SPP1|6696`, 
         CAV-1 = `CAV-1|857`) %>% 
  filter(substr(bcr_patient_barcode, 
14, 15) == "01") %>%  
  # only cancer samples 
  mutate(bcr_patient_barcode =  
           substr(bcr_patient_barcode, 
1, 12)) -> GBM.rnaseq_v2 
 
GBM.surv %>% 
  left_join(GBM.rnaseq_v2, 
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            by = "bcr_patient_barcode") -
> 
  GBM.surv_rnaseq 
 
 
GBM.surv_rnaseq <- 
GBM.surv_rnaseq %>% 
  filter(!is.na(cohort)) 
 
 
 
library(survminer) 
 
GBM.surv_rnaseq.cut <- 
surv_cutpoint( 
  GBM.surv_rnaseq, 
  time = "times", 
  event = "patient.vital_status", 
  variables = c("TSP1", "cohort", 
"CAV-1") 
) 
summary(GBM.surv_rnaseq.cut) 
 
 
GBM.surv_rnaseq.cat <- 
surv_categorize(GBM.surv_rnaseq.c
ut)  
GBM.surv_rnaseq.cat <- 
GBM.surv_rnaseq.cat %>%  
  mutate(group = ifelse(TSP1 == 
'high' & CAV-1 == 'high', 
'TSP1+/CAV-1+', 'other')) 
 
library(survival) 
 
fit <- survfit(Surv(times, 
patient.vital_status) ~ CAV-1 + 
TSP1, 
               data = 
GBM.surv_rnaseq.cat) 
 
ggsurvplot( 
  linetype = c(1, 2, 3, 4),          # 
change linetypes, the first element is 
for first group, the second for the 
2nd group 
  pval.coord = c(470, 0.7),    # 
coordinates of the p-value 
apperance 
  censor = FALSE,              # should 
censoring be included in survival 
plots 
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  pval.method = TRUE,          # 
should the p-value method name be 
plotted 
  pval.method.coord = c(470, 0.8),  # 
coordinates for the test for which the 
p-value was calculated 
  fit,                     # survfit object with 
calculated statistics. 
  risk.table = TRUE,       # show risk 
table. 
  pval = TRUE,             # show p-
value of log-rank test. 
  conf.int = FALSE,         # show 
confidence intervals for  
  # point estimaes of survival curves. 
  xlim = c(0,1750),        # present 
narrower X axis, but not affect 
  # survival estimates. 
  break.time.by = 250,    # break X 
axis in time intervals by 500. 
  surv.median.line = "v", 
  ggtheme = theme_light(), # 
customize plot and risk table with a 
theme. 
  palette = 
c("#000000","#000000","#000000","
#000000"), 
  risk.table.y.text.col = T, # colour 
risk table text annotations. 
  risk.table.y.text = FALSE # show 
bars instead of names in text 
annotations 
  # in legend of risk table 
) 
 
surv_median(fit) #returns median 
survival with upper and lower for 
each curve 
survdiff(Surv(times, 
patient.vital_status) ~ CAV-1 + 
TSP1, data = GBM.surv_rnaseq.cat) 
#log rank test 
coxph(Surv(times, 
patient.vital_status) ~ CAV-1 + 
TSP1, data = GBM.surv_rnaseq.cat) 
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APPENDIX 7: TOP 500 GENES POSITIVELY CORRELATED TO 
CAV-1 IN GBM 
 
HUGO R-value R-pvalue 
 
HUGO R-value R-pvalue 
1 PRSS23 0.69 1.16E-73 126 TIMP1 0.428 1.45E-23 
2 CAV2 0.645 3.10E-61 127 PTRF 0.428 1.67E-23 
3 SERPINE1 0.639 8.96E-60 128 EHD2 0.428 1.59E-23 
4 MYOF 0.617 1.83E-54 129 DUSP1 0.427 2.14E-23 
5 P4HA2 0.583 3.58E-47 130 STC2 0.426 2.80E-23 
6 GBE1 0.576 9.89E-46 131 MET 0.426 2.56E-23 
7 BACE2 0.564 2.08E-43 132 ARPC1B 0.425 3.52E-23 
8 CD44 0.555 8.70E-42 133 TGFB1I1 0.425 3.87E-23 
9 UPP1 0.549 8.68E-41 134 RBM47 0.425 3.45E-23 
10 ANXA2P2 0.547 1.91E-40 135 LMNA 0.424 4.47E-23 
11 ITGB1 0.547 1.97E-40 136 REXO2 0.422 7.29E-23 
12 CSDA 0.546 2.58E-40 137 DSE 0.422 8.01E-23 
13 LOX 0.545 4.26E-40 138 CHSY1 0.421 1.15E-22 
14 SRPX2 0.544 4.98E-40 139 CTSL1 0.42 1.24E-22 
15 GPRC5A 0.542 1.17E-39 140 SYNPO 0.42 1.48E-22 
16 MMP19 0.54 2.67E-39 141 TNFRSF1B 0.42 1.48E-22 
17 EMP1 0.536 1.01E-38 142 MAFF 0.42 1.48E-22 
18 LOXL2 0.536 1.23E-38 143 SPAG4 0.419 1.73E-22 
19 PLAUR 0.529 1.80E-37 144 RGS2 0.417 3.50E-22 
20 CFI 0.528 2.31E-37 145 WBP5 0.416 4.51E-22 
21 NAMPT 0.526 4.98E-37 146 C1RL 0.416 3.70E-22 
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22 CA12 0.521 3.51E-36 147 CAST 0.415 4.98E-22 
23 PROS1 0.521 3.69E-36 148 SERPINH1 0.414 6.00E-22 
24 ANXA2 0.519 7.42E-36 149 WWTR1 0.413 8.03E-22 
25 ITGA5 0.518 1.09E-35 150 POLD4 0.413 8.97E-22 
26 TREM1 0.517 1.40E-35 151 S100A6 0.413 7.72E-22 
27 COL5A1 0.515 3.05E-35 152 FSTL1 0.409 2.21E-21 
28 MVP 0.51 1.49E-34 153 TPM4 0.409 2.67E-21 
29 DPYD 0.509 2.72E-34 154 DAB2 0.407 4.39E-21 
30 VCL 0.507 4.59E-34 155 PTP4A2 0.406 4.92E-21 
31 TNC 0.507 4.79E-34 156 CHPF2 0.406 5.98E-21 
32 CA9 0.504 1.33E-33 157 NDRG1 0.405 7.00E-21 
33 C5AR1 0.503 2.15E-33 158 IGFBP6 0.405 7.13E-21 
34 FOSL1 0.502 2.77E-33 159 LY96 0.405 6.08E-21 
35 FLNA 0.496 2.61E-32 160 MFSD1 0.405 7.70E-21 
36 LAMB1 0.496 2.33E-32 161 LDHA 0.404 8.03E-21 
37 CEBPB 0.494 4.55E-32 162 BHLHE40 0.404 8.02E-21 
38 GFPT2 0.491 1.09E-31 163 TNFAIP3 0.404 8.06E-21 
39 P4HA1 0.491 1.36E-31 164 TRAM2 0.403 1.19E-20 
40 THBS1 0.489 2.12E-31 165 FAM129A 0.403 1.03E-20 
41 IL1R1 0.489 2.19E-31 166 IBSP 0.402 1.27E-20 
42 FAM114A1 0.489 2.35E-31 167 MYLK 0.401 1.79E-20 
43 CTSB 0.488 3.00E-31 168 ABCA1 0.401 1.63E-20 
44 ADM 0.488 3.67E-31 169 FNDC3B 0.401 1.85E-20 
45 GEM 0.486 6.65E-31 170 RAB13 0.4 2.19E-20 
46 TGFBI 0.485 7.11E-31 171 ANPEP 0.4 2.49E-20 
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47 C1R 0.485 8.28E-31 172 FCGR2B 0.399 2.79E-20 
48 CALD1 0.485 7.69E-31 173 VKORC1 0.399 2.73E-20 
49 SHC1 0.483 1.33E-30 174 CLCF1 0.399 2.77E-20 
50 PLAU 0.482 1.83E-30 175 LUM 0.398 3.37E-20 
51 GLIPR1 0.482 2.35E-30 176 ATF3 0.398 4.03E-20 
52 HK2 0.481 2.72E-30 177 MSR1 0.398 4.14E-20 
53 SLC39A14 0.481 3.30E-30 178 COL3A1 0.398 3.64E-20 
54 FN1 0.48 3.45E-30 179 MYL9 0.397 4.39E-20 
55 ANXA1 0.479 5.89E-30 180 FCGR2A 0.397 5.22E-20 
56 ADAM9 0.479 5.11E-30 181 PDIA5 0.397 5.24E-20 
57 TMEM43 0.478 6.74E-30 182 FAS 0.397 4.74E-20 
58 PLP2 0.477 1.04E-29 183 GSN 0.396 5.96E-20 
59 PLOD2 0.476 1.22E-29 184 TCIRG1 0.396 5.72E-20 
60 C8orf4 0.474 3.01E-29 185 RALA 0.396 6.07E-20 
61 S100A11 0.473 3.90E-29 186 BIRC3 0.395 6.77E-20 
62 ABCC3 0.473 4.00E-29 187 SLC11A1 0.394 1.01E-19 
63 TAGLN 0.472 4.85E-29 188 MYH9 0.394 1.03E-19 
64 C1S 0.472 4.45E-29 189 PCOLCE 0.393 1.09E-19 
65 PLOD1 0.469 1.19E-28 190 CXCR4 0.393 1.33E-19 
66 MBD2 0.468 1.89E-28 191 KYNU 0.393 1.18E-19 
67 CD163 0.468 1.68E-28 192 COL5A2 0.393 1.22E-19 
68 PTPN12 0.467 2.45E-28 193 GYS1 0.392 1.58E-19 
69 ANGPTL4 0.467 2.46E-28 194 CCL20 0.392 1.58E-19 
70 ACTN1 0.464 4.91E-28 195 RCAN1 0.392 1.51E-19 
71 S100A10 0.463 8.79E-28 196 LOXL1 0.391 1.88E-19 
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72 IQGAP1 0.462 1.19E-27 197 HILPDA 0.391 2.19E-19 
73 TNFRSF12A 0.459 2.85E-27 198 SLC2A3 0.39 2.55E-19 
74 ACTA2 0.455 1.00E-26 199 DCBLD2 0.39 2.68E-19 
75 PTX3 0.455 7.97E-27 200 TPM2 0.389 3.03E-19 
76 LIF 0.454 1.31E-26 201 TGFBR2 0.389 2.82E-19 
77 ICAM1 0.453 1.68E-26 202 SERPINA1 0.389 2.96E-19 
78 F13A1 0.453 1.49E-26 203 NNMT 0.388 3.62E-19 
79 LTBP2 0.452 2.20E-26 204 ARHGAP29 0.387 5.55E-19 
80 CTSC 0.451 2.73E-26 205 NFKBIA 0.386 6.67E-19 
81 LIMS1 0.451 2.56E-26 206 EFEMP1 0.386 6.92E-19 
82 IL1R2 0.45 3.52E-26 207 FBN1 0.386 7.19E-19 
83 RNASE4 0.45 3.31E-26 208 TNFAIP8 0.386 6.60E-19 
84 COL1A1 0.449 5.33E-26 209 GLB1 0.385 8.34E-19 
85 STC1 0.449 4.42E-26 210 STEAP3 0.385 8.15E-19 
86 AIM1 0.449 5.44E-26 211 P4HB 0.384 9.97E-19 
87 FOSL2 0.449 5.37E-26 212 LRP10 0.384 9.11E-19 
88 SAT1 0.448 6.57E-26 213 ITGA3 0.384 1.10E-18 
89 GNS 0.448 5.86E-26 214 FHL2 0.384 1.08E-18 
90 SLC16A3 0.447 7.63E-26 215 NFIL3 0.384 1.06E-18 
91 PYGL 0.447 8.62E-26 216 KLF6 0.383 1.19E-18 
92 TMEM45A 0.445 1.64E-25 217 RBMS1 0.383 1.18E-18 
93 IL13RA1 0.444 2.20E-25 218 EDNRA 0.382 1.77E-18 
94 COL6A2 0.444 1.96E-25 219 VEGFA 0.382 1.57E-18 
95 SH3BGRL3 0.444 2.19E-25 220 B4GALT1 0.381 2.00E-18 
96 ELL2 0.443 2.65E-25 221 IFI16 0.381 2.15E-18 
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97 TNFRSF1A 0.442 3.78E-25 222 RND3 0.381 2.01E-18 
98 RAB27A 0.442 4.08E-25 223 SLC39A8 0.38 2.32E-18 
99 COL6A1 0.442 3.55E-25 224 SLC2A1 0.379 3.37E-18 
100 GBP2 0.441 4.59E-25 225 SRGN 0.379 3.22E-18 
101 BCL3 0.441 4.33E-25 226 TNIP1 0.379 3.39E-18 
102 ALDH3B1 0.441 4.59E-25 227 IL10RB 0.379 3.00E-18 
103 NRP1 0.441 4.58E-25 228 ZFP36L1 0.379 2.83E-18 
104 COL1A2 0.439 7.15E-25 229 FXYD5 0.379 3.40E-18 
105 HEXB 0.438 1.15E-24 230 CD93 0.378 4.07E-18 
106 PLOD3 0.437 1.46E-24 231 SLAMF8 0.378 4.35E-18 
107 HSPA5 0.437 1.61E-24 232 S100A4 0.377 5.06E-18 
108 MAFB 0.437 1.26E-24 233 SH2B3 0.377 4.93E-18 
109 RRAS 0.436 1.77E-24 234 GADD45A 0.377 5.24E-18 
110 CEBPD 0.435 2.50E-24 235 OLFML2B 0.377 5.26E-18 
111 ANG 0.435 2.40E-24 236 ELF4 0.376 5.80E-18 
112 CYR61 0.433 4.49E-24 237 EHD4 0.375 7.12E-18 
113 PALLD 0.432 6.60E-24 238 GRN 0.374 1.05E-17 
114 AHNAK2 0.432 5.50E-24 239 CD14 0.374 1.01E-17 
115 NPC2 0.431 7.35E-24 240 RAI14 0.374 1.06E-17 
116 COL6A3 0.431 7.66E-24 241 STAB1 0.374 9.87E-18 
117 ADAM12 0.431 7.59E-24 242 CLIC1 0.374 1.03E-17 
118 THBD 0.431 7.27E-24 243 FTH1P5 0.374 1.03E-17 
119 SOCS3 0.431 8.36E-24 244 IGFBP7 0.373 1.26E-17 
120 ARL4C 0.43 9.78E-24 245 SDC1 0.373 1.19E-17 
121 ELK3 0.43 9.77E-24 246 MAPKAPK2 0.373 1.14E-17 
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122 CALU 0.429 1.26E-23 247 MAN2A1 0.373 1.35E-17 
123 CNN2 0.429 1.39E-23 248 ERP44 0.373 1.19E-17 
124 HSPB1 0.429 1.24E-23 249 ERO1L 0.373 1.34E-17 
125 TIPARP 0.429 1.34E-23 250 HMOX1 0.372 1.65E-17 
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APPENDIX 8: CAV-1/TARGET GENES EXPRESSION 
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APPENDIX 11: LIST OF PUBLICATIONS, ORAL 
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7.1.18 PUBLICATIONS 
Moriconi, C, Palmieri, V, Tornillo, G, Fillmore H, Pilkington, G, Gumbleton, M 
. Caveolin-1, a driver of invasive phenotype in in-vitro 3D-spheroid assays 
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phenotype. January 2018 Neuro-Oncology 20(suppl_1):i13-i13.DOI10.1093/ 
neuonc/nox238.058 
 Moriconi, C, Palmieri, V, Di Santo, R, Tornillo, G, Papi, M, Pilkington, 
G, De Spirito, M & Gumbleton, M 2017, 'INSIDIA: a FIJI macro delivering 
high-throughput and high-content spheroid invasion analysis' Biotechnology 
Journal. DOI: 10.1002/biot.201700140.  
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Gumbleton, M . Pp80. Caveolin-1 implicated as a pro-invasive gene in high-
grade glioma cell models: implementation of a 3d spheroid matrix invasion 
assay. January 2017 Neuro-Oncology 19(suppl_1):i21-i22. 
DOI10.1093/neuonc/now293.080 
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 Best Poster Award at the BNOS2016 Conference. Leeds, UK. Poster 
title: Caveolin-1 implicated as a pro-invasive gene in high-grade glioma cell 
models: Implementation of a 3D spheroid matrix invasion assay. 
 Best Poster Award at the Research Day 2016, School of Pharmacy 
and Pharmaceutical Sciences, Cardiff University, UK. Poster title: Caveolin-1 
implicated as a pro-invasive gene in high-grade glioma cell models: 
Implementation of a 3D spheroid matrix invasion assay. 
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 BNOS 2017 “Engaging Science Enhancing Survival”, Edinburgh, UK 
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 GIF 2017 “Glioma Invasion Forum”, with talk contribution, Piran, (23-
25 April 2017) 
 BNOS 2016 “trials, technologies and T cells”, Leeds, UK (29 June-1 
July 2016) 
 “Tumour Microenvironment and Signalling” EMBL Symposium (3-6 
April 2016) 
 II International Symposium on Clinical and Basic Investigation in 
Glioblastoma (9-12 September 2015, Toledo, ES) 
 BNOS 2015 “Neuro-oncology across the ages” (1-3 July 2015 
Nottingham, UK) 
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